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7OVERALL RESULTS OF THE RISK ASSESSMENT
CAS Number: 85535-85-9
EINECS Number: 287-477-0
Alkanes, C14-17, chloro
Medium-chained chlorinated paraffins (MCCPs)
Human health assessment
Workers
( ) i) There is a need for further information and/or testing.
(x) ii) There is at present no need for further information and/or testing and for risk 
reduction measures beyond those which are being applied already.
(x) iii) There is a need for limiting the risks; risk reduction measures which are 
already being applied shall be taken into account.
Conclusion (iii) is reached for workers exposed during oil-based MWF use. The calculated 
margins of safety for this scenario in relation to repeated dose toxicity, carcinogenicity, 
effects mediated via lactation and effects at the time of parturition are unacceptably low. For 
all remaining scenarios, there are no concerns in relation to repeat dose effects, 
carcinogenicity, effects mediated via lactation and effects at the time of parturition, and 
hence, conclusion (ii) is reached.
Consumer exposure
( ) i) There is a need for further information and/or testing.
(x) ii) There is at present no need for further information and/or testing and for risk 
reduction measures beyond those which are being applied already.
( ) iii) There is a need for limiting the risks; risk reduction measures which are 
already being applied shall be taken into account.
Consumer exposure to MCCPs is generally very low. Most applications of MCCPs are not 
designed for consumer contact and most exposures are negligible. The only consumer 
exposure scenarios for which significant exposures could occur are the wearing of leather 
clothes treated with MCCPs and the use of metal working fluids.
The calculated margins of safety (MOS) for repeated exposure toxicity, carcinogenicity, 
effects mediated via lactation and effects at the time of parturition are sufficient to provide 
reassurance that adverse effects would not occur and thus conclusion (ii) is reached. 
Exposure via the environment
( ) i) There is a need for further information and/or testing.
(x) ii) There is at present no need for further information and/or testing and for risk 
reduction measures beyond those which are being applied already.
( ) iii) There is a need for limiting the risks; risk reduction measures which are 
already being applied shall be taken into account.
Regional exposures
For exposures at a regional level, the calculated margins of safety for repeated dose toxicity, 
carcinogenicity, effects mediated via lactation and effects at the time of parturition are 
8considered to provide sufficient reassurance that adverse health effects would not occur and 
thus conclusion (ii) is reached.
Local exposures
For local sources of exposure, the calculated margins of safety for repeated dose toxicity, 
carcinogenicity, effects mediated via lactation and effects at the time of parturition are 
considered to provide sufficient reassurance that adverse health effects would not occur and 
thus conclusion (ii) is reached.
Infants exposed via breast milk and cow’s milk
Very large margins (5 orders of magnitude) have been calculated between the estimated infant 
intake of MCCPs and the levels at which adverse effects mediated via lactation have been 
seen in animals. Also, due to concerns identified by the environmental risk assessment, an 
environmental risk reduction programme is currently under development and this could lead 
to reductions in point source and diffuse environmental emissions in due course. Furthermore, 
industry has shown a formal commitment to initiating a monitoring programme of levels of 
MCCPs in breast and cow’s milk. Therefore, overall, conclusion (ii) is reached.
Combined exposure
A combined exposure scenario, taking account of the potential for exposure as a consumer 
and via environmental sources is not relevant, given that consumer exposures are infrequent, 
rather than repeated daily exposures. Therefore no risk characterisation for this scenario has 
been performed.
Risks from physicochemical properties
( ) i) There is a need for further information and/or testing.
(x) ii) There is at present no need for further information and/or testing and for risk 
reduction measures beyond those which are being applied already.
( ) iii) There is a need for limiting the risks; risk reduction measures which are 
already being applied shall be taken into account.
There are no significant risks to humans from the physicochemical properties of 
medium-chained chlorinated paraffins. Therefore conclusion (ii) is reached.
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1 GENERAL SUBSTANCE INFORMATION
1.1 IDENTIFICATION OF THE SUBSTANCE
CAS No: 85535-85-9
EINECS No: 287-477-0
IUPAC Name: Alkanes, C14-17, chloro
Molecular formula: CxH(2x-y+2) Cly, where x=14-17 and y=1-17
Example structural
formulae:
Molecular weight: see 
Section 1.2.1
Synonyms:
chlorinated paraffin (C14-17); chloroalkanes, C14-17; chloroparaffin; 
chloroparaffine, C14-17; medium-chain chlorinated paraffins; paraffine 
clorurate (C14-17); paraffine clorurate a catena media.
In this assessment the name medium-chain chlorinated paraffin (or MCCP) will be used for 
the substance as this is the more common name. The commercially supplied products are 
usually mixtures of different carbon chain lengths (reflecting the carbon chain length 
distribution in the parent n-paraffin feedstocks used), and have different degrees of 
chlorination, although all have a common structure in that no secondary carbon atom carries 
more than one chlorine atom. MCCPs are produced by the chlorination of straight-chain 
hydrocarbons of 14-17 carbon atoms in length. The degree of chlorination can vary generally 
from 20-70% by weight, although most commercially available products fall in the range 40-
70%. Because of the variation in combinations of carbon chain length and degree of 
chlorination, a wide range of products are available with an average chain length usually 
being specified by the manufacturer and a chlorination degree being random but defined by 
weight. Information on chain length distribution is not available for commercially available 
MCCP products.
Two other groups of chlorinated paraffins are made commercially. These are known as short-
chain (typically C10-13) and long-chain (typically C20-30). This assessment is only concerned 
with the medium-chain (C14-17) chlorinated paraffins, but some information on the other types 
is included when it is considered to be useful and relevant to the assessment. The short-chain 
chlorinated paraffins have been assessed previously under Regulation (EEC) 793/93.
1.2 PURITY/IMPURITIES, ADDITIVES
1.2.1 Purity
Table 1.1 shows the theoretical % weight chlorine content of several compounds that can be 
considered as medium-chain chlorinated paraffins. The amount of chlorine present in the 
commercial products is usually expressed as a percentage by weight (% wt. Cl), but since the 
C14H24Cl6
C17H29Cl7
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commercial products contain a number of components with different carbon chain lengths, it 
is not possible to identify exactly which compounds are present in a given product, although 
Table 1.1 can be used as a guide. Wherever possible in this report, the actual carbon chain 
length (or range of chain length) and the degree of chlorination (% wt. Cl) will be given.
Although it is theoretically possible to produce MCCPs with chlorine contents up to 70% wt. 
Cl, such products are not manufactured commercially. The highest chlorine content of the 
commercial MCCPs normally available is around 58-60% wt. Cl, although products with a 
chlorine content of up to 62-63% have recently been developed. The lowest chlorine content 
of the commercial MCCPs is around 40% wt. Cl, but the largest tonnages of MCCPs have 
chlorine contents between 45 and 52% wt. Cl (Euro Chlor, 1999).
The purity of the produced chlorinated paraffin is related to the purity of the n-paraffin 
feedstock. In Western Europe, chlorinated paraffins are made from purified n-paraffin 
feedstocks containing no more than 1-2% isoparaffins and <100 mg aromatics/kg (the 
aromatics are removed by treatment of the n-paraffin with sulphuric acid). For some 
high-stability applications, n-paraffin fractions with <1% isoparaffins and 
<10-100 mg aromatics/kg are used (BUA, 1992).
Table 1:1  Theoretical chlorine content of some MCCPs
Formula Molecular 
weight
% Cl by 
weight
Formula Molecular 
weight
% Cl by 
weight
Formula Molecular 
weight
% Cl by 
weight
Formula 232.5 15.3 C15H24Cl8 488.0 58.2 C16H18Cl16 778.0 73.0
C14H27Cl3 301.5 35.3 C15H20Cl12 626.0 68.1
C14H24Cl6 405.0 52.6 C15H17Cl15 729.5 73.0 C17H35Cl 274.5 12.9
C14H21Cl9 508.5 62.8 C17H32Cl4 378.0 37.6
C14H18Cl12 612.0 69.6 C16H33Cl 260.5 13.6 C17H29Cl7 481.5 51.6
C14H16Cl14 681.0 73.0 C16H30Cl4 364.0 39.0 C17H26Cl10 585.0 60.7
C16H27Cl7 467.5 53.2 C17H23Cl13 688.5 67.0
C15H31Cl 246.5 14.4 C16H24Cl10 571.0 62.2 C17H21Cl15 757.5 70.3
C15H28Cl4 350.0 40.6 C16H21Cl13 674.5 68.4 C17H19Cl17 826.5 73.0
Commercial products are complex mixtures of isomers and standard analytical methods do 
not permit separation and identification of these. Work by Könnecke and Hahn (1962) 
provides a basis for estimating the distribution of the chlorine contents present in a given 
product (although this work was actually carried out with C26 chlorinates, it is thought that 
similar distributions will apply to all chlorinated paraffins). This work gives a prediction of 
approximately 80% of the isomers present lying within ±10% of the stated average chlorine 
content and 90% within ±15%. Thus in a medium-chain 50% wt. Cl product, there is likely to 
be only around 5% of mono- and dichloro isomers present (with a corresponding low 
percentage of highly chlorinated material) (ICI, 1995).
Any impurities present in the commercial chlorinated paraffins are likely to be related to those 
present in the n-paraffin feedstock, in which the major non-paraffinic impurity is a small 
proportion of aromatics (generally in the range 50-100 ppm). However, there is some 
evidence that the chlorination reaction does not favour chlorination of aromatics. No specific 
analytical methods are currently available for the detection of possible impurities present in 
the commercial products (ICI, 1995).
CHAPTER 1. GENERAL SUBSTANCE INFORMATION
13
The levels of chlorinated paraffins of chain lengths other than C14-17 present in the current 
commercial products are <1%.  The producers of MCCPs (represented by Euro Chlor) have, 
since 1991, used paraffin feedstocks in the production process with a C10-13 content of <1% 
(the actual levels are often much lower than this), and a >C18 content of <1% (Euro Chlor, 
1999).
1.2.2 Additives
It is known that additives/stabilisers such as long-chain epoxidised soya oil or glycidyl ether 
are added to some chlorinated paraffins to inhibit the release of HCl at elevated temperatures.  
These are used at concentrations of <1% by weight. For some high thermal stability 
formulations, other additives e.g. organophosphorus compounds, have been reported to be 
used in conjunction with these (BUA, 1992).
1.2.3 Medium-chain impurities present in other chlorinated paraffin 
products
It has recently been reported that some long-chain chlorinated paraffins based on a C18-20
carbon chain length may contain a substantial proportion of C17 chlorinated paraffins, with 
only very small amounts of chlorinated paraffins of shorter chain lengths (EA, 2001). The 
typical levels reported were 17% C17 and <1% C16, although the range of the C17 impurity was 
given as 10-20%. The amounts of chlorinated paraffins with carbon chain lengths of C15 or 
lower present in the C18-20 liquid products would be negligibly small.
These impurities are considered later in the regional exposure estimates for C14-17 chlorinated 
paraffins, and the risk characterisation.
1.3 PHYSICOCHEMICAL PROPERTIES
The physicochemical properties of MCCPs are discussed below and summarised in Table 1.2.
Since the products produced contain many components, the physicochemical properties of the 
various products can vary, reflecting the different components of the products. Representative 
values have therefore been selected for the key parameters used for environmental modelling. 
The effect of the variation of these properties on the risk characterisation is analysed in 
Appendix H.
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Table 1:2  Physicochemical properties of some MCCPs
Property Chlorine content (% wt) Value Remarks
Physical state (at ntp) 40-63 Liquid
Pour point -45 °C to 25 °C commercial mixtures - no 
distinct melting point
Boiling point (at ntp) >200 °C decomposition with release of 
HCl
Density 41 1.095 g/cm3 at 20 °C
56 1.315 g/cm3 at 20 °C
40-58 1.1-1.38 g/cm3 at 25 °C
56 1.28-1.31 g/cm3 at 60 °C
Vapour pressure 45 2.27´10-3 Pa at 40 °C
0.16 Pa at 80 °C
52 1.3´10-4-2.7´10-4 Pa at 20 °C
1.07´10-3 Pa at 45 °C
6.0´10-3 Pa at 60 °C
0.051 Pa at 80 °C
Water solubility 0.005-0.027 mg/l
Log octanol-water 45 5.52-8.21 measured by a high
partition coefficient 52 5.47-8.01 performance thin layer 
chromatography method
Flash point >40 >210 °C closed cup
Autoflammability not stated
Explosivity not applicable
Oxidising properties none
Note:  ntp = normal temperature and pressure.
1.3.1 Physical state (at ntp)
MCCPs are liquids at room temperature.
1.3.2 Melting point
Commercial MCCPs do not have a distinct melting point.  Pour points in the range -40°C to -
7°C and -45°C to 0°C have been reported for these materials in IUCLID.  BUA (1992) reports 
a similar pour point range of -50°C to 0°C. It has been reported that MCCPs with a very high 
chlorine content (62-63% wt. Cl) have a pour point of around 25°C (Euro Chlor, 1999).
1.3.3 Boiling point
The exact boiling point of MCCPs is unknown as they start to decompose (with liberation of 
HCl) at temperatures of around 200°C. The boiling point can therefore be considered to be 
>200°C.
CHAPTER 1. GENERAL SUBSTANCE INFORMATION
15
1.3.4 Relative density
The density varies with chlorine content of the product. Values reported in IUCLID include 
1.095 g/cm3 for 41% wt. Cl product and 1.315 for 56% wt. Cl product at 20°C, 1.1-1.38 g/cm3
at 25°C for products with chlorine contents in the range 40-58% wt. Cl and 1.275-1.305 g/cm3
at 60°C for a 56% wt. Cl product.
Kirk-Othmer (1993) gives the following similar values for the density of C14-17 chlorinated 
paraffins at 25°C: 1.10 g/cm3 for a 40% wt. Cl product, 1.16 g/cm3 for a 45% wt. Cl product; 
1.25 g/cm3 for a 52% wt. Cl product and 1.36 g/cm3 for a 58% wt. Cl product.
1.3.5 Vapour pressure
A vapour pressure of 2.27x10-5 hPa (2.27x10-3 Pa) at 40°C has been reported in IUCLID for 
MCCPs with a chlorine content of 45% wt. Cl. A vapour pressure of 0.16 Pa has been 
reported for a similar chlorinated paraffin at 80°C (BUA, 1992). 
The vapour pressure of a C14-17, 52% wt. Cl product has been reported as 
1x10-6-2x10-6 mmHg (1.3x10-4-2.7x10-4 Pa) at 20°C by Campbell and McConnell (1980).  
Vapour pressures for a C14-17, 52% wt. Cl product at elevated temperatures have been reported 
as 1.07x10-3 Pa at 45°C, 6x10-3 Pa at 60°C and 0.051 Pa at 80°C (BUA, 1992).
It has been reported that the volatility of chlorinated paraffins in general decreases with 
increasing chlorine content (Kirk-Othmer, 1993), and this is borne out by the above figures.
Recently, Drouillard et al (1998) determined the vapour pressures of a series of short-chain 
(C10-13) chlorinated paraffins at 25°C using a vapour pressure - gas-liquid chromatography 
technique. They found that vapour pressures of the short-chain chlorinated paraffins 
decreased with both increasing carbon chain length and degree of chlorination.  They derived 
the following equation relating vapour pressure (in Pa at 25°C) to the number of carbon and 
chlorine atoms present in a molecule:
log (vapour pressure) = -(0.353 x no. of C atoms) - (0.645 x no. of Cl atoms) + 4.462
Using this equation, vapour pressures for all possible medium-chain chlorinated paraffin 
congeners can be estimated. This is shown in Appendix B for all possible combinations of 
carbon and chlorine numbers. It should be noted that the reliability of this equation for the 
medium-chain chlorinated paraffins is unknown, however the values estimated for C14-17, ~51-
53% Cl chlorinated paraffins are in the region 5x10-5 Pa for C14, 2x10-5 Pa for C15, 2x10-6 Pa 
for C16 and 9x10-7 Pa for C17, which agrees reasonably well with the measured data above, 
particularly as the measurements on the commercial mixture will be dominated by the more 
volatile components (shorter chain length, lower chlorinated components).
For the environmental assessment, the vapour pressure of 2.7x10-4 Pa at 20°C measured by 
Campbell and McConnell (1980) will be used as a representative value for a commercial 
product. The vapour pressures of individual isomers are likely to cover a large range of 
values, being dependent on the carbon chain length and number of chlorine atoms present.
1.3.6 Water solubility
The water solubility of a 14C-labelled chlorinated n-pentadecane (51% wt. Cl) has been 
determined to be 0.005 mg/l by parent compound measurement and 0.027 mg/l by 14C 
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analysis after 6 months at 20°C. The test substance was prepared by mixing 
n-pentadecane-8-14C with unlabelled C14-17 paraffin prior to chlorination to 51% wt. Cl.  
Approximately 50 mg of the test substance was weighed out onto a glass microscope slide 
and this was then placed in 5 litres of water. The test was carried out by stirring the 
chlorinated paraffin in water for 91 days and then allowing the solution to settle (no stirring) 
for a further 87 days to ensure that equilibrium was reached. Light was excluded from the test 
solution. The authors suggested that the discrepancy between the water solubility obtained by 
the two methods may indicate that some degradation had occurred during the test (Madeley et 
al, 1983a). However, this discrepancy could also, in part, be due to the different analytical 
methods used. Given that the substance tested is a complex mixture, the solubility values 
obtained by the different methods are in reasonable agreement.
Campbell and McConnell (1980) reported the solubility at 16-20oC of a C16, 52% wt. Cl
chlorinated paraffin to be 10 µg/l in freshwater and 4 µg/l in seawater, based on radioactivity 
measurements. Few other details are available about the method used, but the results obtained 
are comparable with those reported by (Madeley et al, 1983a) above.
A water solubility value of 0.027 mg/l will be used in the assessment. It is likely that the 
water solubility will vary with both carbon chain length and degree of chlorination.
1.3.7 Partition coefficient
Calculated values for log Kow between 5.5 and >6 are reported in IUCLID for medium-chain 
chlorinated paraffins.
Log Kow values of 6.95 for C14H26Cl4 (42.2% wt. Cl), 6.37 for C14H23Cl7 (56.5% wt. Cl), 
8.54 for C17H32Cl4 (37.5% wt. Cl) and 7.94 for C17H27Cl9 (58.0% wt. Cl) have been calculated 
using the CLOGP 3.4 computer program (BUA, 1992).
Renberg et al (1980) determined the octanol-water partition coefficients for medium-chain 
chlorinated paraffins using a high performance thin layer chromatography (HPTLC) method.  
The partition coefficients determined (log values) were 5.52-8.21 for a C14-17, 45% wt. Cl 
product and 5.47-8.01 for a C14-17, 52% wt. Cl product.  The range quoted reflects the 
different HPTLC retention times, and hence octanol-water partition coefficients, of the 
various components of the commercial products. These measured values are in good 
agreement with the values estimated above.
Fisk et al (1998b) determined the octanol-water partition coefficients of two 14C-labelled 
medium-chain chlorinated paraffins of single carbon chain length (C16). The two compounds 
used were C16H21.7Cl3.3, 35% wt. Cl and C16H20.6Cl13.4, 69% wt. Cl. The mean log Kow values 
determined by a HPLC method were reported to be 7.2 for the 35% wt. Cl substance (range of 
log Kow was 4.7-6.6, 6.6-7.8, 7.8-8.0 and 8.0-8.3 for the four main components of this 
substance) and 7.4 for the 69% wt. Cl substance (range of log Kow was 6.9-7.8). These are 
consistent with the other values determined above.
For the environmental assessment, a log Kow value of 7 (approximately the middle of the 
range of measured values) will be used as a representative value.
1.3.8 Flash point
A flash point of >210°C (closed cup) is reported in IUCLID for a C14-17, >40% wt. Cl product.
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1.3.9 Autoflammability
Decomposition starts to occur above 200°C with liberation of hydrogen chloride.
1.3.10 Explosivity
Not explosive.
1.3.11 Oxidising properties
No oxidising properties.
1.4 CLASSIFICATION
Classification (according to the 30th ATP of Directive 67/548/EEC)
N;R50/53 
R64
R66
Environment
This classification is based on the toxicity seen with Daphnia magna (48-hour EC50 = 0.0059 
mg/l), a high fish bioconcentration factor of 1,087 and the lack of biodegradability in standard 
biodegradation test systems, N Dangerous for the environment
R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects 
in the aquatic environment.
Human health
R64 May cause harm to breast-fed babies
R66 Repeated exposure may cause skin dryness or cracking
S-phrases
(S1/2 Keep locked up and out of reach of children). For use only if sold to the public.
S36 Wear suitable protective clothing
S37 Wear suitable gloves
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2 GENERAL INFORMATION ON EXPOSURE
2.1 PRODUCTION
Medium-chain chlorinated paraffins are currently manufactured at five sites in the EU. The 
current total production capacity as reported in IUCLID is in the range 
45,000-160,000 tonnes/year.
Chlorinated paraffins are manufactured by adding chlorine gas into the starting paraffin in a 
stirred reactor. Depending on the chain length of the paraffin feedstock, the temperature of the 
reaction is maintained between 80 and 100 °C, with cooling if necessary. Catalysts are not 
usually needed for the reaction to proceed, but ultraviolet light may be used to aid the 
reaction. Once the desired degree of chlorination has been reached (as determined by density, 
viscosity or refractive index measurements), the flow of chlorine gas into the reaction is 
stopped. Air or nitrogen is then used to purge the reactor of excess chlorine and hydrochloric 
acid gas and small quantities of a stabiliser (e.g. epoxidised vegetable oil) may be added to the 
product. The product is then typically filtered and piped to batch storage tanks for filling 
drums, tankers or bulk storage tanks. The main by-product from the process is hydrogen 
chloride gas. This is collected by absorption in water and re-used as hydrochloric acid (BUA, 
1992).
2.2 USES
The main uses of medium-chain chlorinated paraffins are as secondary plasticisers in 
polyvinyl chloride (PVC), as extreme pressure additives in metal working fluids, as 
plasticisers in paints, as additives to adhesive and sealants, in fat liquors used in leather 
processing and as flame retardants in rubbers and other polymeric materials.
Estimates for the amounts of medium-chain chlorinated paraffins used in the various 
applications within the EU are given in Table 2.1 (Euro Chlor, 1998).
Figures have been provided for the use of medium-chain chlorinated paraffins in the EU in 
1998 (Euro Chlor, 1999).  These were provided in a slightly different form to those in Table 
2.1 but indicate that the overall use of medium-chain chlorinated paraffins during 1998 had 
fallen from the 1997 level to a similar level as in 1994.  The reduction in use of medium-chain 
chlorinated paraffins compared with 1997 was generally spread over all the uses, with the 
exception of metal cutting working/cutting fluids, which showed a small increase in use, and 
paints, sealants and adhesives, which remained approximately at the 1997 level.  The 1997 
consumption figures are used in the environmental assessment to represent a realistic worst 
case for the amounts used in the various applications. 
In a previous assessment of the short-chain (C10-13) chlorinated paraffins, risk reduction 
measures were identified for use in metal cutting/working fluids and leather fat liquors. The 
medium-chain chlorinated paraffins have similar uses, and can be considered as replacements 
for the short-chain chlorinated paraffins in some of these applications.  Any reductions in use 
of the short-chain chlorinated paraffins in these areas could lead to an increased use of 
medium-chain chlorinated paraffins as replacement.  The effect of such substitutions on the 
amounts of medium-chain chlorinated paraffins likely to be used in the future as a result of 
risk reduction measures applied to the short-chain chlorinated paraffins is currently unknown, 
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although an increasing trend in use in metal working/cutting fluids is evident from Table 2.1. 
Appendix E considers this issue further.
Table 2:1  Use of medium-chain chlorinated paraffins in the EU
Application Industry category Use category Quantity used (tonnes/year)         (Percentage of 
total use given in brackets)
1994 1995 1996 1997
PVC 11 (polymers industry) 47 (softeners) or 22 
(flame retardant and 
fire preventing 
agents)
45,476
(80.2%)
48,640
(82.9%)
49,240 
(83.0%)
51,827
(79.4%)
Metal 
working/
cutting
8 (metal extraction, refining 
and processing industry
35 (lubricants and 
additives)
2,611
(4.6%)
2,765
(4.7%)
3,302
(5.6%)
5,953
(9.1%)
Paints, 
adhesives 
and 
sealants*
14 (paints, lacquers and 
varnishes industry) and 15 
(others)
47 (softeners) or 22 
(flame retardant and 
fire preventing 
agents)
3,079
(5.4%)
2,392
(4.1%)
2,638
(4.4%)
3,541
(5.4%)
Rubber/poly
mers (other 
than PVC)
11 (polymers industry) 47 (softener) or 22 
(flame retardant and 
fire preventing 
agents)
2,497
(4.4%)
2,767
(4.7%)
2,324
(3.9%)
2,146
(3.3%)
Leather fat 
liquors
7 (leather processing industry) 47 (softeners) 1,614
(2.8%)
1,270
(2.2%)
1,172
(2.0%)
1,048
(1.6%)
Carbonless 
copy paper
12 (pulp, paper and board 
industry)
48 (solvent) 1,296
(2.3%)
837
(1.4%)
630
(1.1%)
741
(1.1%)
Total 56,673 58,671 59,306 65,256
Note:  *approximate split is 2/3 used in sealants and 1/3 used in paints (CEFIC, 1999).
It is thought that around 50% of the leather fat liquor formulations produced in the EU are 
exported for use outside the EU.
For use in PVC and other polymers, it is possible that pellets (masterbatch) containing 
medium-chain chlorinated paraffins could be manufactured outside the EU and then imported 
into the EU for further processing to give the final product. Similarly, such pellets could be 
manufactured within the EU and exported for subsequent processing.  A similar situation may 
also exist with finished products containing medium-chain chlorinated paraffins. The actual 
amounts of medium-chain chlorinated paraffins imported into and exported out of the EU in 
this way are very difficult to estimate. For the purpose of this assessment it will be assumed 
that net import into the EU of these products will be small compared with the amount 
presented in Table 2.1.
Some information is available on the amounts of total PVC (flexible and rigid) manufactured 
and imported into the EU (ECVM, 2000) that is useful in this issue. The total Western 
European market for PVC was estimated to be 5,594,000 tonnes/year in 1997, compared to 
the total amount of PVC produced in Western Europe of 5,528,000 tonnes/year in the same 
year. This gives a net import of PVC into the EU of around 66,000 tonnes/year, or 1.2% of the
total produced. This indicates that the net import of medium-chain chlorinated paraffins into 
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the EU in PVC or masterbatch is likely to be small compared to the amounts produced in the 
EU presented in Table 2.1.
In Sweden, the use of all chlorinated paraffins in metal working fluid has been reduced by 
80% overall (a 95% reduction in water-oil emulsions (i.e. 160 tonnes in 1986 and 8.5 tonnes 
in 1993) and a 75% reduction in straight oil based cutting fluids (i.e. 520 tonnes in 1986 and 
130 tonnes in 1993)) between 1986 and 1993, and is expected to reduce further (Stenhammar 
and Björndal, 1994). More than 80% of the chlorinated paraffins used in emulsion cutting 
fluids and at least 20% of the chlorinated paraffins used in straight oil applications were 
reported to be C10-13 chlorinated paraffins (the remainder would include the C14-17 chlorinated 
paraffins).
Further information on the use of medium-chain chlorinated paraffins has been obtained from 
the Danish product register. In the register, 28 tonnes/year of medium-chain chlorinated 
paraffins were reported in a total of 42 products. The product types identified included 
fillers/sealants (typically 10-20% chlorinated paraffin content), cutting fluids, process 
regulators (e.g. hardeners) and paints, lacquers and varnishes (typically 1-5% chlorinated 
paraffin content). Most products contained medium-chain chlorinated paraffin in the range 
10-20% by weight of the formulation.
Information has been provided on the breakdown of use of medium-chain chlorinated 
paraffins by country (Euro Chlor, 1999). This information is considered confidential but did 
indicate that the main user countries are Italy and the United Kingdom, with use in the United 
Kingdom accounting for just over 25% of the total EU use. The use pattern in the main user 
countries was broadly in line with that outlined in Table 2.1.
2.2.1 Use as a plasticiser
2.2.1.1 PVC 
Medium-chain chlorinated paraffins are used as secondary plasticisers mainly in PVC.  The 
primary plasticisers used are generally phthalates or phosphate esters (Kirk-Othmer, 1993).  
The phosphate esters are normally used only when flame retardant benefits are needed (Euro 
Chlor, 1999). The medium-chain chlorinated paraffins may also be used in some other 
plastics, but here the major function is likely to be as a flame retardant rather than as a 
plasticiser (see Section 2.2.2.2).
Primary plasticisers in PVC are used to increase the elongation properties and softness of the 
polymer. Secondary plasticisers, when used in combination with primary plasticisers, cause 
an enhancement of the plasticising effects and so are also known as extenders. The majority 
of secondary plasticisers used in PVC applications are medium-chain chlorinated paraffins 
with chlorine contents around 45% wt. Cl or 50-52% wt. Cl, with only very small amounts 
(<1% of total sales) of medium-chain chlorinated paraffins with higher (e.g. 56-58% wt. Cl) 
or lower (e.g. ~40% wt. Cl) chlorine contents being used in PVC (Euro Chlor, 1999).  
There are two main types of PVC produced e.g. suspension and paste-forming (emulsion) 
PVC, and the methods for incorporation of plasticisers in the two types are different. 
Worldwide, approximately 70% of PVC resin is suspension, with 20% emulsion and small 
amounts of bulk (9% of total resin production; produces irregular particles with little or no 
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impurities) and solution (1% of total resin production; used to make specialised resins for 
metal coatings, record manufacture, powder coatings and surface coatings) (Rubin, 1990).
Polymers of suspension PVC (also known as pearl, bead or granular) are produced by 
suspending vinylchloride monomer in water and carrying out the polymerisation using a 
monomer-soluble initiator.  This results in the PVC particles formed having a relatively large 
particle size (e.g. 100-150 µm).  These particles are highly porous and so can absorb large 
amounts of plasticiser.  The PVC particles are typically processed using a dry-blend cycle.  In 
this cycle, all the polymer formulation ingredients, including plasticisers, are heated to around 
70-110°C and mixed to form a dry powder product. This can be either stored or further 
processed immediately. Processing of the dry powder can take the form of extrusion, injection 
moulding or calendering. The powder can also be extruded and chipped to form pellets of 
PVC compound which can subsequently be further processed to give the final product. Many 
producers of PVC products purchase PVC compound as it is easy to store and similarly many 
companies exist that produce PVC compound (Kirk-Othmer, 1996).
Paste-forming (plastisol) PVC polymers are produced as a paste or plastisol rather than a dry 
powder (a plastisol is a suspension of a solid in a liquid in which it does not dissolve, but does 
form an homogenous mixture at elevated temperatures; the term organosol is used for a 
plastiol that contains more than 10 parts of a solvent per 100 parts of resin (Rubin, 1990)).  
Microsuspension polymerisation or emulsion polymerisation is usually used to form the PVC 
for these applications.  Both these processes result in the formation of PVC particles with a 
much smaller particle size than produced by suspension polymerisation processes. The small 
particle size means that the initial product has low porosity and so formulation with additives 
(e.g. plasticisers) is not possible using a dry-blending cycle, and instead a paste is formed.  
This paste or plastisol can then be spread, coated, rotationally cast or sprayed onto the desired 
item, or may be semi-gelled for storage (i.e. heat is applied to convert it into a semi-solid 
form).  A wide range of plasticisers are used in these applications as the choice affects the 
viscosity of the plastisol, which is important in the further processing steps, and it is common 
for 2 or 3 different plasticisers to be used in a single formulation to achieve the desired final 
properties (Kirk-Othmer, 1996).
During the formation of finished products, the PVC formulation may be exposed to 
temperatures of 180 °C for up to several minutes.  In some processes, for example sheet and 
film production by calendering or spread coating there is the potential for volatilisation of the 
plasticiser as the hot plastic is exposed to the surrounding air.  Processes involving injection 
moulding and extrusion are carried out in closed equipment and so little exposure of the hot 
product to air occurs and so the potential for volatilisation of the plasticiser is reduced.  In 
some facilities filtering or incineration of the exhaust gas is used to reduce the air emissions 
from the process.  It has been reported that concentrations of primary plasticiser (e.g. 
di-(2-ethylhexyl) phthalate (DEHP)) are typically 500 mg/m3 in air extracted from spread 
coating ovens, which can be reduced to <20 mg/m3 by the use of filtration equipment, with 
exhaust air incineration reducing the emission to practically zero (Kirk-Othmer, 1996).  It has 
been reported (Kirk-Othmer, 1996) that the use of filters and/or incinerators in calendering 
and spread coating plants has been steadily increasing in recent years.  Figures for 1990 are 
shown in Table 2.2. The figures refer to the percentage of the total phthalate plasticiser 
processed in each application. Of the processes listed in Table 2.2, medium-chain chlorinated 
paraffins are used mainly in spread coating (e.g. for wall coverings and PVC “leather cloth”) 
and calendered flooring.
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Table 2:2  Exhaust air treatment in Western Europe by process in 1990 (Kirk-Othmer, 1996)
Process Amount of phthalate plasticiser used 
in process
Percentage of phthalate use 
undergoing exhaust air treatment
(tonnes/year) Filter treatment Incineration
Spread coating 192,000 53% 22%
Slush, dip and rotational moulding 17,000 26% 6%
Automotive underseal 67,000 100%
Calendered sheet and film 138,000 23% 25%
Calendered flooring 31,000 15% 56%
The majority of flexible PVC is thought to be used in applications such as flooring, wall 
covering, upholstery, and sheaths for wire and cable.
The properties and compatibility of the chlorinated paraffin with both PVC and the primary 
plasticiser vary with both the carbon chain length and the degree of chlorination. Generally, as 
the chain length of the chlorinated paraffin is increased, its volatility decreases and so the 
potential for migration from the finished PVC is reduced.  At the same time, however, the 
compatibility with PVC and the primary plasticiser is reduced.  On the other hand, the 
compatibility of chlorinated paraffins with PVC and the primary plasticiser increases with 
increasing chlorination, and so the potential for migration is reduced, but the flexibility of the 
final product is also reduced. As a result of these properties, medium-chain chlorinated 
paraffins with varying degrees of chlorination are used in most applications (BUA, 1992).
For soft PVC products that require a high flexibility at normal and low temperatures, 
medium-chain chlorinated paraffins with chlorine contents around 40-45% wt. Cl are used as 
secondary plasticiser.  Examples of applications for this type of PVC include coatings, some
types of flooring, garden hose and shoe compounds.  The secondary plasticiser is added at 
10-15% by weight of the total plastic (BUA, 1992; Euro Chlor, 1999).
Medium-chain chlorinated paraffins with higher degrees of chlorination (typically around 
50-52% wt. Cl) are more compatible with PVC and have a lower volatility than lower 
chlorinated analogues.  They are used as secondary plasticisers in calendered flooring, cable 
sheathing and insulation and in general purpose PVC compounds.  In heavily filled products, 
such as some types of calendered flooring, they can be used as the sole plasticiser at levels of 
around 10% in the finished product (Euro Chlor, 1999). 
The more highly chlorinated medium-chain paraffins (e.g. 56-58% wt. Cl) are less volatile 
still and are used for softening plastics that are subject to higher temperatures during 
processing (BUA, 1992).
2.2.1.2 Paints and varnishes
Medium-chain chlorinated paraffins, with chlorine contents around 50-60% wt. Cl are used as 
plasticisers in some paints, varnishes and other coatings. The main areas of application appear 
to be in corrosion or weather resistant coatings/paints for steel constructions, ships, industrial 
flooring, containers, swimming pools, facades and road markings (BUA, 1992).
The medium-chain chlorinated paraffins can be used as plasticisers in paints based on many 
resins, but are most commonly used in chlorinated rubber or vinyl copolymer-based paints.  
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The chlorinated rubber-based paints are used in aggressive marine and industrial 
environments whereas the vinyl copolymer-based paints are used principally for the 
protection of exterior masonry. 
A survey of the use of chlorinated paraffins in paints and coatings in the United Kingdom has 
been carried out (BCF, 1999).  A total of 141 companies were contacted and initial responses 
were obtained from 106 of these.  Of the companies responding, 22 (~21%) indicated that 
they used medium-chain chlorinated paraffins or other chlorinated paraffins.  More detailed 
information on the use of chlorinated paraffins was obtained from 12 (~55%) of the 
22 companies.  The chlorine content of the chlorinated paraffins used range from around 40% 
wt. Cl to 70% wt. Cl (with the 70% wt. Cl substances being long-chain length (<C18
products).   The types of paint/coating and the typical chlorinated paraffin contents are shown 
in Table 2.3.
Table 2:3  Chlorinated paraffin content of paints (BCF, 1999)
Coating type Chlorinated paraffin content
(% by weight)
Organic solvent borne chlorinated rubber primers and topcoats 1-5
Organic solvent borne chlorinated rubber systems for swimming 
pools/fishponds
5-20
Organic solvent borne zinc rich (epoxy) primers 2-5
Organic solvent borne acrylic container coatings 2-10
Organic solvent borne chemical and water resistant coatings 5-20
Organic solvent borne vacuum metallising lacquers 1-5
Organic solvent borne flame retardant coating for wood 1-5
Organic solvent borne intumescent coating for structural steel 20-30
Organic solvent borne floor paints 5-10
Organic solvent borne water-proofing coatings for walls 5
Euro Chlor (1999) reported that the typical level of a medium-chain chlorinated paraffin in 
the formulated paint would be 4-15% by weight. After drying (evaporation of solvent) the 
medium-chain chlorinated paraffin content of the coating would be around 5-20% by weight.
In tonnage terms, the amount of chlorinated paraffins used in the United Kingdom in 
paints/coatings appears to be small, with a total of up to around 34 tonnes/year being 
identified in the BCF survey (it is not possible to extrapolate this figure to give the total 
United Kingdom or EU usage).  Further, it was found that paints containing chlorinated 
paraffins make up only a very small proportion of the total paint manufactured at a site 
(typically <1-2% of the total, up to 5% in some cases). The total number of sites in the United 
Kingdom manufacturing paints and coatings containing medium-chain chlorinated paraffins is 
estimated at around 30 (BCF, 1999). 
The BCF (1999) survey also tried to identify the number of sites where coatings containing 
medium-chain chlorinated paraffins might be used in the United Kingdom, but this did not 
prove to be possible.  The major users of the paints are professional painters and specialist 
applicators, but some DIY paints containing medium-chain chlorinated paraffins may be used 
by the general public. In the United Kingdom, it was estimated that there would be around 
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40,000 users of coatings containing medium-chain chlorinated paraffins for water proofing of 
walls, with around 1,000-1,500 users of paints and coatings for other uses. 
2.2.1.3 Adhesives/sealants
Chlorinated paraffins, including medium-chain ones, are used as plasticisers/flame retardants 
in adhesives and sealants.  Examples include polysulphide, polyurethane, acrylic and butyl 
sealants used in building and construction and in sealants for double and triple glazed 
windows.  The chlorinated paraffins are typically added at amounts of 10-14% wt. of the final 
sealant but could be added at amounts up to 20% wt. of the final sealant in exceptional cases.  
The medium-chain chlorinated paraffins used in these applications generally have a chlorine 
content of 50-58% wt. Cl (BUA, 1992; Euro Chlor, 1999).
The difference between an adhesive and sealant can be fairly blurred in that some sealants are 
used as adhesives and vice versa.  Generally, sealants are considered to be materials that are 
installed into a gap or joint to prevent water, wind, dirt or other contaminants from passing 
through the joint or crack.  Adhesives, on the other hand, are used to transfer loads and are 
typically designed with much higher tensile and shear strength than sealants (Palmer and 
Klosowski, 1997). The main use of medium-chain chlorinated paraffins in this area is in 
sealants.
2.2.2 Use as a flame retardant plasticiser
Chlorinated paraffins are used as flame retardant additives in some applications.  However, 
when used primarily as a flame retardant, chlorinated paraffins with a high chlorine content 
(e.g. 70% wt. Cl) are used.  As medium-chain chlorinated paraffins are not produced with 
these high chlorine contents, then they are not considered primarily as flame retardants.  
However, some applications make use of both their plasticising and flame retardant 
properties.
2.2.2.1 Rubber
Medium-chain chlorinated paraffins are used as softener (or process oil) additives with flame 
retardant properties for rubber.  The chlorinated paraffins used generally have a high chlorine 
content and are present at up to 15% wt. of the total rubber.  The rubber is used in conveyor 
belts and also in building and automotive applications (BUA, 1992).
2.2.2.2 Plastics
As well as acting as (secondary) plasticisers in PVC and plastics, chlorinated paraffins also 
act as flame retardants in these materials.  When used as a plasticiser, the chlorinated paraffin 
with moderate chlorine contents (e.g. >50% wt. Cl) will reduce to some extent the 
flammability of the final product, but when used specifically as a flame retardant, chlorinated 
paraffins with a high degree of chlorination (e.g. >C20 70-72% wt. Cl) are used, along with a 
synergist e.g. antimony trioxide.  When used as a flame retardant additive, up to around 5% 
wt. for PVC and up to 15% wt. for polystyrene and unsaturated polyester resins of the 
chlorinated paraffin may be added (BUA, 1992; Euro Chlor, 1999).
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There are no medium-chain chlorinated paraffins available with a 70-72% wt Cl contents and 
so they are not considered as specific flame retardant additives in plastics.  The medium-chain 
chlorinated paraffins are generally used as flame retardant plasticisers (Euro Chlor, 1999).
2.2.2.3 Adhesives/sealants
Medium-chain chlorinated paraffins are used as flame retardant additives in some sealants.  
They also act as plasticisers and so have a dual function and no distinction is made between 
the two functions in this report as the amount (and types) of chlorinated paraffin used in a 
given sealant is similar regardless of whether the primary function is as a plasticiser or as a 
flame retardant (chlorinated paraffins with higher chlorine contents may be more effective as 
flame retardants).
2.2.3 Extreme pressure additive (metal cutting/working fluids)
Medium-chain chlorinated paraffins are used in a wide variety of cooling and lubricating 
fluids used during metal cutting, grinding and forming operations.  The two main types of 
lubricants used are water-based emulsions, whose function is mainly cooling, and oil-based 
lubricants.  The medium-chain chlorinated paraffins used generally have a chlorine content of 
between 40 and 55% wt. Cl. The amount of chlorinated paraffin present in a given fluid 
depends on the final application (BUA, 1992).  
For oil-based fluids the chlorinated paraffin content of the fluid ranges from about 5% wt. for 
light machining to up to 70% wt. for heavy drawing processes (metal forming fluids) (BUA, 
1992).
The market for metal forming fluids in the United Kingdom is around 500 tonnes/year.  These 
contain up to 70% by weight of chlorinated paraffin, but the average content is around 50% 
by weight. (Euro Chlor, 1998).  The chlorinated paraffin used in these applications is likely to 
be short-chain (C10-13), for which no suitable alternative appears to be currently available.
The amount of medium-chain chlorinated paraffin present in the water-based cooling 
lubricant concentrate is up to 4% as chlorine (i.e. around 8% as chlorinated paraffin).  This is 
diluted with water to give a 3-5% aqueous emulsion that is used in grinding, rough machining 
and sawing applications (BUA, 1992). Thus the concentration of medium-chain chlorinated 
paraffin in the final water-based fluid is around 0.4% wt.
2.2.4 Fat liquors (for leather)
Medium-chain chlorinated paraffins are used in fat liquors for leather. They are used in 
conjunction with sulphated or sulphonated oils (Kirk-Othmer, 1993), chlorosulphonated 
paraffins, natural fats and oils (Euro Chlor, 1998). Typically, medium-chain chlorinated 
paraffins with a relatively low chlorine content (e.g. 40% wt. Cl) are used in these 
applications.
In general the chlorinated paraffins are used in leathers for the top end of the quality range 
and give the following advantages (Euro Chlor, 1998):
· High light-fastness
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· Strong binding to the leather compared to other additives (low migration)
· Dry feel surface finish with excellent suppleness.
The formulation of leather fat liquors is by a simple mixing process using an enclosed system 
at ambient temperature. The main components of the fat liquor are water, natural fats (e.g. fish 
oils), surfactants and the chlorinated paraffin. The chlorinated paraffin accounts for about 
10% (range 5-15%) by weight of the formulated fat liquor.
The fat liquor is applied to the leather as a diluted solution. The fat liquoring step is the last 
stage of leather preparation. The amount of fat liquor used in this step is around 7-12%, based 
on the shaved weight of the leather to be treated (i.e. around 70-120 g of fat liquor/kg of 
leather). Since the fat liquor typically contains around 10% (range 5-15%) chlorinated 
paraffin, the amount of chlorinated paraffin used in this step is around 7-12 g chlorinated 
paraffin/kg leather (range 3.5-18 g chlorinated paraffin/kg leather). The process itself takes 
place in enclosed rotating drums at temperatures in the region of 40-60oC, with each batch 
taking around 1-4 hours depending on the end product being produced. The pH of the reaction 
is carefully controlled throughout the process by the addition of formic acid to the emulsion 
(pH is changed from around 5.5 at the start to 3.6 at the end of the process). The pH is used to 
affect the nature of the leather surface, the rate of absorption of the fat liquor and the stability 
of the emulsion. The high binding efficiency of the leather for the chlorinated paraffin means 
that the relative composition of the additives in the fat liquor solution change with time during 
the process. It is believed that not more than 2% of the original amount of chlorinated paraffin 
is present in the spent fat liquor solution at the end of the process. (Industry estimate based on 
experience of the process (Euro Chlor, 1998)).
2.2.5 Carbonless copy paper
Another use that has been reported for chlorinated paraffins in general is as a solvent used in 
carbonless copy paper (BUA, 1992). The European consumption of carbonless copy paper 
was around 710,000 tonnes/year in 1996, but was predicted to fall to around 
660,000 tonnes/year by 1998. Only a small proportion of this paper will contain 
medium-chain chlorinated paraffins. The most common applications for carbonless copy 
paper include delivery dockets, credit card slips and business forms.
Carbonless copy paper consists of at least 2 sheets of paper.  It is produced by coating the 
back side of the top piece of paper with gelatine (or synthetic polymer) capsules containing a 
colour former in a solvent.  Medium-chain chlorinated paraffins can be used as the solvent in 
some applications. Binders, such as modified starch, polyvinylalcohols, acrylates or 
carboxylated styrene-butadiene rubber latices, are used to attach the gelatine capsules to the 
paper. The upper surface of the bottom sheet is coated with reactive montmorillonite clay.  
For copy paper with three or more sheets, the middle sheets would be coated with the reactive 
clay on the upper surface and the gelatine capsules on the lower surface. Writing pressure 
results in breakage of the gelatine capsule which releases the colour former. This then reacts 
with the clay to form the colour on the surface of the lower sheet.
The majority of European manufacturers of carbonless copy paper are members of the 
Association of European Manufacturers of Carbonless Paper (AEMCP). About 6 years ago, 
all members of the AEMCP agreed to stop using chlorinated paraffins in the production of 
carbonless copy paper, and this agreement still remains in force today. Members of the 
AEMCP account for around 95% of the carbonless copy paper that is used in Europe.  
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Based on the figures reported, the amount of carbonless copy paper containing medium-chain 
chlorinated paraffins in the EU is at most 5% of the 660,000 tonnes/year i.e. 
33,000 tonnes/year. This assumes that the 5% of companies not covered by the AEMCP 
agreement use medium-chain chlorinated paraffins in all the carbonless copy paper that they 
produce, which would appear to be unlikely.
2.3 EXISTING CONTROL MEASURES
In Germany, chlorinated paraffin-containing wastes e.g. metal working fluids with 
>2 g halogen/kg and halogen-containing plasticisers, are classified as potentially hazardous 
waste and are incinerated (BUA, 1992).
28
3 ENVIRONMENT
An environmental risk assessment of alkanes, C14-17, chloro (medium-chain chlorinated 
paraffins or MCCPs) produced in accordance with Council Regulation (EEC) 793/931 was 
published in December 2005 and subsequently updated in August 2007. 
  
1 O.J. No. L 084, 05/04/1993 p. 0001-0075.
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4 HUMAN HEALTH
4.1 HUMAN HEALTH (TOXICITY)
4.1.1 Exposure assessment
4.1.1.1 Occupational Exposure
4.1.1.1.1 General Introduction
Definitions and limitations
The general discussion sections summarise the important issues arising from the exposure 
assessments and brings together measured exposure data and predictions from the EASE 
(Estimation and Assessment of Substance Exposure) model. EASE is a general purpose 
predictive model for workplace exposure assessments. It is an electronic, knowledge based, 
expert system which is used where measured exposure data are limited or not available. The 
model is in widespread use across the European Union for the occupational exposure 
assessment of new and existing substances.
All models are based upon assumptions; their outputs are at best approximate. EASE is only 
intended to give generalised exposure data and works best in an exposure assessment when 
the relevance of the modelled data can be compared with and evaluated against measured 
data.
EASE is essentially a series of decision trees. For any substance, the system asks a number of 
questions about the physical properties of the substance and the circumstances of its use. For 
most questions, the EASE user is given a multiple-choice list from which to select the most 
appropriate response. Once all the questions have been answered, the exposure prediction is 
determined absolutely by the choices made. EASE can be used to estimate inhalation and 
dermal exposure - dermal exposure is assessed as the potential exposure rate to the hands and 
forearms (a total skin area of approximately 2,000 cm2). The dermal model is less developed 
than the inhalation model, and its outputs should be regarded as no more than first 
approximation estimates.
The output ranges generated by EASE relate to steady-state conditions, and estimate the 
average concentration of the substance in the atmosphere over the period of exposure which 
in this review is taken to be the working shift.
Where real exposure data is not available, EASE has been used to predict exposures. Details 
of the reasoning behind any assumptions made during the course of EASE predictions are 
made clear in the relevant sections.
In this document, unless otherwise stated, the term exposure is used to denote personal 
exposure as measured or otherwise assessed without taking into account the effect of any 
personal protective equipment (PPE) which might be in use. This definition permits the 
effects of controls other than PPE to be assessed and avoids the problem of trying to quantify 
the actual protection provided by PPE in use. 
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In addition, with the exception of the use of MWFs, the predicted exposures by both the 
inhalation and dermal routes do not take account of the fact that the MCCPs will only 
constitute a proportion of the volatile components in the various formulations containing 
them. Although the percentage of MCCPs in the formulations are known, we do not know the 
actual concentration available for both the inhalation and dermal exposure. Where MCCPs are 
contained in formulations it was not possible to establish the extent to which they would be 
trapped in the polymer, and thus the extent to which dermal or inhalation exposure may occur. 
Also there may be preferential volatilisation of MCCPs due to its higher volatility, thus this 
would increase its percentage in the vapour for inhalation exposure and would decrease the 
percentage in any surface contamination for dermal exposure. The predicted exposures to 
MCCPs are therefore expected to be overestimated. The extent of the overestimate is not 
known but will depend upon the proportion of the MCCP in the formulation and the extent of 
the above factors.
Following discussion at the TM, industry have collected some exposure data at PVC 
compounding, plastisol manufacture and use, calendering, extrusion and at rubber 
manufacturing. This data is presented in Section 4.1.1.3.
Overview of exposure
Occupational exposure to MCCPs occurs during the:
· manufacture of MCCPs;
· manufacture of PVC formulations containing MCCPs and their use;
· manufacture and use of paints containing MCCPs;
· manufacture and use of sealants and adhesives containing MCCPs;
· manufacture of rubber containing MCCPs;
· manufacture and use of MWFs containing MCCPs;
· manufacture and use of fat liquors for leather treatment; and
· manufacture of carbonless copy paper containing MCCPs.
HSE’s National Exposure Database does not have any measurements of exposure to airborne 
C14 to C17 chlorinated paraffins (MCCPs) during their manufacture and use. Industry has 
provided exposure data for PVC compounding, plastisol manufacture and use, calendering, 
extrusion and rubber manufacture. Data have also been provided for paint spraying. Where 
MCCPs are used in metal working fluids, the exposure to MCCP has been estimated using 
data gathered on exposure to metal working fluids themselves and knowledge of the 
concentrations of MCCPs in these fluids. For all other scenarios the EASE model has been 
used to predict exposures of workers to airborne MCCP.
MCCPs are viscous liquids with very low vapour pressures. For the environmental assessment 
(see Section 1.3.5) a vapour pressure of 2.7 x 10-7 kPa at 20 °C for the 52% chlorinated 
MCCP has been used as a representative value for all MCCPs regardless of the percentage 
chlorination. This vapour pressure corresponds to a saturated vapour concentration (SVC) of 
0.0027 ppm or 0.051 mg.m-3 (assuming a molecular weight of 450) at 20 °C and has been 
used for the workplace exposure assessment. Thus personal exposures to MCCP vapour at 
ambient temperature in the workplace will be very low, the maximum theoretical vapour 
concentration being 0.0027 ppm (0.051mg.m-3). This was taken into account when 
considering values of exposures to vapour at workplace ambient temperature predicted by the 
EASE model. Although processing temperatures are often in excess of 20°C, the temperature 
of the working environment will usually be about 20°C. Therefore this prediction for 
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maximum vapour concentration based on the SVC will still hold where the process is at a 
higher temperature. At the point of release of hot vapour from the process there will be a 
mixture of vapour and mist. The mist is formed as the hot vapour cools and condenses to form 
liquid droplets, thus in the worker’s breathing zone there will be vapour, at a maximum of the 
SVC, and mist. The extent of the exposure to the mist will be dependent on the processing 
temperature and the controls. This is discussed in the following sections. 
Four personal sampling results from plastisol manufacture were provided by industry from 
two different operators: there are 0.02, 0.03, 0.03 and 0.08 mg.m-3 8hr TWA. Sampling data 
were also provided by industry from plastisol use: 12 personal samples (8hr TWA) were 
collected over two days. Values ranged from <0.1 to 0.12 mg.m-3, with a median of 0.02 
mg.m-3 and a 90th percentile of 0.12 mg.m-3. However, the results indicated that exposures 
were higher on day 1, ranging from <0.01 to 0.12 mg.m-3, than day 2 which ranged form 
<0.01 to 0.02 mg.m-3. This was attributed to a malfunctioning extraction system on one of the 
ovens on day 1 which was repaired by day 2. Most of the small number of measured data are 
below the EASE value of 0.05 mg.m-3 and range from 0.02 to 0.08 mg.m-3. The highest value 
of 0.08 mg.m-3 will be taken forward to risk characterisation as the RWC. A range of <0.003 
to 0.44 mg.m-3 MCCP exposures was found from 32 personal samples taken from 4 EU sites 
carrying out PVC compounding. The median of these exposures is 0.03 mg.m-3 and the 90th
percentile is 0.15 mg.m-3. Four samples were taken at a site carrying out the application of 
PVC insulation, by extrusion, to electrical cables. The values are <0.01, <0.01, 0.03 and 0.44 
mg.m-3. A range of 0.01 to 0.07 mg.m-3 MCCP exposures was found during rubber 
manufacture from 7 personal samples taken at one site.
A range of 9-18 mg.m-3 8hr TWA was derived from EASE data for the mist in situations 
where poor control of this mist was felt to be a possibility. These were calendering of 
plasticised PVC, compounding of plasticised PVC, extrusion and moulding of plasticised 
PVC, and rubber manufacture. 
In addition to the possibility of exposure to MCCP aerosols created by condensation, there are 
situations where aerosols may be created by mechanical agitation, in particular, during the use 
of metal working fluids (MWFs) containing MCCP in the engineering industry and during the 
spraying of paints which contain MCCP. Values for exposure to airborne MCCP derived from 
exposure in a recent unpublished survey of the exposure of workers to metal working fluids 
indicate reasonable worst case (RWC) 8-hour TWA exposures of 0.03 mg.m-3 for water-based 
MWFs and 2.4 mg.m-3 for oil-based MWFs. NB. Metal working fluids constitute only 10% of 
the total EU usage of MCCPs. 
De Pater et al., 1999 (draft), provides a model for predicting exposure to non-volatile 
compounds during spray painting, which gave a result of 5 mg.m-3 8hr TWA.
The measured exposure data, with the exception of PVC calendering, clearly shows that 
personal exposures are significantly lower than the values derived from EASE predictions. 
Where relevant, the measured data will be used to determine the values taken forward to risk 
characterisation in preference to the EASE predictions.
Because of the very low level of exposure to MCCP vapour, skin contact will constitute the 
major source of personal exposure to MCCP. 
The number of persons potentially exposed to MCCP in the EU is not known but is expected 
to be of the order of many thousands. 
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Occupational exposure limits
There are no occupational exposure limits for MCCPs.
4.1.1.1.2 Occupational exposure during manufacture of MCCPs
As already described in Section 2.1, the chlorination of C14 to C17 paraffins is carried out as a 
batch process within closed chemical plant at process temperatures in the region of 100 °C.  
Blending and holding tanks are maintained at temperatures between 40 and 80 °C to maintain 
workable viscosities. The containment in these vessels will be breached when filters are 
removed for cleaning and when product samples are taken. For tanker filling and drumming 
of the MCCP product similar temperatures are maintained to ensure adequate mobility of the 
material.
At each MCCP manufacturing plant it is likely that in the region of 30 to 40 workers may be 
involved with operating the process, including drum and tanker filling. It is also likely that 
various patterns of job rotation will be followed. It is estimated that between 150 and 200 
workers may be potentially exposed to MCCPs during their manufacture within the EU.  
Because of the degree of containment exposure to MCCP is only likely to occur when the 
containment is breached, for example, during sampling, filter cleaning, maintenance and 
during drumming off and tanker filling.
Modelled inhalation exposure data
Neither the HSE nor industry has made measurements of exposure to airborne MCCP during 
its manufacture.
EASE predicts that, for substances with a vapour pressure which is less than 0.001 kPa at the 
processing temperature, exposures to airborne substance will be within the range 0-0.1 ppm, 
regardless of pattern of use or pattern of control. Thus because the vapour pressure of MCCP, 
as calculated within the EASE model, remains below 0.001 kPa for processing temperatures 
up to 125 °C the predicted exposure for processes temperatures below 125 °C will be 
independent of patterns of work or control and will be within the range 0-0.1 ppm. Predicted 
inhalation exposures to MCCP during the manufacture of the substance will therefore clearly 
be within the range 0-0.1 ppm as all the activities associated with manufacturing process 
operate at temperatures below 125 °C. Furthermore, as the saturated vapour concentration at 
ambient temperature (20 °C) is only 0.0027 ppm (0.051mg.m-3), the upper limit of this range 
of predicted exposures to MCCP vapour will be reduced to 0.0027 ppm. (see Overview of 
Exposure above). 
These predictions of exposure to vapour do not take account of the possibility that there might 
in some instances be a slight, transient exposure to a fine mist of MCCP formed by the 
cooling of vapour emitted by hot MCCP when the plant containment is breached for 
sampling, filter cleaning, and possibly maintenance. This small release of fine mist is likely to 
quickly dissipate and therefore the contribution to the worker’s total exposure is likely to be 
minimal. EASE is not capable of addressing such circumstances. There is no activity during 
the manufacture of MCCPs which involves vigorous agitation which might produce a mist or 
spray to which workers could be exposed   
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Modelled dermal exposure
In the manufacturing process the activity leading to the greatest likelihood of dermal exposure 
will be for the workers engaged in drumming off. Assuming that semi-automated drumming 
plant is utilised, the appropriate EASE scenario is non-dispersive use with direct handling and 
intermittent contact for which the model predicts that exposure to 210cm2 will be in the range 
0.1-1 mg/cm2/day. In practice, dermal exposures will be reduced by the workers wearing PPE, 
in particular gloves.
4.1.1.1.3 Occupational exposure during use in PVC formulating
Introduction
The major application of MCCPs in the EU is in the plasticisation of PVC. The properties of 
suspension and emulsion grade polymers and the function of plasticisers have been discussed 
at Section 2.2.1.1. In PVC formulations the MCCPs act as secondary plasticisers. Sometimes 
referred to as plasticiser extenders, they enable the formulator to reduce the amount of the 
more expensive primary plasticisers such as phthalate and phosphate esters. The MCCPs may 
also be used to enhance the flame retardant properties of the formulation.  
There are two main categories of PVC polymer, namely, emulsion polymer and suspension 
polymer:
a) PVC emulsion polymer when mixed with plasticisers at ambient temperature forms 
a mobile, liquid mass known as a plastisol. This can be coated onto a variety of substrates 
before being passed through heated ovens to gel and fuse the plastisol and produce laminates 
such as wallcoverings, floor coverings, leathercloth for upholstery, luggage and garments, 
tarpaulins and conveyor belting.
b) PVC suspension polymer when mixed with plasticisers initially produces a "dry 
mix" known as pre-mix which is subsequently mixed at elevated temperature to produce a 
plastic mass.  This may in turn be calendered to form PVC sheeting or extruded and chipped 
to produce material which can be subsequently co-extruded as cable insulation or sheathing, 
extruded into profiles, or moulded into shaped articles.
Industry has made some measurements of exposure to airborne MCCPs during their use as 
secondary plasticisers in PVC. It is not known how many workers may be potentially exposed 
to MCCPs during the manufacture and use of plasticised PVC formulations containing 
MCCPs in the EU.
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Figure 1  Use profile of MCCPs in PVC formulations (not an exhaustive list)
The exposure to MCCPs in the plasticisation of PVC is considered under the following 
headings: PVC plastisol manufacture, PVC plastisol use, calendering of plasticised PVC, 
compounding of plasticised PVC, and extrusion and moulding of plasticised PVC.  
PVC plastisol manufacture 
The ingredients of the plastisol formulation are added to the enclosed mixing vessel, the 
plasticisers including MCCPs being piped from bulk storage, and blended together by means 
of mechanical stirring. In general the MCCP used in plastisols is 45% chlorinated and may be 
used within the range 5-30% of the mix. The plastisol is finally put through a sieve to remove 
undispersed particles before being piped to intermediate storage for in-house use or to 
containers for transporting to third party user companies. Throughout the mixing cycle the 
plastisol is maintained at a temperature below 40 °C to prevent premature gelation. Thus only 
relatively gentle mechanical stirring is used in order to prevent heat build-up which could 
occur if high shear forces were to be created by, for example, by the use of high speed 
stirring.  Such gentle agitation will be insufficient to create a spray.  
Industry inhalation data
Sampling data was provided by industry for one site (Hughson 2003b). This site manufactures 
various grades of PVC flooring, on one of two continuous coating lines. Plastisol is prepared 
by adding the necessary ingredients, including MCCP to a mixer via a charge hopper. The 
mixing process is contained with in a closed vessel, though this needs to be opened up for 
short periods of time for inspection and for cleaning, although this is only done after purging. 
The hoppers are fitted with local exhaust ventilation. Four personal samples were collected 
over two days from two different operators: 0.02, 0.03, 0.03 and 0.08 mg.m-3 8hr TWA.
Modelled inhalation exposure data
As for manufacturing of MCCPs, the predicted exposure, for processing temperatures up to 
125 °C will be within the range 0-0.1 ppm. The upper limit of the range of predicted 
exposures to MCCP vapour will again be reduced to 0.0027 ppm (0.051mg.m-3) at 20 °C (i.e. 
the SVC).
PVC formulations
plastisol 
manufacture
compounding
plasticised PVC plasticised PVC
plastisol use
wall coverings flooring
leathercloth
extrusion moulding
flooring industrial
film & Sheet
calendering
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The possibility that there might be any exposure to a fine mist of MCCP formed by the 
cooling of vapour emitted by plastisols containing MCCPs when the temperature is kept 
below 40 °C is discounted. There is no activity during the manufacture of plastisols containing 
MCCPs which involves vigorous agitation which might produce a mist or spray to which 
workers could be exposed.
Conclusion
Most of the small number of measured data are below the EASE value of 0.05 mg/m3 and 
range from 0.02 to 0.08 mg/m3. The highest value of 0.08 mg/m3 will be taken forward to risk 
characterisation as the RWC.
Modelled dermal exposure data
In the manufacture of PVC plastisols containing MCCP a number of activities may give rise 
to the potential for dermal contact with MCCP or formulations containing it, for example 
during weighing out and transfer to the mixing vessel, during sieving, during transfer to 
holding tanks, and during sampling for laboratory testing. It is likely that on any one 
workshift these activities will be shared among 2 or 3 workers making about 4 or 5 batches of 
plastisol per shift. It seems reasonable therefore to assume an EASE model scenario of either 
non-dispersive use with direct handling and intermittent contact or incorporation in a matrix 
with direct handling and intermittent contact for both of which the prediction is that exposure 
to 420 cm2 will be in the range 0.1 to 1mg/cm2/day. For maintenance workers, such a 
prediction would probably represent a worst case situation. In practice dermal exposures will 
be reduced where workers wear PPE, in particular gloves, when handling MCCP or plastisol 
containing it.
PVC plastisol use
PVC plastisols may be used in a variety of ways. The predominant process involves the 
spread coating of plastisol onto a substrate material before passing it through a curing oven in 
which the plastisol coating is gelled and fused. Products so formed are wallcoverings, 
floorcoverings and leathercloth, the latter being used, for example, in the manufacture of 
upholstery. Alternatively for example a textile web may be dip coated with plastisol before 
undergoing a similar oven curing to form conveyor belting. The temperature of the coated 
web whilst passing through the curing oven generally rises to between 160 and 180 °C with a 
maximum in the region of 200 °C.  The curing ovens are normally subjected to exhaust 
ventilation which feeds the contaminated air to an incinerator or to an electrostatic precipitator 
from which the liquid condensate may be recovered for re-use. The escape of volatile material 
such as plasticiser, i.e. MCCP, from the oven into the work environment is thus minimised. 
The curing oven may be divided into zones of different temperature allowing the plastisol 
coating to be subjected to a gradual rise in temperature as it is gelled and fused. There may be 
a cooling zone through which the hot web passes before exiting from the oven. As the web 
leaves the oven it may also pass immediately between a pair of chilled embossing rollers to 
impart a particular surface pattern. This embossing process has the added benefit of reducing 
the temperature of the cured plastisol thereby further reducing the emission of volatile 
material from the coated web into the general work atmosphere.
Industry inhalation data
Sampling data was provided by industry for one site (Hughson 2003b). This site manufactures 
various grades of PVC flooring, on one of two continuous coating lines. Mixed batches of 
plastisol are loaded onto open tank trailers and transported to the production line using an 
electric tow-truck. Liquid is automatically pumped to the coating head and evenly spread out 
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onto a roll. The product then passes through ovens for curing. At the end of the coating line 
the product is automatically trimmed before being fed through the packing station where it is 
inspected, cut to length and wrapped in polythene. The curing ovens are fitted with extract 
ventilation. Twelve personal samples (Table 4.1) were collected over two days. Values ranged 
from <0.1 to 0.12 mg.m-3, with a median of 0.02 mg.m-3 and a 90th percentile of 0.12 mg.m-3. 
However, the results indicated that exposures were higher on day 1, ranging from <0.01 to 
0.12 mg.m-3, than day 2 which ranged form <0.01 to 0.02 mg. m-3. This was attributed to a 
malfunctioning extraction system on one of the ovens on day 1 which was repaired by day 2. 
Table 4:1  Industry data from PVC plastisol use
Sample Code Job Sample Time
(minutes)
Concentration MCCPs
(mg.m-3)
Day 1
UK/02/03 Tug driver 424 0.04
UK/02/04 1st coat spreader operator 226 0.12
UK/02/05 2nd coat spreader operator 233 0.09
UK/02/06 Back coat operator 234 0.04
UK/02/07 Base coat operator 222 0.12
UK/02/08 Process leader 227 <0.01
Day 2
UK/02/10 Process leader 482 0.01
UK/02/11 1st coat spreader operator 481 0.01
UK/02/12 Tug driver 405 <0.01
UK/02/13 2nd coat spreader operator 478 0.01
UK/02/14 Base coat operator 471 0.02
UK/02/15 Back coat operator 476 <0.01
Modelled inhalation exposure data
The primary potential source of exposure to airborne MCCP will be the curing oven. The 
appropriate EASE scenario for the curing process is inclusion into a matrix with the provision 
of LEV. Using this scenario the EASE model predicts an exposure to MCCP in the range of 
0.5-1 ppm for processes operating between 126 and 282 °C. However, the range for exposure 
to vapour will be markedly less than that predicted because of the very low value of the 
saturated vapour concentration at ambient temperature. The upper limit for vapour exposure at 
20 °C will thus be 0.0027 ppm (0.051mg.m-3). It is possible that there might be some escape 
of hot vapour laden air from the curing oven, either through leaks or from the hot, cured web 
as it leaves the oven. Such vapours could, on cooling, give rise to the formation of a fine mist 
containing MCCP and could thereby provide exposure over and above that caused by the 
airborne vapour. Nevertheless, as most curing ovens are likely to be efficiently exhausted as 
described above, there should be relatively little escape of hot vapour laden air from the oven 
which might in turn condense on cooling to form a fine airborne mist in the workplace 
environment. 
The actual plastisol coating of the substrate takes place at ambient temperature prior to the 
oven gelling and fusion. The application of the plastisol is carried out by means of roller 
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devices which transfer an even and measured coating of plastisol from a holding trough to the 
moving substrate. Alternatively the textile web may be dip-coated by being passed through a 
trough containing the plastisol. As already indicated above, because the coating operation 
takes place at ambient temperature (i.e. substantially below 126 °C), EASE predicts worker
exposure to MCCP at the coating process will be in the range 0-0.1 ppm regardless of pattern 
of use or pattern of control. Moreover because the saturated vapour concentration is 
0.0027 ppm at ambient temperature the actual exposure range will be 0-0.0027 ppm 
(0.051mg.m-3).  
There is no likelihood of exposure to a fine mist of MCCP formed by the cooling of vapour 
emitted by plastisols containing MCCP as the coating takes place at ambient temperature. In 
addition, neither method used for the coating process will give rise to the mechanical 
production of plastisol spray.
Thus the exposure to MCCP vapour of the one or two workers operating a plastisol coating 
line will be within the range 0-0.0027 ppm (0.051mg.m-3), with the possibility of slight 
exposure to MCCP mist if there is any leak of hot vapour laden air from the oven(s).
Conclusion
Although the range of the measured data was from <0.1 to 0.12 mg.m-3 the higher values 
came from day 1 when the extraction system was not working correctly. On day 2 when the 
extraction was working correctly the values ranged from <0.01 to 0.02 mg.m-3. The EASE 
value predicted for this scenario is 0.05 mg.m-3 and as most of the measured results on day 2 
were below this value, 0.05 mg.m-3 will be taken forward to risk characterisation as the RWC.
Modelled dermal exposure data
In the use of PVC plastisols containing MCCP, only in transferring plastisol to the coating 
head and in setting and adjusting the coater is there potential for skin contact. It is likely that 
on any one workshift these activities will be shared among 1 or 2 workers per coating line per 
shift. It seems reasonable therefore to assume an EASE model scenario of incorporation in a 
matrix with direct handling and intermittent contact, for which the prediction is that exposure 
to 420 cm2 will be in the range 0.1-1 mg/cm2/day. This estimate can be further reduced taking 
into account that a maximum of 30% of the plastisol is MCCPs, giving a range of 0.03 – 0.3 
mg/cm2/day over 420 cm2. In practice dermal exposures will be reduced by the workers 
wearing PPE, in particular gloves, when handling plastisol containing MCCP.
Calendering of plasticised PVC
There appears to be relatively little use of MCCPs in calendered PVC sheet formulations.  
Where MCCPs are used their main purpose it is to contribute to the flame retardant properties 
of the product. The 52% chlorinated product is normally used in this application. 
The ingredients of the formulation, namely suspension grade PVC, primary plasticiser, MCCP 
and other components are added to a closed mixing vessel in which they are blended to form 
the pre-mix. The plastisers, including the MCCP, will normally be piped directly into the 
mixer. During this first mixing stage the temperature of the mix can rise to temperatures 
between 60 and 110 °C depending upon the type of mixer employed and the shear forces 
imparted to the mix. The pre-mix is then transferred, usually by gravity, to a sealed internal 
mixer specifically designed to impart high shear forces to the mix. During this mixing the 
high shear forces raise the temperature of the mix to between 150 and 175 °C and bring about 
gelation and fusion. From the internal mixer hot mix is discharged into an extruder, which is 
used to provide an extrudate to continuously feed the top nip of the calender. An additional 
mixing step may sometimes take place between the internal mixer and the extruder whereby 
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the hot plastic mass is blended on a two roll mill on which the mix is subjected to further high 
shear mixing. On the calender the hot plastic mass is sequentially passed through three nips, 
provided by four large rollers usually in an inverted "L" configuration, which gradually 
squeeze the material into a continuous sheet of the desired width and thickness. The 
temperature of the mass as it travels through the calender may rise to values in the region of 
200 °C.  As the sheet leaves the bottom calender roller it passes through a series of cooling 
rollers so that it is at a temperature close to ambient before being wound up. 
Modelled inhalation exposure data
At each stage where the hot plastic mass is open to the atmosphere there is generally some 
provision of LEV which exercises a good degree of control of exposure of the workers to the 
volatile emissions from the material. The MCCP vapour, which is evolved by the hot plastic 
mass will, because of its low vapour pressure, quickly condense to a fine mist as it comes into 
contact with cool ambient air. Thus any MCCP to which workers will be exposed will 
comprise both vapour and mist.
It is not known how many workers are potentially exposed to MCCP during its use in 
calendering PVC either in the UK or in the EU. However, it is likely that between 3 and 5 
workers will be involved per shift in running a calender line.
The EASE scenario that best represents the calendering of PVC is inclusion into a matrix with 
provision of LEV. For the initial mixing operation for which process temperatures may be 
between 60 and 110 °C the predicted exposure to MCCP vapour is in the range 0-0.1 ppm 
whereas the prediction for the subsequent mixing and calendering operation, where 
temperatures may be between 150 and 200 °C, is in the range 0.5-1.0 ppm. As the operations 
are likely to all be in the same vicinity it would seem appropriate to take the latter higher 
prediction as representing the exposures experienced by all the workers on the calendering 
line. However, both predictions overstate the exposure to MCCP vapour. As has already been 
discussed for other processes, the upper limit of predicted exposure to MCCP vapour can be 
no greater than the saturated vapour concentration at ambient temperature, namely, 
0.0027 ppm (0.051mg.m-3). There will also be some exposure to the mist formed by MCCP 
vapour condensation, but the EASE model is not able to address such a situation. Mist that is 
not removed by the local exhaust ventilation is likely to quickly condense on nearby cold 
surfaces and contribute to dermal exposure. It is likely that most plants will have a reasonable 
standard of LEV and therefore the level of uncontrolled mist will be minimal.
Where the extraction is insufficient there is the potential for more significant release of mist 
into the workplace and therefore increased occupational exposure. The EASE predictions for 
vapour at 200 °C are overestimates, since the actual working environment will be closer to 
ambient and the SVC is only 0.0027 ppm. However, we can use the EASE predictions for 
vapour as a rough approximation for exposure to mist. If we assume that all the vapour 
condenses to form mist then the vapour range of 0.5-1.0 ppm becomes 9-18 mg.m-3 8-hour 
TWA to represent the mist. These figures are likely to be overestimates and only 
representative of a poor standard of control of the vapour and mist.
Industry Data
Industry inhalation data
Good quality sampling data was provided by industry for one site (Hughson 2003c). At this 
site sheets of PVC flooring are manufactured from raw materials using a calendering process. 
PVC resin, MCCP and other ingredients are blended in one of two mixer and the products 
discharged to 2-roll mills where they are compressed into thin sheets. Each mill has a fume 
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extraction hood situated above it. Strips of material from the mills are conveyed to a rotary 
shredder and the mixture passed through the marbling mill. The output is fed to the calender 
mill where the material is blended. The calender mills are fitted with a fume extraction 
system. A continuous sheet of PVC from the calender passed through a heating unit and 
embosser and finally a cooling/conditioning unit before being cut into sections and stacked 
onto pallets. 
Eighteen measurements were collected over two days (Table 4.2). Values ranged from 0.03 to 
1.2 mg/m-3, with a median of 0.35 mg.m-3 and a 90th percentile of 1.01 mg.m-3. However, the 
results indicated that exposures were higher for mill, calender and relief operators than for all 
other workers who are not directly involved in working with hot PVC. The values recorded 
for the mill, calender and relief workers ranged from 0.18 to 1.2 mg.m-3, whereas the values 
for the other workers ranged from 0.03 to 0.22 mg.m-3. The report concluded that fume 
emissions from the mills and calender were not being controlled by the ventilation equipment 
currently provided.
Table 4:2  Industry data from PVC calendering
Sample Code Job Sample Time
(minutes)
Concentration MCCPs
(mg.m-3)
Day 1
UK/04/08 Premix operator 379 0.03
UK/04/02 Mill No. 1 operator 385 0.95
UK/04/01 Mill No. 2 operator 385 0.40
UK/04/05 Relief operator 374 0.43
UK/04/03 Calender operator 377 0.68
UK/04/04 Calender operator 383 0.56
UK/04/06 Foreman 376 0.09
UK/04/07 Panel man 366 0.04
UK/04/09 QC Inspector 365 0.03
Day 2
UK/04/10 Premix operator 401 0.04
UK/04/11 Mill No. 1 operator 402 1.2
UK/04/13 Mill No. 2 operator 397 0.18
UK/04/12 Relief operator 213 0.35
UK/04/14 Calender operator 395 0.93
UK/04/15 Calender operator 394 1.1
UK/04/18 Foreman 393 0.21
UK/04/16 Panel man 396 0.22
UK/04/17 QC Inspector 397 0.17
Two data points are also available from calendering during rubber manufacture, 0.01 and 0.03 
mg.m-3 MCCP (see section 4.1.1.1.6). The calendering process in these two industries are 
likely to be similar and therefore it is possible to consider these data here, although we have 
no information as to how representative they would be. 
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Conclusion
Although we have no indication of how representative the new data from industry (Hughson 
2003c) would be of calendering as a whole, they do indicate that the exposures of the mill, 
calender and relief workers are likely to be higher than previously thought. At the specific 
factory where the sampling was carried out calendering of plasticised containing MCCPs was 
not carried out every day, usually 2-3 days per week. This is likely to similar in other 
manufacturers as a wide range of different PVCs are available and there appears to be 
relatively little use of MCCPs in calendered PVC sheet formulations.  
Taking this new data into account it is proposed that 1mg.m-3 be taken forward as the RWC.
Modelled dermal exposure data
In the calendering of plasticised PVC containing MCCP, there is a potential for skin contact 
with MCCP itself or the PVC material containing it. There is, as described above, the 
potential for dermal contact with contaminated surfaces. For the 3 to 5 workers involved it 
seems reasonable therefore to assume an EASE model scenario of either non-dispersive use or 
incorporation in a matrix with direct handling and intermittent contact, for both of which the 
prediction is that exposure to 420cm2 will be in the range 0.1-1 mg/cm2/day. For maintenance 
workers, such a prediction would also apply. In practice dermal exposures will be reduced by 
the workers wearing PPE, in particular gloves, when handling MCCP or any PVC material 
containing it other than the finished sheet.
Compounding of plasticised PVC
MCCP is used as a secondary plasticiser and flame retardant in flexible grades of PVC 
(Hughson 2006a). The primary plasticiser is di-octylphthalate (DOP). It is common practice 
in the PVC manufacturing industry to vary the proportion of MCCP and DOP according to 
their respective market prices. This is done without affecting the performance specifications 
of the PVC, so it is difficult to be certain about how much MCCP is used in a particular 
product.
The purpose of compounding plasticised PVC is to provide a chipped form of the product 
suitable to feed directly to an extruder or injection moulding machine. For these applications 
the 52% chlorinated MCCP is used at concentrations between 12 and 30%, with most being 
between 15 and 20%. The MCCP is primarily present as a plasticiser extender, but it does 
confer some flame retardancy on the formulation. The product goes mainly into the electrical 
cable insulation and sheathing. The activity is undertaken by specialist compounding firms. It 
is not known how many workers are involved in compounding PVC for these applications 
either in the UK or in the EU.
The mixing process is similar to that described for calendering of plasticised PVC, except that 
a 2 roll mill is not usually employed. The material after leaving the high shear mixer is 
transferred to an extruder fitted with a die face cutter which produces a chipped material. The 
chip is enclosed and air conveyed to the packaging line by which time it has cooled to 
temperatures only a little above ambient.
New information (personal communication) has recently been provided by industry on PVC 
compounding. Many PVC compounders do not use MCCPs at all, and of the compounders 
that do use MCCPs all the larger ones only run MCCP formulations about once a month. A 
significant proportion of the MCCPs is used for plastisols, although some big users have 
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recently stopped using MCCPs when they have reformulated away from the primary 
plasticiser DOP. 
Modelled inhalation data
By analogy with the mixing regime which precedes calendering of plasticised PVC, the 
workers engaged in compounding plasticised PVC will have exposures to MCCP vapour in 
the range 0-0.0027 ppm (0.051mg.m-3). Although there may be some exposure to mist from 
condensing hot MCCP vapour, it is likely to be less than that experienced in calendering as 
there are no activities such as the use of the 2 roll mill and the calender for which the hot PVC 
mass is more open to the workplace atmosphere.
Where the control is again insufficient as described with calendering of plasticised PVC the 
exposure to mist is again predicted to be 9-18 mg.m-3 8-hour TWA as rough approximation. 
These figures are likely to be overestimates.
Industry data
Sampling data were provided by industry from four sites in the UK, Italy and Spain and are 
given in Table 4.3.
Table 4:3  Industry data from PVC compounding
Site Number of 
samples
Minimum
(mg.m-3)
Maximum
(mg.m-3)
1 7 <0.003 <0.02
2 4 <0.01 0.02
3 13 0.03 0.44
4 8 0.02 0.15
The median of all 32 samples is 0.03 mg.m-3 and the 90th percentile is 0.15mg.m-3. The work 
at all four sites was essentially the same and is believed to be representative of this type of 
work throughout the EU. 
Site 1 used a batch process, with many different grades of PVC and different colours 
necessitating cleaning of mixers and extruders after each batch. Control at this site appeared 
to be good, as even though there was a spillage of MCCP during the sampling period and the 
operators had to clean it up all results are below the limit of detection.
Site 2 used a continuous process, with few different colours, thereby reducing the amount of 
cleaning (and potential exposure) the operators did.
Site 3 also used a batch process, with cleaning after each run. One operator spent the majority 
of the working time in the control room with the other three in the production area. This site 
appeared to have less good control than sites 1 and 2. A significant amount of airborne dust 
was created when the mixers were cleaned, using hand brushes, scrapers and compressed air 
jets. There also appeared to be significant leakage of dust from gaps in the intake manifold of 
the mixer. The two highest levels (0.32 and 0.44 mg.m-3) were taken from the same worker on 
different days and probably reflect the working methods of this particular operator as the rest 
of the results were all below 0.15 mg.m-3. 
Site 4 had 2 production lines, one batch and one continuous. Cleaning was carried out at the 
end of each run on the batch line. This site also appeared to have less good control than sites 1 
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and 2. There were potential exposure points that did not have LEV, e.g. at the discharge from 
the mixer to the feed hopper. There were also indications that the ventilation system was not 
operating as intended, e.g. there was a net outward flow of air from the enclosure round the 
extruders and a significant amount of dust spillage around the mixing vessels.
The 90th percentile of the measured data is 0.15 mgm-3 will be taken forward to the risk 
characterisation as the RWC.
Modelled dermal exposure data
In the compounding of plasticised PVC containing MCCP, there is relatively little potential 
for skin contact with MCCP itself or the PVC material containing it, except during cleaning of 
mixers. For the workers involved it seems reasonable therefore to assume an EASE model 
scenario of either non-dispersive use or incorporation in a matrix with direct handling and 
incidental contact, for both of which the prediction is that exposure will be in the range 0 - 0.1 
mg/cm2/day over 840cm2. Incidental contact has been used as the task will only be carried out 
infrequently and it is unlikely to be done more than once per day when MCCP containing 
PVC is being made.
A small number ( two people sampled from 2 workplaces) of dermal sampling results have 
been provided by industry (Hughson 20006a) from a study whose purpose was to develop a 
dermal sampling method for MCCPs. The measured dermal exposure levels from the 
compounding workers were collected from worst-case situations where contact with MCCP 
and MCCP contaminated surfaces was most likely and the samples were collected 
immediately after the tasks were completed, thereby minimising the potential for skin 
absorption or transfer from the skin to other surfaces.
The dermal exposures for the hands were all in the range 2.2 - 14.1 µg/cm2, with very similar 
levels for the forearms. However, the levels for the neck and face were higher at 23.1 – 60.3 
and 27.5 – 113µg/cm2 respectively. This is simply due to the fact that the face and neck were 
unprotected and exposure has perhaps resulted from deposition of MCCP from the air or from 
transfer to the skin from contaminated clothing. 
Given the small number of measurements and that the method is still in development the 
EASE value of 0.1 mg/cm2/day over 840cm2 will be used for risk characterisation.
In practice dermal exposures will be reduced by the workers wearing PPE, in particular 
gloves, when handling MCCP or any PVC material containing it other than the finished 
chipped compound.
Extrusion and moulding of plasticised PVC compound
For co-extrusion of plasticised PVC in wire insulation and cable sheathing, apart from the 
extrudate itself, the hot mass of PVC is enclosed. The exit from the extruder is rapidly cooled 
and provided with LEV. The same conditions are likely to apply to any other extrusion 
application of plasticised PVC which is formulated with MCCP. Injection moulding of PVC 
compound takes place within closed moulds which are cooled before opening.
Modelled inhalation data
The EASE model scenario for extrusion of plasticised PVC formulations containing MCCP is 
incorporation in a matrix with LEV provision. The range of exposures for such scenario with 
process temperatures between 126 and 282 °C is 0.5-1.0 ppm. However, as in all the PVC 
scenarios, this range will reduces to 0-0.0027 ppm (0.051mg.m-3) because of the very low 
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vapour pressure of MCCP at ambient temperature. The cooling and LEV arrangements will 
minimise the possibility of exposure to mist resulting from the cooling of hot vapours 
escaping from the hot process.
Where the control is again insufficient the exposure to mist is again predicted to be 
9-18 mg.m-3 8-hour TWA as rough approximation. These figures are likely to be 
overestimates and only representative of a poor standard of control of the vapour and mist.
Industry Data
Site 2 (see above) also had a separate area where PVC insulation is applied , by extrusion, to 
electrical cables. Various sizes of cables are produced, from computer signal to heavy 
electrical power cable. There are 4 extrusion machines, which apply a coating of PVC to the 
cable as it passes through the coating head. Each extrusion head has LEV and the cable is 
quenched in a water bath as it leaves the head. The operators spend the majority of their time 
at the workstation, near the extruder. However, they do move away from there at certain times 
to set up or remove cable drums. On each day sampling took place, the cables being processed 
were large diameter power cables, which use a relatively large quantity of PVC and therefore 
likely to represent a worst case scenario.
Four personal sample results were collected from different operators; <0.01, <0.01, 0.03 and 
0.44 mg.m-3. The last result appears to be atypical for this process as all the other results are 
substantially below this. Also, two static samples were taken at the workstations and gave 
levels of <0.01 and 0.09 mg.m-3, which also indicates that the 0.44 mg.m-3 result is likely to 
be spurious.
Taking all of this into consideration it is proposed to take 0.1 mg.m-3 forward to the risk 
characterisation as the reasonable worst case.
Modelled dermal exposure data
In the compounding of plasticised PVC containing MCCP, there is no possibility of skin 
contact with MCCP itself although there may be some contact the PVC material containing it.  
For the workers involved it seems reasonable therefore to assume an EASE model scenario of 
incorporation in a matrix with direct handling and incidental contact, for which the prediction 
is that exposure to 210cm2 will be in the range 0-0.1 mg/cm2/day. For maintenance workers, 
such a prediction would also apply. In practice dermal exposures will be reduced by the 
workers wearing PPE, in particular gloves, when handling any PVC material containing 
MCCP.
4.1.1.1.4 Occupational exposure during manufacture and use in paints
MCCPs are used as plasticisers in a limited number of specialised paint systems, for example, 
in water proofing paints for walls, in chlorinated rubber systems for lining swimming pools 
and ponds and in solvent based floor paints. The MCCPs used have chlorination values 
between 40 and 52% and are added mainly in the range 4-15% of the paint as manufactured. 
It is not known how many workers may be exposed during the manufacture of these products 
or during their use.
Industry inhalation data
Sampling data has been provided by industry from 2003 (Hughson 2003). Sampling was 
carried out at 2 locations, (i) a college of further education and (ii) a residential property. At 
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the college the area painted was an external brick wall and at the residential property the area 
painted was the internal concrete walls of a prefabricated garage. Although these tasks were 
small scale operations, they can be considered representative of typical spray painting tasks.
The same paint, a modified acrylic, containing 5.6% MCCP was used for both tasks. At the 
college the spray paint equipment used was a Titan 440 airless sprayer with a tip size of 
0.48mm. The paint was not tinned prior to use, in accordance with the manufacturers 
instructions. During the spraying the weather was dry with a light wind, and the work area 
was sheltered from direct sunlight and from the wind. The work was carried out by one 
experinced and qualified painter. One coat of paint was applied to the wall and this took 20 
minutes. A second coat was applied one hour later and again took 20 minutes to complete. 
The painter wore disposable overalls and nitrile gloves as well as a a disposable organic 
vapour respirator (3M type 4251). At the residential property the area painted was the internal 
walls of a self-contained concrete garage. The walls had been cleaned prior to the sampling. 
The equipment used was a Graco G-max airless spray paint system, with a 0.53mm tip. 
During the survey there was a light wind. The painter was a vehicle mechanic with experince 
of spray painting. During spray painting the cantilever garage door was closed in order to 
prevent over-spray affecting adjacent vehicles and properties. The painter wore a cotton 
overall, nitrile rubber gloves and a North organic vapour respirator with twin A2 filters. The 
paint was applied in 2 coats, leaving approximately 1 hour between coats. The total spraying 
time was 35 minutes.
The results are shown in Table 4.4.
Further inhalation sampling data has been provided by industry (Hughson 2006) from a 
survey of one  site, where a spray painting trial was carried out specifically to obtain exposure 
measurements for this assessment. However, the work was designed to be representative of a 
typical outdoor industrial spray painting job, done by an experienced spray painter. The 
surface being painted was a steel storage container and two different paints were applied, both 
suited to the aggressive marine and industrial atmospheres and are used for painting ships, 
chemical plant, storage tanks, bridges and sewerage works. The first paint used was a 
modified acrylic, containing 5.7% MCCP by weight, with a chlorination level of 52%. The 
second paint was a chlorinated rubber paint and contained 8.2% MMCP by weight, with a 
chlorination level of 52%. 
The spray painting tasks were of short duration and air monitoring was carried out only 
during the spraying work. The levels presented are therefore task specific measurements 
rather than 8 hr TWAs. During the survey period the weather was cold with a persistent fog 
and there was no noticeable wind. The relative humidity was about 90% due to the fog. Spray 
painting would not normally be done under these environmental conditions as the paint finish 
would be adversely affected. This however, was not a consideration for this exercise.
A Graco G-Max airless spray paint system, with a tip size 0.53mm was used. This is a heavy-
duty airless spray unit intended for industrial application of all types of paint. The container 
was sprayed until the acrylic paint (20l) was used up. This exercise was repeated using 25 
litres of chlorinated rubber paint. The spray painter wore disposable overalls, PVC coated 
gloves and a Sundstrom SR100 half mask respirator, with A2 organic vapour filter cartridge. 
Samples were collected using an OSHA versatile sampler (SKC type 226-30-16) and analysed 
using gas chromatography with mass spectrometry. As there was a limited time available for 
collecting measurements the painter was fitted with 2 samplers, one worn on each side of the 
body. The results are shown in Table 4.4. The measured values for all sampling periods were 
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in the range 0.3 – 5.1 mg/m3, with a median value of 2.7 mg/m3 and a 90th percentile value of 
3.9 mg/m3. 8-hr TWAs have been calculated, assuming that there was no further exposure to 
MCCP-containing paint in that day. The results range from 0.004 – 0.19 mg/m3, with a 
median value of 0.04 mg/m3 and a 90th percentile value of 0.1 mg/m3. The exposure data do 
not indicate that airborne concentrations were higher or lower for the different paint types.
Table 4:4 Results of task-based personal inhalation sampling for MCCP during paint spraying task
Sample Task Duration 
(minutes)
Concentration MCCP
(mg/m3)
8-Hr TWA 
MCCP
(mg/m3)
2006 data -Modified acrylic paint
1 Fenced side (preparation and 5 min spray time) 49 0.3 0.03
2 ditto 49 0.4 0.04
3 Spraying fenced side 6 1.5 0.02
4 Ditto 6 2.7 0.03
5 Spraying open side &end door 10 2.1 0.04
6 Ditto 10 1.5 0.03
7 Spraying monoflex extension 10 3.0 0.06
8 Ditto 10 2.5 0.05
9 Spraying monoflex extension 6 3.3 0.004
10 ditto 6 2.5 0.03
2006 data - Chlorinated rubber paint
11 Spraying fenced side 10 4.0 0.08
12 Ditto 10 3.8 0.079
13 Spraying open side and end door 10 2.8 0.06
14 Ditto 10 2.7 0.06
15 Spraying monoflex extension 18 3.5 0.13
16 ditto 18 5.1 0.19
2003 data -modified acrylic paint
17 external brick wall 40 0.05 0.002
18 ditto 40 0.08 0.006
19 self-contained prefabricated concrete garage 35 0.6 0.04
20 ditto 35 0.58 0.04
Taking into account all of the data from Table 4.4 the 8-hour TWA exposures for paint 
spraying range from 0.002 – 0.19 mg.m-3, with a median value of 0.04 mg.m-3and a 90th
percentile value 0.085 mg.m-3. 
Modelled inhalation exposure data
As there are no other measurements of exposure available to airborne MCCP during its use in 
paints, the EASE model has been used to predict the personal exposure of workers to airborne 
MCCP arising from this use.
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As with previous scenarios the exposure predicted using EASE is 0 to 0.1 ppm, for processing 
temperatures up to 125 °C. The mixing processes used to prepare paints containing MCCP are 
carried out in closed vessels. The processing temperature is mostly at ambient, with a possible 
rise to a maximum between 50 and 60 °C during the initial pre-mixing involving high shear 
forces. Thus the predicted inhalation exposures to MCCP during its use in the production of 
paints will clearly be within the range 0-0.1 ppm and can be reduced to an upper limit of 
0.0027 ppm (0.051mg.m-3) at 20 °C. The processing temperatures for paint manufacture are 
such that the possibility of the creation of a mist resulting from the cooling of hot vapours can 
be discounted. In addition, the process will not produce mechanically induced spray formation 
to which workers could be exposed.
It is understood that some 90% of the paint formulations incorporating MCCPs are applied by 
brushing. As already explained for such a procedure carried out at room temperature 
exposures of workers to MCCPs present in the formulation will be in the range 0-0.0027 ppm. 
There will be neither exposure to mist from condensation of hot vapour nor to mechanically 
generated spray. Some 10% of the paint formulations containing MCCPs may be applied 
using spraying techniques. For such procedures the application of the EASE model is 
confounded by the very low volatility of the MCCPs. Thus exposure predictions cannot be 
derived. This spraying is understood to be usually undertaken outside, for example, to line 
swimming pools. De Pater et al, 1999, provides a model for predicting exposure to non-
volatile compounds during spray painting. Data is provided for polyisocyanates, HDI 
monomer and dusts, and from these reasonable worse case scenarios (RWS) of 10 mg.m-3, 
0.2 mg.m-3 and 50 mg.m-3 respectively are provided in the report. Using the polyisocyanate 
data for this scenario as a similar non-volatile liquid the report suggests the following formula 
to take account of the concentration of the substance in the formulation.
E = 10 x C / 30
E = estimated exposure in mg.m-3
C = the percentage of substance in the paint
10 = RWS exposure for polyisocyanates in mg.m-3
30 = RWS concentration of polyisocyanate in the paint
Since the paint considered in this assessment contains 15% MCCP, the equation becomes.
E = 10 x 15 / 30
The predicted exposure is therefore 5 mg.m-3 8-hour TWA MCCP.
There are many complicating factors that make it difficult to simply accept this result. The 
report does state that more work is needed to refine this method. The exact method of 
application will influence exposure. For example, whether the spraying is inside or outside, 
the extent of any ventilation used, and the type of spray guns being used. The MCCPs based 
paints are applied to surfaces outside, whereas the polyisocyanate paints were probably 
applied inside. The nature of the paint will also affect exposure. Some components maybe 
chemically or physically bound with the polymer matrix of the paint. In the absence of other 
data the above is a reasonable first approximation.
Conclusions
Although the measured data provided by industry are task specific, 8hr TWAs can be 
calculated. It is assumed that no other exposure to MCCPs occurs in the same day. This would 
appear to be a reasonable assumption given that complete tasks were sampled. Overall the 
exposures ranged from 0.002 to 0.19 mg.m-3, with a median value of 0.04 mg.m-3 and a 90th
percentile value of 0.085 mg.m-3.
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Spray painting can be used as the worst case scenario for painting tasks and is likely to 
produce higher exposures. The de Pater model predicts that exposure for non-volatile 
compounds during spray painting would be 5 mg.m-3 8-hour TWA MCCP. Although the task 
specific values produced by the sampling exercises are within the same order of magnitude of 
this, the comparable 8hr TWA values are not. Therefore it is proposed to take forward the 
highest 8hr TWA value (0.19 mg.m-3) forward to risk characterisation. This value is preferred 
to the 90th percentile value to take into account the potential variability of exposures during 
paint spraying.
Industry dermal exposure data
Hughson 2006 also presents some dermal exposure measurements, which were collected as a 
pilot exercise during the method development phase of a study to assess dermal exposure to 
MCCPs. A total of 18 separate tape strip samples were collected at the same time as the 
inhalation samples during the paint spraying exercise (see above). While the worker wore 
protective gloves and a disposable overall, there were measurable levels of MCCP in the skin 
contaminant layer, from the hands, forearms, face and neck. The dermal exposures were 
generally low (i.e. typically 1-3 µg/cm2). As the sampling and analytical procedures are still 
in the process of being validated, these data can only be considered to be preliminary 
estimates and will not be used in determining the value for risk characterisation.
Modelled dermal exposure data
In the manufacture of paints containing MCCP, there is possibility of skin contact with 
MCCP itself during its addition and with material containing it. For the workers involved  the 
appropriate EASE model scenarios will be either non-dispersive use or incorporation in a 
matrix, both with direct handling and incidental contact. The predictions for both scenarios 
are that MCCP exposure to 420 cm2 (assuming manual addition of liquid) will be in the range 
0-0.1 mg/cm2/day. For maintenance workers, such a prediction would also apply. In practice 
dermal exposures will reduced if the workers wear PPE, in particular gloves, when handling 
any MCCPs and paints containing them.
For workers applying paints containing MCCP with brush or by spraying, the appropriate 
EASE scenario will be incorporation into a matrix with direct handling and intermittent 
handling. The prediction for this scenario is that MCCP exposure will be in the range 0.1-1 
mg/cm2/day over 840cm2.When the percentage (15%) of MCCPs in the paint is taken into 
account the prediction becomes 0.015 – 0.15 mg/cm2/day over 840cm2. In practice, dermal 
exposures will be reduced if the workers wear PPE, in particular gloves, when handling any 
paints containing MCCPs.
4.1.1.1.5 Occupational exposure during manufacture of sealants
MCCPs are used as plasticisers in a number of sealant systems. They also are used because 
they confer in some formulations a degree of flame retardancy. The MCCPs used have 
chlorination values between 50 and 60% and are added mainly in the range 15-20% of the 
formulation. It is not known how many workers may be exposed during the manufacture of 
these products or during their use.
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Modelled inhalation exposure data
Neither the HSE nor industry has made measurements of exposure to airborne MCCP during 
its use in sealants. Consequently the EASE model has been used to predict the personal 
exposures of workers to airborne MCCP arising from this use.
As with previous scenarios the exposure predicted using EASE is 0-0.1 ppm, for processing 
temperatures up to 125 °C. The mixing processes used to prepare sealants containing MCCP 
are carried out in closed vessels. The processing temperature is mostly at ambient, with a 
possible rise to a maximum between 50 and 60 °C, during mixing which involves fairly high 
shear forces. The temperature of the mix when transferred from the mixer to the packaging 
system is between 35 and 40 °C. Thus the predicted inhalation exposures to MCCP during its 
use in the production of sealants will clearly be within the range 0-0.1 ppm and can be
reduced to an upper limit of 0.0027 ppm (0.051mg.m-3) at 20 °C. The processing temperatures 
for sealant manufacture are such that the possibility of the creation of a mist resulting from 
the cooling of hot vapours can be discounted. In addition, the process will not produce 
mechanically induced spray formation to which workers could be exposed.
Modelled dermal exposure data
In the manufacture of sealants containing MCCP, there is possibility of skin contact with 
MCCP itself during its addition and with material containing it. For the workers involved the 
appropriate EASE model scenarios will be either non-dispersive use or incorporation in a 
matrix, both with direct handling and incidental contact. The predictions for both scenarios 
are that exposure to 420cm2 will be in the range 0-0.1 mg/cm2/day. For maintenance workers, 
such a prediction would also apply. In practice dermal exposures will reduced if the workers 
wear PPE, in particular gloves, when handling any MCCPs and sealants containing them.
4.1.1.1.6 Occupational exposure during rubber manufacture
There is some use of the MCCPs of higher degree of chlorination (60-70%) as flame retardant 
additives in rubber. The main application is in manufacture of conveyor belting. The initial 
addition and mixing of ingredients is very similar to that employed in the compounding and 
calendering of PVC and will give rise to comparable worker exposures. (See Section 
4.1.1.1.3) The final hot moulding of the rubber sheet will take place in closed presses which 
are equipped with LEV to capture any rubber fume including MCCP emitted when the presses 
are opened. Although somewhat different to the calendering of PVC, the process is considered 
to give rise to a similar degree of exposure. It is understood that throughout the EU, there may 
be a few hundred workers involved in producing rubber which contains MCCPs.
Modelled inhalation exposure
The EASE model has been used to predict the personal exposures of workers to airborne 
MCCP arising from this use.
By analogy with use of MCCPs in PVC formulation, workers exposure will be in the range 
0-0.0027 ppm (0.051mg.m-3). Mist that is not removed by the local exhaust ventilation is 
likely to quickly condense on nearby cold surfaces and contribute to dermal exposure. Where 
the extraction is insufficient there is the potential for more significant release of mist into the 
workplace and therefore increased occupational exposure.
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Where the control is again insufficient as with the use of MCCPs in PVC formulation the 
exposure to mist is again predicted to be 9-18 mg.m-3 as rough approximation. These figures 
are likely to be overestimates and only representative of a poor standard of control of the 
vapour and mist.
Industry Data
Industry have provided sampling results from one rubber compounding manufacturing site in 
Italy. The plant produces an intermediate rubber compound from raw materials using a 
Banbury mixer and a calender mill. The product is shipped to customers for secondary 
processing into cables and other rubber goods. Production using MCCP is by  a batch process, 
which on average only runs two days per month. There were four operators on the production 
line, two usually present in the mixer area, one at the calender and one at the packaging 
machine. There is no rotation of tasks and the operators remain at their workstations for the 
majority of the shift.
The MCCP is delivered to the mixer via enclosed pipelines. The mixer and the calender plant 
have LEV, which appeared to efficiently capture the process emissions. At the packaging 
area, the operator supervises the material as the rubber strips load into open storage baskets. 
There was no visible emissions from the product. The sampling results are shown in Table 
4.5.
Table 4:5  Industry data from rubber manufacture
Job Sampling result
(mg.m-3)
Mixer operator 0.02
Calender operator 0.01
Packaging operator 0.02
Mixer operator 0.01
Calender operator 0.03
Packaging operator 0.01
Mixer operator 0.07
Taking into consideration the measured results and the similarities in process with PVC 
compounding and calendering it is proposed to take the highest measured value of 0.07mg.m-3 
forward to the risk characterisation as the reasonable worst case.
Modelled dermal exposure
Again by analogy with PVC formulation it is assumed that predicted dermal exposures for 
420cm2 of workers involved in the manufacture of rubber will be in the range 
0.1-1 mg/cm2/day. In practice this exposure will be reduced if workers wear PPE, in 
particular, gloves.
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4.1.1.1.7 Occupational exposure in the manufacture and use of metal working 
fluids
MCCPs are used as extreme pressure additives in a wide variety of cooling and lubricating 
fluids used during metal cutting, grinding and forming operations. These fluids are commonly 
referred to as metal working fluids (MWFs). The MCCPs used may be between 45 and 55 % 
chlorinated and added at concentrations ranges between 5 and 10% in water-based MWFs and 
typically between 5 to 10% in oil-based MWFs, although for some heavy duty applications 
MCCP content is typically between 50 and 70% (Cherrie, 2006). In terms of tonnage used in 
Europe, water-based MWF containing between 5 and 10% MCCP vastly outsell those with 
higher contents. Also, in practice, it is usual for the end user to dilute the water-based MWF 
products with water. This has the effect of reducing the in-use concentration of MCCP. The 
recommended dilution is about 5% aqueous emulsion. Therefore, the estimated maximum in-
use concentration of MCCP in water-based MWFs is approximately 0.5%. Oil-based MWFs 
are not diluted by the end user, with MWF products containing as little as 2% MCCP and as 
high a level as 100% MCCP, which is used for heavy duty applications such as broaching. 
However, the main uses for oil-based MWFs are for those containing 5 to 10% MCCP. The 
usage of this type of MWF differs between European countries. However, some heavy-duty 
applications are also used, in which there are higher levels of MCCP, typically 50 – 70%.
The components of both oil and water-based MWFs are blended by the manufacturers in 
closed vessels at ambient temperatures, although on occasion temperatures may rise to about 
40 °C.  The application of MWFs to rotating workpieces produces a mechanically induced 
mist to which the worker may be exposed. 
For metal forming operations, MCCPs with higher levels of chlorination are used and are 
present in the oil at concentrations up to 50%. These metal forming activities do not give rise 
to mechanically produced mist.
The number of people potentially exposed to MCCPs in the manufacture of MWFs is not 
known, but many thousands are likely to be potentially exposed to MCCPs in their use in 
MWFs throughout the EU.
Modelled and derived inhalation data  
Neither the HSE nor industry has made measurements of exposure to airborne MCCP during 
the manufacture and use in MWF formulations containing it. Therefore the EASE model has 
been used to predict worker exposures during the manufacture of MWFs. 
For the use of MWFs, exposures are derived from measured data on exposure to oil mist and 
to spray from water-based MWFs.
EASE predicts that, for substances with a vapour pressure which is less than 0.001 kPa at the 
processing temperature, exposures to airborne substance will be within the range 0-0.1ppm, 
regardless of pattern of use or pattern of control. Thus because the vapour pressure of MCCP, 
as calculated within the EASE model, remains below 0.001 kPa for processing temperatures 
up to 125 °C the predicted exposure for processes temperatures below 125 °C will be 
independent of patterns of work or control and will be within the range 0-0.1 ppm. Predicted 
inhalation exposures to MCCP during the use of the substance in the production of MWFs 
will therefore clearly be within the range 0-0.1 ppm as all the activities associated with 
manufacturing process operate at temperatures very much below 125 °C. Furthermore, as the 
saturated vapour concentration at ambient temperature (20 °C) is only 0.0027 ppm, the upper 
limit of this range of predicted exposures to MCCP vapour will be reduced to 0.0027 ppm 
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(0.051mg.m-3). In this situation the possibility of production of mechanically induced spray or 
of mist formation by the condensation of hot vapour can be discounted.
A HSE report describes results of a wide ranging survey of worker exposure to MWFs; 31 
sites were surveyed. At 12 of these sites a total of 40 personal exposures to oil-based MWF 
were measured and at 28 sites a total of 298 personal exposures to water-based MWF were 
measured. In the latter case the results are quoted as MWF concentrate.  For the oil-based 
MWF the 95th percentile result was 3.4 mg.m-3 8-hour TWA and for the water-based MWF 
the 95th percentile result was 1.6 mg.m-3 8-hour TWA. Assuming the upper limit of MCCP 
concentration in oil-based MWF to be 70% then this corresponds to 8-hour TWA exposures 
of 2.4 mg/m3. For water-based MWF the maximum in-use concentration is 0.5%. These 
results correspond to 8-hour TWA exposures of 0.008 mg/m3 MCCP. Although, HSE’s work 
found poorly prepared concentrate strengths of up to 37.5%, the more recent water-based 
MWF concentration values of 1 to 15% (median 7%) from Semple et al, indicate that 0.5% is 
a realistic maximum in-use concentration. Therefore the value of the 95th percentile 8-hr 
TWA, 0.008 mg/m3 will be used as a reasonable worse case scenario for water-based MWFs, 
without adjustment. These results relate to exposure to liquid droplets containing MCCP, i.e. 
the MCCP is in liquid form. There will also be some exposure to MCCP vapour. However, as 
explained already the fact that the saturated vapour concentration of MCCP is 0.0027 ppm at 
20 °C (equivalent to 0.051mg.m-3) means that the contribution of the vapour to the total 
exposure to MCCP will be quite small.
The HSE survey did not include an investigation of exposure to MCCP into the use of MWFs 
in metal forming. For this application there may be exposure to a mist formed by the 
condensation of hot vapour. The extent of this will depend upon the extent to which the 
oil/MCCP mixture is heated. 
Modelled and derived dermal exposure data
For the exposure to MCCPs in the manufacture of MWFs the appropriate EASE scenario for 
predicting dermal exposure is non-dispersive use with direct contact and incidental exposure. 
The corresponding prediction for dermal exposure to 420cm2 is in the range 0-0.1 
mg/cm2/day. 
A report has been commissioned by industry (Cherrie, 2006) to provide estimates of dermal 
exposure to MCCPs during use of MWFs based on data from existing studies, taking into 
account technical information on the use of MCCP in MWFs for use in this RAR.
Although dermal exposure data were evaluated from 3 published studies: Semple et al. 
(2005), Roff et al. (2004) and van Wendel de Joode et al. (2005), only the data from Semple 
et al. (2005) were used to produce the final estimates of exposure for MCCP from the use of 
MWF. The data reported by Semple et al. (2005) provided the largest available set of 
information about MWF exposure and is the only source that represents exposure data from 
workers without protective gloves. From experience and the observations of the other authors 
it was believed that gloves are not commonly worn in this work situation and they may not be 
consistently worn throughout the workshift. The data from this study along with information 
on the range and average MCCP content in MWF were used to extrapolate estimates of the 
typical and RWC dermal exposures of MCCP exposure when using MWFs. Because the 
estimates of dermal exposure to MCCP in MWF were obtained from surrogate data, 
allowance was also made for the uncertainties associated with the overall estimates to ensure 
that the final information did not underestimate likely dermal exposure.
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Semple et al. (2005) collected data on MWF exposure from six engineering companies in 
Scotland, which although not representative of the entire engineering sector, did cover a wide 
range of product and service delivery. The study was designed as an intervention study to 
assess the effectiveness of different safety training approaches. Five of the six sites employed 
over 100 workers, whilst the sixth employed less than 50 people; although the numbers 
involved in the   machine tool department were much lower than this. The number of workers 
directly exposed to MWF was between 10 and 40. The samples were collected by wipe 
sampling and the samples analysed by ICP/AES using boron as a marker of MWF 
contamination. There are no standardized methods for measurements of demal exposure. Use 
of boron as a marker for MWF contamination is based on MDHS 95/2 – Measurement of 
personal exposure of metal working machine operators to air-borne water mix MWFs (HSE, 
2003). In total there were 196 pairs of measurements of exposures on right and left hands and 
there was no statistical difference between left and right hand measurements. For the purposes 
of this assessment the average exposure measurement for both hands was used. Further 
analysis showed that the training intervention resulted in a reduction of dermal exposure and 
so this analysis was only carried out on the baseline data from each of the sites and repeat 
visit data for the 3 control sites. This resulted in 16 measurements being available for work 
with oil-based MWF and 96 for work with water-based MWF. The concentration of water-
based MWF in the sump was also measured as part of this study and data were available for 
93 of the dermal samples. The values ranged from 1 to 15%, with a median of 7%.
Use of water-based MWF
For the use of water-based MWFs the EASE scenario is non-dispersive use with direct 
handling and extensive handling for which the predicted range is 1-5 mg/cm2/day. Taking into 
account the fact that for water mix MWFs the MCCP is present at a maximum in-use 
concentration of 0.5% (Cherrie, 2006) the predicted range of dermal exposure for use of 
water-based MWFs will be to 0.0005 to 0.025 mg/cm2/day over 840cm2. The predicted 
reasonable worst-case exposure would be 21 mg MCCP per day.
From Semple et al. (2005) the 90th percentile exposure measurements of MWF on the hands 
was 36,000 mg. The data from the two types of MWF were not significantly different from 
each other. Assuming the maximum in-use concentration of MCCP in water-based fluids to 
be 0.5%, the RWC hand exposure (90th percentile) would be 180 mg.
Use of oil-based MWF
For the use of MWFs the EASE scenario is non-dispersive use with direct handling and 
extensive handling for which the predicted range is 1-5 mg/cm2/day. For oil-based fluids, if it 
is assumed that there will be 70% MCCP in the fluid and as there is no further dilution the 
EASE predicted range would be 0.7 to 3.5 mg/cm2/day, over 840 cm2. Therefore the EASE 
predicted RWC would be 2,940 mg/day.
From Semple et al. (2005) the 90th percentile exposure measurements of MWF on both hands 
was 36,000 mg. The data from the two types of MWF were not significantly different from 
each other. For oil-based fluids it is not necessary to adjust the in-use exposure for dilution 
effects. It is assumed, therefore that the maximum typical in-use concentration is 70% MCCP. 
This gives a RWC estimate (90th percentile exposure with highest proportion MCCP) of 
25,000 mg MCCP on the hands.
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Conclusions
Dermal exposure to MCCPs during use of MWFs will be assessed separately for the two 
different types of MWF; water-based and oil-based.
EASE predicts that the exposure to MCCP during use of water-based MWFs is 0.005 to0.025 
mg/cm2/day over 840cm2. Therefore the predicted RWC would be 21 mg MCCP per day. For 
oil-based fluids, the predicted range is 0.7 to 3.5 mg/cm2/day, over 840 cm2. Therefore the 
predicted RWC would be 2,940 mg/day.
Cherrie (2006) gives estimates for dermal exposure during the use of both water-based and 
oil-based MWFs. Using the information from this report the RWC exposure given for water-
based MWFs is 180 mg/day and for oil-based MWFs the RWC is 25,000 mg/day.
There is a large difference between the EASE predicted exposures and the estimates produced 
from real sampling data of dermal exposure to MWF. As the estimates in Cherrie (2006) are 
based on 112 good quality real sampling data as well as information on MWF formulations, 
these data will be preferred to the EASE estimates in deciding the RWC levels for both water-
based and oil-based MWFs. Therefore, the values taken forward for risk characterisation are 
180 mg/day for water-based MWFs and 25,000 mg/day for oil-based MWFs.
4.1.1.1.8 Occupational exposure in the manufacture and use of fat liquor in 
leather treatment
Leather fat liquor is made via a simple mixing process in an enclosed system at ambient 
temperature, the main components being water natural fats, surfactants and MCCP. The 
MCCP, which may be chlorinated at levels between 40 and 50%, accounts for about 10% w/w 
of finished fat liquor. The fat liquor is transported in drums or FBCs to the tanneries.
At the tannery the liquor is manually weighed out and added to a closed mixing vessel in 
which it is diluted with water (40-60% liquor, the remainder water). During this blending 
operation the temperature will generally be about 40 to 50 °C, possibly up to 60 °C.
The leather to be treated with fat liquor is placed in a closed rotatable horizontal drum 
together with warm water and dyestuff and rotated at between 8 and 12 rpm. On completion 
of the dying stage the fat liquor is added to the drum by gravity via the hollow axle. The fat 
liquor is thereby effectively diluted with the water already in the drum at a ratio of about 5 of 
water to 1 of diluted fat liquor. The fat liquoring process takes place as the drum continues to 
rotate for a further 30-60 minutes during which time the temperature will be between 45 °C 
and ambient. Before the leather is removed from the drum a sample is taken for testing. When 
the quality is acceptable the leather is removed and mangled to remove surplus liquid. Finally 
drying will be undertaken either by vacuum drying at temperatures between 50 and 95 °C or 
by tumble drying at temperatures between 75 and 80 °C.
A single worker will look after six drums and will attend to the process from the initial 
weighing out of the MCCP through to the removal of the leather from the drum. Apart from 
weighing out the fat liquor it is only during sampling of the leather in the drum that the 
worker will come into contact with liquor. It is likely that each drum will complete two 
treatments per day.  Thus the operator will take leather samples from the drums about 
12 times per day. The worker would normally be expected to wear PPE comprising gloves, 
apron and wellington boots. It is not known how many workers are potentially exposed to 
MCCPs during the treatment of leather with fat liquor.
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Modelled inhalation exposure data
Neither the HSE nor industry has made measurements of exposure to airborne MCCP during 
the manufacture and use in fat liquors containing it. Therefore the EASE model has been used 
to predict worker exposures during the manufacture of fat liquors.
As with previous scenarios the exposure predicted using EASE is 0-0.1 ppm, for processing 
temperatures up to 125 °C. As the mixing processes used to prepare fat liquors containing 
MCCP are carried out in closed vessels at ambient temperature, the predicted inhalation 
exposures to MCCP during its use in the production of paints will clearly be within the range 
0-0.1 ppm. Moreover, as the saturated vapour concentration at ambient temperature is only 
0.0027 ppm (0.051mg.m-3), the upper limit of the range of predicted exposures to MCCP 
vapour will be reduced to give an upper limit of 0.0027 ppm at 20 °C. The processing 
temperatures for fat liquor manufacture are such that the possibility of the creation of a mist 
resulting from the cooling of hot vapours can be discounted. In addition, the process will not 
produce mechanically induced spray formation to which workers could be exposed.
The fat liquoring process also takes place at temperatures at or below 45 °C. Thus exposures 
to MCCP vapour will again be in the range 0-0.0027 ppm (0.051mg.m-3) (upper end of the 
EASE predicted range corrected to the SVC). The processing temperatures for fat liquoring 
are such that the possibility of the creation of a mist resulting from the cooling of hot vapours 
can be discounted. In addition, the process will not produce mechanically induced spray 
formation to which workers could be exposed.
Finally in the drying process, even with temperatures up to 95 °C, the EASE exposure 
predictions will be still be within the range 0 to 0.0027 ppm (upper end of the EASE predicted 
range corrected to the SVC). The temperature achieved in drying the treated leather such that 
there is little possibility of the creation of a mist resulting from the cooling of hot vapours. In 
addition, the process will not produce mechanically induced spray to which workers could be 
exposed.
Modelled dermal exposure data    
For workers involved in using MCCPs in manufacture of fat liquor the appropriate EASE 
scenario would be non-dispersive use with direct handling and incidental contact. For this the 
predicted dermal exposure for 420cm2 is within the range 0-0.1 mg/cm2/day.
In the case of the workers involved during the fat liquoring of the leather the scenario will be 
non-dispersive use with direct handling and intermittent contact yielding a predicted exposure 
to 840cm2 in the range between 0.1 and 1 mg/cm2/day. As only 10% of the fat liquor is 
MCCPs then the prediction is reduced to 0.01 – 0.1 mg/cm2/day over 840cm2.
Finally for the workers involved in the leather drying process the scenario will be non-
dispersive use with direct handling and incidental contact with a resultant prediction in the 
range 0-0.1 mg/cm2/day over 420cm2. As only 10% of the fat liquor is MCCPs then the 
prediction is reduced to 0 – 0.01 mg/cm2/day over 420cm2.
In practice dermal exposures will be reduced as the workers would normally be expected to 
wear PPE, in particular gloves, when handling any materials containing MCCPs.
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4.1.1.1.9 Occupational exposure during the manufacture of carbonless copy 
paper
As indicated in Section 2.2.5, only 5% of the EU production of carbonless copy paper is 
manufactured using MCCPs as solvent for the colour former contained within the 
microcapsules. No further information on how MCCPs are added to the process is available. 
The microencapsulation process takes place within an enclosed vessel at ambient temperature. 
This is the only part of the process where there is the possibility of exposure to MCCP, as 
once the material is encapsulated, it is contained within the impervious microcapsule wall.
Modelled inhalation exposure data
Neither the HSE nor industry has made measurements of exposure to airborne MCCP during 
the of carbonless copy paper. Therefore the EASE model has been used to predict worker 
exposures during the manufacture of these materials.
As with previous scenarios the exposure predicted using EASE is 0-0.1 ppm, for processing 
temperatures up to 125 °C. As the process in which MCCP is microencapsulated is carried out 
in closed vessels at ambient temperature, the predicted inhalation exposures to MCCP during 
this process will clearly be within the range 0-0.1 ppm. Moreover, as the saturated vapour 
concentration at ambient temperature is only 0.0027 ppm, the upper limit of the range of 
predicted exposures to MCCP vapour will be reduced to give an upper limit of 0.0027 ppm 
(0.051mg.m-3) at 20 °C. The processing temperatures for microencapsualtion of MCCP are 
such that the possibility of the creation of a mist resulting from the cooling of hot vapours can 
be discounted. In addition, the process will not produce mechanically induced spray formation 
to which workers could be exposed.
Modelled dermal exposure data
For workers involved in using MCCPs in microencapsulation of the solution of colour former 
in MCCP the appropriate EASE scenario would be non-dispersive use with direct handling 
and incidental contact. For this the predicted dermal exposure for 420cm2 (assuming manual 
addition) is within the range 0-0.1 mg/cm2/day. In practice dermal exposures will be reduced 
if the workers wear PPE, in particular gloves, when handling any material containing MCCPs.
4.1.1.1.10 Summary of inhalation exposure 
HSE’s National Exposure Database does not have any measurements of exposure to airborne 
C14 to C17 chlorinated paraffins (MCCPs) during their manufacture and use. Industry has 
provided exposure data for PVC compounding, extrusion, calendering, plastisol manufacture 
and use, and rubber manufacture. Individuals were sampled for the majority of the working 
shift and results are indicative of 8 hour time weighted averages (TWAs).
For all other scenarios the EASE model has been used to predict exposures of workers to 
airborne MCCP. Unfortunately the very low vapour pressure of MCCPs has meant that the 
EASE parameters are at the limits of the model’s facility to predict exposure. Thus for the 
lowest exposure range the upper limit of 0-0.1 ppm is greatly in excess of the saturated vapour 
concentration for MCCPs at 20 °C (ambient temperature), namely, 0.0027 ppm (0.051mg.m-
3). It should be borne in mind that the saturated vapour concentration is the theoretical 
maximum achievable concentration in a steady state environment which will rarely, if ever, be 
achieved in practice in an industrial situation. In all the situations where MCCPs are used in 
the workplace vapour exposures are governed by this restriction, i.e. exposures to vapour will 
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be significantly below 0.0027 ppm (0.051mg.m-3). Thus this upper limit to vapour exposure 
applies to all uses of MCCPs and materials containing them.
An added complication is that processes which operate in excess of 100 °C, in particular the 
hot processing of plasticised PVC formulations at up to temperatures of 200 °C, there is the 
possibility that as hot vapour laden air moves away from its source the MCCP will begin to 
condense to form a mist to which workers will be exposed in addition to the low 
concentration of vapour. EASE is not capable of dealing with this situation. It is therefore 
difficult to quantify the incremental effect that the mist will have on the assumed vapour 
concentration. However, good local exhaust ventilation at the PVC processes such as 
calendering will minimise the contribution of mist to the overall exposure to MCCPs.
Where the extraction is insufficient there is the potential for more significant release of mist 
into the workplace and therefore increased occupational exposure. The EASE predictions for 
vapour up to 200 °C are overestimates, since the actual working environment will be closer to 
ambient and the SVC is only 0.0027 ppm (0.051mg.m-3). However, we can use the EASE 
predictions for vapour as a rough approximation for exposure to mist. If we assume that all 
the vapour condenses to form mist then the vapour range of 0.5-1.0 ppm becomes 9-18 mg.m-
3 8-hour TWA.  These figures are likely to be overestimates and only representative of a poor 
standard of control of the vapour and mist. These scenarios where there is the possibility of 
exposure to mist where inadequate LEV or other such controls are in place, are:
· plastisol use
· calendering of plasticised PVC;
· compounding of plasticised PVC;
· extrusion and moulding of plasticised PVC; and
· rubber manufacture.
Sampling data, collected over 2 days were also provided by industry from plastisol use. 
Values ranged from <0.1 to 0.12 mg.m-3, with a median of 0.02 mg.m-3 and a 90th percentile 
of 0.12 mg.m-3. However, the results indicated that exposures were higher on day 1, ranging 
from <0.01 to 0.12 mg.m-3, than day 2 which ranged form <0.01 to 0.02 mg. m-3. This was 
attributed to a malfunctioning extraction system on one of the ovens on day 1 which was 
repaired by day 2. Most of the small number of measured data are below the EASE value of 
0.05 mg/m3 and range from 0.02 to 0.08 mg/m3. The highest value of 0.08 mg/m3 will be 
taken forward to risk characterisation as the RWC.
Although originally no measured data were available for calendering of PVC a RWC of 0.1 
mg.m-3 for this scenario was proposed by using analogous measured data and judgement.  
After new measured data were provided by industry this RWC value has now been revised to 
1mg.m-3. However, as it appears likely that calendering of MCCP-containing PVC will not be 
carried out every day at the workplaces that make these products it should be noted that the 
value of 1mg.m-3 will only apply to days when calendering of MCCP-containing PVC occurs.  
A range of <0.003 to 0.44 mg.m-3 MCCP exposures was found from 32 personal samples 
taken from 4 EU sites carrying out PVC compounding. The median of these exposures is 0.03 
mg.m-3 and the 90th percentile is 0.15 mg.m-3, which is the value taken forward as the RWC 
for this scenario.
Four samples were taken at a site carrying out the application of PVC insulation, by extrusion, 
to electrical cables. The values are <0.01, <0.01, 0.03 and 0.44 mg.m-3. taking into account 
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the small amount of data, the similarities in process with other PVC processes and using 
judgement a value of 0.1 mg.m-3 is taken forward as the RWC for extrusion. 
A range of 0.01 to 0.07 mg.m-3 MCCP exposures was found during rubber manufacture from 
7 personal samples taken at one site. Taking into consideration the measured results and the 
similarities in process with PVC compounding and calendering it is proposed to take the 
highest measured value of 0.07 mg.m-3 forward to the risk characterisation as the RWC.
Another exposure situation that EASE cannot readily handle is mechanically produced spray 
produced adventitiously by rapid mechanical agitation, “semi adventitiously” in the use of 
metal working fluids and purposely in the case of paint spraying. The difficulty is accentuated 
because of the very low vapour pressure of MCCPs. De Pater et al., 1999 (Draft), provides a 
model for predicting exposure to non-volatile compounds during spray painting, which gave a 
result of 5 mg.m-3 8-hour TWA. Spray painting can be used as the worst case scenario for 
painting tasks and is likely to produce higher exposures. The de Pater model predicts that 
exposure for non-volatile compounds during spray painting would be 5 mg.m-3 8-hour TWA 
MCCPs. Although the task specific values produced by the sampling exercises are within the 
same order of magnitude of this, the comparable 8hr TWA values are not. Therefore it is 
proposed to take forward the highest 8hr TWA value (0.19 mg.m-3) forward to risk 
characterisation. This value is preferred to the 90th percentile of the sampling results to take 
into account the potential variability of exposures during paint spraying. 
The exposure data from an HSE survey of premises using metal working fluids has provided 
some “real” exposure data which has been used to derive possible exposures to MCCP in the 
MWF spray generated by the rotation of the metal work piece. For the oil-based MWF the 
95th percentile result was 3.4 mg.m-3 8-hour time weighted average (TWA) and for the water-
based MWF the 95th percentile result was 1.6 mg.m-3 8-hour TWA. Assuming a maximum 
in-use concentration of 0.5% in and water-based MWFs this result corresponds to an 8-hour 
TWA exposure of 0.008 mg.m-3 MCCP for for water-based MWFs. For oil-based MWFs, if it 
is assumed that the maximum in-use concentration of MCCP is 70% then the corresponding 
RWC 8-hr TWA is 2.4 mg.m-3.
These results relate to exposure to liquid droplets containing MCCP, i.e. the MCCP is in 
liquid form. There will also be some exposure to MCCP vapour. However, as explained 
already the fact that the saturated vapour concentration of MCCP is 0.0027 ppm at 20 °C 
(equivalent to0.051 mg.m-3) means that the contribution of the vapour to the total exposure to 
MCCP will be quite small.
The table below summarises the inhalation data to be taken forward for the risk 
characterisation (Table 4.6).
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Table 4:6  Summary of occupational inhalation exposure data for risk characterisation
Industry Inhalation exposure
vapour
(ppm)
Mist
(EASE)
(mg/m3)
Measured data
(mg/m3)
RWC
(mg/m3)
Manufacture of MCCPS 0.0027 neg 0.05
PVC plastisol manufacture 0.0027 neg 0.08
plastisol use 0.0027 neg 0.05
calendering of plasticised PVC 0.0027 9 to 18 0.03 to 1.2
(0.01, 0.03)
1
compounding of plasticised PVC 0.0027 9 to 18 <0.003 - 0.44 0.15
PVC 
formulatin
g
extrusion and moulding of  plasticised PVC 0.0027 9 to 18 <0.01 - 0.4 0.1
Manufacture of paints containing MCCPs 0.0027 neg 0.05
Use of paints containing MCCPs (spraying) 0.0027 5
0.002 – 0.19
0.19
Manufacture of sealants containing MCCPs 0.0027 neg 0.05
Rubber manufacture 0.0027 9 to 18 0.01 – 0.07 0.07
Manufacture of MWFs containing MCCPs 0.0027 neg 0.05
Use of water-based MWFs containing MCCPs 0.0027 0.008
(95th percentile)
0.008
Use of oil-based MWFs containing MCCPs 0.0027 2.4 
(95th percentile)
2.4
Manufacture of fat liquor in leather treatment 0.0027 neg 0.05
Use of fat liquor in leather treatment 0.0027 neg 0.05
Manufacture of carbonless copy paper 0.0027 neg 0.05
Neg: negligible exposure. See text of respective sections.
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4.1.1.1.11 Summary of dermal exposure 
Table 4.7 below summarises the dermal data to be taken forward for the risk characterisation.
With the exception of the use of MWFs, EASE has been used to predict all dermal exposures 
values for risk characterisation. There are two types of MWFs; water-based and oil-based. 
These will be assessed separately as there are differences in the MCCP content of the two 
types of MWFs. Although EASE can be used to predict dermal exposures to MWFs, 112 real 
measured datapoints from Semple et al. (2005), have been used together with use 
concentration information to estimate dermal exposures to MCCP in MWFs. These data give 
RWC estimates of 180 mg/day MCCP for water-based MWFs and 25,000 mg/day MCCP for 
oil-based MWFs.
Table 4:7  Summary of occupational dermal exposure data for risk characterisation
Industry Dermal exposure
Exposure
(mg/cm2/day)
Area
Exposed 
(cm2)
Source RWC
(mg/day)
Manufacture of MCCPS 0.1 – 1 210 EASE 210
PVC plastisol manufacture 0.1 – 1 420 EASE 420
plastisol use 0.03 – 0.3 420 EASE 126
calendering of plasticised PVC 0.1 – 1 420 EASE 420
compounding of plasticised PVC 0 – 0.1 840 EASE 84
PVC 
formulatin
g
extrusion and moulding of  plasticised PVC 0 – 0.1 210 EASE 21
Manufacture of paints containing MCCPs 0 – 0.1 420 EASE 42
Use of paints containing MCCPs (spraying) 0.015 – 0.15 840 EASE 126
Manufacture of sealants containing MCCPs 0 – 0.1 420 EASE 42
Rubber manufacture 0.1 – 1 420 EASE 420
Manufacture of MWFs containing MCCPs 0 – 0.1 420 EASE 42
Use of water-based MWFs containing MCCPs 36,000 mg MWF both hands Derived 180
Use of oil-based MWFs containing MCCPs 36,000 mg MWF both hands Derived 25,000
Manufacture of fat liquor in leather treatment 0 – 0.1 420 EASE 42
Use of fat liquor in leather treatment 0 – 0.1 840 EASE 84
Manufacture of carbonless copy paper 0 – 0.1 420 EASE 42
4.1.1.2 Consumer exposure
C14-C17 chlorinated paraffins are not sold directly as consumer products (see section 2.2). 
They are found in the following materials to which consumers could be exposed:
· In fat liquors used in leather processing,
· As an additive to adhesive and sealants,
· Use in rubber and plastics,
· As a plasticiser in paints,
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· As an extreme pressure additive in metal working fluids;
These are largely for industrial or commercial applications. However, there may be the 
potential for indirect consumer exposure and this is considered below. Investigations by the 
rapporteur indicate that exposure is negligible for some uses. However, exposure estimates 
are provided for the wearing of leather clothes and for the use of metal working fluids. The 
scenarios presented below are reasonable worst case exposures.
4.1.1.2.1 Leather clothes
There are varying reports regarding the use of MCCP usage in leather treatment. It has been 
reported that about 1048 tonnes of C14-C17 chlorinated paraffins were used in the leather 
industry in 1997, showing a decline since 1994 when 1614 tonnes were used (CEFIC, 1999).  
Conversely, it has also been reported that there is no usage of MCCP in fat liquors in the 
leather producing industries (personal communication). However, from the available data, 
about 50% of the leather formulations are exported outside the EU. It is employed within the 
EU as a constituent of some fat liquors. MCCPs are used in conjunction with sulphated or 
sulphonated oils, chlorosulphonated paraffins, natural fats and oils. They improve surface 
sheen and help impart “wear and tear” and light fading resistance when used in some 
applications. These applications tend to occur in the top end quality range.
Inhalation exposure during the use of leather garments is considered to be negligible. The 
only potential realistic route of exposure is the dermal route, if such garments were worn next 
to the skin. It is possible to estimate a worst case dermal exposure scenario for leather 
garments which are worn regularly. An exposure scenario is presented below, for a consumer 
wearing leather coat and trousers.
Dermal exposure scenario for the use of chlorinated paraffins in leather coats and 
trousers
Around 3% of fat liquor is present in the formulation that is added to raw leather, of which 
approximately 10% is MCCPs. Around 2-2.5% of the added formulation is taken up by the 
leather. Therefore the amount of MCCPs present in the leather is up to about 0.0075% 
(information supplied by industry).
Assuming that a leather coat and trousers are worn next to the skin and weigh a total of 5 kg, 
there will be a maximum of 0.375 g of MCCPs in the clothing. Assuming that all of this 
migrates out of the leather over a period of one year, then the maximum daily exposure will 
be 0.375 g/365 = 1 mg/day.
This assumes that the leather clothing is worn continuously next to the skin, without a lining 
or other garments and that the migration rate is as high as suggested. However, if the 
garments are dry-cleaned, then most if not all of the chlorinated paraffins will be removed in 
this procedure (information from UK leather industry). Indeed, following dry-cleaning, oils 
(which are unlikely to contain chlorinated paraffins) are put back into the garments to 
maintain their suppleness.
A worst case daily exposure of 1 mg MCCPs/day will be taken forward to the risk
characterisation. However, it should be noted that for the reasons given above, this is likely to 
significantly over-estimate actual exposure.
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4.1.1.2.2 Adhesives and sealants
Chlorinated paraffins, including medium chain chlorinated paraffins (typically 55-65% 
chlorine content), are used as plasticisers/flame retardants in adhesive/sealants used for a 
variety of applications. Typical amounts are up to about 15 % by weight of the sealants 
(section 2.2.1.3). The sealants are likely to be applied by a caulking gun in larger applications 
which would lead to limited dermal exposure. Given the infrequency and short duration of use 
by a consumer (fitting a window frame for example), that they form a small proportion of the 
final product, and the physicochemical properties of very low volatility (around 2.2 x 10-3 Pa, 
see section 1.3), the inhalation exposure will be negligible, even assuming 100% absorption.
4.1.1.2.3 Use in rubber and plastics
Rubber goods 
MCCP is used at up to 15% of the total weight of the rubber (Section 2.2.2.1). The treated 
rubber finds uses in conveyor belts (see section 4.1.1.1.6) and in building and automotive 
applications. Due to the nature of the products, consumer contact will be very unlikely. 
Exposure from the building and automotive applications of MCCPs are not applicable for the 
consumer because consumers do not come into contact with these products.
Plastic goods
MCCPs act as (secondary) plasticisers in PVC (typically 40-45% Cl) and other plastics, 
(section 2.2.1.3). They also have flame retardant applications but they are not specifically 
added for this purpose, instead being generally regarded as flame retardant plasticisers.  
Door frame plastics for underground vehicles such as those used in mines, may be made from 
plastics with an MCCP content, due to its fire resistant property and there is no evidence to 
suggest there is any exposure to MCCPs (personal communication). Typical applications 
include garden hoses, floorings etc. These types of PVC products are not used for food 
contact purposes so exposure via the mouth to leaching plasticiser or flame retardant is not 
considered here. Additionally, leaching rates are likely to be minimal due to the amounts used 
and the physicochemical properties of the MCCPs, including low volatility and low solubility 
in water. Inhalation and dermal exposure to consumers from such products may also therefore 
be considered negligible.  
Hence, there are no exposure values from this use to be taken forward to the risk 
characterisation.
4.1.1.2.4 Paints
Medium chain length chlorinated paraffins, with about 50-58 % chlorine content are used as 
plasticisers in some paints, varnishes and coatings. They are used at between 4-15 % w/w of 
the total paint. The main areas of application are mainly for industrial and commercial use and 
not in the kinds of paints or coatings commonly purchased by consumers. One exception is in 
the use of some paints used for coating swimming pools. The exposure from this source has 
not been measured but is thought to be negligible (personal communication).
Hence, there are no exposure values from this use to be taken forward to the risk 
characterisation.
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4.1.1.2.5 Extreme pressure additives (metal cutting/working fluids)
Medium chain chlorinated paraffins are used in a wide variety of cooling and lubricating 
fluids used during metal cutting and metal working operations (section 2.2.3). These are 
industrial operations and no precise information is available about whether MCCPs are used 
in such fluids outside of the workplace. It is possible that metal working fluids containing 
these substances could be used in lathes for home or voluntary group use (e.g. car or engine 
restoring). However, there are no data to support this and such uses are likely to be infrequent 
and exposures will be for a short time period compared to an industrial worker. An individual 
working at home is unlikely to have the same degree of prolonged exposure that would arise 
over a full working day, nor would there be exposure to mists generated by a number of 
machines working simultaneously and/or continuously. In addition, systems used by 
consumers will have lower coolant capability than those used industrially, again reducing the 
potential exposure in comparison with workers. Therefore, both the level and duration of 
exposure would be much less than in an industrial setting and consequently dermal and 
inhalation exposure would be very much lower. Consequently, for consumers, the exposure 
information available for the workplace is likely to be an overestimate. The degree of 
overestimation is uncertain, but continuous exposure for 8 hours daily for a working week is 
unlikely. For the purposes of risk assessment, exposure will be considered as singular events 
averaged over a day rather than repeated exposures.
In section 4.1.1.1.7, exposure data indicated that a reasonable worst case daily inhalation 
intake of  MCCP during the use of oil based metal working fluids is 5 mg/day (based on an 8-
hour TWA of 0.5 mg.m-3, 8-hour shift and a breathing rate of 1.25 m3.hour-1); during the use 
of water based metal working fluids, a reasonable worst case estimate is 0.9 mg/day.
To take account of the factors that are likely to lead to lower exposures for consumers, this 
worker daily inhalation intake will be reduced by a factor of 10 even taking into account that 
adequate ventilation is unlikely to be available in the consumer setting. It must be stressed 
that the use of this factor of 10 is judgemental to take account of the reduced duration and 
frequency of consumer exposure. It takes also account of the reduced airborne levels that 
inevitably would occur in the consumer scenario where there are not several machines 
working simultaneously and/or continuously. Thus, using the highest workplace daily 
inhalation intake of 5 mg/day, the equivalent intake for a consumer would be 0.5 mg/event .
Summary
Most applications of MCCP are not designed for consumer contact, and therefore exposures 
are clearly negligible. The only consumer exposure scenarios for which there may be 
exposure to MCCP are the use of metal working fluids and the wearing of leather clothes 
treated with MCCPs. For the use of metal working fluids, the estimated exposure is 0.5 
mg/event, however, any such exposure from this scenario will be infrequent and should be 
considered as a single event, rather than repeated exposure. The wearing of leather clothes 
results in dermal exposure only (estimate of 1 mg/day); any such exposure from this scenario 
should be regarded as potentially a repeated exposure.
4.1.1.3 Indirect exposure via the environment
Medium-chain chlorinated paraffins have several uses that could result in releases to air and 
water. The uptake of medium-chain chlorinated paraffins from water by marine organisms, 
although it does occur, may be less than the very high log Kow values for this group of 
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substances would indicate. The potential for bioaccumulation in the environment appears to 
decrease with increasing chlorine in the group.  This is discussed further in Section 3.1.0.5.
The EUSES model has been used to estimate various concentrations of medium-chain 
chlorinated paraffins in food, air and drinking water. Default calculations using the EUSES 
model identified uptake into root crops from soil as potentially a significant route for 
exposure of man through food. In order to refine the calculations for this source of exposure, a 
study investigating the actual accumulation of medium-chain chlorinated paraffins in roots of 
carrot (Daucus carota) has been carried out (Thompson et al., 2005).
This study was carried out using a 14C-labelled 52.5% wt. chlorinated n-pentadecane that was 
produced as a mixture with unlabelled C14-17 52.5% wt. chlorinated paraffin.  The mean 
bioaccumulation factor (defined as the concentration in root (mg/kg fresh 
weight)/concentration in soil (mg/kg wet weight)) was determined to be 0.045 over days 50 to 
70 of the experiment. Overall the bioaccumulation factor based on the carrot study results is 
around 136 times smaller than the equivalent bioaccumulation determined for medium-chain 
chlorinated paraffins using the TGD/EUSES default methods. Using the methods outlined in 
the TGD, this bioaccumulation factor is equivalent to a value for the Kplant-water of 330 m3/m3
(this is the partition coefficient between plant tissue and water). This value has been used in 
the EUSES 2.0.3 program in place of the default value to obtain a more reliable estimate of 
the resulting concentrations in root crops (and hence other parts of plants such as leaves) and 
so the likely exposure of man via the environment.
The resulting concentrations in the food chain for human exposure using this value for the 
Kplant-water are summarised in Table 4.8 and the estimated daily human intakes from 
environmental sources are summarised in Table 4.9. The calculations used regional 
concentrations based on measured data of 0.1 µg/l for surface water and 0.088 mg/kg wet wt. 
for agricultural soil (as used in the environmental parts of the risk assessment). The measured 
data are taken from representative industrial areas in the United Kingdom and the agricultural 
soil samples were from sites that were known to receive sewage sludge from treatment plants 
where chlorinated paraffins were known to be released (further details of these sites are given 
in EU (2005)).
In the EUSES model, a log Kow value of 7 has been used as being representative for the 
group as a whole. A fish bioconcentration factor of 1,087 l/kg (see Section 3.1.0.5) has been 
used in the model to estimate the concentration in wet fish (no biomagnification factor (BMF) 
has been used in the calculations). For other parts of the food chain, particularly leaf crops, 
meat and milk, EUSES estimates the concentrations in these using methods that rely on log 
Kow as no equivalent measured accumulation factors exist for medium-chain chlorinated 
paraffin. It is not known if these methods would be applicable to medium-chain chlorinated 
paraffins. 
It should also be noted that the change to the Kplant_water coefficient value also affects the 
predicted concentrations in plant leaves and hence meat and milk.
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Table 4:8  Estimated concentrations in food for human daily intake 
Estimated concentration in human intake mediabScenario Step
Wet fish 
(mg/kg)
Root crops 
(mg/kg)
Leaf crops 
(mg/kg)
Drinking water 
(mg/l)
Meat (mg/kg) Milk (mg/kg) Air (mg/m3)
Site A 0.11 negligiblea negligiblea 2.6´10-5 negligiblea negligiblea negligiblea
Site B 0.19 negligiblea negligiblea 4.4´10-5 negligiblea negligiblea negligiblea
Site C 0.26 negligiblea negligiblea 6.0´10-5 negligiblea negligiblea negligiblea
Production
Site D 0.11 negligiblea negligiblea 2.5´10-5 negligiblea negligiblea negligiblea
Compounding  - O 0.15 0.024 7.1´10-4 5.0´10-5 0.014 4.3´10-3 negligiblea
Conversion – O 0.42 0.15 6.1´10-3 3.2´10-4 0.085 0.027 4.8´10-5
Use in PVC –
plastisol 
coating
Compounding/conversion - O 0.46 0.17 6.1´10-3 3.6´10-4 0.092 0.029 4.8´10-5
Compounding  - O 0.26 0.076 2.3´10-3 1.6´10-4 0.04 0.013 1.8´10-5
Compounding – PO 0.94 0.40 9.4´10-3 8.4´10-4 0.19 0.059 7.4´10-5
Compounding – C 0.18 0.037 1.4´10-3 7.9´10-5 0.022 7.1´10-3 1.1´10-5
Conversion – O 0.57 0.22 8.8´10-3 4.7´10-4 0.13 0.040 7.0´10-5
Conversion – PO 0.61 0.24 9.4´10-4 5.1´10-4 0.13 0.042 7.4´10-5
Conversion – C 0.53 0.20 8.1´10-3 4.3´10-4 0.11 0.036 6.4´10-5
Compounding/conversion – O 0.73 0.30 0.010 6.3´10-4 0.16 0.050 8.2´10-5
Compounding/conversion - PO 1.4 0.63 0.018 1.3´10-3 0.31 0.099 1.4´10-4
Use in PVC –
extrusion/other
Compounding/conversion - C 0.60 0.24 8.8´10-3 5.0´10-4 0.13 0.041 7.0´10-5
Compounding 0.19 0.040 1.2´10-3 8.6´10-5 0.022 6.9´10-3 9.2´10-6
Conversion 0.37 0.13 5.2´10-3 2.7´10-4 0.072 0.029 4.1´10-5
Use in 
plastics/rubber
Compounding/conversion 0.44 0.16 5.6´10-3 3.4´10-4 0.087 0.028 4.5´10-5
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Table 4.8 continued 
Estimated concentration in human intake mediabScenario Step
Wet fish (mg/kg) Root crops 
(mg/kg)
Leaf crops 
(mg/kg)
Drinking water 
(mg/l)
Meat (mg/kg) Milk (mg/kg) Air (mg/m3)
Use in 
sealants
Formulation and use negligiblea negligiblea negligiblea negligiblea negligiblea negligiblea negligiblea
Formulation 0.36 0.12 2.2´10-3 2.6´10-4 0.054 0.017 1.7´10-5
Industrial application 0.21 0.050 7.1´10-4 1.1´10-4 0.023 7.2´10-3 negligiblea
Use in paints
Domestic application 0.11 4.0´10-3 7.1´10-4 2.5´10-5 7.2´10-3 2.3´10-3 negligiblea
Formulation 1.5 0.65 7.3´10-4 1.4´10-3 0.23 0.071 negligiblea
Use in oil-based fluids 
(large)
0.66 0.26 7.2´10-4 5.6´10-4 0.094 0.030 negligiblea
Use in oil-based fluids 
(small)
0.61 0.24 7.2´10-4 5.1´10-4 0.086 0.027 negligiblea
Use in emulsifiable fluids 0.15 0.024 7.1´10-4 5.0´10-5 0.014 4.3´10-3 negligiblea
Use in metal 
cutting/workin
g fluids
Use in emulsifiable fluids –
intermittent release
0.94c 2.1c 7.7´10-4 c 4.4´10-3 c 0.70c 0.22c negligiblea
Formulation 0.28 0.083 0.011 1.8´10-4 0.089 0.028 8.6´10-5
Use – complete processing 
of raw hides
1.6 0.71 7.3´10-4 1.5´10-3 0.24 0.077 negligiblea
Use in leather 
fat liquors
Use – processing of wet blue 6.1 2.8 7.9´10-4 6.0´10-3 0.95 0.30 negligiblea
Use in 
carbonless 
copy paper
Paper recycling 0.35 0.14 7.1´10-4 3.0´10-4 0.053 0.017 negligiblea
Regional 
sources
0.11 4.0´10-3 7.1´10-4 2.5´10-5 7.2´10-3 3.3´10-3 5.6´10-6
Note: a) The process makes no significant contribution to the concentration in food/air. b) Figures are calculated based on the measured regional water and soil concentrations of 0.1 µg/l and 0.088 mg/kg wet 
wt. respectively. c) Assumes dilution of sewage sludge at wwtp before application to soil (see EU, 2005).  O = Open systems; PO = Partially open systems; C = Closed systems.
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Table 4:9  Estimated human daily intake of medium-chain chlorinated paraffins via environmental routes 
Estimated human daily intake (mg/kg body weight/day)cScenario Step
Wet fish Root crops Leaf crops Drinking 
water 
Meat Milk Air Total
Site A 1.8´10-4 - - 7.5´10-7 - - - 1.8´10-4
Site B 3.1´10- - - 1.3´10-6 - - - 3.1´10-4
Site C 4.3´10-4 - - 1.7´10-6 - - - 4.3´10-4
Production
Site D 1.8´10-4 - - 7.1´10-7 - - - 1.8´10-4
Compounding  - O 2.5´10-4 1.3´10-4 1.2´10-5 1.4´10-6 5.9´10-5 3.5´10-5 1.6´10-6 4.9´10-4
Conversion – O 6.8´10-4 8.2´10-4 1.0´10-4 9.0´10-6 3.7´10-4 2.2´10-4 1.4´10-5 2.2´10-3
Use in PVC –
plastisol coating
Compounding/conversion - O 7.5´10-4 9.3´10-4 1.0´10-4 1.0´10-5 3.9´10-4 2.3´10-4 1.4´10-5 2.4´10-3
Compounding  - O 4.3´10-4 4.2´10-4 3.9´10-5 4.6´10-6 1.7´10-4 1.0´10-4 5.2´10-6 1.2´10-3
Compounding – PO 1.5´10-3 2.2´10-3 1.6´10-4 2.4´10-5 8.0´10-4 4.7´10-4 2.1´10-5 5.2´10-3
Compounding – C 2.9´10-4 2.1´10-4 2.5´10-5 2.3´10-6 9.6´10-5 5.7´10-5 3.3´10-6 6.8´10-4
Conversion – O 9.4´10-4 1.2´10-3 1.5´10-4 1.4´10-5 5.4´10-4 3.2´10-4 2.0´10-5 3.2´10-3
Conversion – PO 1.0´10-3 1.3´10-3 1.6´10-4 1.5´10-5 5.7´10-4 3.4´10-4 2.1´10-5 3.4´10-3
Conversion – C 8.7´10-4 1.1´10-3 1.4´10-4 1.2´10-5 4.9´10-4 2.9´10-4 1.8´10-5 2.9´10-3
Compounding/conversion –
O
1.2´10-3 1.6´10-3 6.8´10-4 1.8´10-5 6.8´10-4 4.0´10-4 2.4´10-5 4.1´10-3
Compounding/conversion -
PO
2.4´10-3 3.5´10-3 3.1´10-4 3.8´10-5 1.3´10-3 7.9´10-4 4.1´10-5 8.3´10-3
Use in PVC –
extrusion/other
Compounding/conversion - C 9.9´10-4 1.3´10-3 1.5´10-4 1.4´10-5 5.6´10-4 3.3´10-4 2.0´10-5 3.4´10-3
Compounding 3.1´10-4 2.2´10-4 2.0´10-5 2.5´10-6 9.4´10-5 5.5´10-5 2.6´10-6 7.0´10-4
Conversion 6.0´10-4 6.9´10-4 8.9´10-5 7.6´10-6 3.1´10-4 1.8´10-4 1.2´10-5 1.9´10-3
Use in 
plastics/rubber
Compounding/conversion 7.3´10-4 8.9´10-4 9.7´10-5 9.8´10-6 3.8´10-4 2.2´10-4 1.3´10-5 2.3´10-3
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Table 4.9 continued 
Estimated human daily intake (mg/kg body weight/day)cScenario Step
Wet fish Root crops Leaf crops Drinking 
water
Meat Milk Air Total
Use in sealants Formulation and use - - - - - - - negligibleb
Formulation 5.9´10-4 6.7´10-4 3.7´10-5 7.4´10-6 2.3´10-4 1.4´10-4 4.9´10-6 1.7´10-3
Industrial application 3.4´10-4 2.8´10-4 1.2´10-5 3.0´10-6 9.7´10-5 5.7´10-5 1.6´10-6 7.9´10-4
Use in paints
Domestic application 1.8´10-4 2.2´10-5 1.2´10-5 7.1´10-7 3.1´10-5 1.8´10-5 1.6´10-6 2.6´10-4
Formulation 2.4´10-3 3.6´10-3 1.3´10-5 4.0´10-5 9.7´10-4 5.7´10-4 1.6´10-6 7.6´10-3
Use in oil-based fluids (large) 1.1´10-3 1.4´10-3 1.2´10-5 1.6´10-5 4.0´10-3 2.4´10-4 1.6´10-6 3.2´10-3
Use in oil-based fluids (small) 1.0´10-3 1.3´10-3 1.2´10-5 1.5´10-5 3.7´10-4 2.2´10-4 1.6´10-6 2.9´10-3
Use in emulsifiable fluids 2.5´10-4 1.3´10-4 1.2´10-5 1.4´10-6 5.9´10-5 3.5´10-5 1.6´10-6 4.9´10-4
Use in metal 
cutting/working 
fluids
Use in emulsifiable fluids –
intermittent releasea
1.5´10-3 0.011 1.3´10-5 1.3´10-4 3.0´10-3 1.8´10-3 1.6´10-6 0.018
Formulation 4.5´10-4 4.5´10-4 1.9´10-4 5.0´10-6 3.8´10-4 2.3´10-4 2.5´10-5 1.7´10-3
Use – complete processing of 
raw hides
2.6´10-3 3.9´10-3 1.3´10-5 4.3´10-5 1.1´10-3 6.2´10-4 1.6´10-6 8.2´10-3
Use in leather 
fat liquors
Use – processing of wet blue 0.010 0.016 1.4´10-5 1.7´10-4 4.1´10-3 2.4´10-3 1.6´10-6 0.032
Use in 
carbonless 
copy paper
Paper recycling 5.8´10-4 7.8´10-4 1.2´10-5 8.6´10-6 2.3´10-4 1.4´10-4 1.6´10-6 1.8´10-3
Regional 
sources
1.8´10-4 2.2´10-5 1.2´10-5 7.1´10-7 3.1´10-5 1.8´10-5 1.6´10-6 2.6´10-4
Note: a) Intermittent release – likely to occur 2-6 times/year only.
b) Process does not contribute significantly to estimated daily intake.
c) Figures are calculated using a measured regional surface water and soil concentration of 0.1 •g/l and 0.088 mg/kg wet weight respectively.
O = Open systems; PO = Partially open systems; C = Closed systems.
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The exposure data from Table 4.9 to be taken through to the risk characterisation (see section 
4.1.3.3) are as follows:
Local exposure: 0.032 mg/kg/day (equivalent to an internal exposure of 0.016 
mg/kg/day based on 50% oral and inhalation absorption): use in leather fat liquors.
Regional exposure: 2.6x10-4 mg/kg/day (equivalent to an internal exposure of 1.3x10-4
mg/kg/day based on 50% oral and inhalation absorption).
Few measured levels for C14-17 chlorinated paraffins in food exist. The available data are 
summarised in Section 3.1.4.2.
In one survey (Campbell and McConnell, 1980), the average levels of C10-20 chlorinated 
paraffins found in human foodstuffs were 0.3 mg/kg in dairy products, 0.15 mg/kg in 
vegetable oils and derivatives, 0.005 mg/kg in fruit and vegetables and not detected 
(<0.05 mg/l) in drinks.  Levels of C10-20 chlorinated paraffins of up to 12 mg/kg have been 
measured in shell fish close to sources of discharge (Campbell and McConnell, 1980).  As 
these measured levels represent the total C10-20 chlorinated paraffins, the medium-chain 
(C14-17) will contribute to, but will not be the only source of, the level of chlorinated paraffin 
measured.
Levels of total (C10-24) chlorinated paraffins in food and fish have also been reported by 
Greenpeace (1995). The mean levels reported (on a fat weight basis) were 271 µg/kg fat in 
mackerel, 62 µg/kg fat in fish oil (herring), 98 µg/kg fat in margarine containing fish oil, 69 
µg/kg fat in pork, 74 µg/kg fat in cows milk and 45 µg/kg fat in human breast milk. Further 
information on the breast milk sampling was obtained from the author of the report. The mean 
level in human breast milk was derived from pooled samples of two groups of women, one of 
non-fish eaters (n=2) and one of fish eaters (n=6). The average chlorine content of the 
chlorinated paraffins detected was around 33%, although a value of 50% was assumed in the 
calculation of chlorinated paraffin content from the measured levels of n-alkanes. Medium 
chain length chlorinated paraffins were thought to make up between 6 and 29% of the total 
chlorinated paraffins found in biota samples as a whole. For the breast milk samples, an actual 
content of 10 and 22% can be deduced for the groups of non-fish eaters and fish eaters 
respectively. Taking an average value for MCCP content of about 17%, the concentrations of 
medium chain length chlorinated paraffins present can be estimated from the data as 46 µg/kg 
fat in mackerel, 12 µg/kg fat in fish oil, 28 µg/kg fat in margarine, 11 µg/kg fat in pork, 
16 µg/kg fat in cows milk and 7 µg/kg fat in mothers milk. Alternatively, based on the highest 
MCCP content (29% for food and fish and 22% for human breast milk) as a worst case 
estimate, the concentrations of MCCPs present in food and fish would be 80 µg/kg fat in 
mackerel, 18 µg/kg fat in fish oil, 28 µg/kg fat in margarine, 10 µg/kg fat in pork, 21 µg/kg 
fat in cows milk and 9 µg/kg fat in mothers milk.
A recent Industry sponsored study has found medium-chain chlorinated paraffins to be 
present in human breast milk samples from the United Kingdom (Thomas and Jones, 2002). 
In all, 22 breast milk samples were analysed (8 from Lancaster and 14 from London, 
apparently randomly chosen) and medium-chain chlorinated paraffins were found in one 
sample from London at a concentration of 61 mg/kg fat but was below the limit of detection in 
the remaining 21 samples. The detection limit of the method varied with sample size but 
ranged from16 mg/kg fat to 740 mg/kg fat (mean level of 100 mg/kg fat). It is noted that these 
detection limits are higher than the measured levels in breast milk reported in the Greenpeace 
study. This suggests that the analytical method used in Thomas and Jones, 2002 was less 
sensitive than that used in the Greenpeace study. The fact that MCCPs were only found in 
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1/22 samples does not mean that it was not present in the other samples at levels below the 
detection limit.
Thomas et al (2003) have recently carried out a further investigation of the levels of 
medium-chain chlorinated paraffins in human breast milk samples from the United Kingdom. 
In this study, relatively large samples of human milk-fat were collected from the London (20 
samples) and Lancaster (5 samples) areas of the United Kingdom between late 2001 and June 
2002. It should be noted that some of London samples were taken from the same mother, such 
that 20 samples were from 13 mothers; five samples were provided from one mother over a 
three-day period, two samples were provided from another mother over a two-day period, a 
further two samples were provided by another mother over a five-day period, and a further 
two samples were provided by another mother over an unknown period. The analysis was 
carried out using high resolution gas chromatograph (HRGC) coupled with electrochemical 
negative ionisation (ECNI)-high resolution mass spectrometry (HRMS) detection. The 
analytical standard used was a commercial medium-chain chlorinated paraffin (C14-17, 52% 
wt. Cl). In addition to total medium-chain chlorinated paraffins, twelve samples (four from 
Lancaster and eight from London) were also analysed in more detail to determine the various 
types of chlorinated paraffin (in terms of chlorine number and carbon chain length 
distributions) present in the samples.
Medium-chain chlorinated paraffins were found to be present in all 25 samples analysed. The 
median, 97.5th percentile value and range of concentrations found were 21 µg/kg lipid, 130.9 
µg/kg lipid and 6.2-320 µg/kg lipid respectively. The levels found in the samples from 
Lancaster were not thought to be significantly different from the levels found in the samples 
from London. The more detailed analysis of the types of chlorinated paraffins present 
indicated that, in general, the pattern of medium-chain chlorinated paraffins found in the milk-
fat samples was heavily skewed towards the C14-chain length compared to the distribution 
found in the medium-chain chlorinated paraffin used as analytical standard. The C14-17, 52% 
wt Cl substance used as an analytical standard was sourced from the United States. Thomas et 
al. (2003) indicated that discussions between European and US producers of medium-chain 
chlorinated paraffins had identified a possible difference in the carbon chain distribution of 
their products, with the products produced in Europe more likely to have a distribution 
skewed towards the shorter chain length components compared to a more Gaussian 
distribution in products in the United States. This is a possible explanation for the findings. 
Other explanations include different volatilities between the different components affecting 
transport from source uses to human exposure media and differences in human absorption 
efficiencies and in metabolism for the different components. It is not possible to determine 
which of these, or other, possibilities accounts for the findings.
Overall, given that of the three studies that are now available on levels of MCCPs in breast 
milk, the most recent one, Thomas et al., 2003 is a very well conducted study, a risk 
characterisation will be performed using the 97.5th percentile level of 130.9 µg/kg fat 
identified from this study.
In addition to human breast milk, Thomas and Jones (2002) also determined the levels of 
medium-chain chlorinated paraffins in a single sample of cow’s milk from Lancaster and 
single butter samples from various regions of Europe (Denmark, Wales, Normandy, Bavaria, 
Ireland, and Southern and Northern Italy). Medium-chain chlorinated paraffins were present 
in the cow’s milk sample at a concentration of 63 mg/kg fat and were found in the butter 
samples from Denmark at 11 mg/kg fat, Wales at 8.8 mg/kg fat and Ireland at 52 mg/kg fat. 
MCCPs were not detected in any other sample. The detection limit for the other butter 
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samples ranged between 8.0 and 11 mg/kg fat. Butter is regularly used as a convenient way of 
obtaining milk-fat samples and therefore the MCCPs levels measured in these butter samples 
can be considered equivalent to the levels present in cow’s milk. For risk characterisation, the 
highest measured level of MCCPs in cow’s milk/butter will be used. This value is 63mg/kg 
fat.
4.1.1.4 Combined exposure
For combined exposure, consideration should be given to a consumer exposed to MCCP and 
who is also exposed indirectly via the environment. However, consumer exposure is 
considered to be an infrequent event rather than repeated daily exposure. Therefore combined 
daily exposures are not relevant and will not be considered in this risk assessment.
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4.1.2 Effects assessment: hazard identification and dose (concentration) -
response (effect) assessment
Introduction
As indicated earlier (see Section 1), medium-chain chlorinated paraffins (MCCPs) are 
produced by the chlorination of straight-chain hydrocarbons of 14-17 carbon atoms in length. 
The degree of chlorination can vary generally from 20-70% by weight, although most 
commercially available products fall in the range 40-70%. Because of the variation in 
combinations of carbon chain length and degree of chlorination, a wide range of products are 
available with an average chain length usually being specified by the manufacturer and a 
chlorination degree being random but defined by weight. Some studies describe the use of a 
MCCP of defined carbon chain length (e.g. C15 or C16). This seems unlikely as the paraffins 
produced during a ‘cracking’ process would be distilled off at temperature ranges that would 
lead to a mixed paraffin (e.g. C14-17, perhaps predominantly C15).
Owing to the wide range of combinations of chain length and chlorination available, it is not 
reasonable to expect there to be a full dataset of toxicology information that would cover each 
possibility. Hence, where data are not available on one particular MCCP product it may be 
possible to read across to information available from another MCCP product. Furthermore, 
short-chain chlorinated paraffins (SCCPs - C10-13, 40-70% chlorination) are also closely 
related to MCCPs, and read-across from SCCP data may also be reasonable, particularly if the 
only difference is in the number of carbon atoms in the backbone of the molecule. MCCPs are 
produced by the chlorination of straight-chain hydrocarbons of 14-17 carbon atoms in length. 
The degree of chlorination can vary generally from 20-70% by weight, although most 
commercially available products fall in the range 40-70%. This compares to SCCPs which are 
produced in a similar way but differ inasmuch as they are composed of chlorinated straight-
chain hydrocarbons of 10-13 carbon atoms also with 40-70% chlorination. Thus, other than a 
small number of carbon atoms in the main ‘backbone’ of the molecule, there is little structural 
difference between MCCPs and SCCPs.
SCCPs were reviewed recently as part of the EU ESR programme (SCCP ESR Risk 
Assessment Report, 2000). Typical physicochemical data for C10-13 SCCPs (SCCP ESR Risk 
Assessment Report, 2000) include: vapour pressure 2x10-2 Pa (50% chlorination, at 40 °C), 
measured log Pow 4.4-6.9 (49% chlorination), 5.7-8.7 (70% chlorination), water solubility 
(59% chlorination) 0.15-0.47 mg/l (at 20 °C). This compares with MCCPs (see Section 1.3): 
vapour pressure 2.7x10-4 Pa (52% chlorination, at 20oC), measured log Pow 5.5-8 (52% 
chlorination), water solubility ~0.027 mg/l. As the degree of chlorination increases so does 
the viscosity at any given temperature (concomitantly, vapour pressure decreases) giving the 
potential for considerable overlap in the range of vapour pressures of SCCPs and MCCPs (see 
Section 1.3). Typical relevant physicochemical data for C10-13 SCCPs and C14-17 MCCPs are 
tabulated below:
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Physicochemical property SCCPs MCCPs
Physical state Liquid Liquid
Boiling point > 200oC > 200oC
Density (at 25oC) 1.2-1.6 g/cm3 1.1-1.3 g/cm3
Vapour pressure 2.1x10-2Pa(50% chlorination, 40oC) 2.7x10-4Pa(52% chlorination, 20oC)
Log Pow 4.4-6.9 (49% chlorination) 5.5-8.0 (45% chlorination)
Water solubility (at 20oC) 0.15-0.47mg/l             (59% 
chlorination)
0.005-0.027 mg/l
Broadly, it can be seen that MCCPs have a lower vapour pressure but they seem to have 
generally similar physicochemical properties. 
For many toxicological endpoints (where such data exist), there is a similarity, at least in 
qualitative terms in the profile of information obtained on MCCPs and SCCPs. Relevant 
toxicological data for C10-13 SCCPs and C14-17 MCCPs are tabulated below:
Toxicological property SCCPs MCCPs
Acute toxicity Low oral and dermal toxicity Low oral toxicity; no dermal data
Irritation No skin and eye irritation No skin and eye irritation
Sensitisation Not a skin sensitiser Not a skin sensitiser
Repeated dose toxicity Target organs: liver, thyroid and 
kidney
Target organs: liver, thyroid and 
kidney
Mutagenicity Not mutagenic Not mutagenic
Carcinogenicity Liver, thyroid and kidney tumours No data
Reproductive toxicity - fertility No effects on fertility No effects on fertility
Reproductive toxicity - development No effects on development No effects on development
Reproductive toxicity – effects 
mediated via lactation
No data Effects on the offspring mediated via 
lactation
Overall, it seems reasonable to suggest that a ‘read-across’ of toxicological data from SCCPs 
is valid where none exist for the MCCPs.
4.1.2.1 Toxicokinetics, metabolism and distribution
4.1.2.1.1 Studies in animals
Inhalation
No studies are available.
Oral
Studies in rats
As part of a repeated-exposure study in which groups of 25 male and 25 female F344 rats 
received 0, 10 or 625 mg.kg-1.day-1 of a mixed C14-17 chlorinated paraffin (52% chlorination) 
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in the diet for 13 weeks, there was an assessment of toxicokinetics (IRDC, 1984 - see also 
Section 4.1.2.6). At the end of the 13-week treatment period, 18 rats/group received a single 
oral gavage dose of either 10 or 625 mg.kg-1 [8-14C] chlorinated n-pentadecane mixed with 
corn oil (this marker substance is anticipated to have similar absorptive properties to the 
MCCPs used in the previous 13 weeks as it is itself a component of the MCCPs). From the 
original 25 animals per group, 7 animals per group were killed and discarded with no further 
investigations to leave 18 per group for the toxicokinetic studies. Animals were housed in 
groups of 3 in glass metabolism cages. During the first 12 hours after the single oral 
administration of radiolabelled material urine, faeces and CO2 were collected from 3 rats per 
dose group. These animals were then killed and samples of whole blood, the contents of the 
alimentary tract, and samples of tissues (adipose, brain, gonads, heart, kidney and liver) taken 
for analysis of the distribution of radiolabelled material. At 24 and 48 hours post-
administration, 3 animals per dose group were killed, with blood samples only being taken. A 
further 3 animals per dose group were also housed for 7 days for the continuous collection of 
urine, faeces and CO2. These animals were killed on completion of the 7 days and samples of 
whole blood, the contents of the alimentary tract, and samples of tissues (adipose, brain, 
gonads, heart, kidney and liver) taken for analysis of the distribution of radiolabelled material. 
Additionally, 3 animals per dose group were killed after 28 and 90 days and samples of 
tissues (adipose, brain, gonads, heart, kidney and liver) taken for analysis of the distribution 
of radiolabelled material. Within this study, no attempts were made to identify potential 
metabolites.
The tissue distribution data of radiolabelled material was poorly presented; no units were 
provided for figures presented, although they were clearly not expressed as a percentage of 
the original dose administered. Hence, it is only possible to present a summary of distribution 
data in relative terms. There was no obvious dose-related pattern to the numbers presented, 
although as expected, the tissue concentrations recorded for animals receiving 
625 mg.kg-1.day-1 were considerably greater (occasionally by an order of magnitude or more) 
than the concentrations at 10 mg.kg-1.day-1 The liver, kidneys and ovaries contained the 
highest initial (first 7 days) concentrations of radioactivity, followed by an increase in adipose 
tissue levels as the levels in the former tissues declined. This latter trend was less apparent in 
‘pretreated’ compared to naive animals. Elimination of radioactivity from adipose tissue 
occurred more slowly than from the liver or the kidneys. No information on the half-life of 
elimination from adipose tissue was given.
In both ‘pretreated’ and naive animals, the faeces was the major route of elimination of 
radiolabelled material. The extent of faecal elimination was broadly similar in pre-treated and 
naive animals. About 40-48% of the total administered radioactivity was recovered in 7 days 
in males at 10 mg.kg-1.day-1 and around 53-61% over 7 days in males at 625 mg.kg-1.day-1. 
For females at 10 mg.kg-1.day-1 around 30% was recovered in the faeces during these first 
7 days, and at 625 mg.kg-1.day-1 the recovery over the first 7 days was markedly greater at 
around 62-74%. For both males and females the majority of the radiolabel eliminated via the 
faeces occurred within the first 2 days after dosing. Recovery of radioactivity in urine and 
exhaled air within 7 days amounted to only 0.8-3% and 0.1-0.3% respectively for both naive 
and pre-treated males and females at 10 and 625 mg.kg-1.day-1.
The recovery data were poorly presented and it is unclear how recovery was calculated. It is 
presumed that the values given refer to the pooling of radiolabelled material from all of those 
tissues examined in the 90 days following the single oral administration; for males at 
10 mg.kg-1.day-1, the total recovery of radiolabel amounted to around 67% of that 
administered, the remaining 33% being unaccounted for. For males at 625 mg.kg-1.day-1 total 
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recovery was about 85%; for females at 10 mg.kg-1.day-1, about 60%, and for females at 
625 mg.kg-1.day-1, about 80%. Overall, at the higher exposure level a greater percentage of 
radiolabelled material was eliminated via the faeces, and the total recovery was also greater.
In summary, the results indicate that, in rats, the radiolabelled material from a C15 MCCP 
(52% chlorination) was absorbed by the oral route and widely distributed. The total recovery 
of radiolabelled material was incomplete (around 30-40% material at 10 mg.kg-1.day-1, and 
15-20% at 625 mg.kg-1.day-1 was unaccounted for) making it difficult to draw many firm 
conclusions. A large proportion of the administered material was rapidly eliminated via the 
faeces and at the highest exposure level used, 625 mg.kg-1.day-1, there was evidence for 
increased faecal elimination. It is not clear if this was as the parent substance and/or 
metabolites. Furthermore, it is unclear whether faecal radioactivity represented material that 
was not absorbed or had been absorbed and then excreted via the biliary route. Of the material 
absorbed into the body, there was also evidence for uptake into fatty tissue.
In a study briefly summarised in a review by Birtley et al (1980), male Wistar rats were fed 
either 0.4 or 40 ppm [36Cl]-mixed C14-17 chlorinated paraffin (52% chlorination, and 
presumably randomly radiolabelled) in the diet for 10 or 8 weeks respectively. Assuming a 
mean bodyweight for males of 250g, and 200g for females, and food consumption of 
20g.day-1 for males and 16g.day-1 for females (using data from a repeated dose toxicity study 
presented in this review), these dietary inclusion levels correlate to approximately 0.03 and 
3 mg.kg-1.day-1 for both males and females. Groups of 3 animals were killed at weekly 
intervals beginning at week 1 of treatment. On completion of the 10-week treatment period, 
surviving animals that had received 0.4 ppm only were returned to a control diet, and 
3 animals were killed at various time points over an 8-week post-treatment period to assess 
the elimination half-life. Immediately after sacrifice, the level of radiolabelled material 
present in the liver, brain, adrenal glands and abdominal adipose tissue was assessed. For 
animals that received 40 ppm, samples of liver and adipose tissue were only taken during the 
first 8 weeks of the treatment period; there was no assessment of tissue retention and 
excretion on cessation of exposure.
At both 0.4 and 40 ppm, equilibrium levels of radioactivity were reached within 1 week for 
the liver and 7 weeks of treatment for adipose tissue. For each of the tissues examined (liver 
and adipose) the mean tissue concentration of radioactive material was approximately one 
hundred times as great in rats that had been administered 40 ppm 36Cl MCCP compared to 
those adminstered 0.4 ppm. No radioactivity was found in the brain or the adrenals. The 
half-life for removal of radioactivity from the abdominal fat after treatment with 0.4 ppm was 
estimated as approximately 8 weeks, whilst in the liver, no radioactivity was detected at 
1 week after the cessation of the radiolabelled dose. No attempts were made to identify 
potential metabolites or determine routes of elimination. 
This study demonstrates absorption (via the oral route), and distribution of a mixed MCCP 
(52% chlorination) to the liver and adipose tissue. It also suggests that there is a relatively 
rapid elimination from the liver, but considerably slower release from adipose tissue, and at 
the concentrations used, an equilibrium between plasma levels and adipose levels of 
radiolabelled material is reached. However, in view of the dosing regime employed (dietary 
administration rather than gavage dosing), the reliability of the estimated equilibrium time is 
uncertain. Overall, given that an elimination half-life from adipose tissue of 8 weeks was 
measured, it can be concluded that MCCPs are sequestred for a protracted period in adipose 
tissue and therefore have the potential to accumulate in this tissue.
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As part of a standard repeated-exposure study (Poon et al, 1995 see Section 4.1.2.6) samples 
of liver and adipose tissue were taken at termination from groups of 4 Sprague-Dawley rats 
that had received 0, 5, 50, 500, and 5000 ppm (approximately 0, 0.4, 4, 36, and 
360 mg.kg-1.day-1 in males and 0, 0.4, 4, 42 and 420 mg.kg-1.day-1 in females) C14-17 MCCP 
(52% chlorination) by dietary administration for 13 weeks. There was a dose-dependent 
increase in the concentration of the parent compound in both of these tissues, with particularly 
high concentrations in adipose tissue. Data were not presented, although the authors stated 
that there was no bioconcentration (levels in adipose tissue did not rise to greater than the 
external concentration administered). Other tissues were not analysed.
In a recent QA-compliant study conducted to determine the elimination half-life of MCCPs in 
the rat following a single oral administration, 18 male F344 rats were given a single dose of 
[8-14C]-labelled C15 chlorinated paraffin (52% chlorination) in corn oil at 525 mg/kg by 
gavage (day 1) (CXR, 2005a). Immediately after dosing, 3 animals were individually housed 
in metabolism cages for collection of urine and faeces once daily on days 2-5. The remaining 
15 animals were housed together in normal cages. At 24 hours after dosing (day 2), 3 of these 
15 animals were sacrificed and blood and tissues collected for analysis. The 3 rats 
individually housed in metabolism cages were sacrificed on day 5 and blood and tissues 
collected. On day 8 a second group of 3 rats were placed in metabolism cages and urine and 
faeces collected on days 9-12. The animals were then sacrificed on day 12 and blood and 
tissues collected. The same procedure was repeated with the remaining 3 sets of 3 rats each on 
days 22, 50 and 85 with animals being sacrificed on days 26, 54 and 89 respectively.
Twenty-four hours after dosing, the liver, kidney, fat and skin/fur contained the highest 
concentrations of radioactivity (1.6, 0.07 and 2.7% of the administered dose respectively). 
Thereafter, concentrations of radioactivity declined in all tissues except for the fat and the 
skin/fur. The amount of the administered dose recovered from body tissues including blood 
remained at approximately 7% until day 12, but it declined to approximately 2% by day 89. 
Although the amount of radioactivity (as % of the administered dose) recovered from the 
body was the same during the first 12 days, there was a re-distribution into fat (a maximum of 
2.5% on day 12) and skin/fur (a maximum of 3.7% on day 12) over this time. At 24 hours 
after dosing (day 2), the liver contained 1.6% of the administered dose but this rapidly 
declined, and by day 5 only 0.3% of the administered dose was recovered from the liver. For 
well-perfused tissues such as the liver and kidney, the tissue:plasma distribution ratios of 
radioactivity remained constant throughout the study, indicating good equilibrium between 
the plasma and these tissues. For the fat and skin/fur, the tissue:plasma distribution ratios 
changed over time with radioactivity accumulating in these tissues over the first 12 days and 
thereafter slowly declining. Distribution into the liver and kidney was rapid, with the highest 
levels seen on day 2. Distribution into fat and skin/fur was slow with the highest levels seen 
on days 5 and 12. Elimination of radioactivity from body tissues occurred with an elimination 
half-life of approximately 2-5 days (tissues such as liver and kidney) or approximately 2 
weeks (tissues such as white adipose).
Excretion via the faeces was the major route of elimination of radiolabelled material. 
Approximately 50% of the administered dose was rapidly eliminated in the faeces within the 
first 24 hours after dosing. It is reasonable to assume that this radioactivity represents material 
that was not absorbed by the gastro-intestinal (GI) tract. Therefore, it can be concluded that 
approximately 50% of the administered dose was absorbed from the GI tract following gavage 
administration of [8-14C]-labelled C15 chlorinated paraffin at 525 mg/kg.  Approximately 
70% of the dose was recovered in the faeces and approximately 5% in the urine by day 5. 
Over this time the total recovery of radiolabelled material was high (83.6%). On completion 
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of the study (day 89) approximately 2% of the administered radioactivity remained in the 
tissues, primarily in the skin/fur. 
In summary, the results of this study indicate that, in the male rat, approximately 50% of a 
single dose of [8-14C]-labelled C15 chlorinated paraffin was absorbed from the GI tract and 
this was widely distributed. The faeces were the major route of elimination of the 
radiolabelled material. The elimination half-life of a single dose of [8-14C]-labelled C15
chlorinated paraffin and/or its metabolites in tissues such as liver and kidney was 2-5 days 
and in tissues such as white adipose was about 2 weeks. Since C15 chlorinated paraffin is itself 
a component of MCCPs, it is reasonable to assume that MCCPs will have similar kinetic 
properties to those shown in this study by C15 chlorinated paraffin. 
The final report of a QA-compliant study investigating the bioaccumulation potential of 
MCCPs in the rat following repeated administration has recently become available (CXR, 
2005b). Groups of 48 F344 rats/sex were administered MCCPs (52% chlorination) in the diet 
at a concentration of 3000 ppm (equivalent to 200/233 mg/kg/d in males/females) for 14 
weeks, time at which steady state level of MCCPs in white adipose tissue was achieved. This 
was monitored by sacrificing groups of 8 animals (4 males and 4 females) at 3-week intervals. 
After 14 weeks exposure, the remaining rats were transferred to control diet. Groups of 8 rats 
(4 males and 4 females) were then sacrificed at weeks 15, 16, 18, 22, 30, 40 and 52 (weeks 1, 
2, 4, 8, 16, 26 and 38 post-dosing) to determine the elimination of MCCPs from white adipose 
tissue, liver and kidney. The MCCPs content of these tissues was extracted in hexane and 
analysed by gas chromatography.
Recovery of MCCPs (in the hexane extract) from tissues was estimated using a limited 
number of samples collected from rats administered via gavage a single dose of 525 mg/kg 
14C-MCCP (CXR, 2005a; previous study) and stored at -70°C. Recovery was calculated as the 
fraction of radioactivity present in the hexane extract compared to the radioactivity present in 
the tissue homogenate. Mean recovery of MCCPs from adipose tissue was estimated to be 
approximately 55%, and ranged from 37% to 72%. Mean recovery of MCCPs from kideny 
and liver was estimated to be approximately 10% and 15%, respectively. It is not known why 
recovery from kidney and liver was lower than from adipose tissue, but one possible 
explanation is that the extraction of lipids into hexane might facilitate the excretion of MCCPs 
from adipose tissue.
The MCCPs content in white adipose tissue after correction for recovery increased with time 
until week 13, with females showing approximately twice the amount of MCCPs per gram of 
white adipose tissue than males (from 903 mg MCCPs/g tissue at 3 weeks up to 3110 mg 
MCCPs/g tissue at 13 weeks in females and from 826 mg MCCPs/g tissue at 3 weeks up to 
1731 mg MCCPs/g tissue at 13 weeks in males). It should be noted that although steady state 
in the adipose tissue was reached at week 13, levels of MCCPs in this tissue were already 
close to the steady state levels by week 9 (2654 and 1621 mg MCCPs/g tissue in females and 
males respectively). Following exposure (with achievement of the steady state level), the 
elimination of MCCPs from adipose tissue appeared to be biphasic, with a rapid first phase of 
approximately 4-5 weeks (from wk 14 to wk 18) and a much slower second phase of 
approximately 34 weeks (from wk 18 to wk 52). Both male and female rats quickly 
eliminated MCCPs in the first phase with an initial half-life of 4.7 weeks (4.4 weeks in 
females and 5.0 weeks in males), followed by a markedly slower second phase. By week 22 
(8 weeks into the wash-out phase), the concentration of MCCPs in adipose tissue of both 
sexes was similar (1198 and 984 mg MCCPs/g tissue in females and males respectively). The 
concentration of MCCPs in adipose tissue slowly decreased between weeks 22 and 52 (740 
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and 623 mg MCCPs/g tissue in females and males respectively). Analysis of the terminal 
elimination phase of MCCPs from white adipose tissue, using data from weeks 22 to 52 
inclusive, elicited a second phase half-life of approximately 44 weeks for the females and 
approximately 42 weeks for the males. 
It was not possible to quantify MCCPs in liver or kidney tissue. This was due to the poor 
recovery of MCCPs in the hexane extract and to the high background from endogeneous 
compounds.
Studies in mice
The distribution and excretion of a single dose of approximately 1 mg.kg-1 of 
uniformly-labelled [14C]- poly-chlorinated hexadecane (PCHD) was studied in female C57Bl 
mice treated via oral gavage administration (Biessmann et al, 1983). Expiration of 14CO2 was 
monitored for 8 hours post-treatment and urine and faeces collected every 8 hours for 4 days 
for radioactivity determinations. A further group of mice received about 10 mg.kg-1 via oral 
gavage and whole body autoradiography (WBA) was conducted on one animal at 4 hours, 
1 day, 4 days, 12 days and 30 days post-administration. 
WBA conducted at 4 hours, 1, 4, 12 and 30 days after the 10 mg.kg-1 dose revealed that the 
administered radioactivity was concentrated mainly in the corpora lutea, liver, adrenal cortex 
and brown and white adipose tissue. Only a small number of sample autoradiographs were 
presented. These indicated a concentration of radiolabelled material (at 4 days) in the liver, 
brown adipose tissue, and corpora lutea. Thirty days post-administration, the corpora lutea 
and brown fat still showed high levels of radioactivity.
The major route of elimination was via the faeces; 66% of the administered radioactivity was 
eliminated via this route in 4 days, with a substantial proportion (57%) of the administered 
dose, being eliminated within the first 16 hours. With the 1 mg.kg-1 dose, approximately 1% 
of the administered radioactivity was exhaled as 14CO2. The remaining 34% of radiolabelled 
material was not directly accounted for, although the indication from WBA (see below) is that 
much was retained in the carcass (principally adipose tissue). 
A similar study using i.v. administration was also conducted using the same experimental 
protocol as for oral dosing. Of the administered dose, again the major route of elimination was 
via the faeces with 43% of the administered dose being eliminated within 4 days of treatment; 
approximately 1% appeared in expired air as 14CO2. This suggests that much of the faecal 
elimination following oral dosing represented excretion of material previously absorbed into 
the body, rather than the substance simply passing through the GI tract. However, in contrast 
to oral exposure, during the first 8 hours after treatment, faecal elimination following i.v. 
administration accounted for only 2% of the administered dose (compared to 22% by the oral 
route) indicating that excretion via the bile and faeces takes some time and perhaps that the 
early faecal levels are due to elimination rather than excretion. Urinary excretion accounted 
for 3% of the administered dose.
Overall, this study also indicates absorption, and widespread distribution via the oral route of 
a MCCP (69% chlorination) or metabolites. Substantial elimination of the parent substance 
and/or metabolites occurred via the faeces but there was limited excretion as exhaled CO2 and 
via urine. Autoradiography studies demonstrated substantial retention of radiolabelled 
material in white adipose tissue, but also in corpora lutea, liver and adrenal cortex.
A group of 3 female C57Bl mice was given a single oral gavage dose of approximately 
0.15 mg.kg-1 [1-14C]-radiolabelled PCHD via oral gavage (Darnerud and Brandt, 1982). One 
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animal was then sacrificed at each of 4 and 24 hours, and 4 days post-dose and sectioned for 
WBA. A further group of 5 pregnant females received a similar dose of [1-14C]-radiolabelled 
PCHD by i.v. administration; animals were sacrificed on gestation day 10 and sectioned for 
WBA at each of 6 hours and 24 hours after the i.v. injection, and on gestation day 17 at each 
of 6 hours, 24 hours, and 2 days after the i.v. injection. In addition, one group of 8 females 
received a similar dose of [1-14C]-radiolabelled PCHD by i.v. administration and one animal 
was sacrificed at each of the following timepoints after injection: 5 minutes, 20 minutes, 
1 hour, 4 hours, 24 hours, 4 days, 12 days, and 30 days. Similarly, another group of two males 
received [1-14C]-radiolabelled PCHD by i.v. administration with one animal sacrificed 
24 hours post-administration and another at 30 days.
To determine tissue retention, 4 female mice were given a single oral gavage dose of around 
0.01 mg.kg-1 [1-14C]-radiolabelled PCHD. One group of 4 mice was sacrificed at each of 
1 hour, 4 hours, 24 hours, 4 days, and 12 days after oral administration and samples taken of 
blood, liver, kidney, white and brown adipose tissue, and the brain for analysis of the tissue 
levels of radioactivity. Ether extracts of tissues taken at 1 hour were separated by thin-layer 
chromatography (TLC) and localised autoradiographically.
In addition, one group of 4 mice received a single oral gavage dose of approximately
0.02 mg.kg-1 [1-14C]-radiolabelled PCHD. Pooled samples of exhaled air were collected 
between 15 minutes and 12 hours post-administration for analysis for 14CO2. The total 
radioactivity was measured for pooled urine and faeces samples collected over this 12-hour 
period.
The WBA showed that at 4 hours following oral gavage administration, as expected, there 
was intense radioactivity in the stomach and GI tract. Twenty four hours post-administration, 
the most intense radioactivity was seen in brown adipose tissue, liver, kidney, adrenals, bone 
marrow, Harderian gland, salivary glands, pancreas, and intestinal mucosa. 
At 12 days, following i.v. injection, high concentrations of the radiolabel were noted in the 
adrenal cortex, adipose tissue and gall bladder. It was stated that radioactivity was 
concentrated mainly in the brain and liver 30 days after i.v. administration (although no 
sample autoradiograph was presented to demonstrate this). The study in which pregnant mice 
received radiolabelled material by the i.v. route showed a broadly similar pattern of 
distribution, although the passage of radiolabelled material to the developing fetus was also 
observed.
The quantitative studies of tissue distribution did not present levels of radioactive material as 
a percentage of that administered. However, the data showed measurable levels of 
radiolabelled material in all tissues examined (blood, liver, kidney, white and brown adipose 
tissue, and brain). The peak plasma level was noted at 1 hour post-administration, gradually 
declining over the next 12 days. For liver and kidneys, peak levels were observed at 4 hours, 
with a subsequent decline. However, the highest levels were measured in brown adipose 
tissue, and to a lesser extent in white adipose tissue, and these tissue levels declined much 
more slowly. No quantitative data were presented for the brain. 
TLC of samples taken from the liver, kidney, and brown adipose tissue 1 hour after the oral 
administration of radiolabelled material showed the presence of a radiolabelled substance that 
eluted in the same position as a referent sample of the parent compound (PCHD). There were 
no further attempts to quantify or identify these radiolabelled fractions but the implication is 
that these mixed MCCPs were distributed to these tissues without further metabolism.
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In contrast with studies reviewed above, a substantial proportion (33%) of the administered 
radioactivity was eliminated as 14CO2 in expired air within 12 hours of dosing. Approximately 
6 and 14% of the administered dose appeared in the urine and faeces respectively. The 
remaining radiolabel was not accounted for in the balance study, although the qualitative 
(WBA) and quantitative studies indicate that much may have been distributed in other tissues 
around the body.
The study demonstrates extensive absorption from the GI tract following oral administration 
of this MCCP (34% chlorination). The WBA examinations showed widespread distribution 
although no meaningful quantitative data were presented. However, in common with other 
studies on MCCPs (of greater chlorination), the adipose tissue was seen to be a site of uptake 
of radiolabel. Transplacental passage of radiolabelled material was seen following i.v. 
administration, and given the similarities seen in the profile of distribution from oral and i.v. 
routes, it is presumed that this may also occur following oral administration of these MCCPs. 
There is evidence to suggest that, at least initially, this MCCP can reach the liver, kidneys and 
adipose tissue in an unmetabolised form. It is unclear what happens thereafter, although the 
production of radiolabelled CO2 indicates that metabolism can and does occur. The relatively 
small degree of elimination via the faeces in this study differs markedly from that seen in the 
Biessmann et al (1983) study also conducted in mice, and the one available rat study 
exploring elimination (IRDC, 1984). The difference in elimination pattern may be attributable 
to the difference in the degree of chlorination for the MCCP used in this study, resulting in it 
being handled somewhat differently in the body.
Groups of 6 neonatal/pre-weaning NMRI mice (aged 3, 10 or 20 days old) received a single 
oral gavage dose of 1.1 mg.kg-1 uniformly-labelled 14C-PCHD (69% chlorination) (Eriksson 
and Darnerud, 1985). Animals were killed 1 and 7 days after treatment, and the only 
quantitative determinations of levels of radioactivity made were for the brain and liver. A 
further 2 mice (aged 3, 10 or 20 days old) received a single oral gavage dose of about 
7 mg.kg-1 uniformly-labelled 14C-‘PCHD’ (69% chlorination) and following sacrifice 
(presumably also on days 1 and 7 after administration of the radiolabelled PHCD), sections 
were taken for WBA.
For mice that were 3 days old at the time of treatment, the level of radioactivity in the brain 
was around 3% of the dose administered, and for 20-day old mice, about 0.5% at the 24-hour 
time-point. Curiously, the level of radioactivity in the liver of 3-day old mice was stated to be 
around 150% of the dose administered, and for 10-day old mice was 100% at the 24-hour time 
point. For mice of each age (3 days, 10 days or 20 days) the level of radioactivity was lower at 
7 days compared to 24 hours in both brain and liver samples.
WBA sections taken 7 days after the administration of radiolabelled material in 10-day old 
mice revealed high levels of radioactivity in adipose tissue, adrenals, and in myelinated areas 
of the brain. No data were presented for 3-day or 20-day old mice, but the results from these 
young animals seem to support other published autoradiography studies in more mature mice.
Dermal
No studies are available investigating dermal absorption of MCCPs in vivo.
In a briefly presented in vitro study, a 14C-labelled C14-17 MCCP (52% chlorination) was 
applied to a human epidermal membrane for 55 hours apparently using a static collection 
system (Scott, 1984). The source of human skin and position of radiolabel on the paraffin 
were not indicated. A range of different receptor fluids was used (100% ethanol, 50% aqueous 
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ethanol, 20% horse serum in saline, a non-ionic surfactant, and an emulsifying agent). No 
absorption of radiolabelled material was detected during the 56 hours of exposure. 
In a recent in vitro skin absorption study conducted to GLP and OECD guidelines, [8-14C]-
labelled C15 chlorinated paraffin (52% chlorination; specific activity 1.33 mCi/ml) was 
applied to human skin membranes using a flow through apparatus (Johnson, unpublished, 
2005). Discs of approximately 3.3 cm diameter of epidermal membranes from at least three 
subjects being checked for integrity were mounted in diffusion cells. Doses of 10 ml/cm2
(equivalent to 12.6 mg/cm2) and 100 ml/cm2 (equivalent to 125.8 mg/cm2) of the test 
substance were applied to the skin membranes for 24 hours. The cells dosed with 10 ml/cm2
were left unoccluded while the cells dosed with 100 ml/cm2 were occluded. At 2, 4, 8, 12, 16, 
20 and 24 hours after dosing, 0.5 ml samples of the receptor fluid (6% polyoxyethylene 20 
oleyl ether in water) were taken for analysis. At the end of the exposure period, the epidermal 
surface was decontaminated by gently swabbing the application site and the surface of the 
skin was allowed to dry naturally. To assess penetration through the stratum corneum, 
successive layers of the stratum corneum were removed by the repeated application of 
adhesive tape to a maximum of 5 strips and analysed. The remaining epidermis was removed 
from the receptor chamber, digested and analysed.
The mass balance recovery for both dose levels was excellent, in the range 90.1-113% of the 
applied dose, with the vast majority of the applied dose (97%) being removed by the washing 
procedure, 0.702% being found in the epidermis and 2.15% being recovered from the stratum 
corneum. For the unoccluded dose of 10 ml/cm2 and the occluded dose of 100 ml/cm2
respectively, 0.002% and 0.001% of the applied dose was recovered in the receptor fluid by 
24 hours. By assuming that the material absorbed is made of the fraction present in the 
receptor fluid and of that found in the epidermis, the maximal dermal absorption of a C15
chlorinated paraffin through human skin after 24 hours was approximately 0.704% 
(0.002+0.702) of the dose applied. Since C15 chlorinated paraffin is itself a component of 
MCCPs, it is reasonable to assume that MCCPs will have a similar dermal absorption to that 
shown in this study by C15 chlorinated paraffin. It is noted that this percentage is likely to be 
an overestimate as this study was specifically designed to measure skin penetration under the 
most conservative conditions. Epidermal membranes were used (not whole skin); a 
solubilising receptor phase containing surfactant was used (not saline) to ensure free 
partitioning of the test substance; and a worst case continuous exposure for 24 hours under 
occluded conditions was studied. It is also deemed that under the condistions of this study the 
fraction present in the stratum corneum represents unabsorbable material that would be lost by 
desquamation in vivo. This is supported by evidence showing that the test substance had not 
moved beyond this outer layer in 24 hours and by the lack of a significant lag phase (based on 
the absorption profile between 2 and 24 hours).  
Other studies 
In a limited assessment of the formation of potential metabolites, a group of 4 bile-duct 
cannulated female Sprague-Dawley rats received 5-6 mg.kg-1 uniformly labelled PCHD (65% 
chlorination) by i.v. injection (Ahlman et al, 1986). Bile was collected for up to 3 days and 
potential metabolites analysed chromatographically. Urine and faeces were collected over a 2-
day period. Animals were killed on completion of these collections and radioactivity was 
measured in liver, kidneys, adipose tissue, muscle, adrenals and ovaries.
A total of around 20-30% of the administered radiolabel was eliminated via the bile in 3 days, 
with around 10% eliminated within 24 hours of treatment. Unchanged parent compound 
accounted for up to a maximum of 3% of the radiolabelled material present in the bile. Very 
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low levels of radioactivity were found in the urine and faeces samples collected over 2 days 
(less than 0.5% in each case). Radioactivity was also detected in each of the tissues removed 
at sacrifice, with the highest levels being observed in liver, adrenals and ovaries. However, 
the data were not quantified as a percentage of the amount administered. There was no 
quantitation of the proportion of the dose administered represented by these metabolites.
The TLC analysis of urine samples indicated metabolites that were tentatively identified as 
mercapturic acids and methylated mercapturic acids of the MCCP, indicating conjugation of 
the MCCPs with glutathione. Similarly, analysis of the biliary metabolites suggested the 
presence of a mercapturic acid of the MCCPs.
Overall, this study is limited, but it does demonstrate metabolism of a MCCP (65% 
chlorination) probably involving conjugation with glutathione.
4.1.2.1.2 Studies in humans
The only human data available relates to the presence of chlorinated paraffins in human breast 
milk, indicating that excretion via this route can occur. Greenpeace (1995) reported a mean 
level of 45 µg/kg (on a fat weight basis) chlorinated paraffins in human breast milk. Further 
information on the breast milk sampling was obtained from the author of the report. The 
breast milk analysis was based on pooled samples of two groups of women, one of non-fish 
eaters (n=2) and one of fish eaters (n=6). The average chlorine content of the chlorinated 
paraffins detected was around 33%, although a value of 50% was assumed in the calculation 
of chlorinated paraffin content from the measured levels of n-alkanes. Medium chain length 
chlorinated paraffins were thought to make up between 6 and 29% of the total chlorinated 
paraffins found in the biota sampleas as a whole, although an actual content in breast milk of 
10 and 22% can be deduced for the groups of non-fish eaters and fish eaters respectively. 
Taking an average value for MCCPs of about 17%, this is equivalent to an estimated MCCP 
concentration of 7 µg/kg in breast milk; alternatively, based on the highest MCCP content 
(22%) as a worst case estimate, this is equivalent to a concentration of about 9.0 µg/kg in 
breast milk. The pattern of carbon chain length alkanes reported does not reflect that of a 
typical C14-17 chlorinated paraffin.
A recent Industry sponsored study has found medium-chain chlorinated paraffins to be 
present in human breast milk samples from the United Kingdom (Thomas and Jones, 2002). 
In all, 22 breast milk samples were analysed (8 from Lancaster and 14 from London, 
apparently randomly chosen) and medium-chain chlorinated paraffins were found in one 
sample from London at a concentration of 61 mg/kg fat but was below the limit of detection in 
the remaining 21 samples. The detection limit of the method varied with sample size but 
ranged from 16 mg/kg fat to 740 mg/kg fat (mean level of 100 mg/kg fat). It is noted that these 
detection limits are higher than the measured levels in breast milk reported in the Greenpeace 
study. This suggests that the analytical method used in Thomas and Jones, 2002 was less 
sensitive than that used in the Greenpeace study. The fact that MCCPs were only found in 
1/22 samples does not mean that it was not present in the other samples at levels below the 
detection limit.
Thomas et al (2003) have recently carried out a further investigation of the levels of 
medium-chain chlorinated paraffins in human breast milk samples from the United Kingdom. 
In this study, relatively large samples of human milk-fat were collected from the London (20 
samples) and Lancaster (5 samples) areas of the United Kingdom between late 2001 and June 
2002. It should be noted that some of the London samples were taken from the same mother, 
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such that 20 samples were from 13 mothers; five samples were provided from one mother 
over a three-day period, two samples were provided from another mother over a two-day 
period, a further two samples were provided by another mother over a five-day period, and a 
further two samples were provided by another mother over an unknown period. The analysis 
was carried out using high resolution gas chromatograph (HRGC) coupled with 
electrochemical negative ionisation (ECNI)-high resolution mass spectrometry (HRMS) 
detection. The analytical standard used was a commercial medium-chain chlorinated paraffin 
(C14-17, 52% wt. Cl). In addition to total medium-chain chlorinated paraffins, twelve samples 
(four from Lancaster and eight from London) were also analysed in more detail to determine 
the various types of chlorinated paraffin (in terms of chlorine number and carbon chain length 
distributions) present in the samples.
Medium-chain chlorinated paraffins were found to be present in all 25 samples analysed. The 
median, 97.5th percentile value and range of concentrations found were 21 µg/kg lipid, 130.9  
µg/kg lipid and 6.2-320 µg/kg lipid respectively. The levels found in the samples from 
Lancaster were not thought to be significantly different from the levels found in the samples 
from London.
4.1.2.1.3 Summary of toxicokinetics
The only human data relates to information on the presence of chlorinated paraffins in human 
breast milk, indicating the potential for excretion via this route. No studies have been 
undertaken to investigate the toxicokinetics of MCCPs following exposure of animals via the 
inhalation or dermal routes. A recent GLP- and OECD-compliant in vitro study using human 
skin showed that after 24 hours, approximately 0.7% of a C15 chlorinated paraffin was 
absorbed. A dermal absorption value of 1% is therefore taken forward to the risk 
characterisation.
Absorption following oral exposure in animals has been demonstrated to be significant 
(probably at least 50% of the total administered dose). Overall, therefore, 50% absorption by 
this route will be assumed for risk characterisation purposes. There is no specific information 
for the inhalation route of exposure; however, given that the data indicate 50% absorption by 
the oral route and only 1% by the dermal route, and in view of the very high log Pow and the 
very low water solubility of MCCPs, it reasonable to assume that inhalation absorption is also 
unlikely to be higher than 50%. This figure will therefore be taken forward to the risk 
characterisation in relation to absorption via the inhalation route of exposure. The data 
available do not allow any conclusions to be drawn regarding the way in which the degree of 
chlorination of these substances may affect the extent of absorption following oral 
administration (or any other route).
Following absorption of radiolabelled material via the oral route, as with SCCPs, there is an 
initial preferential distribution of radiolabel to tissues of high metabolic turnover/cellular 
proliferation. Subsequently, there is a re-distribution of radiolabelled material to fatty tissue. 
Following single gavage dosing in the rat, an elimination half-life of approximately 2-5 days 
was estimated for tissues such as the liver and kidney and of about 2 weeks for tissues such as 
white adipose. Following repeated dietary administration, retention in fatty tissue occurs, with 
one study in rats revealing a half-life for elimination from the abdominal fat of 8 weeks. 
Results of a very recent study in the rat have shown that steady state in adipose tissue is 
reached at approximately 13 weeks and that elimination of MCCPs from this tissue appears to 
be biphasic, with an initial half-life of approximately 4 weeks, followed by a markedly slower 
second phase with a terminal half-life of approximately 43 weeks. For most studies, it is 
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unclear whether the distributed material is the parent compound and/or metabolites. However, 
two studies clearly indicate that it is the parent compound that is sequestered in adipose tissue 
and liver. In a later section (see Section 4.1.2.9), there is evidence to suggest that MCCPs or 
metabolites might be transferred to offspring via breast milk; MCCPs have also been 
measured in human breast milk. Transmission of MCCPs (34% chlorination) or metabolites 
via the mother to the developing fetus in utero was evident although it is not clear if this 
occurs with all forms of MCCPs. There are no parallel data from SCCPs in terms of 
transmission of the substance or its metabolites via maternal milk or to the developing foetus. 
In relation to metabolism, one study with a 65% chlorinated MCCP indicated conjugation 
with glutathione. The production of CO2 from MCCPs has also been demonstrated; 
metabolism to CO2 was quite extensive with MCCPs of lower chlorination, but appeared to be 
much more limited with more heavily chlorinated MCCPs (e.g. 69% chlorination). CO2 was 
also produced following oral administration of SCCPs in rodents, and the degree of 
chlorination had a similar influence on the extent of CO2 production. Elimination of MCCPs 
and/or their metabolites occurs via the faeces, via exhaled CO2 with lower chlorinated 
MCCPs (e.g. 34% chlorination), and to a limited extent in the urine. 
Although limited data are available on short-chain chlorinated paraffins, there are many 
parallels in the overall toxicokinetic profile which would tend to support the validity of 
read-across of toxicological data when these are lacking for MCCPs (SCCP ESR Risk 
Assessment Report, 2000).
4.1.2.2 Acute toxicity
It is noted that some of the MCCPs for which toxicity test data are available have had a low 
concentration of an ‘epoxy stabiliser’ added. However close inspection of data (some studies 
having been conducted without any ‘stabiliser’ added) indicates that the presence of the 
stabiliser at the levels used had no effect on the toxicological profile.   
4.1.2.2.1 Studies in animals
Inhalation
No animal studies are available on MCCPs. However, the limited data on structurally-related 
SCCPs (C11-13, 59% chlorination) demonstrate low toxicity by single inhalation exposure; 
there was no evidence of toxicity in rats following a 1-hour exposure to a vapour or aerosol of 
3300 mg.m-3 (cited in SCCP ESR Risk Assessment Report, 2000). Hence, in view of the 
similarities in structure and physicochemical properties (see Introduction to Section 4.1.2) it is 
predicted that MCCPs would also be of low toxicity by single inhalation exposure. This is 
supported by the observation of low toxicity of MCCPs by oral and dermal routes (see below) 
and the generally unreactive nature of these substances.
Oral
A number of unpublished studies are available in which rats received single oral gavage doses 
of up to 15 000 mg.kg-1 MCCPs (40-52% chlorination; containing 0.2-1% epoxy stabiliser) 
(Kuhnert,1986a; Kuhnert,1986b; Chater,1978). No deaths occurred in any of these studies and 
clinical signs of toxicity were confined to urinary incontinence or "oily/moist pelt around the 
anal-genital region" during the first 24-48 hours following administration.
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The results of eight single exposure studies in which Alderley Park (Wistar-derived) rats 
received oral gavage doses of 500-10 000 mg.kg-1 C14-17 MCCPs (51-60% chlorination; with 
or without 0.2% epoxy stabiliser) were cited by Birtley et al (1980). This review also reported 
the results of two single exposure studies using SCCPs. However, it was not possible to 
clearly delineate the results of work on SCCPs and MCCPs. Nonetheless, no mortalities were 
observed. It is reported that clinical signs included piloerection, incoordination and urinary 
incontinence. Histopathologically, hepatocellular vacuolation and focal necrosis were seen in 
the liver, and cloudy swelling of inner cortical cells was seen in the kidney. The limitations in 
reporting make it impossible to ascertain which observations were attributable to treatment 
with MCCPs or SCCPs; if the results applied to both, or the dose levels at which the reported 
effects occurred.
Dermal
No animal studies are available in relation to MCCPs.  However, data are available on SCCPs 
which indicate that no signs of local or systemic toxicity were seen in rats following dermal 
administration of 2800 mg.kg-1 of a 52% chlorinated SCCP (cited in SCCP ESR Risk 
Assessment Report, 2000).  This review also cited a dermal LD50 value of approximately 
13000 mg.kg-1 in rabbits for a 59% chlorinated SCCP (SCCP ESR Risk Assessment Report, 
2000).
Overall, there are no experimental data specifically in relation to the acute dermal toxicity of 
MCCPs. SCCPs have been demonstrated to be of low toxicity by this route, and in 
consideration of the structural and physicochemical similarities, together with the low acute 
oral toxicity of MCCPs, it can be predicted that MCCPs are likely to be of low acute toxicity 
by the dermal route of exposure.
4.1.2.2.2 Human data
There are no data available.
4.1.2.2.3 Summary of single exposure studies
No information is available on the effects of single exposure to MCCPs in humans. There are 
no single inhalation exposure studies available in animals. However, based upon inhalation 
data for SCCPs and oral data for MCCPs it is predicted that the MCCPs are also likely to be 
of low acute inhalation toxicity.
MCCPs are of low acute oral toxicity with no deaths and only limited, non-specific clinical 
signs of toxicity resulting from exposure of rats to very high doses (up to 15000 mg.kg-1). No 
data are available relating to single exposure via the dermal route. However, SCCPs are of 
low toxicity via the dermal route and MCCPs are of low toxicity via the oral route. Hence, it 
is predicted that the MCCPs are of low acute dermal toxicity. Although no information is 
available relating to the degree of chlorination, it is predicted that given the low acute toxicity 
of the MCCPs studied, this is unlikely to be of significance for this endpoint. 
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4.1.2.3 Irritation
4.1.2.3.1 Studies in animals
Skin
Rabbits
Two unpublished studies are available which were performed according to contemporary 
OECD test guidelines (Kuhnert, 1986c; Kuhnert, 1986d). Both studies involved application of 
0.5 ml of undiluted liquid mixed C14-17 MCCPs (40% and 52% chlorination respectively; 
containing 1% epoxy stabiliser) to the shaved skin of 6 rabbits under occlusive conditions for 
4 hours. Observation of the skin was continued for up to 14 days after application. Mean 
24-72 hour scores for erythema and oedema were 1.5 and 0.6 and 1.3 and 0.3 respectively for 
the two studies. Scales were also seen from the 6th to 10th day following exposure, and in the 
case of the first study, drying and hardness (at 72 hours) and “peeling” (observed on days 6-8) 
presumably of the outermost layers of the skin were seen.
The skin irritation potential of two types of C14-17 40% or 45% chlorinated paraffins was 
investigated in briefly reported, unpublished studies conducted in rabbits (Chater, 1978). An 
unspecified amount of undiluted liquid material was applied to the skin for 24 hours under an 
occlusive dressing and signs of irritation scored at 24 and 72 hours post-treatment. No signs 
of skin irritation were seen with the C14-17 45% chlorinated paraffin tested, and only "slight" 
erythema was reported in one animal at 24 hours using the 40% chlorinated paraffin.
Rats
In a briefly reported, unpublished study, groups of 6 Alderley Park (Wistar-derived) rats 
received single application of an unstated, but presumably undiluted, volume of C14-17 MCCP 
(45% chlorination, containing 0.2% epoxy stabiliser) or at least 5 repeated applications of the 
same material (Moses, 1980). The report did not indicate if occlusive conditions were used, or 
what the duration of exposure was. Following single exposure, slight desquamation was noted 
in 3 of these animals “at some stage during the test”. By repeated exposure, one of the six test 
animals developed slight desquamation after the 4th and 5th applications. Other animals were 
stated to be unaffected.
In a briefly reported, unpublished study a group of 3 female Alderley Park (Wistar-derived) 
rats received 6 daily applications of 0.1 ml undiluted, C14-17 40% chlorinated paraffin under 
occlusive conditions (Chater, 1978). "Slight" (not further defined) erythema and/or 
desquamation were noted after 3-5 applications, progressing to cracking and thickening of the 
skin.
The results of 9 unpublished skin irritation studies using C14-17 chlorinated paraffins (51-60% 
chlorination, some of which contained 0.2% epoxidised vegetable oil stabiliser) are cited 
(Birtley et al, 1980). Groups of 3 rats received, under occlusive conditions, up to 6 repeated 
applications of 0.1ml undiluted MCCPs or MCCPs in an unspecified vehicle for 24 hours. 
Twenty-four hour treatment-free periods separated each application. "A mild skin irritancy 
response" was produced. No further details were given.
Overall, all of these studies, although having some limitations in reporting, are consistent and 
indicate that MCCPs have only slight skin irritation potential. However, there was some 
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potential for cracking of the skin following repeated dermal application of liquid MCCPs, 
probably because of defatting.
Eye
In two unpublished studies conducted according to contemporary OECD testing guidelines, 
C14-17 chlorinated paraffins (40 or 52% chlorination; containing 1% epoxy stabiliser) were 
tested for their potential to cause eye irritation in rabbits (Kuhnert, 1986e; Kuhnert, 1986f). 
Undiluted material (0.1ml) was instilled into the conjunctival sac of one eye of each of 
3 rabbits.
No iridial or corneal effects were noted in either study. Conjunctival redness (score 1) was 
noted in all 3 animals at 1 hour in the second study and 1 animal at 24 hours (both studies) 
and 48 hours (first study only). Discharge was noted in 1-2 animals at 1 hour in both studies 
and also at 48 hours in the second study. Overall, the samples tested were judged to be of low 
irritant potential.
Two types of undiluted C14-17 chlorinated paraffins (40 and 45% chlorination respectively; 
containing 0.2% epoxy stabiliser) were instilled into the conjunctival sac of each of 3 rabbits 
(Chater, 1978). A "slight" initial pain response (2 on a 0-5 point scale) was seen for both 
samples, and what was described as "slight transient conjunctivitis" (score of 3 out of 8 for 
conjunctival effects) within 1-2 hours of instillation. No effects were seen at 24, 48 or 
72 hours.
The results of 6 unpublished eye irritation studies are briefly reported (Birtley et al, 1980): no 
ocular irritation was noted following a single application of different types of C14-17 MCCPs 
(51-60% chlorination) into the eyes of groups of 3 rabbits.
Overall, these studies indicate that MCCPs have low eye irritation potential.
Respiratory tract
There are no data in relation to respiratory irritation in humans or animals. However the lack 
of any reports relating to this endpoint given the widespread use of these substances, suggests 
that they lack the potential to cause such an effect. The low skin and eye irritation potential 
and generally unreactive nature of this group of substances lends further support to this view.
4.1.2.3.2 Human data
No studies are available.
4.1.2.3.3 Summary of irritation
No data are available in humans relating to skin or eye irritation. However, based upon two 
standard animal studies, C14-17 chlorinated paraffins have been shown to cause only slight skin 
irritation on single exposure. The observation of somewhat more pronounced irritation 
following repeated application to the skin is considered to be due to a defatting action. Studies 
conducted in rabbits indicate that C14-17 chlorinated paraffins produce only slight eye 
irritation. Similar findings arising from repeated exposures of the eyes have been seen with 
SCCPs. There are no data specifically in relation to respiratory tract irritation, but on the basis 
of the low skin and eye irritation potential and generally unreactive nature, and the lack of 
human reports, it is anticipated that MCCPs are unlikely to cause such an effect.
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Although there is only limited information the degree of chlorination does not appear to be of 
significance for these endpoints.
4.1.2.4 Corrosivity
There are no human data available. However, based on the animal data for the skin and eyes 
(Section 4.1.2.3), it can be concluded that MCCPs do not have corrosive effects.
4.1.2.5 Sensitisation
4.1.2.5.1 Studies in animals
Skin
An unpublished report of a guinea pig maximisation test conducted to current regulatory 
guidelines is available (Murmann, 1988). Twenty and 10 animals were utilised in the treated 
and control groups respectively. For intradermal induction, a 20% C14-17 chlorinated paraffin 
(40% chlorination, containing 1% epoxy stabiliser) in maize oil was used. At topical 
induction, undiluted material was applied producing "intense, sometimes haemorrhagic, 
purulent inflammation” (given that MCCPs do not have any significant irritation potential, 
this reaction is most likely to be related to pre-treatment with Freund’s Adjuvant). An initial 
challenge using the undiluted C14-17 chlorinated paraffin was conducted. Following the 
observation in one test and one control animal of a reaction at 48 hours (scores of 1 and 3 
respectively) a second challenge was conducted using 50% material in maize oil. No skin 
responses were seen. Overall, these results indicate a negative response in this test system.
The outcome of two other guinea pig maximisation tests conducted on samples of C14-17
chlorinated paraffins (40-45% chlorination, containing 0.2% epoxy stabiliser) is reported 
within an unpublished paper (Chater, 1978). These studies are only briefly summarised, but 
were stated to have been performed using the Magnusson and Kligman method. A 5% 
concentration of sample material in olive oil was given intradermally followed by topical 
application at 20%. Challenge was also conducted with 20% preparations. No skin reactions 
were produced either in test or control animals with any of the samples. No further details 
were provided such as numbers of test and control animals used and whether any signs of 
irritation were seen at topical induction.
4.1.2.5.2 Human data
No studies are available.
Respiratory tract
There are no data relating to this endpoint in humans or animals. However, the generally 
unreactive nature of this group of substances and lack of skin sensitisation potential suggests 
that they do not possess the potential to causerespiratory sensitisation.
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4.1.2.5.3 Summary of sensitisation
No data are available on skin sensitisation potential in humans. No evidence of skin 
sensitisation was produced in guinea pig maximisation tests using C14-17 MCCPs (40 or 45% 
chlorination). Overall, the available data and generally unreactive nature of MCCPs (and data 
on SCCPs) indicate an absence of skin sensitisation potential.
Although there are no data relating to respiratory sensitisation in humans or animals, the 
generally unreactive nature of this group of substances and the lack of skin sensitisation 
potential suggests that they do not possess the potential to cause such an effect. 
4.1.2.6 Repeated dose toxicity
4.1.2.6.1 Studies in animals
Inhalation
No studies are available.
Oral
A number of studies are available which have all investigated the repeated dose toxicity of a 
commercially available C14-17 MCCP (52% chlorination). This section reports studies of a 
more conventional design. Further, detailed investigations exploring the mechanisms 
underlying some of the observed effects and their relevance to human health are reported in 
another section (see Mechanisms of Toxicity below).
Studies in rats
In a recent study conducted to GLP standards and QA assessment, groups of 10 male and 10 
female Fischer 344 rats received 30, 100, 300 or 3000 ppm C14-17 MCCP (52% chlorination) 
by dietary administration for 90 days (CXR, 2005c). The resultant dose levels were: 2.38, 
9.34, 23.0 and 222 mg.kg-1.day-1 for males and 2.51, 9.70, 24.6 and 242 mg.kg-1.day-1 for 
females. A control group of 20 male and 20 female animals received powdered diet ad libitum
for the duration of the study. Investigations included clinical observations, body weight and 
food consumption analysis, clinical chemistry and extensive, GLP-compliant 
histopathological examinations of liver, thyroid and kidney. Further, detailed investigations 
exploring parameters related to MCCPs-induced liver, thyroid and kidney toxicity (hepatic 
T4-UDPGA glucuronyl transferase activity, hepatic peroxisome proliferation, free and total 
plasma T4, T3 and TSH levels and renal and hepatic a2u globulin levels) were also 
performed at the end of the study.
No treatment-related deaths or clinical signs were observed and there were no adverse effects 
on terminal bodyweight, bodyweight gain or food consumption. Small but statistically 
significant decreases in plasma triglycerides (by 28-39%) and cholesterol (by 14-23%) were 
observed in the top dose animals only. In the 3000 ppm animals liver and kidney weights 
were significantly increased by 13-31% and 9-13% of the control values respectively. No 
effects on liver or kidney weights were observed at the lower dose levels. In males, small but 
statistically significant decreases in plasma free T3 levels were seen at the two highest dose 
levels (by 26 and 22% at 300 and 3000 ppm respectively). However, there were no effects on 
total T3 levels or on free and total T4 levels. In males, there was also a slight increase in 
CHAPTER 4.HUMAN HEALTH
89
plasma TSH levels (by 17%) but at the top dose only. In females, there were no effects on 
plasma free or total T3 levels, or on plasma total T4 levels, but a statistically significant 
increase (by 41%) in plasma free T4 levels was seen at the top dose. The biological 
significance of this increase (rather than a decrease) is unclear and it is considered likely to be 
a chance finding. A dose-related increase in plasma TSH levels was observed in female 
animals of the two highest dose levels (by 20 and 39% at 300 and 3000 ppm respectively).
Hepatic microsomal T4-UDPGA glucuronyl transferase activity was increased in the top dose 
males (by 82%) and in the 100, 300 and 3000 ppm females (by 30, 30 and 252% 
respectively). There was no effect of MCCPs administration on hepatic peroxisome 
proliferation as determined by palmitoyl CoA oxidation. Alfa2u globulin levels (determined 
by Western blotting) from kidney or liver homogenates were also unaffected by treatment in 
males. As expected, a2u globulin was not detected in female kidney or liver homogenates. No 
treatment-related histopathology was observed in the kidney or thyroid of the treated animals, 
but minimal centrilobular hepatocyte hypertrophy was noted in 9/10 top dose males.
The effects on the liver (the increased liver weight observed in the top dose animals and the 
minimal centrilobular hepatocyte hypertrophy reported in the top dose males) are likely to be 
related to increased metabolic activity associated with xenobiotic metabolism, and hence, are 
considered to be an adaptive response of no toxicological significance. This is confirmed by 
the observation of significant liver enzyme induction (increased levels of hepatic microsomal 
T4-UDPGA glucuronyl transferase activity) at the top dose. The effects on thyroid hormones 
(decreases in free T3 levels in the 300 and 3000 ppm males and increases in TSH levels in the 
top dose males and in the 300 and 3000 ppm females) appear to be slight, inconsistent 
changes likely to be related to altered liver metabolic activity. In view of this and given that 
no concurrent thyroid histopathology was observed, these effects are not considered to be 
adverse. However, decreases in plasma triglycerides and cholesterol and increased kidney 
weights were observed at the top dose. Therefore, overall, there were no adverse effects in 
this 90-day study in F344 rats at exposure levels up to 300 ppm (23.0 and 24.6 mg/kg/day in 
males and females respectively) MCCPs.
Groups of 10 male and 10 female Sprague-Dawley rats received 0, 5, 50, 500 or 5000 ppm 
C14-17 MCCP (52% chlorination) by dietary admixture for 90 days (Poon et al, 1995). These 
dietary inclusion levels equated to dose levels of approximately 0, 0.4, 4, 36, and 
360 mg.kg-1.day-1 in males and 0, 0.4, 4, 42 and 420 mg.kg-1.day-1 in females. Investigations 
included urinalysis at 4 and 12 weeks, and haematological and blood biochemistry 
determinations at study termination. Extensive histopathological examinations were also 
performed at the end of the study. 
No treatment-related deaths or clinical signs were observed and there were no adverse effects 
on bodyweight gain or food consumption. Increased serum cholesterol was observed on 
completion of 13-weeks administration of MCCP amongst females only, attaining statistical 
significance at 50 ppm (4 mg/kg/day) and above. At 5 (0.4 mg/kg/day), 50 (4 mg/kg/day), 500 
(36/42 mg/kg/day males/females) and 5000 ppm (360/420 mg/kg/day males/females) 
respectively, increases were 7%, 18%, 18% and 28% above the mean control value. No 
similar trend was observed in males. Individual values varied by up to 50% of the means for 
each group of females. Hence, it is likely that this apparent increase in serum cholesterol has 
arisen fortuitously rather than as a result of MCCP administration. In addition, in males at 
5000 ppm (360 mg/kg/day), there was a slight increase in aspartate aminotransferase (ASAT) 
activity (about 20% higher than control) indicative of minimal liver damage and inorganic 
phosphate (about 13% higher than control), which may be indicative of kidney damage. 
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Changes seen in some of the haematology parameters were minor in degree and likely to have 
arisen fortuitously.
At 5000 ppm (360/420 mg/kg/day males/females) significant increases in absolute and 
relative liver weights were seen in males and females (28% and 48% greater than control 
respectively for absolute weights). Absolute and relative kidney weight was increased (by 
11%) in both sexes at 5000 ppm (360/420 mg/kg/day males/females). Histopathologically, in 
the liver, minimal to mild anisokaryosis and vesiculation of the nuclei was seen in males and 
females at 500 (36/42 mg/kg/day males/females) and 5000 ppm (360/420 mg/kg/day 
males/females) (7-10 animals affected). In addition, in the 5000 ppm males (360 mg/kg/day) 
and in the 500 (42 mg/kg/day) and 5000 ppm (420 mg/kg/day) females there was an increase 
in ‘perivenous homogeneity’ of the liver (an increase in cellular volume involving the mid-
zonal hepatocytes, or centrilobular hypertrophy). Single cell necrosis was also reported in the 
liver of males and females at 5000 ppm (360/420 mg/kg/day males/females) although the 
incidence was not stated. There were no histological changes in the liver at 50 ppm (4 
mg/kg/day) or less. Dose-related morphological changes were observed in the thyroid glands 
of both males and females, affecting both the architecture (reduced follicle sizes and collapsed 
angularity) and the epithelium (increased height, cytoplasmic vacuolation and nuclear 
vesiculation). The changes were generally minimal to mild in nature and were observed in the 
males at 500 (36 mg/kg/day) and 5000 ppm (360 mg/kg/day) and in the females starting at 50 
ppm (4 mg/kg/day).
Changes in the kidney included increased hyaline-droplet like cytoplasmic inclusions 
(considered further in ‘Mechanisms of Toxicity’) in males of all doses. The severity of this 
effect was rated as minimal to mild, and significant accumulation of hyaline droplets was 
observed only at 5000 ppm (360 mg/kg/day). These changes were not observed in females. 
Also in the kidney, a dose-related inner medullary tubular dilation (of minimal severity) was 
recorded in females and was seen in 0/10, 0/10, 1/10, 4/10, 8/10 animals respectively at 0, 5 
(0.4 mg/kg/day), 50 (4 mg/kg/day), 500 (42 mg/kg/day) or 5000 ppm (420 mg/kg/day) dietary 
levels of MCCP, but was not seen in any treated groups of males. 
The toxicological significance of the effects observed in the liver is unclear and may be 
related to increased metabolic activity associated with xenobiotic metabolism. This is 
discussed in more detail in ‘Mechanisms of Toxicity’. There is also some concern with the 
observation of single cell necrosis at 5000 ppm (360/420 mg/kg/day males/females) (this 
effect was not seen at lower exposure levels). The slight effects seen in the thyroid starting 
from 50 ppm (4 mg/kg/day) (females only) are likely to be related to altered liver metabolic 
activity; however, since in this same study, induction of liver enzyme activity was not 
measurable at doses below 5000 ppm (360/420 mg/kg/day males/females) and hepatic 
morphological changes were not seen at doses below 500 ppm (36/42 mg/kg/day 
males/females)  (see Mechanisms of Toxicity), it cannot be completely ruled out that the 
thyroid changes represent primary adverse effects. The increased hyaline-droplet like 
cytoplasmic inclusions in the kidney can be considered as of doubtful relevance to human 
health. However, inner medullary tubular dilation (seen in females at 4 mg.kg-1.day-1 or more) 
remains as an indicator of renal damage that may be of importance to human health. 
Questions have been raised over the validity and reliability of this study’s findings, in 
particular in relation to the scoring system used for classifying the histopathological findings. 
It is noted that the effects on female kidney reported in this study starting from the relatively 
low dose of 4 mg/kg/day have not been seen in other rat 90-day studies even at higher dose 
levels. It is also noted that although histopathological findings of the thyroid have been 
described in other rat 90-day studies, only this study has reported them from the relatively low 
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dose of 4 mg/kg/day. It is clearly apparent that this study is unrepresentative of the repeated 
dose toxicity profile of MCCPs and hence, it should not be used for risk characterisation 
purposes. It could possibly be argued that these differences in findings in the different studies 
are due to the different strain of rats used by Poon and colleagues (Sprague-Dawley) 
compared to that (F344) employed in the other 90-day studies. However, at present, there is 
no evidence indicating that Sprague-Dawley rats differ from F344 rats in any kinetic or 
dynamic factor.
In an unpublished study, groups of 15 male and 15 female F344 rats were administered C14-17
MCCP (52% chlorination) in the diet at levels corresponding to 0, 10, 100 or 
625 mg.kg-1.day-1 for 90 days (IRDC, 1984; see also Section 4.1.2.1). Observations included 
haematology, blood biochemistry and urinalysis at various timepoints throughout the study, 
and an ophthalmoscopic examination pre-terminally. A comprehensive histopathological 
examination was also performed.
There were no treatment-related mortalities although one control female and one female at 
100 mg.kg-1.day-1 died during the study. These deaths were apparently the result of blood 
collection and not related to treatment. No treatment-related clinical signs of toxicity were 
noted amongst any animals. There were no treatment-related ophthalmoscopic findings. At 
the top dose, slightly reduced body weight gain relative to controls in both sexes was 
associated with a similar reduction in food consumption. In females, a dose-related decrease 
in water consumption was seen (by up to approximately 20% at 625 mg.kg-1.day-1). There 
were no haematological changes that could be considered toxicologically significant. Slight, 
but statistically significant blood biochemistry changes were noted in both sexes (blood urea 
nitrogen increased by 35% at 625 mg.kg-1.day-1, and total protein increased by 13% at 625 
mg.kg-1.day-1). A statistically significant increase (25%) in serum cholesterol was also noted 
in females at the top dose. At 625 mg.kg-1.day-1 there were marked decreases in urinary 
volume noted at each of weeks 5, 8, and 13 (males, 52-72% lower than controls, females 58-
74% lower than controls), with concommitant increases in specific gravity and osmolality. 
Animals in other groups were not adversely affected. In addition, there were slight increases 
in the concentration of urinary protein, ketones, bilirubin and urobilinogen at 625 mg.kg-1.day-
1, which were probably a consequence of the reduction in urinary volume.
Absolute and relative liver weights were statistically significantly increased in males and 
females at 100 and 625 mg.kg-1.day-1 with the increases in absolute values being 22-26% and 
64-92% greater than control values respectively. Absolute and relative kidney weights were 
statistically significantly increased in males and females at 625 mg.kg-1.day-1 only (18% 
greater than controls). There was also a significant increase in absolute thyroid weights in 
males only at the top dose (50% greater than controls) and adrenal weights in both sexes (25% 
greater than controls). 
Histopathology revealed hepatocellular hypertrophy of ‘trace’ severity in 13/15 males and 
13/15 females at 625 mg.kg-1.day-1 with 1/15 males at 100 mg.kg-1.day-1 also affected. Mild to 
moderate thyroid hypertrophy was seen in almost all control and treated male animals 
although there was a trend towards increasing severity with increasing dose. Females were 
unaffected. A similar pattern was observed for thyroid hyperplasia, being of trace to mild 
severity in almost all males, but with a general trend towards increasing severity with 
increasing dose. The effects seen in the liver and thyroid are discussed further in the section 
on Mechanisms of Toxicity, and overall, given the underlying mechanism(s), are considered 
to be of no relevance to human health.
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A significant increase above controls in the incidence of ‘chronic nephritis’ was seen in the 
top dose males (10/15 vs 1/15 in controls), although the effect was graded only as ‘mild’. 
‘Chronic nephritis’ was also reported in 3/15 and 4/15 animals at 10 and 100 mg.kg-1.day-1
respectively. However, at 10 and 100 mg.kg-1.day-1 the severity of these changes was graded 
as ‘trace’. Overall, given the low incidence observed at the low- and mid-dose levels and the 
mildness of the effect reported at all dose levels, although kidney changes were observed from 
10 mg.kg-1.day-1, a lesion considered to be of toxicological significance only occurred at the 
top dose of 625 mg.kg-1.day-1. Chronic nephritis (although not dose-related) was also present 
in some females. Renal tubular pigmentation (yellow-brown granular pigment in the 
cytoplasm of renal tubular epithelial cells) was seen in females only at 625 mg.kg-1.day-1
(9/14 animals). The terminology ‘chronic nephritis’ seems somewhat misleading (given that 
this is a 90-day study rather than ‘life-time’) and possibly reflects the age of the report. The 
‘chronic nephritis’ is described in further detail: ‘a mixed population of interstitial 
inflammatory cells, tubular regeneration and minimal degenerative changes in the tubular 
epithelium occurring alone or in combination.’ These lesions are indicative of renal toxicity 
that, given the age of rats in this study, could not be described as ‘progressive glomerular 
nephropathy’ that is commonly seen in some strains of aging rats (such as Sprague-Dawley), 
nor, by the nature of the description, are they similar to hyaline droplet nephropathy. Overall, 
there is some cause for concluding that the renal changes observed at the top dose represent a 
toxicological significant lesion that is not attributable to hyaline droplet nephropathy. 
Supporting evidence of renal pathology comes from the observation of increases in urinary 
protein, bilirubin and urobilinogen, and reduced water consumption at the top dose.
With kidney changes observed at 625 mg.kg-1.day-1, a NOAEL of 100 mg.kg-1.day-1 is 
identified from this 90-day study in F344 rats.
A 90-day repeated oral exposure study in rats was briefly summarised in a review by Birtley
et al (1980); no original study report was available. Groups of 24 male and 24 female 
Wistar-derived rats were fed diets containing 0, 500, 2500 or 5000 ppm C14-17 MCCP (52% 
chlorination, containing epoxidised vegetable oil as a stabilizer). Assuming a mean 
bodyweight of 300g for males and 250g for females, and a food consumption of 20g.day-1 for 
males and 16g.day-1 for females, the mean intakes of test substance were approximately 0, 33, 
167, 333 mg.kg-1.day-1 (males) and 0, 32, 160, 320 mg.kg-1.day-1 (females). Haematological 
and clinical chemistry analyses were performed pre-study, at 6 weeks and again at study 
termination. An extensive histopathological examination (including liver, kidney and thyroid) 
was conducted at 90 days. At 6 weeks, further groups of 24 male and 24 female rats fed a diet 
containing 250 ppm MCCP (approximately equivalent to 16 mg.kg-1.day-1) were introduced 
into the experiment together with an additional control group of 12 male and 12 female rats. 
These rats were treated in an identical manner to those on the main study.
No deaths or clinical signs of toxicity were noted. Bodyweight gain of males receiving 
2500 ppm and 5000 ppm was statistically significantly reduced (17% and 25% lower than 
controls respectively). The weight gain of males at 500 ppm, and all groups of treated 
females, was not adversely affected. A statistically significant decrease in food consumption 
was noted amongst all treated groups of males. However, when presented on an individual 
basis, the consumption in males receiving 5000 ppm was less than 10% lower than that of 
controls. Food consumption of females was not adversely affected. 
A statistically significant increase in relative liver weight was seen amongst males at 2500 
and 5000 ppm (15% and 22% greater than controls, respectively), and amongst females at 
500, 2500 and 5000 ppm (11%, 21%, 48%). Relative kidney weight was also affected, being 
increased by 15% at 5000 ppm in both sexes. Gross examination revealed a dose-related 
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congestion of the kidney, the incidence and severity of which was not given. However, it was 
stated that no histological abnormalities were observed in any tissues by light microscopy. At 
500 ppm and above, a dose-related proliferation of liver smooth endoplasmic reticulum (SER) 
was observed using electron microscopy.
The observed increases in liver weight and SER proliferation are indicative of an adaptive 
response occurring as a result of enzyme induction in this organ. In view of the brevity of 
reporting in this study, it is not possible to draw firm conclusions on the toxicological profile 
of this MCCP (52% chlorination).
In a study primarily of liver function, groups of 5 male and 5 female F344 rats received 0, 
150, 500, 1500, 5000 or 15000 ppm C14-17 MCCPs (52% chlorination) by dietary 
administration for 14 days (Spicer, 1981). Based on the food consumption and bodyweight 
values, these dietary inclusion levels were equivalent to approximately 0, 18, 58, 170, 550, 
and 1540 mg.kg-1.day-1 in males and 0, 18, 58, 180, 580, and 1290 mg.kg-1.day-1 in females. 
At study termination, hepatic microsomal protein, aminopyrine demethylase, and cytochrome 
P450 levels were determined. Histopathology examinations were limited to liver, kidneys, 
spleen, and ovaries. There were no further investigations.
No deaths or clinical signs of toxicity were observed. At 15000 ppm, statistically significant 
decreases in food consumption (by up to 31% in females) were noted, probably related to 
dietary unpalatability. At 5000 and 15000 ppm, a statistically significant elevation (up to 
80%) in both absolute and relative liver weights was seen in all animals. Also, absolute and 
relative ovary weights were significantly decreased (by 38%) in top dose females compared to 
the controls.
Histopathologically, diffuse mild hypertrophy was noted in the liver of all animals at 5000 
and 15,000 ppm; no changes were noted in the liver of animals at 1500 ppm or below. There 
were no histopathological findings in the ovary, indicating that the decrease in weight of this 
organ was of doubtful toxicological importance. 
In summary, the liver hypertrophy produced at dose levels of 550-580 mg.kg-1.day-1 and 
above is considered to be indicative of an adaptive response of this organ to an increase in 
metabolic demand and/or a reflection of peroxisome proliferation (see section on Mechanisms 
of Toxicity).
In a range-finding study, C14-17 MCCP (52% chlorination) were administered by oral gavage 
to rats for 5 days at doses of 0, 1000, 2500 or 5000 mg.kg-1.day-1 in corn oil (IRDC, 1982b). 
No deaths or clinical signs of toxicity occurred. All the animals were sacrificed at the end of 
the 5-day treatment period and subjected to a gross pathological examination. There were no 
macroscopic findings following examination of the contents of the abdominal, thoracic and 
cranial cavities. No further investigations were made, and overall this study is of very limited 
value.
Studies in dogs
An unpublished 90-day repeated exposure dietary study in dogs was reviewed by Birtley et al
(1980); the original study report was not available. Groups of 4 male and 4 female beagles 
received 0, 10, 30, or 100 mg.kg-1.day-1 MCCP (52% chlorination) for 90 days. After 42 and 
90 days of treatment haematological and clinical chemistry determinations were performed. 
Urinalysis and extensive histopathology were carried out at study termination. 
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As the full study report was not available, it is difficult to draw firm conclusions. However, 
the only findings apparently observed related to the liver. There was reported to be a 
statistically significant increase in the activity of serum alkaline phosphatase and in relative 
liver weight at 100 mg.kg-1.day-1, both of which were unquantified in the review. It was also 
stated that cloudy, pale and enlarged hepatocytes and an increase in SER in these cells were 
seen in "some" dogs at 30 and 100 mg.kg-1.day-1. It is considered that these liver changes are 
reflective of a physiological response due to increased metabolic demand. No more 
information from this study is available.
Dermal
No studies are available. 
4.1.2.6.2 Human data
No studies are available.
4.1.2.6.3 Mechanisms of toxicity
A number of studies have been conducted to investigate the possible underlying mechanistic 
events leading to the observed spectrum of toxicity in animals, with the view to assessing 
their relevance to humans. In general, studies in rats have looked at the underlying mechanism 
of effects in the liver, thyroid and kidneys. Studies in mice and guinea pigs have focused 
mainly on the liver.
Liver and thyroid
Studies in rats
Groups of 10 male and 10 female F344 rats received 0, 312 or 625 mg.kg-1.day-1 of a C14-17
MCCP (40% chlorination) via oral gavage for 15, 29, 57 or 91 days (Wyatt et al, 1997). 
Blood samples were collected on day 8 and at termination on days 15, 29, 57 and 91, for 
analysis of T3, T4 and TSH. Replicative DNA synthesis at a number of different organ sites 
was assessed using bromodeoxyuridine incorporation seven days before sacrifice on days 29 
and 91. Liver and thyroid sections were examined histopathologically and hepatic 
microsomes prepared for determination of UDPG-transferase activity (UDPG-T; an enzyme 
playing a key role in the excretion of thyroxine - T4) and peroxisomal fatty acid b-oxidation.
There was a statistically significant increase in relative liver weight at 312 and 
625 mg.kg-1.day-1 at all sacrifice timepoints (both sexes) by up to 37% and 72% respectively. 
Absolute liver weights and data on bodyweights were not presented. Dose-dependent 
centrilobular hypertrophy was apparently observed, but no details on the incidence or severity 
of this finding were reported. A dose-related and statistically significant increase in hepatic 
peroxisomal b-oxidation was noted at 312 and 625 mg.kg-1.day-1 from day 29 onwards (about 
2.7-fold and 3.3-fold respectively at study termination). Also, a dose-related and statistically 
significant increase of at least 100% was seen in UDPG-transferase activity at 312 and 
625 mg.kg-1.day-1 from day 15. It should be noted that UDPG-transferase activity was not 
measured at day 8.
Levels of free and total plasma T3 were reduced relative to controls at both doses and in both 
sexes, but only attained statistical significance on days 15 and 57. Levels of TSH were 
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significantly increased at both doses (up to a 2-fold increase) on day 8 only (males only). By 
day 91, in females only, levels of free T3 had recovered such that in both dose groups the 
values were significantly above control levels. Significant reductions (by up to 25%) in total 
plasma T4 were measured in treated females only, on day 57 of the study. Thyroid follicular 
cell hypertrophy was reportedly apparent at both doses throughout the study, and was said to 
be accompanied by follicular cell hyperplasia on days 55 and 91. However, no information on 
the incidence and severity of these changes was presented. Thyroid cell replicative DNA 
synthesis was significantly increased on day 29 at both dose levels, but not at day 91.
The pattern of these results fits a general hypothesis that an increase in liver 
UDPG-transferase activity leads to decreased plasma T3/T4, leading to increased TSH and 
thyroid stimulation.
In an investigation primarily of the liver and thyroid, groups of 5 F344 rats, received 0, 10, 
50, 100, 250, 500 or 1000 mg.kg-1.day-1 mixed C14-17 MCCP (40% chlorination) by oral 
gavage for 14 days (Wyatt et al, 1993). Liver weights were determined and peroxisomal fatty 
acid b-oxidation assessed as a potential marker for peroxisomal proliferation. In relation to 
thyroid effects, blood levels of thyroid stimulating hormone (TSH), T3 and T4 (both free and 
total forms of each) were measured in samples obtained only from the top dose and control 
animals. The activity of UDPG-transferase was also determined in liver microsomes only at 
1000 mg.kg-1.day-1 and in the controls. 
At 100, 250, 500 and 1000 mg.kg-1.day-1 increases (generally statistically significant, although 
the increase at 250 mg.kg-1.day-1 did not follow the generally dose-related pattern) in absolute 
and relative liver weights were observed (18, 2, 29 and 32% respectively for absolute 
weights). There were no adverse effects on liver weight at 10 and 50 mg.kg-1.day-1. A 
significant increase in peroxisomal fatty acid b-oxidation activity occurred at 500 and 
1000 mg.kg-1.day-1 (around 102 and 170% greater than the control activity, respectively) 
although no significant effects were seen at 250 mg.kg-1.day-1 and below. Significant 
reductions in both free and total plasma T4 levels (by 44 and 53% respectively) and an almost 
2-fold increase in UDPG-transferase activity was noted at 1000 mg.kg-1.day-1. T3 levels 
remained unaffected, whilst TSH levels showed an approximate 1.5-fold increase at 
1000 mg.kg-1.day-1 (notably other exposure levels were not investigated). No other significant 
changes were identified. 
These results show that peroxisome proliferation is a factor in the effects on the liver of 
MCCPs, and that thyroid stimulation could arise from increased TSH, consequent to increased 
clearance of T3/T4 via an increase in hepatic UDPG-transferase. 
As part of a 90-day dietary study in which Sprague-Dawley rats received 0, 5, 50, 500 or 
5000 ppm C14-17 MCCP by dietary admixture (reported in Section 4.1.2.6), a number of 
parameters were measured in relation to liver function (Poon et al, 1995). These included 
measurements of UDPG-transferase, urinary ascorbic acid (a metabolite of glucuronic acid, 
hence a possible indicator of increased UDPG-transferase activity) and liver vitamin A levels 
(vitamin A levels were measured as exposure to, and subsequent tissue accumulation of 
TCDD or PCBs, can lead to decreased levels in the liver).
At termination, in females at 5000 ppm (approximately 400 mg.kg-1.day-1), hepatic 
UDPG-transferase and N-acetylglucosaminidase were significantly elevated (by 70 and 50% 
respectively). No effects on UDPG-transferase or N-acetylglucosaminidase were observed in 
animals receiving 500 ppm or less. At 12 weeks, an approximately 6-fold increase in urinary 
ascorbic acid was measured at 500 ppm (approximately 40 mg.kg-1.day-1) and 5000 ppm 
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(females) and 5000 ppm (males) only; other groups were not affected. Concentrations of liver 
vitamin A were significantly reduced in males and females (by up to 59%) at 5000 ppm and in 
females only at 500 ppm (by 23%). As indicated above, the observation of the decreased 
hepatic vitamin A may be interpreted as circumstantial evidence of uptake of this MCCP.
In an investigation primarily of liver function, groups of 4-5 male and female F344 rats 
received 0 or 1000 mg.kg-1.day-1 C14-17 MCCP (40% chlorination) in corn oil by oral gavage 
for 14 days (Elcombe et al, 1997). Following sacrifice, livers were removed and 
microscopically examined and a number of biochemical determinations (including studies of
peroxisomal b-oxidation and cytochrome P450 levels) conducted on prepared microsomes. 
UDPG-transferase activity was not measured. 
Hepatocellular hypertrophy and proliferation of peroxisomes and smooth endoplasmic 
reticulum was observed in the MCCP-treated rats. The hepatic peroxisome proliferation was 
confirmed by morphometric analysis and described as "marked". Increases (at least 1.5-fold) 
in relative liver weights (absolute values not presented) and levels of cytochrome P450 were 
measured in comparison with the controls and peroxisomal b-oxidation showed up to a 
3.5-fold increase, with the degree of effect in males being almost double that produced in 
females.
Groups of 4 male rats received 1000 mg.kg-1.day-1 C14-17 MCCP (50% chlorination) by i.p. 
administration for 4 days (Nilsen et al, 1981). Following sacrifice on the 5th day, a number of 
liver microsomal enzyme activities were determined. There was a statistically significant 
increase in relative liver weight (12% greater than control), but changes in absolute liver 
weight did not achieve statistical significance. In relation to liver microsomal cytochrome 
P450 enzyme activity, an approximately 1.5-fold increase in benzo(a)pyrene hydroxylase 
activity was demonstrated as measured by the formation of the 4,5-diol metabolite of 
benzo(a)pyrene in vitro. 
Studies in mice
In a study to investigate hepatic effects, groups of 5 male Alderley Park CD-1 mice received 
0, 10, 50, 100, 250, 500 or 1000 mg.kg-1.day-1 mixed C14-17 MCCPs (40% chlorination) by 
oral gavage for 14 days (Wyatt et al, 1993). Liver weight determinations were performed and 
peroxisomal fatty acid b-oxidation was assessed as a marker for peroxisome proliferation. 
Absolute liver weight was significantly increased (by 22%) at 1000 mg.kg-1.day-1. There were 
no changes in liver weight at 500 mg.kg-1.day-1 and below. Significant increases in 
peroxisomal fatty acid b-oxidation activity were noted at 500 and 1000 mg.kg-1.day-1 only 
(272% and 168% respectively); there were no adverse effects at 250 mg.kg-1.day-1 and below.
Groups of 4-5 male and female B6C3F1 mice received 0 or 1000 mg.kg-1.day-1 mixed C14-17
MCCPs (40% chlorination) in corn oil via oral gavage for 14 days (Elcombe et al, 1997). 
Following sacrifice, livers were removed for microscopic examination and following the 
preparation of microsomes, a number of biochemical determinations (including peroxisomal 
b-oxidation and cytochrome P450 levels) conducted. 
At microscopy, liver hypertrophy together with smooth endoplasmic reticulum and 
peroxisome proliferation were seen in the MCCP-treated group. Morphometric analysis 
confirmed the peroxisomal proliferation as "marked". A 20% increase in relative liver weight 
was seen in females compared to the controls, although there was no effect on male relative 
liver weights. No data were provided on absolute liver weights. Elevations in cytochrome 
P450 levels of 15-27% occurred and b-oxidation was increased approximately 2- to 4-fold.
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Male mice received 0 or 400 mg.kg-1.day-1 C14-17 MCCP (70% chlorination) in corn oil for 
5 days by i.p. administration (Meijer et al 1981, Meijer and DePierre, 1987). Liver 
microsomal enzyme activities were measured. Significant increases (28%) in relative liver 
weight were observed compared to the controls, and a 1.5 to 3-fold elevation in epoxide 
hydrolase activity was noted together with a 50% increase in microsomal cytochrome P450 
content.
Studies in guinea pigs
Groups of 4-5 male guinea pigs received 0 or 1000 mg.kg-1.day-1 C14-17 MCCPs (40% 
chlorination) in corn oil by oral gavage for 14 days (Elcombe et al, 1997). Following 
sacrifice, livers were removed and microscopically examined and a number of biochemical 
determinations (including peroxisomal b-oxidation as a marker for peroxisome proliferation) 
and cytochrome P450 levels conducted on prepared microsomes.
Electron microscopy revealed no treatment-related changes in the liver and no evidence of 
peroxisome proliferation was found upon morphometric analysis. However, a 35% elevation 
in b-oxidation was obtained compared to the controls. Relative liver weight was increased by 
35% with absolute values not being reported. Treatment produced virtually no effect in liver 
cytochrome P450 levels.
Kidney
As reported previously, groups of 10 male and 10 female F344 rats received 0, 312 or 
625 mg.kg-1.day-1 of a 40% chlorinated paraffin via oral gavage for 15, 29, 57 or 91 days 
(Wyatt et al, 1997). Replicative DNA synthesis in the kidney was assessed using 
bromodeoxyuridine incorporation seven days before sacrifice on days 29 and 91, and at 
termination kidney sections were examined histopathologically.
In male rats, renal tubular eosinophilia was noted in males at 312 and 625 mg.kg-1.day-1 from 
day 15 onwards, and the incidence and severity of this effect increased with time, and in a 
dose-related manner; from day 29 onwards, this was accompanied by focal, followed by 
multifocal, areas of basophilia. The kidneys of female rats remained unaffected by treatment. 
Significant increases in replicative DNA synthesis in the kidney were seen in males on days 
29 and 91, with no effect seen in females. Immunocytochemical staining demonstrated the 
presence of a statistically significant increase (by 15%) in the amount of a2u-globulin in the 
proximal convoluted tubules of male rats. This was not restricted to hyaline droplets and was 
seen dispersed throughout the cytoplasm; this is not typical of light hydrocarbon nephropathy, 
and is consistent with other repeated-exposure studies in which renal effects were noted as 
being not typical of male rat-specific nephropathy (see Section 4.1.2.6.1).
As part of a 90-day dietary study in Sprague-Dawley rats (reported in Section 4.1.2.6.1), 
urinary b2u globulin was measured in relation to kidney function (Poon et al, 1995). Levels of 
b2u globulin were determined since an increase in this protein is usually associated with 
kidney proximal tubular damage and hyaline-droplet nephropathy. Reduced levels of urinary 
b2u globulin were seen in treated males (59%, 60%, 47%, and 56% lower than controls 
respectively at 5, 50, 500, and 5000 mg.kg-1.day-1). A similar reduction was seen in females 
(13%, 40%, 26%, and 49% respectively). The profile of results does not show a clear 
dose-response relationship, and the apparent reduction in urinary b2u globulin observed in this 
study cannot be readily explained. It is plausible that the apparent changes in relation to 
concurrent controls may be due to unusually high control values although the lack of 
EU RISK ASSESSMENT REPORT – ALKANES, C10-13, CHLORO- FINAL REPORT
98
historical control dat amakes this difficult to clarify. The significance of the reduction in 
urinary b2u globulin is unclear. 
Additional research into the mechanisms of nephrotoxicity and carcinogenicity
The following series of investigations has been conducted to help elucidate the mechanism 
underlying the formation of kidney tumours that have been seen in carcinogenicity studies on 
SCCPs (SCCP ESR Risk Assessment Report, 2000). It is proposed that these will inform 
discussions on the hazard identification of SCCPs. However, as there is extensive read-across 
of toxicological data to MCCPs, these data will also provide information for the hazard 
identification and risk assessment of MCCPs.
As part of a series of mechanistic studies, groups of 3-4 male and 4 female Fischer 344 rats 
received 0 or 1000 mg.kg-1.day-1 of a mixed C10-12 paraffin (58% chlorinated) in corn oil by 
oral gavage 7 days/week for 28 days (Elcombe, 1999). Investigations were focused on the 
liver and kidney and included: light microscopy with immunocytochemical staining for 
a2u globulin, two-dimensional polyacrylamide gel electrophoresis of kidney homogenates 
and subsequent immunochemical staining for a2u, quantification of renal bromodeoxyuridine 
(BrdU) incorporation (to assess S-phase DNA synthesis) using osmotic pumps installed 
7 days before terminal sacrifice, and an assay of cyanide-insensitive palmitoyl CoA oxidation 
(as a marker of peroxisomal b-oxidation activity) from kidney and liver homogenates.
At termination, no histological abnormalities were observed in the kidneys of control males. 
Moderate proximal tubular hypertrophy/eosinophilia was seen in all males receiving 
1000 mg.kg-1.day-1 SCCP. Minimal to moderate cortico-medullary calculi were seen in all 
control females, slight to minimal tubular basophilia in 2/4, and moderate proximal tubular 
hypertrophy/eosinophilia in one control female. Slight to moderate cortico-medullary calculi 
and moderate proximal tubular hypertrophy/eosinophilia were seen in all females at 
1000 mg.kg-1.day-1. No information was presented in relation to histological investigations 
that were stated to have been conducted on the liver. 
On completion of 28 days, control males were judged to have a ‘normal’ content (assessed 
semi-quantitatively) of a2u globulin as determined by immunochemical staining of 2-D 
PAGE and histologically. Localised high concentrations were found in the pars convoluta (the 
expected region of high peroxisomal activity), and with less dense, and diffuse amounts being 
found in the pars recta, the straight portion of the proximal tubules. In this first study, a 
decreased amount of a2u globulin immunostaining in the pars convoluta was observed in 
SCCP-treated males. There was little or no change in the extent of immunostaining in the pars 
recta region. For females, there was no a2u globulin observed in the pars recta of control or 
treated animals, and little or no staining in the pars convoluta. 
At 28 days, there was a statistically significant decrease in BrdU incorporation in two regions 
of the kidney (pars convoluta and pars recta) of male rats treated with the SCCP compared to 
controls. The decrease was more marked in the pars convoluta than the pars recta. In females, 
there was essentially no effect on BrdU incorporation in the pars recta, but a statistically 
significant decrease in the pars convoluta.
In the kidney homogenates taken from rats at 28 days, the rate of peroxisomal b-oxidation 
was increased approximately 2.5-fold in both male and females receiving SCCP compared to 
controls. No data were presented for the enzyme activity in liver homogenates that were 
taken.  
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Overall, this investigation showed histologically-observable kidney lesions (hypertrophy and 
increased eosinophilia in the proximal convoluted tubules) related to treatment with this 
SCCP, with a concommitant decrease in a2u globulin formation and a decrease in cell 
replication in the proximal convoluted tubules. Increased peroxisomal activity was noted in 
kidney of both males and females. No conclusions can be drawn in relation to effects on the 
liver as no data were presented in this report, despite the indication that investigations had 
been performed. 
In another 28-day study by the same author, groups of 4 male and 4 female Fischer 344 rats 
received 0 or 625 mg.kg-1.day-1 of a C12 paraffin (59% chlorinated) in corn oil by oral gavage 
7 days/week. This study also included groups of 4 animals that received 300 mg.kg-1.day-1
1,4-dichlorobenzene (as a ‘positive control’ for a2u globulin renal deposition). As with the 
previous study, kidneys and liver were examined by light microscopy, immuno-stained for 
assessment of a2u globulin deposition (kidneys only), and renal BrdU incorporation 
quantified. In addition, an assay of cyanide-insensitive palmitoyl CoA oxidation was 
performed from kidney and liver homogenates. 
There were no abnormalities observed histologically in the liver or kidneys of control males 
and females (with the exception of slight renal tubular basophilia in one female). Marked 
proximal tubular hypertrophy/eosinophilia was observed in the kidneys of all SCCP-exposed 
males. Marked panlobular or centrilobular eosinophilia/hypertrophy, moderate periportal 
hyperplasia and loss of glycogen were seen in the liver of all SCCP-exposed males. The 
lesions seen in DCB-exposed animals were moderate hyaline droplet nephropathy in the 
kidneys of 3/4 males receiving DCB. In addition, slight renal tubular eosinophilia or proximal 
tubular eosinophilia, and slight, increased intratubular protein in the pars recta were observed 
incidentally. In the liver, slight to moderate centrilobular eosinophilia/hypertrophy was seen 
in all DCB-treated males. In females, slight to moderate proximal tubular 
hypertrophy/eosinophilia was seen in the kidney of all SCCP-exposed animals, with the 
additional observation of tubular basophilia in 1/4 females. Moderate or marked panlobular 
eosinophilia/hypertrophy, moderate or marked periportal hyperplasia were seen in the liver of 
all SCCP-treated females. No abnormalities were seen in the kidneys of DCB-treated females, 
although slight hepatic centrilobular eosinophilia and moderate periportal hyperplasia were 
observed in all or most animals.
On completion of 28 days, slight a2u globulin formation was noted in the pars convoluta of 
control males and in the pars recta, little or no a2u globulin was detected. The same pattern of 
distribution was maintained in SCCP-exposed animals although staining was increased (slight 
to moderate in the pars convoluta) compared to the controls. For DCB-exposed animals, 
staining was more intensive still (moderate to severe). And in the case of SCCP- and DCB-
treated animals, the staining was more intense in the pars convoluta than the pars recta. These 
results contradict those of the first study in this series in which a decreased amount of a2u 
globulin immunostaining in the pars convoluta was observed in SCCP-treated males and little 
or no change in the extent of immunostaining in the pars recta region upon treatment with 
SCCP. For females in this second study, there was no staining of a2u globulin observed in the 
pars recta of controls, SCCP- or DCB-treated animals, and little or none in the pars convoluta.
Again in contrast to the first 28-day study, SCCP caused an increase in BrdU incorporation in 
males and females with the effect being more pronounced in males than females. For males 
receiving DCB, the incorporation was even more pronounced although females were 
unaffected. It is plausible that the contrasting results may be due to the different exposure 
levels used.
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No details were provided on renal peroxisomal b-oxidation activity and as with the first 
28 day study, no data were presented on any of the liver investigations that were documented 
as having been performed (with the exception of light microscopy).
This second 28-day study seems to indicate that SCCP exposure does lead to a preferential 
increase in a2u globulin deposition in the pars convoluta of male rats (which is typical of the 
pattern documented for other agents implicated as causing ‘male rat specific light 
hydrocarbon nephropathy’), and that this is associated with changes seen histopathologically 
in the kidneys. The increase in BrdU incorporation suggests an increase in cell proliferation 
that, given the lack of genotoxic activity of SCCPs, would most likely be associated with the 
postulated cytotoxicity resulting from a2u accumulation. 
The report also presented summary data of the quantification of a2u globulin in kidney 
samples taken at days 15, 29, 57, and 91 from groups of 5 or 10 male of female rats that had 
received 0, 312, or 625 mg.kg-1.day-1 of a C12 paraffin (59% chlorinated) in corn oil. At the 
highest exposure level an increase in the formation of a2u globulin was demonstrated in male 
rats only. 
More recent, further investigations have been conducted at the same laboratories:
Investigation 1: Groups of 20 male and female F344 rats received 0 or 
625 mg.kg-1.day-1 of a SCCP (Chlorowax 500C, C12: 60%Cl) in corn oil, by oral gavage daily 
for 28 days (Warnasuriya et al, 2001). In addition, groups of 10 rats received 
300 mg.kg-1.day-1 1,4-Dichlorobenzene (DCB) and 150 mg.kg-1.day-1 d-limonene (DL) as 
positive controls for a2u deposition. For these mechanistic studies, investigations were 
restricted to the liver and kidney, and all animals were 10-12 weeks old at the start of each 
investigation. Seven days before termination osmotic mini-pumps were implanted to assess 
bromodeoxyuridine (BrdU) incorporation in kidney cells (as a measure of cell proliferation). 
At termination, kidney samples were evaluated for a2u formation using 
immunohistochemical techniques. Liver (where a2u is synthesised) and kidney a2u levels 
were also assessed using immunoblotting after 2-D polyacrylamide gel electrophoresis 
(PAGE) using isoelectric focussing and molecular weight as separation parameters. Palmitoyl 
CoA activity (a marker of peroxisome proliferation) was determined in liver samples. In 
addition, liver mRNA levels and a2u gene transcription products (using a reverse-
transcriptase polymerase chain reaction) were measured spectrophotometrically. 
The immunohistochemical technique (not quantitative) demonstrated the presence of a2u in 
the renal cortex of control and SCCP-treated male rats, with hyaline droplet formation and 
more intense staining in DCB- and DL-treated males. Immunoblotting for a2u of 2-D PAGE 
resolved proteins from kidney homogenates revealed similar migration patterns for control, 
SCCP, DCB and DL-treated male rats. The intensity of staining for a2u was similar in 
controls and SCCP-treated rats and greater in the DCB and DL-treted animals. This was 
further supported by the semi-quantitative assessment of band intensity; levels of a2u were 
broadly similar to controls.
For the liver, immunoblotting for a2u of 2-D PAGE revealed levels that were similar between 
control, DCB- and DL-treated males. However, there was a marked decrease in hepatic a2u 
for SCCP-treated animals. This was also seen in the semi-quantitative intensity assessment. 
Cell proliferation, assessed using BrdU incorporation, was similar in SCCP-animals compared 
to controls (mean percentage of proliferating cells 1.2 and 1.6% respectively). The mean 
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percentage of proliferating cells was higher and attained statistical significance in DCB- and 
DL-treated rats (4.5% and 7.3% respectively).  
An increase in the marker of hepatic peroxisome proliferation (palmitoyl CoA activity) was 
seen in SCCP-treated animals compared to controls (enzyme activity increased approximately 
2-fold). DCB and DL did not affect palmitoyl CoA activity. 
The reverse-transcriptase polymerase chain reaction of liver mRNA showed that a2u 
synthesis was inhibited in SCCP-treated animals, compared with controls, whereas DCB- and 
DL-exposure led to increased a2u mRNA synthesis.   
Investigation 2: In another experiment, groups of 2-4 male and female F344 rats 
received 0 or 625 mg.kg-1.day-1 of a radiolabelled SCCP, 14C tridecane (C13:55% Cl) in corn 
oil, by oral gavage daily for 4 days. The qualitative assessment of binding of this to kidney 
proteins was then assessed by 2-dimensional PAGE of kidney homogenates and visualising 
bound radiolabel using X-ray film; binding of radiolabelled material to 3 isoforms of a2u was 
seen to occur in males but not females. The result indicates male rat-specific binding of SCCP 
to renal a2u.   
Investigation 3: In the final stage, groups of 2 male F344 rats received 0 or 
625 mg.kg-1.day-1 of a radiolabelled SCCP (14C-tridecane, C13: 55%Cl) in corn oil, by oral 
gavage daily for 4 days. Other groups of 1-2 rats received a single oral gavage dose of 0 or 
625 mg.kg-1 14C-tridecane (C13:55%Cl) in corn oil, or 300 mg.kg-1 14C-DCB. After the 
exposure period, the kidneys were removed and homogenised. Quantitative assessment of the 
binding of radiolabelled substance to protein was performed using liquid scintillation 
counting of chromatographically size-separated samples. Kidney a2u levels were also 
assessed using immunoblotting of samples from the chromatography columns.
Single-exposure of 14C-DCB showed a clear peak of radioactivity corresponding to the elution 
time of a2u. A smaller peak was seen with a single dose of 14C-tridecane (55%Cl), although 
there was an additional peak of radiolabelled material that corresponded to albumin. Upon 
repeated exposure of 14C-tridecane (55%Cl), the peak of a2u-related radioactivity was even 
smaller. The binding of the radioactive material corresponded with a2u detected by 
immunoblotting of the collection fraction.
The immunohistochemistry and cell proliferation studies in Investigation 1 indicated that, in 
contrast to DCB and DL, there was no increase in renal a2u or cell proliferation associated 
with SCCP. 
Increased hepatic peroxisome proliferation activity was observed with SCCP (but not DCB 
and DL), and this effect is associated with a decrease in hepatic a2u and down-regulation of 
a2u transcription. A similar response has been seen in the liver of animals exposed to 
ciprofibrate (a well-documented peroxisome proliferator). Again, the SCCP differs in the 
hepatic responses usually associated with agents such as DCB and DL that produce kidney 
tumours by the a2u mechanism; with SCCP there was a reduced synthesis of a2u. However, 
that which was produced seems to be accumulating in the kidney. In fact, although there was 
virtually no a2u expression in the liver of male rats administered SCCP, the level of a2u in 
the kidney was not significantly different to that of control animals. This suggests that even 
though very little a2u was synthesised in the livers of SCCP-treated male rats, the small 
quantity of protein that was expressed was indeed accumulating in the kidney.
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The second investigation demonstrated the specific in vivo binding of SCCP to renal a2u. 
This binding was only observed in male rats, suggesting that this phenomenon is male rat 
specific.  Further evidence for binding was provided by gel filtration chromatography of 
kidney cytosol from male rats treated with a single dose of either DCB or SCCP in the third 
investigation. The peak of a2u-associated radioactivity was smaller in the SCCP-treated rats 
and even smaller in the rats treated with SCCP for 4 days, but this was as expected since 
SCCPs cause down-regulation of a2u synthesis in the liver. 
Overall, these data suggest that a2u-binding is probably the primary mechanism for renal 
toxicity (and ultimately tumour formation) induced by SCCPs in male rats. There is clearly a 
down-regulation in hepatic a2u production (at the transcription level) induced by SCCPs, 
which is consistent with other known peroxisome proliferators. However, that a2u which is 
produced clearly binds to SCCPs as shown by size-exclusion gel chromatography and 
immunoblotting. Thus when transported to the kidney the a2u is deposited and retained; this 
is evidenced by the large increase in the ratio of renal to hepatic a2u seen in SCCP-treated 
rats compared to controls upon repeated exposure for 28 days. Therefore, it may be postulated 
that the SCCP-a2u complex accumulates at a slower rate, however, over a more prolonged 
period of exposure, continued a2u deposition would result in the delayed onset of an a2u 
globulin nephropathy. 
Overall assessment of mechanistic studies
The findings of these mechanistic studies demonstrate that MCCPs are capable of eliciting 
hepatic enzyme induction and proliferation of smooth endoplasmic reticulum indicative of 
increased metabolic demand arising from xenobiotic metabolism. These effects are considered 
to be indicative of physiological adaptation rather than a toxicological response.
In addition, hepatic peroxisome proliferation is induced in rats and mice at higher dose levels 
as evidenced by microscopy, morphometric analysis and enzyme marker activity. Peroxisome 
proliferation was not observed in guinea pigs (this species has been demonstrated to be 
relatively insensitive to the effect) although there was a small elevation in b-oxidation activity 
(much less than in rats or mice). It is clear that humans are also relatively insensitive to the 
induction of hepatic peroxisome proliferation (Bentley et al, 1993; Ashby et al, 1994). Thus 
the changes seen in rats and mice are considered to be of limited relevance to human health.
Similar conclusions in relation to hepatic effects (i.e. the significance of changes related to 
xenobiotic metabolism and peroxisome proliferation) were agreed for SCCPs (SCCP ESR 
Risk Assessment Report, 2000).
Exposure to a MCCP (40% chlorination) has been shown to lead to thyroid effects (follicular 
cell hypertrophy and hyperplasia) in two studies in rats. Effects in this organ have not been 
investigated in mice or guinea pigs. The first study (Wyatt et al, 1993) provides evidence in 
support of the thyroid effects being attributable to stimulation of this organ arising from a 
negative feedback control. Initially an increase in the liver enzyme UDPG-transferase is 
stimulated by treatment with MCCPs resulting in increased glucuronidation and consequent 
excretion of T4, with a resultant reduction in plasma T4 levels. The pituitary responds to the 
decreased levels of T4 by releasing more TSH, which in turn leads to increased production of 
T4 by the thyroid. The continuous stimulation of the thyroid in response to the increased 
excretion of plasma T4 (seen in this 14-day study) is predicted to ultimately give rise to 
hypertrophy and hyperplasia in this organ.
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The second study (Wyatt et al, 1997) is more difficult to interpret since although there was an 
increase in UDPG-transferase activity together with an expected increase in the release of 
TSH, plasma T4 levels remained generally unaffected with significant reductions only being 
seen in females at one timepoint in this 90-day study. Plasma T3 levels were reduced at two 
timepoints, in both sexes. The thyroid follicular cell hypertrophy and hyperplasia observed in 
this study are considered to have arisen as a result of continued stimulation by TSH. It may 
well have been the case in this study the homeostatic balance had been reset such that 
increased TSH levels resulted in “normal” T4 levels and therefore, no detectable decrease in 
this hormone upon measurement.
No toxicologically significant effects on thyroid hormones and TSH levels were observed up 
to the top dose of 222/242 mg/kg/day (males/females) in a recent, well-conducted 90-day 
study in rats.
It has been demonstrated that decreases in T4 or T3 levels in humans produced by altered 
hepatic clearance are typically insufficient to increase TSH levels. The decreased sensitivity 
of the human thyroid-pituitary axis to increased hepatic clearance of thyroxin is not fully 
understood, but appears to be influenced by several important quantitative differences 
between rats and humans. These quantitative differences include: A) The half-life of T4 in 
rats is approximately 12 h, whereas in humans, the half-life is 5-9 days (Dohler et al, 1979). 
The shorter half-life of T4 in rats is likely related to a high-affinity binding globulin for 
thyroxin (TBG) that is present in humans (75% of T4 is bound to TBG, 15% to TTR and the 
remainder to albumin) but absent in rodents Although other binding proteins are present in the 
plasma in rodents such as TTR, their binding efficiency is considerably less than human TBG. 
In the absence of TBG, more free T4 is available for metabolism and hence excretion from the 
body in rodents, compared to humans. On the contrary, in humans, binding of T4 to TBG 
accounts for slower metabolic degradation and clearance. B) Increased turnover and heapatic 
clearance of T4 and T3 renders the basal activity of the thyroid gland markedly more active in 
rats than in humans. In the absence of a functional thyroid gland, a rat requires approximately 
10 times more T4 than and adult human for full reconstitution (Dohler et al, 1979).  C) 
Constitutive TSH levels are nearly 25 times higher in rats than in humans, reflecting the 
increased activity of the thyroid-pituitary axis in rats.Based upon these considerations humans 
are predicted to be less susceptible than rodents to fluctuations in levels of free plasma T4 and 
hence any subsequent thyroid stimulation arising from a reduction in free T4 levels. Again, 
similar effects on thyroid activity were observed for SCCPs (SCCP ESR Risk Assessment 
Report, 2000).
Overall, considering the probable mechanisms outlined above, and the apparent association 
with the observed liver effects, together with the highlighted differences in T4 binding 
capacity between humans and rats, it is considered that the thyroid effects produced in rats 
would be of little relevance to human health at relevant levels of exposure.
Changes seen in the kidneys (increased weight, ‘chronic nephritis’ and tubular pigmentation) 
are considered as being potentially relevant to human health. Mechanistic studies indicated 
some deposition of a2u globulin in proximal convoluted tubules of male rats only at higher 
dose levels. However, this was unrelated to the pathological findings described above. Thus, 
these changes are not considered to be a male rat-specific phenomenon. From the data that are 
available, no adverse effects were seen at 23 mg.kg-1.day-1 in a recent and well-conducted 90-
day study. 
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4.1.2.6.4 Summary of repeated exposure studies
No information is available on the effects of repeated exposure in humans. In animals there 
are no data relating to repeated inhalation or dermal exposure. A number of oral studies in 
several rodent species are available which have investigated the repeated dose toxicity of 
C14-17, 40% or 52% chlorinated paraffins. In the absence of any information on MCCPs 
outside this range it is not possible to assess whether or not the degree of chlorination would 
have an effect upon the resulting toxicity. 
The liver, thyroid and kidney are the target organs for repeated dose toxicity of MCCPs. For 
the liver, increases in weight were seen in rats and dogs at exposure levels of 100 mg.kg-1.day-
1 and above. In addition, enzyme induction and histopathological changes (centrilobular 
hepatocyte hypertrophy) were seen in rats starting from 222 mg.kg-1.day-1, and, from a limited 
study in dogs, at 30 mg.kg-1.day-1 and above. These changes are likely to be related to an 
increase in metabolic demand as an adaptive response, possibly combined with peroxisome 
proliferation in the rat at higher dose levels. Both of these hepatic effects are considered of no 
or limited toxicological significance to human health. However, in rats, at higher exposure 
levels (around 360 mg.kg-1.day-1) single cell necrosis was observed; this effect is not thought 
to be related to increased metabolic demand or to peroxisome proliferation and therefore is 
considered to be of relevance to human health.
For the thyroid, clear pathology (follicular hypertrophy and hyperplasia) was seen at relatively 
high dose levels (312 mg/kg/day and above). Increased TSH levels and decreased T4 levels 
were also seen at similar dose levels. However, no toxicologically significant effects on 
thyroid hormones and TSH were observed up to top dose of 222/242 mg/kg/day 
(males/females) in a recent, well-conducted 90-day study in rats. The thyroid pathology 
observed at relatively high doses of MCCPs is likely to have occurred due to repeated 
stimulation of this organ because of a negative feedback control effect arising from plasma T4
depletion following increased excretion of this hormone. This depletion results from an 
increase in the activity of hepatic UDPG-transferase. Humans, unlike rodents, possess T4-
globulin binding protein and are therefore less susceptible to plasma T4 depletion and hence 
any resultant thyroid stimulation. Overall based on these considerations, the thyroid effects 
observed in rats should be considered not to be of relevance to human health at relevant levels 
of exposure. 
From the data that are available, no adverse renal effects were seen in males and females at 23 
mg.kg-1.day-1 in a recent and well-conducted rat 90-day study. Changes seen in the kidneys at 
222 mg.kg-1.day-1and above (increased weight, ‘chronic nephritis’ and tubular pigmentation) 
are considered as being potentially relevant to human health. Mechanistic studies indicated 
some deposition of a2u globulin in proximal convoluted tubules of male rats only at higher 
dose levels. However, this was unrelated to the pathological findings described above. Thus, 
these changes are not considered to be a male rat-specific phenomenon. In terms of severity, 
an increase in kidney weight of 9-13% was observed at the top dose of 222 mg.kg-1.day-1 in 
one study and of 18% at the top dose of 625 mg.kg-1.day-1 in another study. The increase 
above controls in the incidence and severity of what has been misleadingly termed ‘chronic 
nephritis’ (‘a mixed population of interstitial inflammatory cells, tubular regeneration and 
minimal degenerative changes in the tubular epithelium occurring alone or in combination’) 
was seen in treated males at 10 mg.kg-1.day-1 and above. At 10 mg.kg-1.day-1 the severity of 
these changes was graded as ‘trace’, and even at the highest exposure level, 625 mg.kg-1.day-1, 
was only ‘mild’. Furthermore, a significant increase above controls in the incidence of this 
lesion (10/15 vs 1/15) was only seen at the top dose of 625 mg.kg-1.day-1 with 3/15 and 4/15 
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animals affected at 10 and 100 mg.kg-1.day-1 respectively. It is therefore concluded that, 
although kidney changes were observed from 10 mg.kg-1.day-1, a lesion considered to be of 
toxicological significance only occurred at the top dose of 625 mg.kg-1.day-1.  Tubular 
pigmentation was also seen in females at the top dose of 625 mg.kg-1.day-1.
Overall, a NOAEL of 23 mg.kg-1.day-1is identified for repeated dose toxicity based upon 
effects seen in rat kidney (increased weight at the next dose level of 222 mg.kg-1.day-1 and 
‘chronic nephritis’ and tubular pigmentation at 625 mg.kg-1.day-1). It is noted that at 222 
mg.kg-1.day-1 there were also slight decreases in plasma triglycerides and cholesterol levels.
4.1.2.7 Mutagenicity
4.1.2.7.1 In vitro studies
Bacterial studies
A C14-17 MCCP (40% chlorination) when tested in a standard Ames test up to a maximum 
concentration of 5000 mg/plate produced negative results in S. typhimurium tester strains, 
TA 98, 100, 1535, 1537 and 1538 (Wiegand, 1989). Testing was conducted in the presence 
and absence of metabolic activation, although no data were presented relating to positive 
controls.
In an unpublished study reviewed by Birtley et al (1980), two C14-17 MCCPs (52% 
chlorination, with and without the addition of a 0.2% epoxidised vegetable oil stabilizer) were 
tested in duplicate in S. typhimurium strains TA 98, 100, 1535, and 1538 at concentrations 
between 4 and 2500 mg/plate with and without Aroclor-induced rat liver S9. There did not 
appear to be a separate, replicate assay. No cytotoxicity was observed. In TA 1538, a greater 
than 2-fold increase in the number of revertants was observed at 4 and 20 mg/plate MCCP 
(without stabilizer) compared to the vehicle control. However, these were isolated increases, 
with no dose-related pattern. No increases were seen under any other test conditions. Overall, 
therefore, the assay is considered to have yielded negative results.
Two other studies cited in an IPCS EHC Document (IPCS, 1996) have tested two different 
MCCPs using a range of S. typhimurium tester strains. The first study (Conz and Fumero, 
1988a; the rapporteur was unable to trace the original unpublished study report), tested a 
C14-17 chlorinated paraffin (42% chlorination) whilst the second test (Elliott, 1989a; only 
summary data were available) was conducted using a C14-17, 45% chlorinated paraffin. Testing 
was performed using a standard protocol up to a maximum concentration of 5000 mg/plate 
both in the presence and absence of S9 (source not stated). In both tests negative results were 
apparently obtained. No further details were given. 
Similarly, negative results were obtained in Ames tests that have been conducted with SCCPs 
(SCCP ESR Risk Assessment Report, 2000)  
Mammalian cell studies
No in vitro cytogenetic or gene mutation studies are available. For SCCPs (56% chlorination) 
a negative result was obtained in a well-conducted gene mutation assay conducted up to 
cytotoxic concentrations; a similar negative result could, therefore, be anticipated for MCCPs. 
There were no in vitro cytogenetics data from SCCPs.
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4.1.2.7.2 In vivo studies
In an unpublished report of an in vivo bone marrow chromosomal aberration test, groups of 
8 male rats received 0 (corn oil/saline), 500, 1500 or 5000 mg.kg-1.day-1 C14-17 MCCP (52% 
chlorination) for 5 days via oral gavage (Spicer, 1983). Animals were sacrificed on the day 
after the final treatment, and 100 metaphases/animal were evaluated. No deaths occurred and 
no treatment-related signs of general systemic toxicity were observed. The frequency of 
chromosomal aberrations (including and excluding gaps) in MCCP-treated animals was not 
increased; the positive control produced a clear positive result. Although cytotoxicity in the 
bone marrow was not assessed, the available toxicokinetic data demonstrate that MCCPs 
undergo significant absorption following oral administration, with one study (Darnerud and 
Brandt, 1982), showing distribution to the bone marrow. As such, it is concluded that the 
target organ was exposed in this study and that the negative result is a reliable one.
Two mouse bone marrow micronucleus studies have been reviewed in brief detail within the 
IPCS EHC Document 181 (IPCS, 1996) although the rapporteur has been unable to trace the 
original unpublished study report. A C14-17 MCCP (42% chlorination) was investigated in the 
first study (Conz and Fumero, 1988b cited in IPCS, 1996) with groups of 5 males and 
5 females receiving a single oral gavage dose of 5000 mg.kg-1 in corn oil. Sampling times of 
18, 43 and 66 hours were employed. No increase in the frequency of micronuclei occurred in 
MCCP-treated animals. The positive control substances produced a clear response. No further 
details were available. 
In the second bone marrow micronucleus study a C14-17, 45% chlorinated paraffin was 
evaluated (Elliott, 1989b, summary data only available). Groups of 5 male and 5 female mice 
received a single oral gavage dose of 0, 3125, or 5000 mg.kg-1 in corn oil. Three sampling 
times were employed at 5000 mg.kg-1 (ie. 24, 48 and 72 hours), and only one sampling time 
of 24 hours was used for the lower dose. There were no increases in micronucleus formation 
in any of the MCCP-treated groups. Clear responses were obtained with the positive control 
substance. No further details were available.
Similarly, for SCCPs, negative results were obtained in a rat bone marrow chromosomal 
aberration test, and in a dominant lethal assay (SCCP ESR Risk Assessment Report, 2000).
4.1.2.7.3 Human data
No information is available.
4.1.2.7.4 Summary of mutagenicity
Relatively few data are available on the genotoxicity of MCCPs, and in particular in relation 
to the consequences for mutagenic potential of variation in the degree of chlorination of the 
different compounds included within this family.  
MCCPs (40-52% chlorination) are not mutagenic to bacteria. No in vitro cytogenetic or gene 
mutation studies are available but negative results were obtained for SCCPs in a gene 
mutation assay. Three in vivo bone marrow studies demonstrate that MCCPs are not 
mutagenic towards this target tissue. Negative results for in vivo genotoxicity tests in somatic 
and germ cells have been obtained for SCCPs.
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Overall, the available data on MCCPs and SCCPs indicate that MCCPs do not possess
genotoxic activity.
4.1.2.8 Carcinogenicity
No information is available on the carcinogenicity of SCCPs and MCCPs from studies in 
human populations. However, from animal cancer bioassays only conducted with SCCPs, an 
increased incidence of liver and thyroid tumours was observed in mice, and an increase in 
kidney tumours was seen in male rats. From the available evidence, clear modes of action 
were indicated for the liver and thyroid tumours, namely chronic tissue damage caused by 
peroxisome proliferation in the case of the liver, and for the thyroid, long-term hormonal 
stimulation. For the male rat kidney tumours, the evidence available at that time was 
insufficient to clearly identify a plausible mode of action. Although it had been noted that 
binding to and consequent accumulation of a2u globulin leading to hyaline droplet 
nephropathy might be the underlying mechanism for these tumours, there was no convincing 
evidence for accumulation of a2u. Recently however, work has been conducted to explore 
this further as a plausible mode of action in SCCPs kidney carcinogenesis. In view of this new 
information, the mode of action for the kidney tumours induced in male rats by SCCPs is 
reviewed again. In order to bring transparency to this analysis, and, thereby, promote 
confidence in the conclusions reached, a structured approach as defined in the IPCS 
framework for evaluating a mode of action in chemical carcinogenesis has been used (Sonich-
Mullin et al., 2001). This provides a defined procedure, which mandates a clear and consistent 
documentation of the facts and reasoning including inconsistencies and uncertainties in the 
available data. 
In addition, since SCCPs are structurally related to MCCPs, and have generally similar 
physicochemical and toxicological properties where comparative data are available, it is 
considered prudent to assume that the carcinogenic potential of MCCPs would be comparable 
to that of SCCPs. Thus, this analysis is deemed to be applicable to both SCCPs and MCCPs, 
and relevant data from both groups of chlorinated paraffins are considered in this evaluation.
IPCS conceptual framework for evaluating a mode of action in SCCPs [and by analogy, 
MCCPs] male rat kidney carcinogenesis
Postulated Mode of Action
The mode of action considered is binding of SCCPs to the male rat-specific protein, a2u 
globulin which results in the formation of digestion-resistant complexes within secondary 
lysosomes of the renal proximal tubule epithelium after reabsorption from the urinary 
ultrafiltrate. The resulting accumulation of the a2u globulin complex causes cell death and 
sustained regenerative cell proliferation which, in turn, leads to compensatory hyperplasia and 
ultimately tumour formation. However, since SCCPs also cause peroxisome proliferation 
which, in turn, leads to a down-regulation at the transcriptional level of a2u globulin 
synthesis in the male rat liver, a2u globulin accumulates at a slower rate in the kidney, and 
the typical a2u nephropathy takes longer to appear.
Key Events
The key events considered with respect to SCCPs kidney tumorigenesis in male rats include: 
· binding of SCCPs to a2u globulin;
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· accumulation of a2u globulin in the renal proximal tubule epithelium;
· induction of hyaline droplet nephropathy;
· induction of regenerative renal tubule cell proliferation; 
· induction of kidney tubular cell hyperplasia. 
Binding of SCCPs to a2u globulin
The in vivo binding of SCCPs to a2m globulin has been clearly and consistently measured in 
investigations 2 and 3 by Warnasuriya et al., 2001. These studies showed that SCCPs 
specifically bind in vivo to a2u globulin. SCCPs-a2u globulin complexes were found in male 
rat kidneys following either a single or a repeated (4 days) oral exposure to 625 mg/kg 
SCCPs.
Accumulation of a2u globulin in the renal proximal tubule epithelium
Accumulation of a2u globulin in the renal proximal tubule epithelium has been demonstrated 
in some, but not all of the available studies which have investigated this phenomenon. 
However, the apparent inconsistencies may be explained by the fact that the peroxisome 
proliferation-mediated down-regulation of a2u makes less a2u available for accumulation in 
the kidney over the relatively short periods of time over which investigations have been 
conducted. A marked decrease in hepatic a2u levels was observed in investigation 1 by 
Warnasuriya et al., 2001 in which rats were dosed orally with 625 mg/kg/d SCCPs for 28 
days. This decrease was in association with undetectable levels of a2u mRNA which 
indicates that the down-regulation of a2u synthesis occurs at the transcriptional level.
There are two 90-day studies and three 28-day studies which have adequately investigated 
a2u globulin levels in the kidney. In one 90-day study (Wyatt et al., 1997), a statistically 
significant increase (by 15%) in the amount of a2u globulin was demonstrated by 
immunocytochemical staining in the proximal convoluted tubules of male rats orally given 
625 mg/kg/day MCCPs, but not at 312 mg/kg/day. Although in the other 90-day study (CXR, 
2005b), no increase in a2u globulin levels determined by Western blotting were seen in 
kidney homogenates of male rats given in the diet up to 242 mg/kg/day MCCPs, this is not 
inconsistent with the findings by Wyatt et al (1997), which indicate that a2u globulin 
accumulation only occurs at relatively high levels of MCCPs exposure. Of the three 28-day 
studies, two have shown some evidence of a2u globulin accumulation, while a third one 
(Elcombe, 1999a) has shown a decrease in a2u levels. Increased a2u globulin 
immunostaining was seen in the proximal tubules of male rats orally dosed with 625 
mg/kg/day C12:59%Cl for 28 days by Elcombe (1999b). Renal a2u globulin levels were the 
same in controls and male rats orally administered 625 mg/kg/day C12:60%Cl for 28 days by 
Warnasuriya et al (2001, investigation 1). However, a significant down-regulation of a2u was 
seen in the liver of the treated male rats in this study. Hence, although there was virtually no 
a2u expression in the liver of treated male rats, the level of a2u in the kidney was not 
significantly different to that of control animals. This suggests that even though very little 
a2u was synthesised in the liver of the treated male rats, the small quantity of protein that was 
expressed, was indeed accumulating in the kidney. Decreased a2u globulin immunostaining 
was seen in male rats orally dosed with 1000 mg/kg/day C10-12:58%Cl for 28 days by 
Elcombe (1999a). This decrease, although in apparent conflict with the findings of the other 
two 28-day studies, is not inconsistent with the hypothesis of the peroxisome proliferation-
mediated down-regulation of a2u. It is possible that the higher dose (1000 mg/kg/day) 
employed by Elcombe (1999a) might have produced higher levels of peroxisome 
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proliferation, leading to greater down-regulation of a2u and therefore to a decrease in the 
renal a2u levels. (Expression of a2u in the liver was not assessed in this study).
Induction of hyaline droplet nephropathy
The evidence for the induction of a hyaline droplet nephropathy is limited. However, again, 
the peroxisome proliferation-mediated down-regulation of a2u will lead to a slower 
accumulation of a2u in the kidney and, consequently would result in a delayed onset of the 
typical hyaline droplet nephropathy. Unfortunately, there are no chronic studies available 
either for SCCPs or for MCCPs and the majority of the subchronic studies that have 
investigated kidney pathology either have not found hyaline droplets or have not confirmed 
hyaline droplet formation by immunocytochemical techniques. 
- In the case of SCCPs, the histopathology investigations showed renal tubular eosinophilia, 
increasing in intensity with time, from day 15 in male rats treated with 313 and 625 mg/kg for 
up to 91 days in the study by Elcombe et al. (1994; SCCPs EU RAR). From day 29 increasing 
numbers of males also showed initially focal and then multifocal areas of basophilia at both 
dose levels. It is unclear from the study report whether or not these effects showed a dose-
response relationship. Although no typical hyaline droplets were observed and no 
investigations of a2u levels performed, the authors claimed that this response was indicative 
of an atypical hyaline droplet nephropathy since the increased eosinophilia was an expression 
of smooth endoplasmic reticulum (SER) accumulation in association with peroxisome 
proliferation, and the areas of basophilia represented evidence of proximal tubular 
regeneration. 
Mild nephritis was reported in male rats, but not females, orally dosed (either in the diet or via 
gavage) with 100 or 625 mg/kg/day SCCPs for 90 days by Serrone et al. (1987; SCCPs EU 
RAR). No further description of this lesion was provided, and it is not clear if this was 
indicative of hyaline droplet nephropathy. 
There two studies which repeat a form of nephropathy occurring in both males and females. 
These studies are iincluded here for completeness, but given that the kidney effects are seen in 
females as well as males, it is considered that these effects are not indicative of hyaline 
droplet nephropathy.
Nephropathy was reported in all male rats given by gavage 5000 mg/kg/day SCCPs 5 
days/week for 13 weeks, but not in animals dosed with £ 2500 mg/kg/day (NTP, 1986; 
SCCPs EU RAR). No further description of this finding was provided, but, since it was also 
seen in 3 females at 5000 mg/kg, it is presumed not to be related to a2u nephropathy, and, as 
female rats do not develop kidney tumours, it is therefore unlikely to be relevant to SCCPs 
kidney carcinogenesis. 
A dose-related increase in the incidence and severity of tubular damage and interstitial 
inflammation was observed in male and female rats given by gavage 312 or 625 mg/kg/day 
SCCPs 5 days/week for either 6 or 12 months (the two interim sacrifices of the 2-year cancer 
bioassay by NTP, 1986). However, again, since these lesions were also seen in females, they 
are presumed not to be related to a2u nephropathy, and therefore are unlikely to be relevant to 
SCCPs kidney carcinogenesis.
- In the case of MCCPs, renal tubular eosinophilia was noted from day 15 onwards in male 
rats, but not females, treated with 312 and 625 mg/kg for up to 91 days by Wyatt et al. (1997). 
Multifocal areas of basophilia were also observed from day 29 onwards at both dose levels, 
again in males, but not females. The incidence and the severity of these effects increased with 
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time and in a dose-related manner. In addition, an increased staining for a2u globulin was 
seen throughout the cytoplasm at termination in males, but not females, at 625 mg/kg. The 
authors suggested that, since no obvious increase in hyaline droplets was determined but 
increased a2u globulin levels were measured, the response seen represented an atypical form 
of light hydrocarbon nephropathy. 
A significant increased incidence of chronic nephritis (a mixed population of interstitial 
inflammatory cells, tubular regeneration and minimal degenerative changes in the tubular 
epithelium) of mild severity was reported by IRDC (1984) in male rats orally dosed with 625 
mg/kg/day MCCPs for 90 days. It seems that these lesions were not consistent with either a 
form of nephropathy commonly seen in some strains of ageing rats or a hyaline droplet 
nephropathy. However, since they were also present in some females (although no dose-
response observed), they are unlikely to be related to a2u nephropathy, and therefore are 
unlikely to be relevant to kidney carcinogenesis. 
No treatment-related histopathology was observed in the kidney of rats given in the diet up to 
242 mg/kg/day MCCPs for 90 days (CXR, 2005b).
Overall, there is no histopathological evidence of a clear form of hyaline droplet nephropathy 
either with SCCPs or MCCPs. However, an atypical form of light hydrocarbon nephropathy 
(renal tubular eosinophilia with multifocal areas of basophilia) was observed in males only in 
subchronic studies both with SCCPs and MCCPs. In those studies where renal toxicity 
occurred in both males and females (the chronic nephritis reported for MCCPs by IRDC, 
1984, the nephropathy reported for SCCPs in the 13-week NTP, 1986 study and the tubular 
damage accompanied by interstitial inflammation reported for SCCPs at the 6 and 12 months 
interim sacrifices of the 2-year NTP, 1986 cancer study), the effects seen are presumed not to 
be related to a2u nephropathy; however, since female rats do not develop kidney tumours, it 
is also presumed that this nephropathy does not lead to tumour formation and it is therefore 
irrelevant to SCCPs kidney carcinogenesis. 
Induction of regenerative renal tubule cell proliferation
More recently, a number of mechanistic studies have performed subtler kidney 
histopathological investigations looking at early biomarkers of non-genotoxic kidney 
carcinogenicity. Although the classical signs of hyaline droplet nephropathy have not been 
investigated in these studies, they provide clear evidence that the accumulation of a2u is 
associated with sustained regenerative cell proliferation. 
An increase in replicative DNA synthesis (assessed by BrdU incorporation) in the renal 
tubules was seen in male rats orally dosed with 625 mg/kg/day C12:59%Cl for 28 days by 
Elcombe (1999b). This increase, which is an expression of tubular regeneration, was seen in 
association with a parallel increase in male proximal tubule a2u globulin immunostaining. 
In contrast to this 28-day study, a statistically significant decrease in BrdU incorporation in 
the renal tubules was seen in male rats orally dosed with 1000 mg/kg/day C10-12:58%Cl for 28 
days by Elcombe (1999a). This decrease was seen in association with a parallel decrease in 
male proximal tubule a2u globulin immunostaining, and hence, although in apparent conflict 
with the findings of the other 28-day study, is not inconsistent with the hypothesis of the 
peroxisome proliferation-mediated down-regulation of a2u. It is possible that the higher dose 
(1000 mg/kg/day) employed by Elcombe (1999a) might have produced higher levels of 
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peroxisome proliferation, leading to greater down-regulation of a2u and therefore to a 
decrease in the renal a2u levels and, in turn, to a decrease in replicative DNA synthesis.
No increase above controls in renal tubule cell proliferation (assessed by BrdU incorporation) 
was seen in male rats orally dosed with 625 mg/kg/day C12:60%Cl for 28 days by 
Warnasuriya et al. (2001, investigation 1). However, in consistency with this finding, no 
increase above controls in renal a2u globulin levels was also noted in this study. These 
observations seem to indicate that in the absence of a2u accumulation, no regenerative cell 
proliferation is induced.
Significant increases in renal tubule replicative DNA synthesis were seen on days 29 and 91 
in male rats, but not females, orally given 625 mg/kg/day MCCPs for up to 91 days by Wyatt 
et al. (1997). No effect was seen at the lower dose of 312 mg/kg/day. As with SCCPs, these 
increases, which are expression of tubular regeneration, were seen in association with a 
parallel increase in male proximal tubule a2u globulin immunostaining (also observed at the 
top dose of 625 mg/kg/day), therefore providing clear evidence that a2u accumulation leads 
to sustained regenerative cell proliferation.
Induction of kidney tubular cell hyperplasia
A dose-related increase in the incidence of kidney tubular cell hyperplasia was seen in male 
rats, but not female rats, orally administered 312 or 625 mg/kg/day SCCPs 5 days/week for 
104 weeks (NTP, 1986; SCCP EU RAR). This study is the only cancer bioassay available in 
the rat.
Dose-Response Relationship
In vivo binding of SCCPs to a2u globulin 
In vivo binding of SCCPs to a2u globulin was demonstrated by Warnasuriya et al., 2001, 
investigations 2 and 3 in male rat kidneys following either a single or a repeated (4 days) oral 
exposure to 625 mg/kg SCCPs. These mechanistic studies were conducted at only one high 
dose, and hence correlations with dose level are not observable.
Accumulation of a2u globulin
Accumulation (or relative accumulation) of a2u globulin was observed by two different 
studies (Elcombe, 1999b and Warnasuriya et al., 2001, investigation 1) in male rats orally 
administered 625 mg/kg/day SCCPs for 28 days. Since only one high dose was used in these 
two studies, correlations with dose level are not possible. Accumulation of a2u was also seen 
after 91 days of treatment with 625 mg/kg/day MCCPs, but not with 312 mg/kg/day MCCPs 
(Wyatt et al., 1997) or with 242 mg/kg/day MCCPs and below (CXR, 2005b). 
Hyaline droplet nephropathy
There is no histopathological evidence of a clear form of hyaline droplet nephropathy either 
with SCCPs or MCCPs. However, an atypical form of light hydrocarbon nephropathy (renal 
tubular eosinophilia with multifocal areas of basophilia) was observed in male rats, but not 
females, treated with 312 and 625 mg/kg MCCPs for up to 91 days by Wyatt et al. (1997) and 
with 313 and 625 mg/kg SCCPs for up to 91 days in the study by Elcombe et al. (1994). The 
incidence and the severity of these effects increased with time and in a dose-related manner.
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Regenerative renal tubule cell proliferation
An increase in replicative DNA synthesis (assessed by BrdU incorporation) in the renal 
tubules was seen in male rats orally dosed with 625 mg/kg/day C12:59%Cl for 28 days by 
Elcombe (1999b). Since only one high dose was used in this study, correlations with dose 
level are not possible. Increases in renal tubule BrdU incorporation were also seen after 29 
and 91 days of treatment with 625 mg/kg/day MCCPs, but not 312 mg/kg/day MCCPs (Wyatt 
et al., 1997).
Kidney tubular cell hyperplasia
A dose-related increase in the incidence of kidney tubular cell hyperplasia was seen in male 
rats treated with 312 and 625 mg/kg/day SCCPs 5 days/week for 104 weeks (NTP, 1986). In 
the same study, the 312 mg/kg/day males showed a statistically significant increase in kidney 
tubular cell adenomas. No increase was seen in the high dose (625 mg/kg/day) males, 
although, the absence of any increase is likely to be due to the very low survival rates 
achieved at the end of the study. Kidney tubular cell adenocarcinomas were also noted in the 
low dose males but not in the high dose or control animals. It should be noted that the low 
survival rates achieved at the end of the study in the high dose group could also explain why, 
in contrast to the tumour response, a dose relationship was noted for the hyperplasia. It is 
likely that the high dose animals dying before scheduled termination had already developed 
hyperplasia, but not yet the tumour. 
Overall, except for the hyaline droplet-like cytoplasmic inclusions and the kidney hyperplasia, 
limitations in the database mean that no clear dose-response relationships could be identified 
for the other key events and the tumour response itself. It is therefore difficult to establish 
whether or not the dose-response relationship for any key event parallels the dose-response 
relationship for the male kidney tumours. However, it is worth noting that all the key events 
including the tumours showed a response in the dose range of approximately 300-625 
mg/kg/day. Furthermore, changes in renal tubule relicative DNA synthesis were always seen 
in clear association with parallel changes in proximal tubule a2u globulin immunostaining.
Temporal Association
Although no stop/recovery experiments have been conducted for either SCCPs or MCCPs, the 
findings of the available studies (mechanistic, subchronic and the 2-year cancer bioassay all 
previously described) provide some evidence that events occurred in the following sequence: 
(1) binding of SCCPs to a2u globulin (seen 1-4 days after dosing); (2) accumulation of a2u 
globulin in the renal proximal tubule epithelium (seen at slight levels after 28 days, and at 
significant levels after 91 days of dosing); (3) induction of an atypical form of light 
hydrocarbon nephropathy (seen after 90 days of dosing); (4) sustained regenerative tubular 
cell proliferation (seen at the earliest after 28-29 days of dosing, but also after 91 days); (5) 
induction of kidney tubular cell hyperplasia (seen after 104 weeks); (6) induction of kidney 
tubular cell tumours (seen after 104 weeks). 
Strength, Consistency, and Specificity of Association of Tumour Response with Key Events
Ideally, stop/recovery studies could provide the strongest evidence linking the key events with 
the tumour response. However, in the absence of such studies for either SCCPs or MCCPs, 
there are a number of other elements in the database which seem to indicate a relationship 
between the key events and the tumour response. Each of the key events for the postulated 
mode of action has been observed in at least one study. Some key events, i.e. binding of 
SCCPs to a2u globulin, a2u accumulation and regenerative cell proliferation have been 
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observed in more than one study. The available studies showed that there is a temporal 
relationship or sequence of events since, at similar dose levels, the in vivo binding of SCCPs 
to a2u globulin observed after either a single treatment or 4 days of treatment seemed to 
progress in time to the a2u accumulation seen after 28 and 90 days of treatment, and this in 
turn to the appearance of an atypical form of light hydrocarbon nephropathy after 90 days of 
treatment and ultimately to the kidney hyperplasia and kidney tumours seen in the 2-year 
cancer bioassay. In addition, mechanistic studies which have investigated early biomarkers of 
non-genotoxic kidney carcinogenicity, have shown a clear association between a2u 
accumulation and renal tubule replicative DNA synthesis, providing clear evidence that a2u 
accumulation leads to sustained regenerative cell proliferation.
In relation to consistency and repeatability of events, some inconsistencies have been 
observed in the induction of hyaline droplet nephropathy. One study (Serrone et al., 1987) 
reported a form of mild nephritis the relationship of which to hyaline droplet nephropathy is 
unclear, and two more recent studies reported areas of tubular eosinophilia and basophilia 
which are suggested to represent an atypical expression of hyaline droplet nephropathy. For 
the other key events in the postulated mode of action, a resonable degree of consistency and 
repeatability has been observed.
In relation to specificity, the available evidence has clearly demonstrated that the key events 
in the postulated mode of action are sex-specific and tissue-specific, and the tumours 
produced are only seen in the rat and not in the mouse. Each of the key events including the 
tumours was observed in males, but not in females. The key events also occurred in the renal 
tubule with no other areas of the kidney being affected. Three studies have also reported some 
renal pathology in female rats (chronic nephritis after 90 days of treatment with MCCPs by 
IRDC, 1984, nephropathy after 13 weeks of treatment with SCCPs by NTP, 1986, and tubular 
damage accompanied by interstitial inflammation after 6 and 12 months of treatment with 
SCCPs by NTP, 1986) that is obviously not attributable to a2u globulin and therefore is 
relevant for repeated exposure risk assessment; however, since no kidney tumours were 
observed in females, it is implied that this female renal pathology does not lead to tumour 
formation and it is therefore irrelevant for the mode of action of SCCPs kidney 
carcinogenesis.
Biological Plausibility and Coherence
The postulated mode of action for the kidney tumours induced by SCCPs and the key events 
that are considered in this analysis appear to be generally consistent with what is known about 
a2u globulin-associated nephropathy and neoplasia and with the general current 
understanding of cancer biology. It is widely accepted that toxicity and mitogenesis are of 
critical importance in the expression of non-genotoxic carcinogenicity, and these events have 
been clearly detected in SCCPs-induced kidney carcinogenesis (i.e. nephropathy and 
biomarkers of tubular regeneration for both SCCPs and MCCPs and kidney hyperplasia for 
SCCPs). 
In addition, it seems that tumours induced by chemicals that cause indirect cytotoxicity 
resulting from the impairment of a physiological process, which is the proposed mode of 
action for a2u globulin nephropathy and associated renal carcinogenesis, tend to occur with a 
low incidence (less than 30%) and a long latency, and may exhibit species- and sex-specificity 
(IARC Sci. Publ. 147, 1992). These characteristics have also been observed with the kidney 
tumours induced by SCCPs in the 2-year rat cancer bioassay. Incidence rates of 14% and 6% 
were reported for the tubular cell adenomas at the low and high dose levels respectively, and 
an incidence rate of 4% was recorded for the adenocarcinomas in the low dose males. 
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Additional groups of animals terminated after 6 and 12 months of treatment presented no 
kidney tumours. Males, but not females were affected, and no kidney tumours were observed
in the 2-year cancer bioassay conducted with SCCPs in mice (NTP, 1986; SCCPs EU RAR).
a2u globulin-associated nephropathy and renal neoplasia in the male rat have been observed 
with exposure to a number of other aliphatic hydrocarbons. These positive structure-activity 
relationships therefore give further support to the plausibility of the postulated mode of 
action.
Finally, the available databases on SCCPs and MCCPs indicate a lack of genotoxicity for 
these chemicals. The lack of genotoxicity is obviously one of the essential criteria to be met 
when considering a non-genotoxic mode of action. These data therefore further support the 
coherence of the postulated mode of action.
Other Modes of Action
In view of the available data, no alternative modes of action for SCCPs-induced kidney 
carcinogenesis that logically present themselves can be supported by as significant a body of 
evidence as the one presented in this assessment. However, there is one form of kidney 
toxicity exclusively observed in males and not females, which may or may not be associated 
with a2u globulin nephropathy. Mild nephritis was reported in male rats, but not females, 
orally dosed (either in the diet or via gavage) with 100 or 625 mg/kg/day SCCPs for 90 days 
by Serrone et al. (1987). It is important to note that since this finding occurred at the same 
dose levels at which the tumours were seen or at lower doses, greater relevance can be 
attached to its potential toxicological significance in relation to the SCCPs-induced kidney 
carcinogenesis. In addition, there are still some uncertainties in relation to the significance of 
the areas of tubular eosinophilia and basophilia observed in two 90-day studies and their role 
in hyaline droplet nephropathy. 
Assessment of Postulated Mode of Action
Overall, the weight of evidence appears to indicate that a2u globulin-associated nephropathy 
is the most likely the underlying mechanism for the kidney tumours induced by SCCPs. 
Although the evidence for a classical hyaline droplet nephropathy is limited, mechanistic 
studies which have investigated early biomarkers of non-genotoxic kidney carcinogenicity, 
have shown an association between a2u accumulation and renal tubule replicative DNA 
synthesis, providing clear evidence that a2u accumulation leads to sustained regenerative cell 
proliferation. The association between these two key events should be considered to be far 
stronger evidence in support of the postulated mode of action than a clear observation of a 
hyaline droplet nephropathy, which is only the histopathological expression of a2u 
accumulation. In view of this, it is felt that the level of confidence in the postulated mode of 
action can be reasonably high.
Uncertainties, Inconsistencies, and Data Gaps
The main uncertainty in the postulated mode of action relates to the observation of mild 
nephritis in male rats, but not females, orally dosed (either in the diet or via gavage) with 100 
or 625 mg/kg/day SCCPs for 90 days (Serrone et al., 1987). It cannot be completely ruled out 
that this is a form of male renal toxicity other than a2u globulin nephropathy, and therefore 
its possible role in tumour formation in male rats is unclear. However, it is important to point 
out that this study is relatively old and hence might have limitations with regard to the 
stringency of the histopathological investigations conducted. Certainly, the descriptions of the 
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lesions are brief and somewhat unclear, and similar findings have not been observed as an 
exclusively male rat phenomenon in other more recent, well conducted studies.
It is also noted that the evidence for a classical hyaline droplet nephropathy is rather limited. 
The significance of the areas of tubular eosinophilia and basophilia observed in two 90-day 
studies (one with SCCPs and one with MCCPs) and their role in hyaline droplet nephropathy 
is unclear. However, it should be noted that this atypical picture might simply be due to the 
overlap of two concomitant and interdependent processes, the induction of peroxisome 
proliferation and the induction of a2u globulin-associated nephropathy. Furthermore, in spite 
of the limited evidence in support of a classical hyaline droplet nephropathy, mechanistic 
studies which have investigated early biomarkers of non-genotoxic kidney carcinogenicity, 
have shown a clear association between a2u accumulation and renal tubule replicative DNA 
synthesis, providing clear evidence that a2u accumulation leads to sustained regenerative cell 
proliferation. 
Other studies
C14-17 MCCPs (52% chlorination, with and without the addition of a 0.2% epoxidised 
vegetable oil stabilizer) were tested in cell transformation assays using baby hamster kidney 
cells up to cytotoxic concentrations (Birtley et al, 1980). Negative responses were obtained.
Summary of carcinogenicity 
No carcinogenicity studies in human populations with potential exposure to MCCPs are 
available, and similarly no investigations in animals have been conducted. Although no direct 
information is available, MCCPs are are generally unreactive and not mutagenic. In the 
absence of experimental carcinogenicity data on MCCPs, given the similarities between 
MCCPs and SCCPs in physicochemical properties and in the results obtained in relation to 
other toxicological endpoints, particularly the effects seen on the liver, thyroid and kidneys on 
repeated exposure, it seems reasonable to presume that the carcinogenic potential of MCCPs 
will be similar, at least in qualitative terms, to that of SCCPs. SCCPs have been investigated 
in animal studies and found to induce liver, thyroid and kidney tubular cell adenomas and 
carcinomas. On mechanistic considerations, the liver and thyroid tumours were considered to 
be of little or no relevance to human health. The underlying mechanism for the kidney 
tumours has not been fully elucidated. However, there is recent mechanistic evidence to show 
that a2u-binding is probably the primary mechanism for kidney tumour formation induced by 
SCCPs in male rats. The available evidence strongly suggests that the underlying mechanism 
would not be relevant to humans. Therefore, overall, SCCPs, and by analogy MCCPs, should 
be considered not to pose a carcinogenic hazard to humans. 
In discussions with Member States, uncertainties about this mechanism for the kidney 
tumours have been highlighted. Hence, in January 2004, this issue was referred to the EC 
Group of Specialised Experts in the fields of Carcinogenicity, Mutagenicity and 
Reprotoxicity.
The Specialised Experts agreed that there were still data gaps leading to uncertainty about the 
relevance of these tumours for humans. Some experts argued that there were inconsistencies 
and contradictions in the mechanistic studies which might indicate that alternative 
mechanisms could not be excluded. The relation between a2u mechanism and the kidney 
tumours was not adequately established in this case. These data gaps led the Experts to 
conclude that the criteria for no classification for SCCPs were not met, and hence, they 
recommended that the current classification of SCCPs with Carc Cat 3 be retained. 
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However, the Specialised Experts agreed that a read-across from SCCPs to MCCPs was not 
justified for carcinogenicity, and consequently MCCPs could not be classified for this 
endpoint. They noted the absence of animal tumour data for MCCPs, the toxicological 
differences seen between SCCPs and LCCPs, and the heterogenous nature of all these 
compounds.
Hence, based on the opinion of the Specialised Experts read-across from SCCPs to MCCPs 
for this endpoint is not appropriate in terms of classification. However, in terms of hazard and 
risk, the carcinogenic potential of MCCPs still needs to be addressed. Taking into account all 
the other existing data on MCCPs, specifically the genotoxicity and the repeated dose toxicity 
data, it is noted that MCCPs lack genotoxicity activity, but produce kidney toxicity in male 
and female rats (increased weight at 222 mg.kg-1.day-1 and ‘chronic nephritis’ and tubular 
pigmentation at 625 mg.kg-1.day-1). Based on this evidence, it cannot be completely ruled out 
that this form of kidney toxicity might lead to cancer in male and female rats through a non-
genotoxic mode of action, even though with SCCPs kidney tumours were seen in male rats 
only. Therefore, a risk characterisation for the carcinogenicity endpoint will be conducted 
using the same NOAEL of 23 mg/kg/day identified for repeated dose effects on the kidney.
4.1.2.9 Toxicity for reproduction
4.1.2.9.1 Studies in animals
The majority of the available studies have been conducted using a C14-17, 52% chlorinated 
paraffin.
Effects on fertility
The only data available are those contained in an one-generation study (CXR, 2006) and in an 
unpublished range-finding study performed with the aim of identifying dose levels for a 2-
generation reproduction study; however, the full study was not then conducted (IRDC, 1985). 
In the IRDC (1985) study, groups of Wistar rats (5 males and 10 females) were administered 
0, 100, 1000 or 6250 ppm C14-17 MCCP (52% chlorination) in the diet for 28 days prior to 
mating, during mating and up to post-natal day 21 (females only). These animals constituted 
the F0 (parental) generation. The average doses of test substance received were 0, 6, 62 or 384 
mg/kg/day for males and 0, 8, 74 or 463 mg/kg/day for females. Five male and 10 female F1
pups were selected at random from each group, and were retained (receiving the same diet as 
their parents from weaning) up to 70 days of age. One F1 litter/group was killed on lactation 
days 6 and 7 at the high dose and in the controls, respectively. The remaining F1 animals were 
sacrificed on lactation day 21 and the F0 females after weaning of their offspring. Necropsy 
examination was performed (on kidneys, lungs, ureter, and urinary bladder only) on F0
females but not males. A number of reproductive and litter parameter assessments were 
conducted following sacrifice. Blood samples were collected for haematological analysis from 
F1 pups at various timepoints.
No deaths occurred amongst the F0 (parental) generation, and there were no abnormalities 
noted in the histology examinations of females. The only finding of any note was a 
statistically significant decrease (by 12%) in food consumption in females at 6250 ppm during 
week 5. No treatment-related effects on fertility indices were observed. At birth, F1 pup 
survival in all dose groups was equivalent to that of the control group F1 pups. However, 
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amongst the F1 generation, a marked and statistically significant decrease in pup survival was 
noted during lactation at 6250 ppm, such that none of the pups survived until weaning. 
Reduced pup survival (by 11%) was also evident at 1000 ppm and, although not statistically 
significant, is considered to be of toxicological importance. The effect on survival was further 
investigated in a study (Hart et al, 1985) summarised in the developmental toxicity section.  
Decreased activity and swollen and dark or black eye(s) were observed in a few F1 pups in 1 
or 2 mid- and high-dose litters. Haematological analyses revealed “reductions” (quantified 
data not presented) in erythrocyte counts, haemoglobin concentration and haematocrit among 
a single litter of F1 pups at the top dose on lactation day 6 compared to the controls on 
lactation day 7; however, the small sample size involved precludes the drawing of any firm 
conclusions on the basis of these findings. 
Necropsy of the pups revealed dose-related, but not statistically significant, increases amongst 
F1 pups at 1000 and 6250 ppm in the occurrence and severity of subcutaneous haematoma, 
pallor, blood around the orifices, pale liver, kidneys, lungs and spleen and blood in the cranial 
cavity and brain. Haematoma was noted in all of the litters at 6250 ppm.
In summary, it is difficult to draw firm conclusions in relation to fertility from this study due 
to the small numbers of animals used and limitations in design (although it was only intended 
as a range-finding study). Although this is a limited study, the administration of a C14-17
MCCP (52% chlorination) to rats in the diet at up to approximately 400 mg/kg/day had no 
apparent effect upon fertility. However, significant effects were seen in the developing 
offspring prior to them having been weaned; a concentration of 1000 ppm in the diet 
(~74 mg/kg/day) resulted in a number of necropsy findings in the offspring indicative of 
internal haemorrhaging. All pups born to dams receiving 6250 ppm (equivalent to 
approximately 460 mg/kg/day) died before weaning, probably as a result of the internal 
haemorrhaging. This would indicate that the pups had either died as a result of receiving the 
test substance or metabolites through breast milk, or that the milk that was produced by dams 
was deficient in factors essential for pup survival, or both. Further studies (see below) 
confirmed that this was mediated via the breast milk. From this study, however, no adverse 
effects were seen in offspring at approximately 8 mg.kg-1.day-1 (pre- or post-natally). 
In a recent one-generation study (CXR, 2006) conducted to refine the NOAEL for effects in 
the offspring and to further explore the mechanisms of the haemorrhagic effects, groups of 
12-17 nine-ten weeks old male and female Sprague-Dawley rats were administered 0 (17 
animals/sex), 300 (12 animals/sex), 600 (12 animals/sex) or 1200 (17 animals/sex) ppm C14-17
MCCPs (52% chlorination) via the diet for 4 weeks before pairing, throughout pairing, 
gestation and lactation until termination. The males were terminated after 9 weeks of 
treatment (day 4 of lactation) and the females were allowed to litter and rear their offspring 
until PND 21 and were killed on day 21 of lactation (approximately 11-12 weeks of 
treatment). The offspring were terminated on PND 21. The study was performed in 
accordance with the general principles of the OECD testing guideline 421, although a larger 
number of animals and a longer treatment duration before pairing and during lactation were 
employed. The study was also conducted in compliance with GLP and QA standards. Five 
females and their litters from the control and 1200 ppm group were classed as satellite 
animals and used for additional investigations of blood, liver and milk samples. During the 
study, clinical condition, bodyweight, food consumption, gestation length and parturition 
observations, liver weights and macroscopic pathology investigations were undertaken on the 
F0 females. The F0 males were assessed for clinical condition, bodyweight, food 
consumption and macropathology. Mating performance and fertility were also evaluated. 
Clinical condition, litter size and survival, sex ratio and bodyweight of all offspring were 
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assessed before pathology investigations were undertaken at necropsy. Milk, blood and liver 
samples were obtained from dams and blood and liver samples were obtained from selected 
offspring at specific time points between the birth of litters and day 21 of lactation. The 
analysis of these samples is still underway and will be reported as part of a separate study.
Mean achieved dosages for males prior to pairing were 21, 44 and 84 mg/kg/day in the 300, 
600 and 1200 ppm groups respectively. For females, mean achieved dosages prior to pairing 
were 23, 47 and 99 mg/kg/day in the 300, 600 and 1200 ppm groups respectively. There were 
no adverse effects of treatment on clinical condition, bodyweight, bodyweight gain or food 
intake of the F0 males and females prior to pairing or for females during gestation or 
lactation. Oestrus cycles, mating performance, pre-coital interval, fertility and gestation 
lengths were unaffected by treatment. The 1200 ppm F0 females had marginally higher 
absolute (by 12%) and relative (by 11%) liver weights compared to controls, which is 
consistent with the effects seen in repeated dose toxicity studies. The number of implantations 
and subsequent litter size, sex ratio and offspring survival were unaffected by treatment. The 
clinical condition of the male and female offspring and offspring bodyweights, bodyweight 
gains to weaning, macropathology findings and liver weights were also unaffected by 
treatment. It should be noted that, although no histopatholy was performed in this study, the
macroscopic examination carried out, which involved opening the body cavities and the cranial cavity, 
should have been able to pick up any significant (sufficient to cause death) haemorrhage; this is 
because in small animals (pups) haemorrhage are likely to be visible macroscopically as red or dark 
areas on the surface of the different organs. Overall, based on the results of this study, it can be 
concluded that dietary administration of C14-17 MCCPs (52% chlorination) at levels up to 
1200 ppm (100 mg/kg/d) had no adverse effects on pre- and post-natal survival and growth of 
the F1 offspring up to weaning, following treatment of F0 males and females for 4 weeks 
prior to pairing and throughout mating, gestation and lactation (for a total treatment duration 
of 11-12 weeks).
Similar data were not available for SCCPs (SCCP ESR Risk Assessment Report, 2000).
Developmental studies
Two conventional teratolgy studies are available for MCCPs, one in rats and one in rabbits.
Studies in rats
Groups of 25 mated female rats received 0, 500, 2000 or 5000 mg/kg/day C14-17 MCCP (52% 
chlorination) in corn oil by oral gavage on gestational days 6-19 with sacrifice on day 20 
(IRDC, 1984). The dose levels were chosen based on the results of two preliminary sighting 
studies (IRDC, 1981 and IRDC, 1983). The numbers and location of viable and non-viable 
fetuses, resorption sites and total number of implantations and ovarian corpora lutea were 
determined. All fetuses were examined for external malformations, and one half of the fetuses 
from each litter were then examined for visceral malformations and the other half for skeletal 
malformations.
One mid-dose group female died on gestational day 16; the cause of death was not established 
but was probably not MCCP-related. Clinical signs of maternal toxicity were seen at 2000 and 
5000 mg/kg/day, and constituted wet and/or matted fur in the anogenital region (with red or 
yellow staining) and an increased incidence of soft stool prior to sacrifice. No treatment-
related effects on the uterine parameters examined were seen. There were no treatment-related 
effects on pup weight. No malformations were observed as a result of treatment. In this study, 
there were no developmental effects observed at levels up to 5000 mg/kg/day.
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Studies in rabbits
Groups of 16 previously artificially inseminated rabbits received 0, 10, 30 or 100 mg/kg/day 
C14-17 MCCP (52% chlorination) in corn oil by oral gavage on days 6-27 of gestation (IRDC, 
1983). The doses were selected on the basis of two unpublished range-finding studies, both of 
which were available for assessment (IRDC, 1982a and IRDC, 1982b). Dams were sacrificed 
on day 28 of gestation at which time the numbers and location of viable and non-viable 
fetuses, resorption sites and total number of implantations and ovarian corpora lutea were 
determined. An examination for external malformations was conducted upon all the fetuses, 
followed by examination of half of the fetuses from each litter for visceral malformations and 
the other half for skeletal malformations. There were no treatment-related mortalities or 
clinical signs of toxicity in the dams. Abortions occurred at 0 (1 dam), 30 (2 dams) and 100 
mg/kg/day (2 dams). However, rabbits are known to have a high spontaneous abortion rate, 
and the pattern of results suggests that this is not indicative of a treatment-related effect. The 
only difference seen in the offspring was a statistically significantly increased number of 
viable fetuses at 30 mg/kg/day compared with the controls; the value was within the historical 
control range for this parameter and is of no toxicological significance. No treatment-related 
malformations were seen.
A limitation of this study was that it was not conducted up to maternally toxic dose levels. 
However, its findings are valid for doses up to 100 mg/kg/day. On the basis of the outcome of 
this study, the MCCP (52% chlorination) was not toxic to development in the rabbit at dose 
levels up to 100 mg/kg/day.
4.1.2.9.2 Human data
No data are available.
4.1.2.9.3 Research into the mechanisms of the internal haemorrhages
Following on from previous work (see Section on Effects on fertility), a study was conducted 
with the aim of investigating the possible mechanism of internal haemorrhages seen to 
develop post-natally in pups (Hart et al, 1985). Groups of male and female Wistar rats were 
treated with 0 or 6250 ppm C14-17 MCCP (52% chlorination) in the diet for 4 weeks before 
mating. After confirmation of mating (presence of sperm in a vaginal smear), the females 
were placed into one of the 5 following treatment groups:
Group 1) 16 females fed control diet rearing their own pups
Group 2) 26 females fed chlorinated paraffin diet rearing pups fostered from group 3 
control females
Group 3) 26 females fed control diet rearing pups fostered from group 2 treated females
Group 4) 16 females fed chlorinated paraffin diet rearing their own pups
Group 5) 16 females fed chlorinated paraffin diet up to day 10 of pregnancy, rearing 
their own pups while fed control diet.
Blood samples were obtained from one pup/litter on days 3, 4, 5, 8, and 11, and 2 pups/litter 
on day 22 (the day of sacrifice) post-partum and analysed for clotting factors VIII and X. 
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Prothrombin times were also measured at these timepoints and platelet counts on days 11 and 
22 of the study.  Activated partial thromboplastin time was not measured.
Samples of breast milk were taken from lactating dams of groups 1, 2 and 4 on day 14 
post-partum only, and analysed for the test substance. Sampling proved difficult and only one 
sample was obtained for each of groups 2 and 4; these were found to contain 570 and 
1280 ppm (570 and 1280 mg/l) MCCP respectively.
No deaths or clinical signs of toxicity were seen in the parental animals during the pre-mating 
period and pregnancy. During days 12-22 post-partum, statistically significant increase in pup 
mortality was seen in control pups fostered to treated mothers (group 2) and treated pups 
reared by their own treated mothers (group 4); (77% and 67% deaths respectively compared 
to 4% for group 1). Increased mortality was not observed in any other groups. Of the total 
number of pups found dead, haemorrhages were seen in 17 and 8% respectively of group 2 
and group 4 offspring, with no sign of haemorrhaging noted in the pups born to the other 
dams. Several findings indicative of the occurrence of internal haemorrhages were found in 
pups raised by dams treated with chlorinated paraffin during lactation (i.e. groups 2 and 4). 
These findings consisted of dark red bulging eyes, blood clots within the membranes lining 
the cranium and pale livers. In group 2, a significant reduction in pup bodyweight was 
observed from day 5 post-partum onwards and this was reduced by up to 11% on day 22. 
Throughout lactation, haematological analysis revealed a marked and statistically significant 
reduction in the concentration of clotting factor X amongst control pups fostered to treated 
mothers (i.e. group 2 - reduced by up to 45%) and pups reared by their own treated mothers 
(ie group 4 - reduced by up to 63%) relative to group 1 pups. The concentration of factor X in 
groups 3 and 5 was essentially similar to control group 1. Prothrombin times were increased 
(but not statistically significant) in these two groups. No toxicologically significant changes 
were seen in factor VIII. Significant increases in liver weight were seen in pups from group 2 
(both sexes up to a 5% increase) and in female pups (up to an 18% increase) from group 4. 
The low (similar to control) incidence of death in pups from groups 3 and 5 treated mothers, 
and the high incidence in group 2 and 4 pups clearly indicate that the effect on the pups is 
focused on mother-to-pup transfer during weaning. Comparing the absence of effects in group 
5 pups, where dams received MCCP until day 10 of gestation, to the effects seen in group 2 
and 4 pups where there was continued feeding with MCCP throughout the study suggests that 
for the effect to be mediated there may be a need for continued availability of MCCP. The 
lack of effect in group 5 suggests that uptake of MCCP into fatty tissue (with subsequent 
mobilisation into breast milk) may not be a significant factor in this case. However, in the 
absence of specific measurement of MCCP levels in breast milk from group 5 dams, it is not 
possible to determine whether the lack of toxicity in the pups of this group was due to no 
MCCP being present in the breast milk or whether the levels of MCCP (including any derived 
from fatty tissue) were below a threshold for this effect, however mediated. 
On the basis of the observed decreases in clotting factor X, the study authors proposed that the 
chlorinated paraffin tested was either transferred in the breast milk, causing disruption of the 
clotting system in the pups, or alternatively that the pups received less vitamin K in the breast 
milk due to treatment-related effects upon their mothers and as a consequence the vitamin K-
dependent clotting pathway was impaired. Either mechanism could have led to the 
manifestation that chlorinated paraffin treatment of the dams led to a reduction in the 
haemostatic mechanism in the pups, resulting in pup deaths. This conclusion would appear to 
be reasonable. Overall, therefore, MCCPs are considered to present a hazard to the neonatal 
offspring via the lactating mother. A NOAEL of 47 mg/kg/day as a maternal dose can be 
identified for this effect, from the recent one-generation study (CXR, 2006).
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Further work has been carried out to investigate these two hypotheses. For background 
information, it is important to borne in mind that vitamin K controls the formation of clotting 
factors II (prothrombin), VII, IV and X in the liver; that in adults it is synthesised by the gut 
microflora and it is also obtained from ingested plant and animal tissues. A preliminary study 
(CXR Biosciences Ltd, 2003) has been performed to test the hypothesis that MCCPs induce 
the catabolism of vitamin K in adult female rats leading to decreased plasma concentrations. 
If this occurred in the lactating rat, this could lead to low levels of vitamin K in the milk and a 
decreased supply to the neonates, which are already physiologically compromised in their 
vitamin K status (vitamin K is synthesised by the gut microflora; in the very early days of life, 
the neonatal gut is sterile, therefore the only source of vitamin K in the neonate is from breast 
milk; however breast milk has relatively low levels of vitamin K. Furthermore, the neonatal 
liver is immature with respect to prothrombin synthesis).
Groups of 6 female adult Sprague-Dawley rats on a normal diet or on a vitamin K3 deficient 
diet were administered by oral gavage 0, 500 or 1000 mg/kg/day MCCPs for 21 days. 
Furthermore, two groups of 6 female rats, one maintained on normal diet and one maintained 
on vitamin K3 deficient diet, were treated for 21 days with 0.1% phenobarbitone (PB, an 
inducer of liver cytochrome P450 enzymes), in drinking water (equivalent to a dose of 20 
mg/kg/day). The PB-treated groups were included to test the hypothesis that induction of PB-
type inducible enzymes may increase vitamin K metabolism. At termination, body and liver 
weights were recorded, and blood samples were taken. These were analysed for prothrombin 
clotting times, clotting factors VII and X and vitamin K levels. In addition, liver microsomal 
fractions were prepared and analysed by SDS-PAGE and Western immunoblotting for 
assessment of induction of CYP2B1 and/or CYP2B2 isozymes.
No treatment-related deaths, clinical signs of toxicity or effects on body weight were 
observed, but there was a statistically significant, dose-related increase in liver weight in both 
the normal and the vitamin K3 deficient diet groups (by 42% and 56% at 500 and 
1000 mg/kg/day respectively for the normal diet groups, and by 42% and 49% at 500 and 
1000 mg/kg/day respectively for the vitamin K3 deficient diet groups). Liver weights for the 
PB treated animals were not markedly different from their respective control groups. Factor X 
levels were unaffected by treatment for both dietary regimes, and plasma vitamin K levels 
were lower (by 34%) only in the high dose animals fed vitamin K3 deficient diet.  A 
statistically significant, dose-related decrease (by 18% and 42% at the low and high dose 
respectively) in Factor VII levels was observed in the MCCPs-treated animals fed normal 
diet. A marked decrease in Factor VII levels was also seen in both control and MCCPs-treated 
animals fed vitamin K3 deficient diet (by 25%, 24% and 44% of the normal diet control group 
levels at 0, 500 and 1000 mg/kg/day respectively). PB-treated animals fed normal diet showed 
conversely a statistically significant increase of 43% in Factor VII levels. Prothrombin 
clotting times were slightly statistically significantly decreased (by 12 %) but only at the low 
dose in the normal diet group. The results of the Western immunoblot analysis showed that 
the expression of CYP2B1 and CYP2B2 isozymes was induced at both MCCPs dosages, at 
similar levels in the normal and in the vitamin K3 deficient diet groups. The extent of 
induction by MCCPs was also similar to that observed with PB administration. 
In conclusion, MCCPs administration to adult female rats at dose levels up to 1000 mg/kg/day 
for 21 days produced significant decreases in plasma concentrations of clotting Factor VII in 
the normal diet animals; however these were not of a sufficient magnitude to cause a 
biologically significant increase in prothrombin clotting times. The decrease in Factor VII 
levels observed in the vitamin K3 deficient diet animals was seen not only in the treated 
groups but also in the control rats. It is therefore unlikely that this reduction was due to 
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treatment with MCCPs. Plasma vitamin K levels were unaffected by treatment in the normal 
diet animals, but they were lower in the high dose animals fed vitamin K3 deficient diet. It has 
been speculated by the authors that rats have a homeostatic mechanism which enables them to 
maintain normal plasma levels of vitamin K even when the diet they are consuming is 
deficient in vitamin K3, but that this mechanism might have been compromised by the 
administration of a very high dose of MCCPs (1000 mg/kg/day). It also appears that MCCPs 
cause induction of CYP2B1 and CYP2B2 isozymes in both the normal and vitamin K3
deficient diet groups. 
Overall, it can be concluded that MCCPs are without effect on the blood clotting system in 
adult female rats treated for 3 weeks up to a dose level of 1000 mg/kg/day, and it can be 
deduced that the haemorrhaging effects on the offspring are unlikely to be mediated by 
reduced vitamin K levels in breast milk under the conditions of this preliminary study (CXR 
Biosciences Ltd, 2003).
However, in order to test the other hypothesis, i.e. that MCCPs transferred to the pups through 
breast milk, cause disruption of the pups’ clotting system, a further investigation has been 
recently performed (CXR Biosciences Ltd, 2004). The study design adopted for this 
investigation was a limited one-generation assay modified to provide milk, blood and liver 
samples from lactating dams, and blood and liver samples from suckling pups. The blood and 
milk samples were analysed for levels of MCCPs, clotting factors and vitamin K, while the 
liver samples were examined for induction of the liver isozymes CYP2B1 and CYP2B2.
Groups of 16 male and 32 female Sprague-Dawley rats representing the parental generation 
(F0) were treated in the diet with 0 or 6250 ppm MCCPs (equivalent to a dose averaged over 
the first 4 week of treatment of 0 or 513 and 538 mg/kg/day for males and females, 
respectively) for 4 weeks prior to mating, then throughout mating, gestation and lactation. 
However, because of a very high increase in pup mortality in the test animals, the study was 
terminated prematurely approximately 2 weeks after the first litters were born. The F0 
animals were monitored for clinical signs of toxicity, body weight, food consumption and 
mating performance. The F1 offspring were monitored for survival and growth. Half of the 
dams from each group were assigned for pup sampling and half for milk sampling. Blood and 
liver samples (pup sampling) were obtained from one male and one female pup removed from 
half of the litters on days 1 and 4 of lactation (day 0 is the day of parturition) and at study 
termination (day 12 of lactation). From the remaining females not used for pup sampling, a 
milk sample was obtained on days 1 and 4 of lactation and at study termination when samples 
of maternal liver were also collected.
Five test dams (16%) died or were killed around the time of parturition. All 5 deaths were 
associated with littering although there was no obstruction or other hindrance to the delivery 
process (dystocia), and were considered treatment-related. It is noted that 4 of the 5 dams 
either gave birth to normal litters or were found to have a normal complement of live foetuses 
in their uterus. One exposed male was also found dead during the experiment. The 
clinical/necropsy findings in 3 out of these 5 dams and in the male rat found dead showed 
signs (abnormal red coloured urine, cage stained red, blood around vagina, placenta dark red, 
skin stained, eyes pale, skin pale) suggestive of haemorrhaging. No difference was seen 
between the control dams and the treated dams in relation to clinical signs of toxicity. Body 
weight gains of males and females prior to mating were similar in both groups. Test females 
showed a slight reduction in body weight gain during gestation (by 8%) and lactation (by 
18%). There were slight reductions in food consumption prior to mating in both treated sexes 
(by 10% in males during the first week of treatment and by 13 and 8% in females during the 
first and the fourth week of treatment respectively). In addition, treated females consumed 
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less food (by 17%) compared to the controls during lactation. There were no effects of 
MCCPs on mating performance or duration of gestation.
There were no effects of MCCPs on litter size at birth and on pup mortality from birth to day 
4 of lactation. However, after day 4, pup mortality increased dramatically among the test 
animals (for example, there was a mean number of 5.4 live pups per litter on day 7 of 
lactation vs a mean number of 11.5 live pups per litter on day 1 of lactation) such that only 
few pups survived until the study was terminated, prematurely, around day 12 of lactation. At 
necropsy, the majority of these pups showed internal haemorrhages. Mean pup weight on day 
1 of lactation was marginally lower (by 7-18%) in litters of treated females compared to 
controls. By day 4 of lactation, the weights of treated pups were noticeably lower (by 12-
27%) than controls, and the difference had become more apparent (by 44-48%) by day 7 of 
lactation. On day 1 of lactation, liver weights were only marginally greater (by 7%) in pups 
from treated females compared to controls, however, on day 4, pup liver weights in the test 
group were statistically significantly increased above control pups (by up to 29%).
Levels of MCCPs were analysed in dam milk on day 1 of lactation. Samples from 3 MCCPs 
treated dams and from 3 control dams were obtained. A mean level of 1057 mg/l (SD=±530 
mg/l) was measured. This value was consistent with that obtained in the cross-fostering study 
(925 mg/l) from dams treated with the same dose level of MCCPs (6250 ppm). No MCCPs 
were detected in control milk. Plasma vitamin K levels measured in samples from 10 animals 
from each group on day 12 of lactation were significantly decreased in the treated dams 
(0.03±0.05 ng/ml) compared to the control dams (0.41±0.14 ng/ml). This finding seems to be 
in contradiction with the result obtained in the previous investigation (CXR Biosciences Ltd, 
2003) in which the plasma levels of vitamin K were unaffected by treatment. However, we 
note that this apparent inconsistency could be explained by the fact that in the CXR 
Biosciences Ltd (2003) study treatment with MCCPs was only for 3 weeks while in this 
investigation it was for 7-8 weeks. Furthermore, in the CXR Biosciences Ltd (2003) study 
adult females were treated while in this new study, the treated females went through the 
critical stages of pregnancy and lactation. Decreased maternal plasma vitamin K in the treated 
dams was reflected by decreased vitamin K levels in treated dam milk. Vitamin K was not 
found in pooled days 1 and 4 samples from 4 treated dams compared to a mean level of 0.28
ng/ml (SD=±0.10) in samples from 5 control dams. This finding was confirmed on pooled 
days 9 and 12 samples from treated dams (0.36±0.11 ng/l) and control dams (0.61±0.29 ng/l) 
which showed an approximate 50% decrease in breast milk levels of vitamin K in the test 
dams.
As described above, the concentration of vitamin K in the plasma of adult females having 
gone through pregnancy and lactation was markedly decreased by MCCP treatment. This in 
turn produced a decrease in activity of the plasma clotting factors VII (24.2±13.1) and X 
(87.0±40.7) in the treated dams compared to controls (58.6±19.6 and 119±27.8 for factor VII 
and factor X respectively) on day 12 of lactation. However, this did not affect the prothrombin 
times in the dams, suggesting that the functional reserve in these adult animals was sufficient.
Pup plasma volumes were insufficient to measure vitamin K directly, however, it was 
possible to analyse clotting factor activities as surrogates. The data showed that MCCPs 
treatment led to decreased clotting factor VII and X activities after day 4. Activities of 7.46, 
6.6 and 6.47 were measured for factor VII in plasma of the treated pups on days 4, 9-11 and 
12 post-partum compared to activities of 25.7, 17.4 and 22.7 in the control pups. Activities of
7.12, 6.36 and 3.47 were detected for factor X in plasma of the treated pups on days 4, 9-11 
and 12 post-partum compared to activities of 14.3, 7.6 and 9.69 in the control pups.
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The results on liver enzyme induction in both dams and pups are not yet available.
These new data suggest that MCCPs at a dose level of 6250 ppm (538 mg/kg/day) induce a 
perturbation of the clotting system in lactating neonates of treated mothers. In adult animals, 
decreased levels of vitamin K and of the clotting factors VII and X were found. However, 
these did not affect their prothrombin times, indicating that the functional reserve in these 
adult animals is sufficient. The foetus in utero apparently receives sufficient vitamin K via the 
placenta, but after birth becomes severely deficient in vitamin K and related clotting factors 
when reliant of these factors via the mothers’milk. They also receive through the milk 
considerable levels of MCCPs which may also further reduce their vitamin K levels. This in 
turn will lead to a severe vitamin K deficiency in these neonates (who are already 
compromised in their vitamin K status) and consequently to haemorrhaging.
Maternal death was also seen during parturition in 5 out of 32 dams treated with 538 
mg/kg/day MCCPs. The observation of excessive bleeding in the clinical/necropsy findings of 
these dams and the observed decreased maternal blood levels of vitamin K indicate that these 
deaths were most likely to be due to haemorrhaging and not a direct consequence of 
parturition. It is also expected that the act of parturition would place the dams at a higher risk 
of the consequences of low vitamin K levels.
4.1.2.9.4 Summary of toxicity for reproduction
With regard to effects upon fertility, no information is available in humans. The two available 
animal studies showed that administration of up to approximately 100 and 400 mg/kg/day 
respectively in the diet had no apparent effect upon fertility. The evidence in one study (out of 
the 3 reported) of maternal death during parturition observed in 5 out of 32 dams given 6250 
ppm (538 mg/kg/day) MCCPs in the diet is not considered a direct consequence of 
parturition, but the consequence of low levels of vitamin K and related haemorrhaging. It is 
also expected that the act of parturition would place the dams at a higher risk of the 
consequences of low vitamin K levels.
In relation to developmental effects, there are no data available in humans. No adverse effects 
occurring during gestation were produced in rats or rabbits in two conventional teratology 
studies using doses up to 5000 and 100 mg/kg/day respectively. In contrast, exposure of rats 
to a C14-17 52% chlorinated paraffin from 74 mg/kg/day (1000 ppm) up to approximately 
400 mg/kg/day (6250 ppm) in the diet produced internal haemorrhaging and deaths in the 
neonatal pups, although no such effects were seen in a more recent study with exposure to 
MCCPs for 11-12 weeks at maternal dose levels of 23 (300 ppm), 47 (600 ppm) and up to 100 
mg/kg/day (1200 ppm). This would appear to be a repeated dose effect to which newborns 
during lactation, and possibly pregnant females at the time of parturition, are particularly 
susceptible.
A recent investigation (CXR Biosciences Ltd., 2004) has shown that MCCPs at a dose level 
of 6250 ppm (538 mg/kg/day) induce a perturbation of the clotting system in lactating 
neonates of treated mothers. In adult females that had been treated for 7-8 weeks including 
pregnancy and lactation, decreased levels of vitamin K and of the clotting factors VII and X 
were found, and 5 out of 32 dams showed signs of haemorrhaging during parturition. 
However, these decreases did not affect their prothrombin times, indicating that the functional 
reserve in the majority of these adult animals was sufficient. This implies that the foetus in 
utero receives sufficient vitamin K via the placenta, but after birth the neonate becomes 
severely deficient in vitamin K and related clotting factors when reliant of these factors via 
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the mothers’milk. It has also been shown that the neonate receives through the milk 
considerable levels of MCCPs, which may also further reduce his vitamin K levels. This in 
turn will lead to a severe vitamin K deficiency in these neonates (who are already 
compromised in their vitamin K status) and consequently to haemorrhaging. It has been argued 
that these effects should be considered as developmental toxicity effects as the development 
during the neonatal period of rats corresponds to the development period during the last 
trimester of human pregnancy. Although it is generally accepted that the rat post-natal period 
is equivalent to the last trimester of a human pregnancy, by taking into account what is known 
of the mechanism of these effects, such haemorrhaging effects could only be entirely post-
natal even in humans as they cannot occur in utero as there are supplies of vitamin K from the 
dams. Also, although some dams died as a consequence of haemorrhaging, it should be noted 
that the dams died at parturition and not during the pregnancy and that the act of parturition 
puts the dams at higher risk, maybe as a consequence of blood loss.
From the studies available, an overall NOAEL of 47 mg/kg/day (600 ppm) as a maternal dose 
can be identified for these effects mediated via lactation. However, it should be noted that the 
effects (11% reduction in pup survival and related haemorrhaging) observed at the LOAEL 
(74 mg/kg/day; 1000 ppm) were not statistically significant. Haemorrhaging was also seen in 
one study at the time of parturition in 16% of dams given 538 mg/kg/day (6250 ppm) 
MCCPs, but not up to 100 mg/kg (1200 ppm) in other studies. The NOAEL of 100 mg/kg/day 
(1200 ppm) is therefore selected for the risk characterisation of haemorrhaging effects 
potentially occurring in pregnant women at the time of parturition. 
During the technical discussions of this RAR, a small number of Member States disagreed 
with this interpretation of the data, which was endorsed by the majority of Member States. 
Denmark, Sweden and Norway found that effects concerning internal haemorrhaging and 
death in neonatal pups described in section 4.1.2.9.1 (Fertility) and section 4.1.2.9.3 
(Research into mechanisms of the internal haemorrhages) should be considered as 
developmental toxicity effects and not exclusively as repeated dose toxicity effects as 
mentioned in this summary. The development during the neonatal period of rats corresponds 
to the development period during the last trimester of human pregnancy. It was argued that as 
the effect may be a consequence of increased sensitivity towards low level of vitamin K of the 
new-born rats this would then correspond to increased sensitivity in the human foetus during 
the last trimester. It was also argued that the effect would further imply classification for 
developmental toxicity as the criteria for classification include any effect interfering with 
normal development from gestation up to and including puberty.
4.1.3 Risk characterisation (with regard to the effects listed in Annex 1A of 
Regulation 1488/94)
The section below, entitled ‘General Aspects’ provides an overview of the occupational use, 
exposure and toxicological profile of medium-chained chlorinated paraffins identifying the 
lead effects and where appropriate, identifying NOAELs and/or LOAELs. 
General aspects
Occupational exposure to MCCPs occurs during the:
manufacture of MCCPs;
manufacture and use of PVC formulations containing MCCPs;
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manufacture and use of paints containing MCCPs;
manufacture and use of sealants and adhesives containing MCCPs;
manufacture of rubber containing MCCPs;
manufacture and use of MWFs containing MCCPs;
manufacture and use of fat liquors containing MCCPs for leather treatment; and
manufacture of carbonless copy paper containing MCCPs.
MCCPs are viscous liquids with very low vapour pressures. MCCPs, 52% chlorinated with a 
vapour pressure of 2.7 x 10-7 kPa at 20 °C, have a saturated vapour concentration of 
0.0027 ppm or 0.051 mg.m-3 (assuming a molecular weight of 450) at 20 °C. Thus personal 
exposures to MCCP vapour at ambient temperature in the workplace will be very low, the 
maximum theoretical vapour concentration being 0.0027 ppm. This prediction for maximum 
vapour concentration based on the SVC will still hold where the process is at a higher 
temperature, since the actual working environment will usually be about 20 °C. At the point of 
release of hot vapour from the process there will be a mixture of vapour and mist. The mist is 
formed as the hot vapour cools and condenses to form liquid droplets, thus in the worker’s 
breathing zone there will be vapour, at a maximum of the SVC, and mist. The extent of the 
exposure to the mist will be dependent on the processing temperature and the controls. 
A range of 9 to 18 mg.m-3 8-hour TWA was derived from EASE data for the mist in situations 
where poor control of this mist was felt to be a possibility. These scenarios were calendering 
of plasticized PVC, compounding of plasticised PVC, extrusion and moulding of plasticised 
PVC, and rubber manufacture. In other scenarios, exposure to the mist was discounted as a 
significant contributor to exposure. Either process temperatures were too low or the nature of 
the process was such that releases were very unlikely.
In addition to the possibility of exposure to MCCP aerosols created by condensation, there are 
situations where aerosols may be created by mechanical agitation, in particular, during the use 
of metal working fluids containing MCCPs in the engineering industry and, to a much lesser 
extent, during the spraying of paints which contain MCCPs. Values for exposure to airborne 
MCCPs derived from a recent unpublished HSE survey of the exposure of workers to metal 
working fluids, indicate exposures between 0.09 and 0.5 mg.m-3 8-hour TWA. De Pater et al, 
1999 (draft), provide a model for predicting exposure to non-volatile compounds during spray 
painting, which gave a result of 5 mg.m-3 8-hour TWA.
Dermal exposure to MWFs was predicted using EASE to be 0.006 to 0.75 mg/cm2/day. Seven 
activities gave rise to EASE predicted dermal exposures to MCCPs in the range 0.1 to 
1 mg/cm2/day, namely,
Drumming off MCCPs at the production plant
Manufacture of PVC plastisol
Calendering of PVC
Compounding of plasticised PVC
Application of paints
Rubber manufacture
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Use of fat liquors in leather treatment
The remaining activities described in the report give rise to EASE predictions of dermal 
exposure in the range 0 to 0.1 mg/cm2/day. These values have again been provided as a first 
approximation of this exposure and are based on the limited information obtained. 
The only human toxicokinetics data relate to information on the presence of chlorinated 
paraffins in human breast milk, indicating the potential for excretion via this route. No studies 
have been undertaken to investigate the toxicokinetics of MCCPs following exposure of 
animals via the inhalation or dermal routes. A recent GLP- and OECD-compliant in vitro
study using human skin showed that after 24 hours, approximately 0.7% of a C15 chlorinated 
paraffin was absorbed. A dermal absorption value of 1% is therefore taken forward to the risk 
characterisation.
Absorption following oral exposure in animals has been demonstrated to be significant 
(probably at least 50% of the total administered dose). Overall, therefore, 50% absorption by 
this route will be assumed for risk characterisation purposes. There is no specific information
for the inhalation route of exposure; however, given that the data indicate 50% absorption by 
the oral route and only 1% by the dermal route, and in view of the very high log Pow and the 
very low water solubility of MCCPs, it reasonable to assume that inhalation absorption is also 
unlikely to be higher than 50%. This figure will therefore be taken to the risk characterisation 
in relation to absorption via the inhalation route of exposure. No conclusions can be drawn 
regarding the way in which the degree of chlorination of these substances may affect the 
extent of absorption following oral or any other route of administration.
Following absorption of radiolabelled MCCP via the oral route, there is an initial preferential 
distribution of radiolabel to tissues of high metabolic turnover/cellular proliferation. 
Subsequently, there is a re-distribution of radiolabelled material to fatty tissue. Following 
single gavage dosing in the rat, an elimination half-life of approximately 2-5 days was 
estimated for tissues such as the liver and kidney, and of about 2 weeks for tissues such as 
white adipose. Following repeated dietary administration, retention in fatty tissue occurs, with 
one study in rats showing a half-life for elimination from the abdominal fat of around 8
weeks. Results of a very recent study in the rat have shown that steady state in adipose tissue 
is reached at approximately 13 weeks and that elimination of MCCPs from this tissue appears 
to be biphasic, with an initial half-life of approximately 4 weeks, followed by a markedly 
slower second phase with a terminal half-life of approximately 43 weeks. There is no clear 
information on whether or not the degree of chlorination affects distribution. Also, generally, 
it is unclear whether or not the distributed material is the parent compound and/or metabolites 
although one recent study clearly indicates that it is the parent compound that is taken up in 
adipose tissue and liver. There is evidence from animal studies and human data to indicate 
that MCCPs have the potential to be transferred to offspring via breast milk. Transmission of 
MCCPs (34% chlorination) or metabolites via the mother to the developing fetus in utero was 
evident although it is not clear if this occurs with all forms of MCCPs.
In relation to metabolism, one study with a 65% chlorinated MCCP indicated conjugation 
with glutathione. The production of CO2 from MCCPs has also been demonstrated and was 
quite extensive (~30%) with MCCPs of lower chlorination (e.g. 34% chlorination), but 
appeared to be much more limited (~1%) with more heavily chlorinated MCCPs (e.g. 69% 
chlorination). Elimination of MCCPs and/or their metabolites occurs via the faeces, via 
exhaled CO2 with lower chlorinated MCCPs, and to a limited extent in the urine.
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No toxicological information is available on the effects of single exposure to MCCPs in 
humans. In animals, MCCPs are of low acute oral toxicity, and it is anticipated that the 
MCCPs are likely to be of low acute toxicity by inhalation and dermal routes. No information 
is available relating to the way in which the degree of chlorination might affect results, but 
given the low acute toxicity, this is unlikely to be of significance for this endpoint.
No data are available in humans relating to skin or eye irritation. However, based upon animal 
studies, MCCPs have been shown to cause only slight skin irritation on single exposure, 
although more pronounced irritation was observed following repeated application. MCCPs 
produce only slight eye irritation, and it is anticipated that they are unlikely to cause 
respiratory tract irritation. Amongst the limited range of compounds studied, the degree of 
chlorination was not of significance for these endpoints.
No data are available on skin sensitisation potential in humans but no evidence of skin 
sensitisation was produced in guinea pig maximisation tests and it is expected that MCCPs do 
not possess the potential to cause respiratory sensitisation.
No information is available on the effects of repeated exposure in humans. In animals there
are no data relating to repeated inhalation or dermal exposure. A number of oral dosing 
studies (up to 90 days duration) in rodents are available which have investigated the repeated 
dose toxicity of C14-17, 40% or 52% chlorinated paraffins. However, the extent of the data are 
such that it is not possible to assess whether or not the degree of chlorination, particularly 
outside this range, would have an effect upon the resulting toxicity.
The liver, thyroid and kidney are the target organs for repeated dose toxicity of MCCPs. For 
the liver, increases in weight were seen in rats and dogs at exposure levels of 100 mg/kg/day 
and above. In addition, enzyme induction and histopathological changes (centrilobular 
hepatocyte hypertrophy) were seen in rats starting from 222 mg/kg/day, and, from a limited 
study in dogs, at 30 mg/kg/day and above. These changes are likely to be related to an 
increase in metabolic demand as an adaptive response, possibly combined with peroxisome 
proliferation in the rat at higher dose levels. Both of these hepatic effects are considered of no 
or limited toxicological significance to human health. However, in rats, at higher exposure 
levels (around 360 mg/kg/day) single cell necrosis was observed; this effect is not thought to 
be related to increased metabolic demand or to peroxisome proliferation and therefore is 
considered to be of relevance to human health.
For the thyroid, clear pathology (follicular hypertrophy and hyperplasia) was seen at relatively 
high dose levels (312 mg/kg/day and above). Increased TSH levels and decreased T4 levels 
were also seen at similar dose levels. However, no toxicologically significant effects on 
thyroid hormones and TSH were observed up to top dose of 222/242 mg/kg/day 
(males/females) in a recent, well-conducted 90-day study in rats. The thyroid pathology 
observed at relatively high doses of MCCPs is likely to have occurred due to repeated 
stimulation of this organ because of a negative feedback control effect arising from plasma T4
depletion following increased excretion of this hormone. This depletion results from an 
increase in the activity of hepatic UDPG-transferase. Humans, unlike rodents, possess T4-
globulin binding protein and are therefore less susceptible to plasma T4 depletion and hence 
any resultant thyroid stimulation. Overall based on these considerations, the thyroid effects 
observed in rats should be considered not to be of relevance to human health at relevant levels 
of exposure. 
From the data that are available, no adverse renal effects were seen in males and females at 23 
mg/kg/day in a recent and well-conducted rat 90-day study. Changes seen in the kidneys at 
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222 mg/kg/day and above (increased weight, ‘chronic nephritis’ and tubular pigmentation) are 
considered as being potentially relevant to human health. Mechanistic studies indicated some 
deposition of a2u globulin in proximal convoluted tubules of male rats only at higher dose 
levels. However, this was unrelated to the pathological findings described above. Thus, these 
changes are not considered to be a male rat-specific phenomenon. In terms of severity, an 
increase in kidney weight of 9-13% was observed at the top dose of 222 mg/kg/day in one 
study and of 18% at the top dose of 625 mg/kg/day in another study. The increase above 
controls in the incidence and severity of what has been misleadingly termed ‘chronic 
nephritis’ (‘a mixed population of interstitial inflammatory cells, tubular regeneration and 
minimal degenerative changes in the tubular epithelium occurring alone or in combination’) 
was seen in treated males and females at 10 mg/kg/day and above. At 10 mg/kg/day the 
severity of these changes was graded as ‘trace’, and even at the highest exposure level, 
625 mg/kg/day, was only ‘mild’. Furthermore, a significant increase above controls in the 
incidence of this lesion (10/15 vs 1/15) was only seen at the top dose of 625 mg/kg/day with 
3/15 and 4/15 animals affected at 10 and 100 mg/kg/day respectively. It is therefore 
concluded that, although kidney changes were observed from 10 mg/kg/day, a lesion 
considered to be of toxicological significance only occurred at the top dose of 625 mg/kg/day.  
Tubular pigmentation was also seen in females at the top dose of 625 mg/kg/day.  
Overall, a NOAEL of 23 mg/kg/day is identified for repeated dose toxicity based upon effects 
seen in rat kidney (increased weight at the next dose level of 222 mg/kg/day and ‘chronic 
nephritis’ and tubular pigmentation at 625 mg/kg/day). It is noted that at 222 mg/kg/day there 
were also slight decreases in plasma triglycerides and cholesterol levels. 
Few data are available on the genotoxicity of MCCPs, but the information that is available on 
MCCPs (and by comparison with SCCPs) indicates that MCCPs do not possess genotoxic 
activity.
No carcinogenicity studies in human populations with potential exposure to MCCPs are 
available, and similarly no investigations in animals have been conducted. Although no direct 
information is available, MCCPs are generally unreactive and not mutagenic. In the absence 
of experimental carcinogenicity data on MCCPs, given the similarities between MCCPs and 
SCCPs in physicochemical properties and in the results obtained in relation to other 
toxicological endpoints, particularly the effects seen on the liver, thyroid and kidneys on 
repeated exposure, it seems reasonable to presume that the carcinogenic potential of MCCPs 
will be similar, at least in qualitative terms, to that of SCCPs. SCCPs have been investigated 
in animal studies and found to induce liver and thyroid adenomas and carcinomas and kidney 
tubular cell adenomas and carcinomas. On mechanistic considerations, the liver and thyroid 
tumours were considered to be of little or no relevance to human health. The position agreed 
within the EU for SCCPs is that the underlying mechanism for the kidney tumours has not 
been elucidated and hence the possibility of carcinogenic potential relevant to humans could 
not be ruled out. However, since that evaluation, further evidence for the male rat specific 
mechanism for SCCPs has become available, indicating that a2u globulin formation is the 
likely underlying cause for tumour formation in male rats. Therefore, overall, SCCPs, and by 
analogy MCCPs, should be considered not to pose a carcinogenic hazard to humans.
In discussions with Member States, uncertainties about this mechanism for the kidney 
tumours have been highlighted. Hence, in January 2004, this issue was referred to the EC 
Group of Specialised Experts in the fields of Carcinogenicity, Mutagenicity and 
Reprotoxicity.
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The Specialised Experts agreed that there were still data gaps leading to uncertainty about the 
relevance of these tumours for humans. Some experts argued that there were inconsistencies 
and contradictions in the mechanistic studies, which might indicate that alternative 
mechanisms could not be excluded. The relation between a2u mechanism and the kidney 
tumours was not adequately established in this case. These data gaps led the Experts to 
conclude that the criteria for no classification for SCCPs were not met, and hence, they 
recommended that the current classification of SCCPs with Carc Cat 3 be retained. 
However, the Specialised Experts agreed that a read-across from SCCPs to MCCPs was not 
justified for carcinogenicity, and consequently MCCPs could not be classified for this
endpoint. They noted the absence of animal tumour data for MCCPs, the toxicological 
differences seen between SCCPs and LCCPs, and the heterogenous nature of all these 
compounds.
Hence, based on the opinion of the Specialised Experts read-across from SCCPs to MCCPs 
for this endpoint is not appropriate in terms of classification. However, in terms of hazard and 
risk, the carcinogenic potential of MCCPs still needs to be addressed. Taking into account all 
the other existing data on MCCPs, specifically the genotoxicity and the repeated dose toxicity 
data, it is noted that MCCPs lack genotoxicity activity, but produce kidney toxicity in male 
and female rats (increased weight at 222 mg/kg/day and ‘chronic nephritis’ and tubular 
pigmentation at 625 mg/kg/day). Based on this evidence, it cannot be completely ruled out 
that this form of kidney toxicity might lead to cancer in male and female rats through a non-
genotoxic mode of action, even though with SCCPs kidney tumours were seen in male rats 
only. Therefore, a risk characterisation for the carcinogenicity endpoint will be conducted 
using the same NOAEL of 23 mg/kg/day identified for repeated dose effects on the kidney.
With regard to effects upon fertility, no information is available in humans. The two available 
animal studies (in rats) showed that administration of up to approximately 100 and 
400 mg/kg/day respectively in the diet had no apparent effect upon fertility. The evidence in 
one study (out of the 3 reported) of maternal death during parturition observed in 5 out of 32 
dams given 6250 ppm (538 mg/kg/day) MCCPs in the diet is not considered a direct 
consequence of parturition, but the consequence of low levels of vitamin K and related 
haemorrhaging. It is expected that the act of parturition would place the dams at a higher risk 
of the consequences of low vitamin K levels.
In relation to developmental effects, there are no data available in humans. No adverse effects 
occurring during gestation were produced in rats or rabbits in two conventional teratology 
studies using maternal doses up to 5000 and 100 mg/kg/day respectively. In contrast, 
exposure of rats to a C14-17 52% chlorinated paraffins from 74 mg/kg/day (1000 ppm) up to 
approximately 400 mg/kg/day (6250 ppm) as a maternal dose in the diet produced internal 
haemorrhaging and deaths in the pups, although no such effects were seen in a more recent 
study with exposure to MCCPs for 11-12 weeks at maternal dose levels of 23 (300 ppm), 47 
(600 ppm) and up to 100 mg/kg/day (1200 ppm). This would appear to be a repeated dose 
effect to which newborns during lactation, and possibly pregnant females at the time of 
parturition, are particularly susceptible. A recent investigation (CXR Biosciences Ltd., 2004) 
has shown that MCCPs at a dose level of 6250 ppm (538 mg/kg/day) induce a perturbation of 
the clotting system in lactating neonates of treated mothers. In adult females that had been 
treated for 7-8 weeks including pregnancy and lactation, decreased levels of vitamin K and of 
the clotting factors VII and X were found, and 5 out of 32 dams showed signs of 
haemorrhaging during parturition. However, these decreases did not affect their prothrombin 
times, indicating that the functional reserve in the majority of these adult animals is sufficient. 
The foetus in utero apparently receives sufficient vitamin K via the placenta, but after birth 
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becomes severely deficient in vitamin K and related clotting factors when reliant of these 
factors via the mothers’milk. They also receive through the milk considerable levels of 
MCCPs, which may also further reduce their vitamin K levels. This in turn will lead to a 
severe vitamin K deficiency in these neonates (who are already compromised in their vitamin 
K status) and consequently to haemorrhaging.
From the studies available, an overall NOAEL of 47 mg/kg/day (600 ppm) as a maternal dose 
can be identified for these effects mediated via lactation. However, it should be noted that the 
effects (11% reduction in pup survival and related haemorrhaging) observed at the LOAEL 
(74 mg/kg/day; 1000 ppm) were not statistically significant. Haemorrhaging was also seen in 
one study at the time of parturition in 16% of dams given 538 mg/kg/day (6250 ppm) 
MCCPs, but not up to 100 mg/kg (1200 ppm) in other studies. The NOAEL of 100 mg/kg/day 
(1200 ppm) is therefore selected for the risk characterisation of haemorrhaging effects 
potentially occurring in pregnant women at the time of parturition. 
Overall, the lead health effects of concern are irritation of the skin as a result of repeated 
exposure via a defatting mechanism, repeated dose toxicity, carcinogencity, effects on the 
dams during parturition and effects on the offspring mediated via lactation. There are no 
concerns for acute toxicity, irritation, sensitisation, genotoxicity or effects on fertility and 
therefore conclusion (ii) is reached for these endpoints.
To conduct the risk characterisation for workers and consumers, it is necessary to compare 
human exposure for the inhalation and dermal routes with oral N(L)OAELs from repeated-
dose animal studies, because of the absence of inhalation toxicity data. The human inhalation 
and dermal exposures have been converted to internal body burdens. A breathing rate of 1.25 
m3.hour-1 and body weights of 70 and 60 kg for workers and consumers respectively have 
been assumed. Absorption is considered to be 50% by the oral and inhalation routes and 1% 
by the dermal route.
A NOAEL of 23 mg/kg/day has been identified for repeated dose toxicity based upon effects 
seen in rat kidney (increased weight at the next dose level of 222 mg/kg/day and ‘chronic 
nephritis’ at 625 mg/kg/day). It is noted that at 222 mg/kg/day there were also slight decreases 
in plasma triglycerides and cholesterol levels. 
In relation to carcinogenicity, there are no animal or human data available. Furthermore, read 
across from SCCPs was not considered appropriate by the SE. Hence, taking into account all 
the other existing data on MCCPs, specifically the genotoxicity and the repeated dose toxicity 
data, it is noted that MCCPs lack genotoxicity activity, but produce kidney toxicity in rats 
(increased weight at 222 mg/kg/day and ‘chronic nephritis’ at 625 mg/kg/day). Based on this 
evidence, it cannot be completely ruled out that this form of kidney toxicity might lead to 
cancer through a non-genotoxic mode of action. Therefore, a risk characterisation for 
carcinogenicity will be conducted using the same NOAEL of 23 mg/kg/day identified for 
repeated dose effects on the kidney.
Severe effects (internal haemorrhaging and deaths) have been observed in suckling rat pups 
where the dams had received MCCPs orally. This haemorrhaging would appear to be a 
repeated dose effect to which newborns during lactation, and possibly pregnant females at the 
time of parturition, are particularly susceptible. A very recent investigation (CXR Biosciences 
Ltd., 2004) has shown that MCCPs at a dose level of 6250 ppm (538 mg/kg/day) induce a 
perturbation of the clotting system in lactating neonates of treated mothers. In adult females 
that had been treated for 7-8 weeks including pregnancy and lactation, decreased levels of 
vitamin K and of the clotting factors VII and X were found, and 5 out of 32 dams showed 
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signs of haemorrhaging during parturition. However, these decreases did not affect their 
prothrombin times, indicating that the functional reserve in the majority of these adult animals 
is sufficient. The foetus in utero apparently receives sufficient vitamin K via the placenta, but 
after birth becomes severely deficient in vitamin K and related clotting factors when reliant of 
these factors via the mothers’milk. They also receive through the milk considerable levels of 
MCCPs, which may also further reduce their vitamin K levels. This in turn will lead to a 
severe vitamin K deficiency in these neonates (who are already compromised in their vitamin 
K status) and consequently to haemorrhaging.
The maternal NOAEL (47 mg/kg/day; 600 ppm) identified in a recent one-generation study 
for effects on the F1 offspring, following treatment of F0 males and females for 4 weeks prior
to pairing and throughout mating, gestation and lactation (for a total treatment duration of 11-
12 weeks) will be used in the risk characterisation of an adult population of breastfeeding 
mothers that might be exposed to MCCPs via work activities, consumer products or the 
environment. However, it should be noted that the effects (11% reduction in pup survival and 
related haemorrhaging) observed at the LOAEL (74 mg/kg/day; 1000 ppm) were not 
statistically significant. Haemorrhaging was also seen in one study at the time of parturition in 
16% of dams given 538 mg/kg/day (6250 ppm) MCCPs, but not up to 100 mg/kg/day (1200 
ppm) in other studies. The NOAEL of 100 mg/kg/day (1200 ppm) is therefore selected for the 
risk characterisation of haemorrhaging effects potentially occurring in pregnant women at the 
time of parturition. 
The cross-fostering study and this recent investigation have also identified a concentration of 
MCCPs in samples of rat dam breast milk inducing haemorrhaging effects in the pups, and 
three surveys have measured MCCPs levels in human breast and cow’s milk samples. 
Therefore, a risk characterisation for these effects will also be performed for an infant 
population potentially exposed to MCCPs via breast or cow’s milk.
4.1.3.1 Workers
Irritation
There is evidence for slight irritation of the skin as a result of repeated exposures to MCCPs. 
However, this property is unlikely to be expressed during normal handling and use providing 
good occupational hygiene practices are in operation. Overall, conclusion (ii) is reached.
Repeated exposure toxicity
The body burdens arising from inhalation and dermal exposure in each different worker 
exposure scenario, and the resultant MOSs derived from comparison with the NOAEL for 
effects on the kidney are shown in Table 4.10
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Table 4:10  Body burdens and MOSs for repeated dose toxicity
Process Inhalation 
exposure 
(mg/m3)
Inhalation 
body burden 
(mg/kg)
Dermal 
exposure
(mg/day)
Dermal 
body 
burden  
(mg/kg)
Total 
body 
burden 
(mg/kg)
MOS 
based on 
kidney 
toxicity
NOAEL1
Conclus
ion
Manufacture of MCCPs 0.05 0.0035 210 0.03 0.034 338 (ii)
PVC 
formulation/manufactu
re
0.08 0.0057 420 0.06 0.066 174 (ii)
Plastisol use 0.05 0.0035 126 0.02 0.024 479 (ii)
Calendering 1 0.07 420 0.06 0.13 88 (ii)
Compounding of PVC 0.15 0.011 84 0.012 0.023 500 (ii)
Extrusion/Moulding 0.1 0.007 21 0.003 0.01 1150 (ii)
Paint manufacture 0.05 0.0035 42 0.006 0.01 1150 (ii)
Paint spraying 0.19 0.014 126 0.02 0.034 338 (ii)
Sealant manufacture 0.05 0.0035 42 0.006 0.01 1150 (ii)
Rubber manufacture 0.07 0.005 420 0.06 0.065 178 (ii)
MWF manufacture 0.05 0.0035 42 0.006 0.01 1150 (ii)
Water-based MWF use 0.008 0.0006 180 0.026 0.0266 432 (ii)
Oil-based MWF use 2.4 0.17 25,000 3.6 3.77 3 (iii)
Preparation and use of 
fat liquor
0.05 0.0035 84 0.012 0.016 719 (ii)
Copy paper 
manufacture
0.05 0.0035 42 0.006 0.01 1150 (ii)
Based on NOAEL of 23 mg.kg-1 equivalent to an internal NAEL of 11.5 mg.kg-1based on 50% oral absorption
For all scenarios except PVC calendering and oil-based MWF use, the MOSs are ³ 174. 
These values are considered to provide sufficient reassurance that adverse repeated dose 
effects will not occur even after taking into account variability between and within species 
and the relatively short duration (90 days) of the study from which the NOAEL has been 
identified (subchronic to chronic extrapolation). Further reassurance for the potential of 
MCCPs to biopersist in adipose tissue is not required, as steady state should have been 
reached within the exposure duration of the study from which the NOAEL has been 
identified. Therefore conclusion (ii) is proposed for these scenarios. 
For PVC calendering, the MOS is 88. This value would not normally be sufficient to account 
for variability between and within species and for the relatively short duration (90 days) of the 
study from which the NOAEL has been identified (subchronic to chronic extrapolation). 
However, given that the exposure estimate is likely to be an overestimate of chronic exposure 
as workers are exposed 2-3 times per week rather than 5 days per week, conclusion (ii) is 
proposed for this scenario. 
For oil-based MWF use, the MOS is 3. This value is considered to be too low for taking into 
account variability between and within species and the relatively short duration (90 days) of 
the study from which the NOAEL has been identified. Therefore conclusion (iii) is proposed 
for this scenario. It is important to note that for the oil-based MWF use scenario the MOS is 
heavily affected by the dermal contribution to total body burden.
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Carcinogenicity
Table 4.11 shows the body burdens arising from inhalation and dermal exposure in each 
different worker scenario, and the resultant MOSs derived from comparison with the NOAEL 
of 23 mg/kg/day identified for kidney toxicity, which is considered to have the potential to 
lead to cancer formation through a non-genotoxic mode of action. 
Table 4:11  Body burdens and MOSs for carcinogencic effects
Process Inhalation 
exposure 
(mg/m3)
Inhalation 
body burden 
(mg/kg)
Dermal 
exposure
(mg/day)
Dermal 
body 
burden  
(mg/kg)
Total 
body 
burden 
(mg/kg)
MOS 
based on 
kidney 
toxicity
NOAEL1
Conclus
ion
Manufacture of MCCPs 0.05 0.0035 210 0.03 0.034 338 (ii)
PVC 
formulation/manufactu
re
0.08 0.0057 420 0.06 0.066 174 (ii)
Plastisol use 0.05 0.0035 126 0.02 0.024 479 (ii)
Calendering 1 0.07 420 0.06 0.13 88 (ii)
Compounding of PVC 0.15 0.011 84 0.012 0.023 500 (ii)
Extrusion/Moulding 0.1 0.007 21 0.003 0.01 1150 (ii)
Paint manufacture 0.05 0.0035 42 0.006 0.01 1150 (ii)
Paint spraying 0.19 0.014 126 0.02 0.034 338 (ii)
Sealant manufacture 0.05 0.0035 42 0.006 0.01 1150 (ii)
Rubber manufacture 0.07 0.005 420 0.06 0.065 178 (ii)
MWF manufacture 0.05 0.0035 42 0.006 0.01 1150 (ii)
Water-based MWF use 0.008 0.0006 180 0.026 0.0266 432 (ii)
Oil-based MWF use 2.4 0.17 25,000 3.6 3.77 3 (iii)
Preparation and use of 
fat liquor
0.05 0.0035 84 0.012 0.016 719 (ii)
Copy paper 
manufacture
0.05 0.0035 42 0.006 0.01 1150 (ii)
1 Based on NOAEL of 23 mg.kg-1 equivalent to an internal NAEL of 11.5 mg.kg-1based on 50% oral absorption
For all scenarios except PVC calendering and oil-based MWF use, the MOSs are ³ 174. 
These values are considered to provide sufficient reassurance that carcinogenic effects will 
not occur even after taking into account variability between and within species and the 
relatively short duration (90 days) of the study from which the NOAEL has been identified 
(subchronic to chronic extrapolation). Further reassurance for the potential of MCCPs to 
biopersist in adipose tissue is not required, as steady state should have been reached within 
the exposure duration of the study from which the NOAEL has been identified. Although, 
normally, the severity of the endpoint would require an additional safety factor, since, in this 
case, the risk characterisation for potential carcinogenicity is based on repeated dose toxicity, 
no additional factor is required. Therefore conclusion (ii) is proposed for these scenarios. 
For PVC calendering, the MOS is 88. This value would not normally be sufficient to account 
for variability between and within species and for the relatively short duration (90 days) of the 
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study from which the NOAEL has been identified (subchronic to chronic extrapolation). 
However, given that the exposure estimate is likely to be an overestimate of chronic exposure 
as workers are exposed 2-3 times per week rather than 5 days per week, conclusion (ii) is 
proposed for this scenario. 
For oil-based MWF use, the MOS is 3. This value is considered to be too low for taking into 
account variability between and within species and the relatively short duration (90 days) of 
the study from which the NOAEL has been identified. Therefore conclusion (iii) is proposed 
for this scenario. It is important to note that for the oil-based MWF use scenario the MOS is 
heavily affected by the dermal contribution to total body burden.
Effects mediated via lactation
Table 4.12 shows the body burdens arising from inhalation and dermal exposure in each 
different worker exposure scenario, and the resultant MOSs derived from comparison with the 
maternal NOAEL (47 mg/kg/day; 600 ppm) for effects mediated via lactation. It should be 
noted that whilst it is possible that a woman might return to work immediately after her 
confinement and start to breastfeed her infant, the blood levels of MCCPs, and, as a 
consequence, the levels in her milk, will have been reduced as a consequence of her period of 
absence from work. This anticipated reduction in body burden has therefore been reflected in 
the calculation of a corrected total body burden by the application of a dividing factor of 2.
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Table 4:12  Inhalation body burdens and resultant MOSs for effects mediated via lactation
Process Inhalation 
exposure 
(mg/m3)
Inhalation 
body 
burden 
(mg/kg)
Dermal 
exposure
(mg/day)
Dermal 
body 
burden  
(mg/kg)
Total 
body 
burden 
(mg/kg)
Corrected 
total body 
burden for 
a 
breastfeed
ing 
mother 
returning 
to work 
after 
maternity 
leave
MOS 
based on 
NOAEL1 
for effects 
via 
lactation
Conclus
ion
Manufacture of 
MCCPs
0.05 0.0035 210 0.03 0.034 0.017 1382 (ii)
PVC 
formulation/manuf
acture
0.08 0.0057 420 0.06 0.066 0.033 712 (ii)
Plastisol use 0.05 0.0035 126 0.02 0.024 0.012 1958 (ii)
Calendering 1 0.07 420 0.06 0.13 0.065 362 (ii)
Compounding of 
PVC
0.15 0.011 84 0.012 0.023 0.0115 2042 (ii)
Extrusion/Mouldin
g
0.1 0.007 21 0.003 0.01 0.005 4700 (ii)
Paint manufacture 0.05 0.0035 42 0.006 0.01 0.005 4700 (ii)
Paint spraying 0.19 0.014 126 0.02 0.034 0.017 1382 (ii)
Sealant 
manufacture
0.05 0.0035 42 0.006 0.01 0.005 4700 (ii)
Rubber 
manufacture
0.07 0.005 420 0.06 0.065 0.0325 722 (ii)
MWF manufacture 0.05 0.0035 42 0.006 0.01 0.005 4700 (ii)
Water-based MWF 
use
0.008 0.0006 180 0.026 0.0266 0.0133 1767 (ii)
Oil-based MWF 
use
2.4 0.17 25,000 3.6 3.77 1.885 12.4 (iii)
Preparation and 
use of fat liquor
0.05 0.0035 84 0.012 0.016 0.008 2938 (ii)
Copy paper 
manufacture
0.05 0.0035 42 0.006 0.01 0.005 4700 (ii)
1 Based on NOAEL of 47 mg/kg equivalent to an internal NAEL of 23.5 mg/kgbased on 50% oral absorption
For all scenarios except oil-based MWF use, the MOSs are ³ 362. These MOSs are 
considered to provide sufficient reassurance that these effects will not occur after allowing for 
the potential toxicokinetic and toxicodynamic differences between and within species, for the 
need to adjust for time to staedy state (13 wk vs an exposure duration in the study from which 
the NOAEL has been identified of 11-12 wk) and for the severity of the effects (11% 
mortality at the LOAEL of 74 mg/kg/day). Further reassurance for subchronic to chronic 
extrapolation is not required, as, for effects via lactation, exposure is not chronic. Hence, 
conclusion (ii) is reached for these scenarios.
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For the remaining scenario, oil-based MWF use, the MOS is 12.4. This MOS value does not 
provide sufficient reassurance that these effects will not occur and therefore conclusion (iii) is 
reached. 
Effects at the time of parturition
Table 4.13 shows the body burdens arising from inhalation and dermal exposure in each 
different worker exposure scenario, and the resultant MOSs derived from comparison with the 
NOAEL (100 mg/kg/day; 1200 ppm) for effects at the time of parturition. It seems reasonable 
to assume that a pregnant woman would not be at work conducting the manual tasks 
described by the exposure scenarios right up to the time of parturition. It is suggested that a 
pregnant woman is likely to cease work at least four weeks prior to her impending 
confinement. Given that the first phase of elimination of MCCPs has been shown to have a 
half-life of 4 weeks (see section 4.1.2.1.3), it seems reasonable to calculate a corrected total 
body burden for the time of parturition by applying a dividing factor of 2.
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Table 4:13  Inhalation body burdens and resultant MOSs for effects at the time of parturition
Process Inhalation 
exposure 
(mg/m3)
Inhalation 
body 
burden 
(mg/kg)
Dermal 
exposure
(mg/day)
Dermal 
body 
burden  
(mg/kg)
Total 
body 
burden 
(mg/kg)
Corrected 
total body 
burden for a 
pregnant 
woman going 
on maternity 
leave at least 
four weeks 
prior to her 
confinement
MOS based 
on NOAEL1 
for effects 
at the time 
of 
parturition
Concl
usion
Manufacture of 
MCCPs
0.05 0.0035 210 0.03 0.034 0.017 2940 (ii)
PVC 
formulation/ma
nufacture
0.08 0.0057 420 0.06 0.066 0.033 1515 (ii)
Plastisol use 0.05 0.0035 126 0.02 0.024 0.012 4167 (ii)
Calendering 1 0.07 420 0.06 0.13 0.065 770 (ii)
Compounding 
of PVC
0.15 0.011 84 0.012 0.023 0.0115 4348 (ii)
Extrusion/Moul
ding
0.1 0.007 21 0.003 0.01 0.005 10,000 (ii)
Paint 
manufacture
0.05 0.0035 42 0.006 0.01 0.005 10,000 (ii)
Paint spraying 0.19 0.014 126 0.02 0.034 0.017 2941 (ii)
Sealant 
manufacture
0.05 0.0035 42 0.006 0.01 0.005 10,000 (ii)
Rubber 
manufacture
0.07 0.005 420 0.06 0.065 0.0325 1538 (ii)
MWF 
manufacture
0.05 0.0035 42 0.006 0.01 0.005 10,000 (ii)
Water-based 
MWF use
0.008 0.0006 180 0.026 0.0266 0.0133 3759 (ii)
Oil-based MWF 
use
2.4 0.17 25,000 3.6 3.77 1.885 26 (iii)
Preparation 
and use of fat 
liquor
0.05 0.0035 84 0.012 0.016 0.008 6250 (ii)
Copy paper 
manufacture
0.05 0.0035 42 0.006 0.01 0.005 10,000 (ii)
1 Based on NOAEL of 100 mg/kg equivalent to an internal NAEL of 50 mg/kg based on 50% oral absorption
For all scenarios except oil-based MWF use, the MOSs are ³ 770. These MOSs are 
considered to provide sufficient reassurance that these effects will not occur after allowing for 
the potential toxicokinetic and toxicodynamic differences between and within species, for the 
need to adjust for time to staedy state (13 wk vs an exposure duration in the study from which 
the NOAEL has been identified of 11-12 wk) and for the severity of the effect (16% 
mortality) at the LOAEL (538 mg/kg/day). Hence, conclusion (ii) is reached for these 
scenarios. For the remaining scenario, oil-based MWF use, the MOS is 26. This MOS value 
does not provide sufficient reassurance that these effects will not occur and therefore 
conclusion (iii) is reached.
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Summary of risk characterisation for workers
The MOSs for effects on the kidney following repeated exposure, for carcinogenicity, for 
effects via lactation and for effects at the time of parturition for oil-based MWF use are 
unacceptably low, and therefore conclusion (iii) is reached for this scenario. For all remaining 
scenarios, the MOSs for all of these effects are considered to be sufficient, and therefore 
conclusion (ii) is reached. 
4.1.3.2 Consumers
The lead health effects for MCCPs are the repeated exposure effects to the kidneys seen in 
adult animals, the potential carcinogenic effects and the internal haemorrhaging observed in 
suckling pups. MCCPs are not skin, eye or respiratory tract irritants following single 
exposures although there is evidence for slight defatting of the skin as a result of repeated 
exposure. This defatting of the skin is considered to be slight and the levels of MCCPs in 
consumer products are very low such that none of the consumer exposure scenarios result in 
repeated dermal exposures that are likely to give rise to concern.
There are two consumer exposure scenarios for which significant exposures could occur: the 
wearing of leather clothes treated with MCCPs and the use of metal working fluids. The 
wearing of leather clothes results in dermal exposure only (estimate of 1 mg/day). For the use 
of metal working fluids, the estimated exposure is 0.5 mg/event (see section 4.1.1.2). The 
endpoints of concern relevant to the consumer are kidney effects following repeated exposure, 
for which a NOAEL of 23 mg/kg/day has been identified, potential carcinogenic effects for 
which the repeated dose toxicity NOAEL of 23 mg/kg/day has been established, effects 
mediated via lactation, for which a maternal NOAEL of 47 mg/kg/day (600 ppm) has been 
identified and effects at the time of parturition, for which a NOAEL of 100 mg/kg/day (1200 
ppm) has been selected.
Repeated exposure toxicity
Dermal exposure resulting from wearing leather clothes treated with MCCPs is estimated to 
be 1 mg/day (see section 4.1.1.2.1). Assuming 1% absorption, this represents a body burden 
of 1.6 x 10-4 mg.kg-1 for a 60 kg consumer. Comparing this body burden with the NOAEL of 
23 mg/kg/day for effects on the kidney (equivalent to an internal NAEL of 11.5 mg/kg/day 
based on 50% oral absorption) gives a MOS of 70,000. This MOS is considered to be 
sufficient even taking into account variability between and within species and the relatively 
short duration (90 days) of the study from which the NOAEL has been identified. Further 
reassurance for the potential of MCCPs to biopersist in adipose tissue is not required, as 
steady state should have been reached within the exposure duration of the study from which 
the NOAEL has been identified. Therefore, conclusion (ii) is reached. 
Inhalation exposure during the use of metal working fluids is estimated to be 0.5 mg/event. 
Assuming 50% absorption, this represents a body burden of 4 x 10-3 mg.kg-1 for a 60 kg 
consumer. Comparing this body burden with the NOAEL of 23 mg/kg/day for effects on the 
kidney (equivalent to an internal NAEL of 11.5 mg/kg/day based on 50% oral absorption) 
gives a MOS of 2,875. This MOS is considered to be sufficient, even taking into account 
variability between and within species and the relatively short duration (90 days) of the study
from which the NOAEL has been identified. Further reassurance for the potential of MCCPs 
to biopersist in adipose tissue is not required, as steady state should have been reached within 
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the exposure duration of the study from which the NOAEL has been identified. Thus, 
conclusion (ii) is reached.
Carcinogenicity
The body burden arising from wearing leather clothes is estimated at 1.6 x 10-4 mg.kg-1. 
Comparing this body burden with the NOAEL of 23 mg/kg/day (equivalent to an internal 
NAEL of 11.5 mg/kg/day based on 50% oral absorption) for potential carcinogenic effects 
gives a MOS of 70,000. This MOS is considered to be sufficient even taking into account 
variability between and within species and the relatively short duration (90 days) of the study 
from which the NOAEL has been identified. Further reassurance for the potential of MCCPs 
to biopersist in adipose tissue is not required, as steady state should have been reached within 
the exposure duration of the study from which the NOAEL has been identified.  Although, 
normally, the severity of the endpoint would require an additional safety factor, since in this 
case, the risk characterisation for potential carcinogenicity is based on repeated dose toxicity, 
no additional factor is required.  Therefore, conclusion (ii) is reached. 
The body burden arising from the use of metal working fluids is estimated at 4 x 10-3 mg.kg-1. 
Comparing this body burden with the NOAEL of 23 mg/kg/day (equivalent to an internal 
NAEL of 11.5 mg/kg/day based on 50% oral absorption) for potential carcinogenic effects 
gives a MOS of 2,875. This MOS is considered to be sufficient even taking into account 
variability between and within species, the relatively short duration (90 days) of the study 
from which the NOAEL has been identified. Further reassurance for the potential of MCCPs 
to biopersist in adipose tissue is not required, as steady state should have been reached within 
the exposure duration of the study from which the NOAEL has been identified.  Although, 
normally, the severity of the endpoint would require an additional safety factor, since, in this 
case, the risk characterisation for potential carcinogenicity is based on repeated dose toxicity, 
no additional factor is required. Therefore conclusion (ii) is reached. 
Effects mediated via lactation
The body burden arising from wearing leather clothes is estimated to be 1.6 x 10-4 mg.kg-1. 
Comparing this body burden with the NOAEL of 47 mg/kg/day (equivalent to an internal 
NAEL of 23.5 mg/kg/day based on 50% oral absorption) for effects mediated via lactation 
gives an MOS of 147,000. 
The body burden arising from the use of metal working fluids is estimated to be 
4 x 10-3 mg.kg-1. Comparing this body burden with the NOAEL of 47 mg/kg/day (equivalent 
to an internal NAEL of 23.5 mg/kg/day based on 50% oral absorption) for effects mediated 
via lactation gives an MOS of 5,875. 
These MOSs are considered to be sufficient that these effects will not occur after allowing for 
toxicokinetic and toxicodynamic differences between and within species, for the need to 
adjust for time to staedy state and for the severity of the effects. Conclusion (ii) is reached for 
both scenarios.
Effects at the time of parturition
The body burden arising from wearing leather clothes is estimated to be 1.6 x 10-4 mg.kg-1. 
Comparing this body burden with the NOAEL of 100 mg/kg/day (equivalent to an internal 
NAEL of 50 mg/kg/day based on 50% oral absorption) for effects at the time of parturition 
gives an MOS of 312,000. 
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The body burden arising from the use of metal working fluids is estimated to be 
4 x 10-3 mg.kg-1. Comparing this body burden with the NOAEL of 100 mg/kg/day (equivalent 
to an internal NAEL of 50 mg/kg/day based on 50% oral absorption) for effects at the time of 
parturition gives an MOS of 12,500. 
These MOSs are considered to be sufficient that these effects will not occur after allowing for 
toxicokinetic and toxicodynamic differences between and within species, for the need to 
adjust for time to staedy state and for the severity of the effect (16% mortality) at the LOAEL 
(538 mg/kg/day). Conclusion (ii) is reached for both scenarios.
4.1.3.3 Humans exposed indirectly via the environment
4.1.3.3.1 Regional exposure
Repeated exposure toxicity, carcinogenicity, effects mediated via lactation and effects at 
the time of parturition
From section 4.1.1.3 the total daily human exposure to medium chain chlorinated paraffins 
from regional sources is 1.3x10-4 mg.kg-1.day-1. The MOSs for repeated exposure toxicity, 
carcinogenicity, effects mediated via lactation and effects at the time of parturition are shown 
in Table 4.14.
Table 4:14  MOSs for repeated exposure toxicity, carcinogenicity, effects mediated via lactation and effects at the time of 
parturition
Effect Regional exposure
(mg.kg-1.day-1)
NOAEL
(mg.kg-1.day-1)
MOS Conclusion
Kidney toxicity 1.3x10-4 11.5 88,000 (ii)
Carcinogenicity 1.3x10-4 11.5 88,000 (ii)
Effects mediated 
via lactation
1.3x10-4 23.5 ~181,000 (ii)
Effects at the time 
of parturition
1.3x10-4 50 385,000 (ii)
In relation to effects on the kidney, the MOS is 88,000. This MOS is considered to be 
sufficient even taking into account variability between and within species and the relatively 
short duration (90 days) of the study from which the NOAEL has been identified. Further 
reassurance for the potential of MCCPs to biopersist in adipose tissue is not required, as 
steady state should have been reached within the exposure duration of the study from which 
the NOAEL has been identified. Thus, conclusion (ii) is proposed.
For potential carcinogenic effects, the MOS is 88,000. This MOS is considered to be 
sufficient even taking into account variability between and within species and the relatively 
short duration (90 days) of the study from which the NOAEL has been identified. Further 
reassurance for the potential of MCCPs to biopersist in adipose tissue is not required, as 
steady state should have been reached within the exposure duration of the study from which 
the NOAEL has been identified.  Although, normally, the severity of the endpoint would 
require an additional safety factor, since in this case, the risk characterisation for potential 
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carcinogenicity is based on repeated dose toxicity, no additional factor is required. Thus, 
conclusion (ii) is proposed. 
For effects mediated via lactation, the MOS is 181,000. This MOS is considered to be 
sufficient to provide reassurance that adverse health effects would not occur, after allowing 
for toxicokinetic and toxicodynamic differences between species, for the need to adjust for 
time to staedy state and for the severity of the effects. Overall, conclusion (ii) is reached.
For effects at the time of parturition, the MOS is 385,000. This MOS is considered to be 
sufficient to provide reassurance that adverse health effects would not occur, after allowing 
for toxicokinetic and toxicodynamic differences between species, for the need to adjust for 
time to staedy state and for the severity of the effect (16% mortality) at the LOAEL (538 
mg/kg/day). Overall, conclusion (ii) is reached.
4.1.3.3.2 Local exposure
Repeated exposure toxicity, carcinogenicity and effects mediated via lactation
In section 4.1.1.3 the highest continuous local exposure is estimated to be 0.016 mg.kg-1.day-1
in the locality of a leather fat liquor plant. 
The margins of safety for local exposure have been calculated using the NOAELs for repeated 
exposure effects on the kidney and for potential carcinogenic effects (internal NAEL of 11.5 
mg/kg/day), for effects mediated via lactation (internal NAEL of 23.5 mg/kg/day) and for 
effects at the time of parturition (internal NAEL of 50 mg/kg/day) in Table 4.15.
Table 4:15  MOSs based on NOAELs for repeated dose toxicity, carcinogenicity, effects mediated via lactation and effects 
at the time of parturition
Effect Exposure
(mg/kg/day)
NOAEL 
(mg.kg-1.day-1)
MOS Conclusion
Kidney and 
thyroid toxicity
0.016 11.5 719 (ii)
Carcinogenicity 0.016 11.5 719 (ii)
Effects mediated 
via lactation
0.016 23.5 1469 (ii)
Effects at the time 
of parturition
0.016 50 3125 (ii)
The calculated margins of safety are large for the effects considered. Therefore, conclusion 
(ii) is proposed. 
4.1.3.3.3 Infants exposed via milk
Severe effects (internal haemorrhaging and deaths) have been observed in suckling rat pups 
from dams that had received MCCPs orally. Internal haemorrhaging or similar haematological 
effects have not been seen in adult rats, so the effects may be associated with an intrinsic 
sensitivity of the pups. A very recent investigation (CXR Biosciences Ltd., 2004) has shown 
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that MCCPs at a dose level of 6250 ppm (538 mg/kg/day) induce a perturbation of the clotting 
system in lactating neonates of treated mothers. In adult females that had been treated for 7-8 
weeks including pregnancy and lactation with 6250 ppm MCCPs, decreased levels of vitamin 
K and of the clotting factors VII and X were found. However, these decreases did not affect 
their prothrombin times, indicating that the functional reserve in these adult animals is 
sufficient. The foetus in utero apparently receives sufficient vitamin K via the placenta, but 
after birth becomes severely deficient in vitamin K and related clotting factors when reliant of 
these factors via the mothers’milk. They also receive through the milk considerable levels of 
MCCPs, which may also further reduce their vitamin K levels. This in turn will lead to a 
severe vitamin K deficiency in these neonates (who are already compromised in their vitamin 
K status) and consequently to haemorrhaging. Since a cross-fostering study in rats and this 
new study have identified a concentration of MCCPs in samples of rat dam breast milk 
inducing haemorrhaging effects in the pups, and three surveys have measured MCCPs levels 
in human breast and cow’s milk samples, a risk characterisation for these effects will be 
performed for an infant population potentially exposed to MCCPs via breast or cow’s milk.
Infants exposed via human breast milk
There is a study that reports levels of chlorinated paraffins (C10-24) in human breast milk 
(Greenpeace, 1995) from which further information on the breast milk sampling was obtained 
from the author of the report. The total level measured (on a fat weight basis) was 45 µg/kg 
fat. The average chlorine content of the chlorinated paraffins detected was around 33% and 
MCCPs were deduced to make up 10 and 22% of the total chlorinated paraffins found in 
groups of non-fish eating and fish eating women respectively. Thus, taking an average level 
of MCCPs of 16%, the concentration of MCCPs present in breast milk can be estimated at 
about 7 µg/kg fat; taking the highest concentration of MCCPs, of 22%, the concentration 
present in milk is about 9.0 µg/kg fat.
More recently, an Industry sponsored study has also found MCCPs to be present in human 
breast milk samples from the United Kingdom (Thomas and Jones, 2002). 22 breast milk 
samples were analysed (8 from Lancaster and 14 from London) and MCCPs were found in 
one sample from London at a concentration of 61µg/kg fat but was below the limit of 
detection in the remaining 21 samples. The detection limit of the method varied with sample 
size ranging from 16 µg/kg fat to 740 µg/kg fat (mean level of 100 µg/kg fat). It is noted that 
these detection limits are higher than the measured levels in breast milk reported in the 
Greenpeace study. This suggests that the analytical method used in Thomas and Jones, 2002 
was less sensitive than that used in the Greenpeace study. The fact that MCCPs were only 
found in 1/22 samples does not mean that it was not present in the other samples at levels 
below the detection limit.
Thomas et al (2003) have recently carried out a further investigation of the levels of 
medium-chain chlorinated paraffins in human breast milk samples from the United Kingdom. 
In this study, relatively large samples of human milk-fat were collected from the London (20 
samples) and Lancaster (5 samples) areas of the United Kingdom between late 2001 and June 
2002. Medium-chain chlorinated paraffins were found to be present in all 25 samples 
analysed. The median, 97.5th percentile value and range of concentrations found were 21 
µg/kg lipid, 130.9 µg/kg lipid and 6.2-320 µg/kg lipid respectively. The levels found in the 
samples from Lancaster were not thought to be significantly different from the levels found in 
the samples from London.
Overall, given that of the three studies that are now available on levels of MCCPs in breast 
milk, the most recent one, Thomas et al., 2003 is a very well conducted study, a risk 
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characterisation will be performed using the 97.5th percentile level of 130.9 µg/kg fat 
identified from this study. To perform a risk characterisation on the basis of this exposure 
information, it is necessary to derive an estimated daily infant intake of MCCPs for 
comparison with an estimated intake for the rat pup. Information is available on the levels of 
MCCPs in the milk of lactating female rats from two studies (the cross-fostering investigation 
and the CXR Biosciences Ltd., 2004 study) in which 100% mortality and haemorrhaging was 
seen in the offspring or fostered pups of dams administered 6250 ppm MCCPs in the diet. 
This was the only exposure level used in these studies. The levels of MCCPs measured in the 
milk of these dams were 570 and 1280 ppm (mean of 925 ppm) in the cross-fostering study 
(570 and 1280 mg/l, equivalent to about 570 and 1280 mg/kg milk, assuming a density of 
1 g/l) and 1561, 504 and 1106 mg/l (mean 1057 mg/l) in the CXR Biosciences Ltd., (2004) 
study (equivalent to about 1561, 504 and 1106 mg/kg milk, assuming a density of 1 g/l). 
These levels are fairly consistent. For risk characterisation purposes, a very conservative 
approach will be taken using the lowest level of MCCPs in dam breast milk (504 mg/kg milk) 
causing haemorrhaging effects and mortality in 100% of the suckling pups (a sort of LOAEL 
for very severe effects). Although there is no information on the levels of MCCPs in the milk 
of lactating female rats at which no effects occurred, a NOAEL could be extrapolated based 
on the assumption of a linear relationship between the dose of MCCPs administered to the 
dams and the level of MCCPs excreted in milk. As no haemorrhaging effects occurred at a 
maternal dose of 600 ppm, but severe effects occurred at a maternal dose of 6250 ppm, which 
elicited a level of MCCPs in milk of 504 mg/kg milk, the equivalent NOAEL of MCCPs in 
milk is 48.5 mg/kg milk. The risk characterisation will therefore also be conducted against 
this extrapolated no effect level.
In evaluating the body burden of MCCPs in an infant as a result of breast-feeding, the MCCPs 
daily intake during the first 3 months only of the infant life will be calculated as the data 
indicate that given the occurrence of the haemorrhaging effects in the suckling rat pups within 
the first 12 days post-partum, the period of infant life of the first 3 months might represent the 
most susceptible stage. It is assumed that over the first 3 months the infant has an average 
weight of 6 kg (data taken from the UK growth charts, published by the Child Growth 
Foundation, 1995; Freeman et al, in press and Cole, 1994), that the infant ingests 0.8 kg of 
milk per day, that 50% of the ingested MCCPs is absorbed and that the breast milk has an 
average fat content of 3.5% (WHO, 1998). It is also assumed that the content of MCCPs 
remains constant during the breast-feeding period.
Using the following equation and the assumptions detailed above, the average daily uptake of 
the breast-feeding infant (ADUinfant) is estimated for the 0-3 month period of infant life. 
ant
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where:
Cmilk-fat is the concentration of MCCPs in mg.kg-1 fat in breast milk
f3 is the fraction of fat in breast milk (3.5%)
f4 is the fraction of ingested MCCPs absorbed (50%)
IRmilk is the ingestion rate of milk (kg.day-1)
BWinfant is the average infant body weight over the exposure period (kg)
MCCPs uptake during 0-3 months, assuming a concentration of MCCPs in human breast milk 
of 130.9 µg/kg (97.5th percentile value):
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Based on these estimates, the daily uptake of MCCPs for the first 3 months is 
30.5 x 10-5 mg.kg-1.day-1.
A similar calculation can be performed for the rat. Pup body weight at birth is around 6 g and 
at weaning is about 40-50 g; an average weight of about 20 g will be assumed for the 
purposes of this calculation. Milk production in the lactating rat varies over the lactation 
period. Sampson and Jansen (1984) derived a model to estimate daily milk yield in the 
lactating rat. Based on this model, on day 10 of lactation, milk yield was estimated to be 
29.5 ml for a dam nursing 8 pups. This equates to about 3.7 ml (or 3.7 g) milk per pup, and 
will be used as the average daily milk consumption for this calculation.
Based on these assumptions, and using the very conservative LOAEL value of 504 mg.kg-1
milk for MCCP content in rat milk, estimated daily pup intake is about 46.5 mg.kg-1.day-1 (i.e. 
level of MCCP per kg whole milk x daily milk consumption (kg)/ pup body weight (kg) = 
504 mg.kg-1 x 3.7 x 10-3 x 0.5/ 20 x 10-3 mg.kg-1.day-1). If the extrapolated NOAEL value of 
48.5 mg.kg-1 milk is used instead, estimated daily pup intake is about 4.5 mg.kg-1.day-1.
Comparing the MCCPs daily pup intake at the LOAEL (46.5 mg.kg-1.day-1) with the human 
infant intake, there is a difference of 5 orders of magnitude (MOE = 152,000) between the 
levels of MCCPs producing severe effects in pups (100% mortality) and human infant 
exposure. Comparing the MCCPs daily pup intake at the extrapolated NOAEL (4.5 
mg.kg-1.day-1) with the human infant intake, there is a difference of 4 orders of magnitude 
(MOE = 14,800) between the levels of MCCPs without effect in the pups and human infant 
exposure. Normally such large Margin of Exposure (MOE) values would lead to little cause 
for concern and thus to a conclusion (ii), especially if it is considered that the calculation of
this MOE was based on a very conservative approach (the 97.5th percentile value for MCCPs 
levels in human breast milk and the lowest concentration of MCCPs in animals causing 
haemorrhage and mortality in 100% of the pups or no effects). However, it is important to 
consider the interpretation of the MOE values in light of the current state of knowledge and 
uncertainties in the analysis. We are of the opinion that a number of uncertainties in the 
analysis have now been reduced/removed. New good quality information on current levels of 
MCCPs in human breast milk has been obtained; new mechanistic data on the haemorrhaging 
effects seen in lactating pups have clarified the underlying mechanism leading to this effect 
(perturbation of the clotting system in lactating neonates; see reproductive toxicity section). 
Furthermore, due to concerns identified by the environmental risk assessment, an 
environmental risk reduction programme is currently under development and this could lead 
to reductions in point source and diffuse environmental emissions in due course. Finally, 
industry has shown a formal commitment to initiating a monitoring programme of levels of 
MCCPs in breast milk for the future years. In our view, this monitoring programme with its 
implications in terms of time trends is able to relieve any residual concern related to the risks 
of effects mediated via lactation in infants exposed to MCCPs via breast milk. Therefore, 
overall, taking into account the knowledge of the likely mechanism, the reliability of the 
current breast milk levels, the downward trend in environmental exposure and the very large 
MOEs obtained in spite of the very conservative approach adopted, conclusion (ii) is 
proposed for this scenario.
Infants exposed via cow’s milk
Greenpeace (1995) reported levels of total chlorinated paraffins in cow’s milk to be 74 µg/kg 
fat. The actual content of MCCPs can be deduced to be 21% of the total chlorinated paraffins 
content, i.e. 16 mg/kg fat. Thomas and Jones (2002) also determined the levels of MCCPs in a 
single sample of cow’s milk from Lancaster and single butter samples from various regions of 
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Europe (Denmark, Wales, Normandy, Bavaria, Ireland, and Southern and Northern Italy). 
MCCPs were present in the cow’s milk sample at a concentration of 63mg/kg fat and were 
found in the butter samples from Denmark at 11mg/kg fat, Wales at 8.8mg/kg fat and Ireland 
at 52mg/kg fat. MCCPs were not detected in any other sample. The detection limit for the 
other butter samples ranged between 8.0 and 11 mg/kg fat. Butter is regularly used as a 
convenient way of obtaining milk-fat samples and therefore the MCCPs levels measured in 
these butter samples can be considered equivalent to the levels present in cow’s milk. 
Using the value of 63 mgMCCPs/kg fat as the worst-case estimate, and applying the same 
assumptions as for infants exposed via breast milk, the infant uptake of MCCPs from cow’s 
milk is 14.5 x 10-5 mg.kg-1.day-1. Again, the difference between infant uptake and the lowest 
level producing severe effects in pups is 5 orders of magnitude (MOE = 320,000). If the 
extrapolated level of MCCPs without effect is used instead, the resultant MOE is 30,800. 
Again, as for the risk characterisation for infants exposed via breast milk, normally such large 
MOE values would lead to little cause for concern and thus to a conclusion (ii), especially if it 
is considered that the calculation of this MOE was based on a very conservative approach (the 
worst-case estimate for MCCPs levels in cow’s milk and the lowest concentration of MCCPs 
in animals causing haemorrhage or no effects). However, it is important to consider the 
interpretation of the MOE values in light of the current state of knowledge and uncertainties 
in the analysis. We are of the opinion that a number of uncertainties in the analysis have now 
been reduced/removed. New good quality information on current levels of MCCPs in cow’s 
milk has been obtained; new mechanistic data on the haemorrhaging effects seen in lactating 
pups have clarified the underlying mechanism leading to this effect (perturbation of the 
clotting system in lactating neonates; see reproductive toxicity section). Furthermore, due to 
concerns identified by the environmental risk assessment, an environmental risk reduction 
programme is currently under development and this could lead to reductions in point source 
and diffuse environmental emissions in due course. Finally, industry has shown a formal 
commitment to initiating a monitoring programme of levels of MCCPs in cows’ milk for the 
future years. In our view, this monitoring programme with its implications in terms of time 
trends is able to relieve any residual concern related to the risks of effects mediated via 
lactation in infants exposed to MCCPs via cow’s milk. Therefore, overall, taking into account 
the knowledge of the likely mechanism, the reliability of the current cow’s milk levels, the 
downward trend in environmental exposure and the very large MOEs obtained in spite of the 
very conservative approach adopted, conclusion (ii) is proposed for this scenario. 
4.1.3.4 Combined exposure
As indicated in section 4.1.1.4, a combined exposure scenario is not relevant, given the nature 
of the consumer exposures to MCCPs, and therefore no risk characterisation for this scenario 
will be performed.
4.2 HUMAN HEALTH (PHYSICOCHEMICAL PROPERTIES) (RISK 
ASSESSMENT CONCERNING THE PROPERTIES LISTED IN 
ANNEX IIA OF REGULATION 1488/94)
The physicochemical properties of MCCPs are not clearly defined and the particular values 
depend on the actual composition of the material, which can vary between manufacturers. 
However, given the low vapour pressure, lack of flammability and the general stability of 
these substances, the risks arising from the physicochemical properties are small. Thus, 
conclusion (ii) is reached  .  
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5 RESULTS
5.1 HUMAN HEALTH
The minimum data requirements according to Article 9(2) of Regulation 793/93 have been 
met. The lead health effects of concern arising from exposure to MCCPs are repeated dose 
toxicity, carcinogenicity, effects on the offspring mediated via lactation and effects at the time 
of parturition. There are no concerns for acute toxicity, irritation, sensitisation, genotoxicity or 
effects on fertility. 
5.1.1 Workers
MCCPs are viscous liquids with very low vapour pressures. Thus personal exposures to 
MCCPs vapour at ambient temperature in the workplace are very low, the maximum 
theoretical vapour concentration being 0.0027 ppm. However, there are some situations where 
there is the potential for exposure to a mixture of vapour and mist; the mist is formed as the 
hot vapour cools and condenses to form liquid droplets. In addition, some scenarios give rise 
to the potential for aerosol generation. Exposures are generally expected to be higher where 
there is the potential for exposure to MCCPs in mist or aerosol form. Dermal exposure to 
MCCPS can also occur; estimates of dermal exposure have been derived from modelling, 
although in some cases measured data were available.
The MOSs for oil-based MWF use in relation to repeated dose toxicity, carcinogenicity, 
effects via lactation and effects at the time of parturition are unaccepatably low. Therefore 
conclusion (iii) is reached. 
Conclusion (iii)         There is a need for limiting the risks; risk reduction measures which are 
already being applied shall be taken into account.
The MOSs for all remaining scenarios in relation to repeated dose toxicity, carcinogenicity, 
effects mediated via lactation and effects at the time of parturition are considered sufficient to 
provide reassurance that adverse effects would not occur and thus conclusion (ii) is reached.
Conclusion (ii) There is at present no need for further information and/or testing or for 
risk reduction measures beyond those which are being applied already.
5.1.2 Consumers
The exposure to MCCPs is generally very low. Most applications of MCCPs are not designed 
for consumer contact and therefore most exposures are negligible. The only consumer 
exposure scenarios for which significant exposure and uptake could occur are the wearing of 
leather clothes treated with MCCPs and the use of metal working fluids.
The calculated margins of safety (MOS) for repeated dose toxicity, carcinogenicity, effects 
mediated via lactation and effects at the time of parturition for both scenarios were sufficient 
to provide reassurance that adverse effects would not occur and thus conclusion (ii) is 
reached. 
Conclusion (ii) There is at present no need for further information and/or testing or for 
risk reduction measures beyond those which are being applied already.
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5.1.3 Indirect exposure via the environment
The exposure estimates for regional sources of exposure are based on measured data; 
however, the local environment exposures are calculated from a model. This model uses 
various assumptions, giving rise to uncertainty in the predicted exposure values.
Regional exposure
The calculated margins of safety for repeated dose toxicity, carcinogenicity, effects mediated 
via lactation and effects at the time of parturition are considered to provide sufficient 
reassurance that adverse health effects would not occur and thus conclusion (ii) is reached.
Conclusion (ii) There is at present no need for further information and/or testing and 
no need for risk reduction measures beyond those, which are being 
applied already.
Local exposure
The calculated margins of safety for repeated dose toxicity, carcinogenicity, effects mediated 
via lactation and effects at the time of parturition are considered to provide sufficient 
reassurance that adverse health effects would not occur and thus conclusion (ii) is reached.
Conclusion (ii) There is at present no need for further information and/or testing and no 
need for risk reduction measures beyond those, which are being applied already.
Exposure of infants via milk
Very large MOEs have been calculated between estimated infant uptake levels and the levels 
of MCCPs which have been found to produce adverse effects via the breast milk. Also, due to 
concerns identified by the environmental risk assessment, an environmental risk reduction 
programme is currently under development and this could lead to reductions in point source 
and diffuse environmental emissions in due course. Furthermore, industry has shown a formal 
commitment to initiating a monitoring programme of levels of MCCPs in breast and cow’s 
milk. Therefore, overall, conclusion (ii) is proposed. 
Conclusion (ii) There is at present no need for further information and/or testing or for 
risk reduction measures beyond those which are being applied already.
5.1.4 Combined exposure
A combined exposure scenario, taking account of the potential for exposure as a consumer 
and via environmental sources is not relevant, given that consumer exposures are infrequent 
rather than repeated daily exposures. Therefore no risk characterisation for this scenario has 
been performed. 
5.1.5 Risks from physicochemical properties
There are no significant risks to humans from the physicochemical properties of medium-
chained chlorinated paraffins. Therefore conclusion (ii) is reached.
Conclusion (ii) There is at present no need for further information and/or testing or for 
risk reduction measures beyond those which are being applied already.
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Abbreviations
ADI Acceptable Daily Intake
AF Assessment Factor
ASTM American Society for Testing and Materials
ATP Adaptation to Technical Progress
AUC Area Under The Curve
B Bioaccumulation
BBA Biologische Bundesanstalt für Land- und Forstwirtschaft
BCF Bioconcentration Factor
BMC Benchmark Concentration
BMD Benchmark Dose
BMF Biomagnification Factor
BOD Biochemical Oxygen Demand
bw body weight / Bw, bw
C Corrosive (Symbols and indications of danger for dangerous substances 
and preparations according to Annex II of Directive 67/548/EEC)
CA Chromosome Aberration
CA Competent Authority
CAS Chemical Abstract Services
CEC Commission of the European Communities
CEN European Standards Organisation / European Committee for 
Normalisation
CEPE European Committee for Paints and Inks
CMR Carcinogenic, Mutagenic and toxic to Reproduction
CNS Central Nervous System
COD Chemical Oxygen Demand
CSTEE Scientific Committee for Toxicity, Ecotoxicity and the Environment (DG 
SANCO)
CT50 Clearance Time, elimination or depuration expressed as half-life
d.wt dry weight / dw
dfi daily food intake
DG Directorate General
DIN Deutsche Industrie Norm (German norm)
DNA DeoxyriboNucleic Acid 
DOC Dissolved Organic Carbon
DT50 Degradation half-life or period required for 50 percent dissipation / 
degradation
DT90 Period required for 90 percent dissipation / degradation
E Explosive (Symbols and indications of danger for dangerous substances 
and preparations according to Annex II of Directive 67/548/EEC)
EASE Estimation and Assessment of Substance Exposure Physico-chemical 
properties [Model]
EbC50 Effect Concentration measured as 50% reduction in biomass growth in 
algae tests
EC European Communities
EC10 Effect Concentration measured as 10% effect
EC50 median Effect Concentration 
ECB European Chemicals Bureau
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ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals
ECVAM European Centre for the Validation of Alternative Methods
EDC Endocrine Disrupting Chemical
EEC European Economic Communities
EINECS European Inventory of Existing Commercial Chemical Substances
ELINCS European List of New Chemical Substances
EN European Norm
EPA Environmental Protection Agency (USA)
ErC50 Effect Concentration measured as 50% reduction in growth rate in algae 
tests
ESD Emission Scenario Document
EU European Union
EUSES European Union System for the Evaluation of Substances [software tool 
in support of the Technical Guidance Document on risk assessment]
F(+) (Highly) flammable (Symbols and indications of danger for dangerous 
substances and preparations according to Annex II of Directive 
67/548/EEC)
FAO Food and Agriculture Organisation of the United Nations
FELS Fish Early Life Stage 
foc Organic carbon factor (compartment depending)
GC Gas chromatography
GC-ECD Gas chromatography with an electron capture detector
GC-ECNI-HRMS Gas chromatography with electron capture negative ion high resolution 
mass spectrometry
GC-EI-MS Gas chromatography with electron impact mass spectrometry
GC-FID Gas chromatography with a flame ionisation detector
GC-HRMS Gas chromatography with high resolution mass spectrometry
GC-LRMS Gas chromatography with low resolution mass spectrometry
GC-MS Gas chromatography with a mass spectrometry detector
GC-NCI-MS Gas chromatography with negative ion chemical ionisation mass 
spectrometry
GLP Good Laboratory Practice
HEDSET EC/OECD Harmonised Electronic Data Set (for data collection of 
existing substances)
HELCOM Helsinki Commission -Baltic Marine Environment Protection 
Commission 
HPLC High Pressure Liquid Chromatography
HPVC High Production Volume Chemical (> 1000 t/a)
IARC International Agency for Research on Cancer
IC Industrial Category
IC50 median Immobilisation Concentration or median Inhibitory Concentration
ILO International Labour Organisation
IPCS International Programme on Chemical Safety
ISO International Organisation for Standardisation
IUCLID International Uniform Chemical Information Database (existing 
substances)
IUPAC International Union for Pure and Applied Chemistry
JEFCA Joint FAO/WHO Expert Committee on Food Additives
JMPR Joint FAO/WHO Meeting on Pesticide Residues
Koc organic carbon normalised distribution coefficient
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Kow octanol/water partition coefficient
Kp solids-water partition coefficient
L(E)C50 median Lethal (Effect) Concentration 
LAEL Lowest Adverse Effect Level
LC50 median Lethal Concentration 
LD50 median Lethal Dose  
LEV Local Exhaust Ventilation
LLNA Local Lymph Node Assay
LOAEL Lowest Observed Adverse Effect Level
LOEC Lowest Observed Effect Concentration
LOED Lowest Observed Effect Dose
LOEL Lowest Observed Effect Level
MAC Maximum Allowable Concentration
MATC Maximum Acceptable Toxic Concentration
MC Main Category 
MITI Ministry of International Trade and Industry, Japan
MOE Margin of Exposure
MOS Margin of Safety
MS Mass spectrometry
MW Molecular Weight
N Dangerous for the environment (Symbols and indications of danger for 
dangerous substances and preparations according to Annex II of Directive 
67/548/EEC
NAEL No Adverse Effect Level 
NOAEL No Observed Adverse Effect Level
NOEL No Observed Effect Level
NOEC No Observed Effect Concentration
NTP National Toxicology Program (USA)
O Oxidizing (Symbols and indications of danger for dangerous substances 
and preparations according to Annex II of Directive 67/548/EEC)
OC Organic Carbon content
OECD Organisation for Economic Cooperation and Development
OEL Occupational Exposure Limit
OJ Official Journal
OSPAR Oslo and Paris Convention for the protection of the marine environment 
of the Northeast Atlantic
P Persistent
PBT Persistent, Bioaccumulative and Toxic
PBPK Physiologically Based PharmacoKinetic modelling
PBTK Physiologically Based ToxicoKinetic modelling
PEC Predicted Environmental Concentration
pH logarithm (to the base 10) (of the hydrogen ion concentration {H+}
pKa logarithm (to the base 10) of the acid dissociation constant
pKb logarithm (to the base 10) of the base dissociation constant
PNEC Predicted No Effect Concentration
POP Persistent Organic Pollutant
PPE Personal Protective Equipment
QSAR (Quantitative) Structure-Activity Relationship
R phrases Risk phrases according to Annex III of Directive 67/548/EEC
RAR Risk Assessment Report
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RC Risk Characterisation
RfC Reference Concentration
RfD Reference Dose
RNA RiboNucleic Acid
RPE Respiratory Protective Equipment
RWC Reasonable Worst Case
S phrases Safety phrases according to Annex IV of Directive 67/548/EEC
SAR Structure-Activity Relationships
SBR Standardised birth ratio
SCE Sister Chromatic Exchange
SDS Safety Data Sheet
SETAC Society of Environmental Toxicology And Chemistry
SNIF Summary Notification Interchange Format (new substances)
SSD Species Sensitivity Distribution
STP Sewage Treatment Plant
T(+) (Very) Toxic (Symbols and indications of danger for dangerous 
substances and preparations according to Annex II of Directive 
67/548/EEC)
TLC Thin layer chromatography
TDI Tolerable Daily Intake
TG Test Guideline
TGD Technical Guidance Document
TNsG Technical Notes for Guidance (for Biocides)
TNO The Netherlands Organisation for Applied Scientific Research
ThOD Theoritical Oxygen Demand
UC Use Category
UDS Unscheduled DNA Synthesis
UN United Nations
UNEP United Nations Environment Programme 
US EPA Environmental Protection Agency, USA
UV Ultraviolet Region of Spectrum
UVCB Unknown or Variable composition, Complex reaction products of 
Biological material
vB very Bioaccumulative
VOC Volatile Organic Compound
vP very Persistent 
vPvB very Persistent and very Bioaccumulative
v/v volume per volume ratio
w/w weight per weight ratio
WHO World Health Organization
WWTP Waste Water Treatment Plant
Xn Harmful (Symbols and indications of danger for dangerous substances 
and preparations according to Annex II of Directive 67/548/EEC)
Xi Irritant (Symbols and indications of danger for dangerous substances and 
preparations according to Annex II of Directive 67/548/EEC)
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Appendix E  
Assessment of possible replacement of short-chain chlorinated paraffins with medium-chain 
chlorinated paraffins
Introduction
The current risk assessment report for short-chain chlorinated paraffins (CAS No: 
85535-84-8) recommended that risk reduction measures should be undertaken for two uses. 
The uses were formulation and use in metal cutting/working fluids and formulation and use in 
leather treatment (fat liquors).
Draft risk reduction strategies have been developed for these two areas. In both cases 
marketing and use restrictions were recommended, and it was identified that the 
medium-chain chlorinated paraffins could be used as an alternative in these applications. This 
Appendix considers the possible effects of replacement of the short-chain by the 
medium-chain chlorinated paraffins in these applications.
Quantities and trends
The available data on the amounts of both short-chain and medium-chain chlorinated 
paraffins used in the EU in these applications are given in Table E.1.
Table E. 1  Trends in use of chlorinated paraffins in the EU
Use Year Quantity of chlorinated paraffin supplied in EU (t/year)
Short-chain Medium-chain Total
Metal cutting/working fluids 1989 11,300a
1990 10,050a
1991 8,350a
1992 7,300a
1993 6,150a; 7,510c
1994 9,380b; 8,690c 2,611b 11,301-11,991
1995 8,502c; 8,490c 2,765b 11,255-11,267
1996 3,302b
1997 5,953b
1998 increasedd
Leather treatment (fat liquors) 1994 390b 1,614b (ca 807) 2,004 (ca 1,000)
1995 1,270b (ca 635)
1996 decreasedd 1,172b (ca 586) decreasedd
1997 1,048b (ca 524)
1998 decreasedd
a) Figures refer to UK, Ireland and continental Western Europe, excluding Italy.
b) CEFIC data for amounts supplied to the EU. For leather treatment, around 50% of the chlorinated paraffin
supplied is exported from the EU after the formulation stage. The figures given in brackets represent the amount 
of chlorinated paraffin taking into account these exports.
c) Reported in RPA, 1996 (figures for EU (excluding Luxembourg)).
d) Figures known but considered as confidential information 
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Metal working/cutting fluids
The available data indicate that in 1994, a combined total of around 12,000 t/year of short and 
medium-chain chlorinated paraffins were used in this application in the EU. Before this date, 
the available information indicates that there was a general decrease in the amounts of 
chlorinated paraffin used in this application. Since this time, there has been a rapid increase in 
the amounts of medium-chain chlorinated paraffin used. This increase is most probably due to 
a move from the short-chain to medium-chain chlorinated paraffins for this application, rather 
than an increase in the total amounts of chlorinated paraffins used.
The draft risk reduction strategy on short-chain chlorinated paraffins (RPA, 1996) indicates 
that medium-chain chlorinated paraffins are most likely to be the preferred alternative for neat 
oil applications. With emulsion-based fluids, the majority of users are expected to move to 
chlorine-free alternatives, due to concerns over the stability of the fluid, although 
medium-chain chlorinated paraffins may also be used.
The individual members of Euro Chlor have voluntarily agreed to reduce the use of 
short-chain chlorinated paraffins in metal cutting fluids to the following timetable: 80% 
reduction in use (from 1993 levels) by 1997, and elimination in use by year 2000.
The switch to medium-chain chlorinated paraffins as replacements for the short-chain 
chlorinated paraffin may result in some changes in the fluid formulation for a given 
application. This arises because the relationship between chlorine content and viscosity is 
slightly different for the two groups of additives. For a given chlorine content, the 
medium-chain chlorinated paraffin generally has a higher viscosity than the short-chain 
chlorinated paraffin. Two important considerations in the formulation of metal 
cutting/working fluids are viscosity and chlorine content of the fluid. Thus, if short-chain 
chlorinated paraffins are replaced by medium-chain length chlorinated paraffins two 
approaches can be taken. Firstly for a given application, a medium-chain chlorinated paraffin 
of similar chlorine content to, but higher viscosity than, the short-chain chlorinated paraffin 
can be used. In this case, in order to maintain the viscosity of the final fluid, the base oil may 
have to be reformulated. The second approach would be to use a medium-chain chlorinated 
paraffin of similar viscosity (and hence lower chlorine content) as the short-chain chlorinated 
paraffin. In this case, the chlorine content of the fluid would be lower than the fluid 
containing short-chain chlorinated paraffin and so the result is that higher concentrations of 
medium-chain chlorinated paraffins (up to 10% by weight rather than the typical level of 5% 
by weight) may have to be used in the fluids (RPA, 1996).
In order to take into account the possible replacement of short-chain chlorinated paraffins by 
medium-chain chlorinated paraffins, it can be assumed as a worst case that the total usage of 
medium-chain chlorinated paraffins could reach a total of around 12,000 t/year (the sum of 
medium- and short-chain chlorinated paraffins for this use in 1994). This should represent the 
likely foreseeable maximum usage of medium-chain chlorinated paraffins in this area as other 
non-chlorinated alternatives for short-chain chlorinated paraffins may be used, particularly in 
emulsifiable fluids (RPA, 1996).
In addition, the effects of a possible increase in concentration of the chlorinated paraffin in the 
fluid from around 5% to 10% will also need to be taken into account.
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Leather fat liquors
The draft risk reduction strategy for short-chain chlorinated paraffins (RPA. 1997) indicated 
that the following substances could possibly be used as alternatives if marketing and use 
restrictions were applied: 
medium-chain chlorinated paraffins (and also longer chain length chlorinated paraffins);
animal oils (usually derived from beef tallow);
vegetable oils (e.g. corn, soya, palm and to some extent rapeseed).
It is clear from the available data reported in Table E1 that there is a general decrease in the 
amounts of chlorinated paraffins used in leather fat liquors in the EU. Further, the 
medium-chain length chlorinated paraffins are much more commonly used that the 
short-chain length chlorinated paraffins in this application. If all the short-chain were replaced 
by medium-chain chlorinated paraffins, then the amount supplied for formulation may reach 
around 2,000 t/year, with around 1,000 t/year of this being subsequently applied to leather in 
the EU. These figures relate to 1994, and represent the highest usage in recent years. These 
figures are likely to represent the foreseeable upper limit of the amount of medium-chain 
chlorinated paraffin used in this application, as it is clear that a decline in use of both 
medium- and short-chain chlorinated paraffins is occurring.
Effect on predicted environmental concentrations
Environmental releases for regional and continental modelling
Using the extrapolated use figures above, and the release factors detailed in the main report, 
the following releases to the environment can be estimated:
Metal cutting/working fluids
Assuming a total usage of 12,000 t/year of medium-chain chlorinated paraffins and the same 
split between oil-based and emulsion fluids as in the main report, gives around 8,060 t/year in 
oil-based fluids and 3,940 t/year in emulsion fluids, then the following releases can be 
estimated:
Formulation of fluids:
Quantity of medium-chain chlorinated paraffins used = 12,000 t/year
Release to the environment = 0.25% to waste water
Total EU release = 30 t/year to waste water
Regional release = 3 t/year to waste water
Continental release = 27 t/year to waste water
Use in Emulsifiable fluids:
Quantity of medium-chain chlorinated paraffins used = 3,940 t/year
Release to the environment = 50% to waste water
Total EU release = 1,970 t/year to waste water
Regional release = 197 t/year to waste water
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Continental release = 1,773 t/year to waste water
Use in Oil-based fluids:
Quantity of medium-chain chlorinated paraffins used  = 8,060
Release to the environment =4% (large/medium facility with swarf reprocessing) to 
waste water
=18% (small and medium sized facilities with no swarf reprocessing) to waste water
Fraction of total use in large/medium facilities = 60%
Fraction of total use in medium/small facilities = 40%
Total EU release to environment = 8,060.((0.04.0.6)+(0.18.0.4)) = 774 t/year to waste water
Regional release = 77.4 t/year to waste water
Continental release = 696.6 t/year to waste water
Leather fat liquors
Assuming a total usage of 2,000 t/year of medium-chain chlorinated paraffins in the 
formulation of leather fat liquors, with around 50% of these liquors (containing 1,000 t/year 
of medium chain chlorinated paraffins) in the EU, then the following releases can be 
estimated:
Formulation of leather fat liquors (default calculation):
Quantity of medium-chain chlorinated paraffins used = 2,000 t/year
Release to the environment = 0.1% to air
= 0.3% to waste water
Total EU release = 2.0 t/year to air
= 6.0 t/year to waste water
Regional release = 0.2 t/year to air
= 0.6 t/year to waste water
Continental release = 1.8 t/year to air
= 5.4 t/year to waste water
Use of leather fat liquors:
Quantity of medium-chain chlorinated paraffins used = 1,000 t/year
Release to the environment = 2% to waste water
Total EU release = 20 t/year to waste water
Regional release = 2 t/year to waste water
Continental release = 18 t/year to waste water
Overall regional and continental releases
Table E.2 shows the total regional and continental releases estimated from the main report for 
the current usage of medium-chain chlorinated paraffins, and the estimated total taking into 
account the revised figures for use in metal working/cutting and leather treatment, assuming 
that medium-chain chlorinated paraffins will totally replace the short-chain chlorinated 
paraffins in these applications.
EU
 risk assessm
ent report –alkanes, c
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Table E. 2  Revised releases for the regional and continental environment
Use Lifestage Estimated release from original report (current 
situation)a
Estimated release assuming replacement of 
short-chain by medium-chain chlorinated paraffins in 
metal working and leather treatment applications
Regional Continental Regional Continental
Metal cutting/working 
fluids
Formulation 1,488 kg/year to water 13,875 kg/year to water 3,000 kg/year to water 27,000 kg/year to water
Use in oil-based fluids 38,100 kg/year to water 342,900 kg/year to water 77,400 kg/year to water 696,600 kg/year to water
Use in emulsifiable 
fluids
99,200 kg/year to water 892,800 kg/year to water 197,000 kg/year to water 1,773,000 kg/year to water
Leather fat liquors Formulation 315 kg/year to water
105 kg/year to air
2,829 kg/year to water
943 kg/year to air
600 kg/year to water
200 kg/year to air
5,400 kg/year to water
1,800 kg/year to air
Use 1,050 kg/year to water 9,430 kg/year to water 2,000 kg/year to water 18,000 kg/year to water
All other uses All 30,255 kg/year to water
16,922 kg/year to air
271,748 kg/year to water
152,250 kg/year to air
30,255 kg/year to water
16,922 kg/year to air
271,748 kg/year to water
152,250 kg/year to air
Total 170,408 kg/year to water 
(split 119,286 kg/year to 
WWTP and 51,122 
kg/year direct to surface 
water)
17,027 kg/year to air
1,533,582 kg/year to water 
(split 1,073,482 kg/year to
WWTP and 460,101 
kg/year direct to surface 
water)
153,193 kg/year to air
310,255 kg/year to water 
(split 217,179 kg/year to 
WWTP and 93,077 
kg/year direct to surface 
water)
17,122 kg/year to air
2,791,748 kg/year to water 
(split 1,954,198 kg/year to 
WWTP and 837,550 
kg/year direct to surface 
water)
154,050 kg/year to air
a) Figures derived in main report
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Local release estimates
In this Section, the local release estimates have been re-calculated using the methods given in 
the main report, but based on the extrapolated use volumes for medium-chain chlorinated 
paraffins.
Metal working/cutting fluids
The releases estimated below are based on the same methods as used in the main report. In 
addition, the possible increase in the medium-chain chlorinated paraffin content from 5% (as 
assumed in the main assessment) to 10%, as may occur when they are used to replace 
short-chain chlorinated paraffins for some applications, is also taken into account.
Formulation of fluids:
Quantity of medium-chain chlorinated paraffins used = 12,000 t/year
Quantity of medium-chain chlorinated paraffins used in region = 1,200 t/year
Fraction used at one site = 1/6 = 200 t/year
Release to the environment = 0.25% to waste water
Number of days = 300 days/year
Local release = 500 kg/year = 1.67 kg/day to waste water
Use in Emulsifiable fluids:
Concentration of chlorinated paraffin in oil phase = 10%
Dilution rate of oil in water = 1:20 oil:water
Weekly loss rate of fluid = 60 litres/week to waste water
Loss rate of chlorinated paraffin = 0.30 kg/week 
Number of days = 300 days/year = 6 days/week
Local release = 0.050 kg/day
In addition, there will be an intermittent loss of 50 kg/event of medium chain chlorinated 
paraffin when the whole system (10,000 litres) is replaced
Use in Oil-based fluids:
Concentration of chlorinated paraffin in fluid = 10%
Amount of cutting fluid contained at large site = 50,000 litres (containing 5,000 kg of 
medium-chain chlorinated paraffin)
Amount of cutting fluid contained at small site = 10,000 litres (containing 1000 kg of 
medium-chain chlorinated paraffin)
Release to environment from large site = 4% to waste water
Release to environment from small site = 18% to waste water
Number of days = 300 days/year
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Local release (large site) = 200 kg/year = 0.67 kg/day
Local release (small site) = 180 kg/year = 0.6 kg/day
Leather fat liquors
The local release estimates and PEC calculations will be the same as in the main report as 
they do not depend on the total amount of medium-chain chlorinated paraffins used in the 
application.
PECregional and PECcontinental
The values for PECregional and PECcontinental estimated using the release data given in Table E.2 
are shown in Table E.3. The values for the current situation are taken from the main report. 
Table E. 3  PECregional and PECcontinental for medium-chain chlorinated paraffins for the current situation and possible future 
increased use as a result of risk reduction measures on short-chain chlorinated paraffins
PEC Current situation (from main report) Possible future situation
PECregional(air) 3.35.10-6 mg/m3 5.45.10-6 mg/m3
PECregional(surface water) 0.39 µg/l 0.71 µg/l
PECregional(agricultural soil) 50.4 mg/kg wet wt. 91.6 mg/kg wet wt.
PECregional(sediment) 8.80 mg/kg wet wt. 16.0 mg/kg wet wt.
PECcontinental(air) 1.03.10-6 mg/m3 1.7.10-6 mg/m3
PECcontinental(surface water) 0.053 µg/l 0.096 µg/l
PECcontinental(agricultural soil) 5.31 mg/kg wet wt. 9.62 mg/kg wet wt.
PECcontinental(sediment) 1.21 mg/kg wet wt. 2.18 mg/kg wet wt.
From the PECs reported in Table E3, it can be seen that in a worst case, replacement of 
short-chain chlorinated paraffins by medium-chain chlorinated paraffins in metal 
working/cutting and leather fat liquoring applications could increase the regional 
concentrations by around a factor of 2.
It should be born in mind that the available monitoring data indicate that the current regional 
concentrations in surface water, sediment and soil are less than predicted using the EUSES 
model. This indicates that the actual regional emissions may be overestimated and/or the 
actual removal rate in the environment may be underestimated in the model used. This adds 
uncertainty to the predicted future concentrations.
PEClocal
The values obtained for the PEClocal for metal working/cutting use, taking into account the 
possible increased emissions of medium-chain chlorinated paraffins are shown below. For 
most of the other uses a change in the PEClocal may result as a consequence of the increase in 
the PECregional. The consequences of these changes are considered in later.
Metal cutting/working
The revised PEClocal for use in metal working fluids are as follows:
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Formulation: PEClocal(water) = 3.81 µg/l
PEClocal(sediment) = 48.8 mg/kg wet wt.
PEClocal(soil) = 30.0 mg/kg wet wt.
PECfish(secondary poisoning) = 2.15-6.45 mg/kg wet wt.
PECworm(secondary poisoning) = 10.3 mg/kg wet wt.
Use in oil-based fluids: PEClocal(water) = 1.95 µg/l
(large site) PEClocal(sediment) = 25.0 mg/kg wet wt.
PEClocal(soil) = 13.1 mg/kg wet wt.
PECfish(secondary poisoning) = 1.32-3.96 mg/kg wet wt.
PECworm(secondary poisoning) = 8.9 mg/kg wet wt.
Use in oil-based fluids: PEClocal(water) = 1.82 µg/l
(small site) PEClocal(sediment) = 23.3 mg/kg wet wt.
PEClocal(soil) = 11.9 mg/kg wet wt.
PECfish(secondary poisoning) = 1.26-3.78 mg/kg wet wt.
PECworm(secondary poisoning) = 8.8 mg/kg wet wt.
Use in emulsifiable fluids: PEClocal(water) = 0.80 µg/l
PEClocal(sediment) = 10.2 mg/kg wet wt.
PEClocal(soil) = 2.63 mg/kg wet wt.
PECfish(secondary poisoning) = 0.81-2.43 mg/kg wet wt.
PECworm(secondary poisoning) = 8.01 mg/kg wet wt.
Use in emulsifiable fluids: PEClocal(water) = 93.6 µg/l
(intermittent release) PEClocal(sediment) = 1,200 mg/kg wet wt.
PEClocal(soil) = 93.5 mg/kg wet wt.
PECfish(secondary poisoning) = 1.60-4.80 mg/kg wet wt.
PECworm(secondary poisoning) = 15.7 mg/kg wet wt.
Effect on PEC/PNEC ratios
The effects of a total replacement of short-chain chlorinated paraffins by medium-chain 
chlorinated paraffins in metal working and leather uses on the PEC/PNEC ratios for all uses 
are considered in Tables E4 to E7. The current situation is taken from the main risk 
assessment report. The future situation includes the effects of the predicted increase in 
regional concentrations on the PEC/PNEC ratios for all uses. 
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The results shown in Tables E.4 to E7 indicate that the biggest potential of the impact of 
replacement occurs on the PEC/PNECs for the aquatic (surface water, sediment, fish) 
compartment, with very little change predicted to occur on the PEC/PNEC for the terrestrial 
compartment.
For surface water and sediment, it can be seen that for many uses, the PEC is dominated by 
the regional contribution. The use of medium-chain chlorinated paraffins in metal 
cutting/working fluids is predicted to have the highest contribution to the total releases of the 
substance to water. In the current situation, the regional contribution to water from this use is 
around 81% (138,788 kg/year out of a total of 170,408 kg/year), and this is predicted to 
increase to around 89% (277,400 kg/year out of a total of 310,255 kg/year). 
166
Table E. 4  Estimated PEC/PNEC ratios for surface water (PNEC = 1 µg/l)
Scenario Step Current situation using 
measured regional 
concentrations
Future situation
PEC (µg/l) PEC/PNEC PEC (µg/l) PEC/PNEC
Production 4 Sites 0.10-0.27 0.10-0.27 0.70-0.87 0.70-0.87
Compounding - O 0.15 0.15 0.75 0.75Use in PVC –
plastisol coating
Conversion – O 0.44 0.44 1.05 1.05
Compounding/conversion – O 0.49 0.49 1.10 1.10
Compounding  - O 0.27 0.27 0.88 0.88Use in PVC –
extrusion/other
Compounding – PO 1.03 1.03 1.63 1.63
Compounding – C 0.18 0.18 0.78 0.78
Conversion – O 0.62 0.62 1.23 1.23
Conversion – PO 0.66 0.66 1.26 1.26
Conversion – C 0.57 0.57 1.18 1.18
Compounding/conversion – O 0.79 0.79 1.40 1.40
Compounding/conversion – PO 1.59 1.59 2.19 2.19
Compounding/conversion – C 0.65 0.65 1.26 1.26
Compounding 0.19 0.19 0.79 0.79Use in 
plastics/rubber
Conversion 0.39 0.39 0.99 0.99
Compounding/conversion 0.48 0.48 1.08 1.08
Use in sealants Formulation and use negligible <1 negligible <1
Use in paints Formulation 0.38 0.38 0.98 0.98
Industrial application 0.21 0.21 0.82 0.82
Domestic application 0.10 0.10 0.71 0.71
Formulation 1.64 1.64 3.81 3.81Use in metal cutting/ 
working fluids
Use in oil-based fluids (large) 0.71 0.71 1.32a [1.95]b 1.32a [1.95]b
Use in oil-based fluids (small) 0.66 0.66 1.26a [1.82]b 1.26a [1.82]b
Use in emulsifiable fluids 0.15 0.15 0.75a [0.80]b 0.75a [0.80]b
Use in emulsifiable fluids –
intermittent release
46.6 46.6 47.1a [93.6]b 47.1a [93.6]b
Formulation 0.29 0.29 0.89 0.89Use in leather fat 
liquors
Use – complete processing of raw 
hides
1.77 1.77 2.38 2.38
Use – processing of wet blue 6.79 6.79 7.39 7.39
Use in carbonless 
copy paper
Paper recycling 0.43 0.43 1.03 1.03
Regional sources 0.1 0.1 0.71 0.71
a) Assuming a 5% medium-chain chlorinated paraffin content in the base fluid.
b) Assuming a 10% medium-chain chlorinated paraffin content in the base fluid.
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Table E. 5  Estimated PEC/PNEC ratios for sediment (PNEC = 5 mg/kg wet wt.)
Scenario Step Current situation using 
measured regional 
concentrations
Future situation
PEC (mg/kg 
wet wt.)
PEC/PNEC PEC (mg/kg 
wet wt.)
PEC/PNEC
Production 4 Sites 1.28-3.46 0.26-0.70 9.0-11.2 1.8-2.2
Compounding  - O 1.88 0.38 9.6 1.9Use in PVC – plastisol 
coating
Conversion – O 5.68 1.1 13.4 2.7
Compounding/conversion - O 6.27 1.3 14.0 2.8
Compounding  - O 3.46 0.7 11.2 2.2Use in PVC –
extrusion/other
Compounding - PO 13.2 2.6 20.9 4.2
Compounding – C 2.30 0.46 10.0 2.0
Conversion – O 7.94 1.6 15.7 3.1
Conversion – PO 8.45 1.7 16.2 3.2
Conversion – C 7.30 1.5 15.1 3.0
Compounding/conversion – O 10.1 2.0 17.9 3.6
Compounding/conversion - PO 20.4 4.1 28.1 5.6
Compounding/conversion - C 8.32 1.7 16.1 3.2
Use in plastics/rubber Compounding 2.38 0.48 10.1 2.0
Conversion 4.99 1.0 12.7 2.5
Compounding/conversion 6.14 1.2 13.8 2.8
Use in sealants Formulation and use negligible <1 negligible <1
Use in paints Formulation 4.86 0.98 12.6 2.5
Industrial application 2.69 0.54 10.4 2.1
Domestic application 1.28 0.26 9.04 1.8
Formulation 21.0 4.2 48.8 9.8Use in metal 
cutting/working fluids
Use in oil-based fluids (large) 9.09 1.8 16.9a [25.0]b 3.4a [5.0]b
Use in oil-based fluids (small) 8.45 1.7 16.2a [23.3]b 3.2a [4.7]b
Use in emulsifiable fluids 1.92 0.38 9.63a [10.2]b 1.9a [2.0]b
Use in emulsifiable fluids –
intermittent release
597 119 604a [1,200]b 121a [240]b
Formulation 3.71 0.74 11.4 2.3Use in leather fat 
liquors
Use – complete processing of 
raw hides
22.7 4.5 30.5 6.1
Use – processing of wet blue 86.9 17.4 94.7 18.9
Use in carbonless 
copy paper
Paper recycling 5.50 1.1 13.2 2.6
Regional sources 0.7 0.14 16.0 3.2
a) Assuming a 5% medium-chain chlorinated paraffin content in the base fluid.
b) Assuming a 10% medium-chain chlorinated paraffin content in the base fluid.
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Table E. 6  Estimated PEC/PNEC ratios for soil (PNEC = 10.6 mg/kg wet wt.)
Scenario Step Current situation using 
measured regional 
concentrations
Future situation
PEC (mg/kg 
wet wt)
PEC/PNEC PEC (mg/kg 
wet wt.)
PEC/PNEC
Production 4 Sites negligible <1 negligible <1
Compounding  - O 0.51 0.048 2.21 0.21Use in PVC – plastisol 
coating
Conversion – O 3.21 0.30 4.92 0.46
Compounding/conversion – O 3.64 0.34 5.34 0.50
Compounding  - O 1.64 0.15 3.34 0.32Use in PVC –
extrusion/other
Compounding – PO 8.53 0.80 10.2 0.96
Compounding – C 0.81 0.076 2.51 0.24
Conversion – O 4.82 0.45 6.52 0.62
Conversion – PO 5.16 0.49 6.86 0.65
Conversion – C 4.40 0.42 6.10 0.58
Compounding/conversion – O 6.37 0.60 8.07 0.76
Compounding/conversion – PO 13.6 1.28 15.3 1.44
Compounding/conversion – C 5.12 0.48 6.82 0.64
Use in plastics/rubber Compounding 0.87 0.082 2.57 0.24
Conversion 2.71 0.26 4.41 0.42
Compounding/conversion 3.5 0.33 5.20 0.49
Use in sealants Formulation and use negligible <1 negligible <1
Use in paints Formulation 2.62 0.25 4.32 0.41
Industrial application 1.08 0.10 2.79 0.26
Domestic application negligible <1 negligible <1
Formulation 14.1 1.33 30.0 2.83Use in metal 
cutting/working fluids
Use in oil-based fluids (large) 5.66 0.53 7.36a [13.1]b 0.69a [1.24]b
Use in oil-based fluids (small) 5.15 0.49 6.85a [11.9]b 0.64a [1.12]b
Use in emulsifiable fluids 0.51 0.048 2.21a [2.63]b 0.21a [0.25]b
Use in emulsifiable fluids –
intermittent release
46 4.3 47.6a [93.5]b 4.49a [8.82]b
Formulation 1.78 0.17 3.49 0.33Use in leather fat 
liquors
Use – complete processing of raw 
hides
15.3 1.44 17.0 1.60
Use – processing of wet blue 60.8 5.74 62.5 5.90
Use in carbonless 
copy paper
Paper recycling 3.02 0.28 4.76 0.45
Regional sources 0.088 0.008 91.6 8.64
a) Assuming a 5% medium-chain chlorinated paraffin content in the base fluid.
b) Assuming a 10% medium-chain chlorinated paraffin content in the base fluid.
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Table E. 7  Estimated concentrations in fish and earthworms for secondary poisoning (PNEC = 0.17 mg/kg)
Scenario Step Current situation using measured regional concentrations Future situation
Fishc Earthworms Fishc Earthworms
PEC (mg/kg) PEC/PNEC PEC (mg/kg) PEC/PNEC PEC (mg/kg) PEC/PNEC PEC (mg/kg) PEC/PNEC
Production Site A 0.11-0.33 0.64-1.9 negligible <1 0.77-2.31 4.5-13.6 negligible <1
Site B 0.15-0.45 0.88-2.6 negligible <1 0.81-2.43 4.8-14.3 negligible <1
Site C 0.19-0.57 1.1-3.4 negligible <1 0.84-2.52 4.9-14.8 negligible <1
Site D 0.11-0.33 0.64-1.9 negligible <1 0.77-2.31 4.5-13.6 negligible <1
Compounding  - O 0.13-0.39 0.76-2.3 1.7 10.0 0.79-2.37 4.6-13.9 264 1,553Use in PVC 
– plastisol 
coating Conversion – O 0.26-0.78 1.5-4.3 9.3 54.7 0.92-2.76 5.4-16.2 270 1,588
Compounding/conversion - O 0.28-0.84 1.6-4.9 10.4 61.2 0.94-2.82 5.5-16.6 270 1,588
Compounding  - O 0.19-0.57 1.1-3.4 4.8 28.2 0.84-2.52 4.9-14.8 267 1,571Use in PVC 
–
extrusion/oth
er
Compounding - PO 0.52-1.56 3.1-9.2 24.1 142 1.18-3.54 6.9-20.8 287 1,688
Compounding – C 0.14-0.42 0.82-2.5 2.5 14.7 0.80-2.40 4.7-14.1 264 1,553
Conversion – O 0.34-1.02 2.0-6.0 13.7 80.6 1.00-3.00 5.9-17.6 273 1,606
Conversion – PO 0.36-1.08 2.1-6.4 14.7 86.4 1.02-3.06 6.0-18.0 277 1,629
Conversion – C 0.32-0.96 1.9-5.6 12.6 74.1 0.98-2.94 5.8-17.3 273 1,606
Compounding/conversion – O 0.42-1.26 2.5-7.4 18.1 106 1.08-3.24 6.4-19.1 280 1,647
Compounding/conversion - PO 0.77-2.31 4.5-13.6 38.3 225 1.43-4.29 8.4-25.2 300 1,764
Compounding/conversion - C 0.36-1.08 2.1-6.4 14.6 85.9 1.01-3.03 5.9-17.8 277 1,629
Use in 
plastics/rubb
er
Compounding 0.15-0.45 0.88-2.6 2.7 15.9 0.81-2.43 4.8-14.3 264 1,553
Conversion 0.24-0.72 1.4-4.2 7.8 45.9 0.90-2.70 5.3-15.9 270 1,588
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Table E7 continued Estimated concentrations in fish and earthworms for secondary poisoning (PNEC = 0.17 mg/kg)
Scenario Step Current situation using measured regional concentrations Future situation
Fishc Earthworms Fishc Earthworms
PEC (mg/kg) PEC/PNEC PEC (mg/kg) PEC/PNEC PEC (mg/kg) PEC/PNEC PEC (mg/kg) PEC/PNEC
Compounding/conversion 0.28-0.84 1.6-4.9 10.0 58.8 0.93-2.79 5.5-16.4 270 1,588
Use in 
sealants
Formulation and use negligible <1 negligible <1 negligible <1 negligible <1
Use in paints Formulation 0.23-0.69 1.4-4.1 7.6 44.7 0.89-2.67 5.2-15.7 270 1,588
Industrial application 0.16-0.48 0.94-2.8 3.3 19.4 0.82-2.46 4.8-14.5 264 1,553
Domestic application negligible <1 negligible <1 negligible <1 negligible <1
Formulation 0.80-2.40 4.7-14.1 39.7 234 2.15-6.45 12.6-37.9 339 1,994Use in metal 
cutting/worki
ng fluids Use in oil-based fluids (large) 0.38-1.14 2.2-6.7 16.1 94.7 1.04-3.12a 
[1.32-3.96]b
6.1-18.4a 
[7.8-23.3]b
277a [293]b 1,629a 
[1,723]b
Use in oil-based fluids (small) 0.36-1.08 2.1-6.4 14.7 86.5 1.02-3.06a 
[1.26-3.78]b
6.0-18.0a 
[7.4-22.2]b
277a [290]b 1,629a 
[1,706]b
Use in emulsifiable fluids 0.13-0.39 0.76-2.3 1.7 10.0 0.79-2.37a 
[0.81-2.43]b
4.6-13.9a 
[4.8-14.3]b
264a [264]b 1,552a 
[1,552]b
Use in emulsifiable fluids –
intermittent release
0.52-1.56 3.1-9.2 129 759 1.18-3.54a [1.6-
4.8]b
6.9-20.8a 
[9.4-28.2]b
389a [517]b 2,288a 
[3,041]b
Formulation 0.19-0.57 1.1-3.4 5.2 30.6 0.85-2.55 5.0-15.0 267 1,571Use in 
leather fat 
liquors Use – complete processing of 
raw hides
0.86-2.58 5.1-15.2 43.0 253 1.51-4.53 8.9-26.6 303 1,782
Use – processing of wet blue 3.10-9.30 18.2-54.7 171 1,006 3.75-11.3 22.1-66.2 432 2,541
Use in 
carbonless 
copy paper
Paper recycling 0.23-0.69 1.4-4.1 8.8 51.8 0.89-2.67 5.2-15.7 270 1,588
a) Assuming a 5% medium-chain chlorinated paraffin content in the base fluid.
b) Assuming a 10% medium-chain chlorinated paraffin content in the base fluid.
c) The concentration in fish is estimated using the methods outlined in the Technical Guidance Document, taking into account accumulation through the food chain. The range reflects the rangefor the BMF (1-3).
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Appendix H  
Effects of variability in physico-chemical properties and degradation rate on the 
environmental modelling of medium-chain chlorinated paraffins
Physico-chemical properties
Medium-chain chlorinated paraffins are complex mixtures. This presents some problems over 
the values of physico-chemical properties to be chosen for the environmental modelling of 
these substances. In order to simplify the environmental modelling the main risk assessment 
report a set of physical chemical properties were chosen as being representative of the 
medium chain chlorinated paraffins as a group. However, for the majority of the 
physico-chemical properties relevant for the environmental modelling, a range of values has 
been determined. This Appendix considers the effect of varying some of the key 
physico-chemical properties within the range measured on the predicted environmental 
concentration. In order to do this simply, the EUSES model was run several times using the 
release estimates for one local scenario (Use in rubber/plastics – conversion site; this is 
chosen as an example as it has releases to both air and waste water) and the total regional and 
continental releases as determined in the main report. This then allows the resulting 
concentrations to be compared directly with those obtained in the main report.
The physico-chemical properties for medium-chain chlorinated paraffins are discussed in 
Chapter 1 of the main risk assessment report. The values used as input data used in the 
various example calculations are shown in Table H1. The values chosen reflect the range of 
values measured for medium-chain chlorinated paraffins. In all calculations, 93% removal in 
the waste water treatment plant due to adsorption onto sewage sludge was assumed. Table H2 
gives the resulting PECs from this approach.
Table H3 outlines the PEC/PNEC ratios obtained for surface water, sediment, soil and 
secondary poisoning, using the various physico-chemical properties (the PNECs for sediment 
and soil are based on the equilibrium partitioning approach). For the soil and sediment 
endpoints, both the PEC and PNEC depend on the value for the organic carbon-water 
partition coefficient used. 
EU
 risk assessm
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Table H. 1  Input data for EUSES model for the various scenarios considered
Model input Value used in EUSES calculation
Main 
assessment
A B C D E F G H I J
Molecular weight 
(g/mole)
488 488 405c 419d 468e 481 488 488 488 488 488
Water solubility (µg/l) 27 5 27 27 27 27 27 27 27 27 27
Vapour pressure (Pa) 2.7.10-4 2.7.10-4 5.10-5 c 2.10-5 d 2.10-6 e 9.10-7 f 2.7.10-4 2.7.10-4 2.7.10-4 2.7.10-4 2.7.10-4
Henrys Law constanta
(Pa.m3.mole-1)
4.88 26.4 0.75 0.31 0.035 0.016 4.88 4.88 4.88 4.88 4.88
Log Kow 7 7 7 7 7 7 5.5 6 6.5 7.5 8
Kocb (l/kg) 5.89.105 5.89.105 5.89.105 5.89.105 5.89.105 5.89.105 3.59.104 9.13.104 2.32.105 1.5.106 3.8.106
PNECwater (µg/l) 1 1 1 1 1 1 1 1 1 1 1
PNECsediment (mg/kg wet 
wt.)g
12.8 12.8 12.8 12.8 12.8 12.8 0.78 2.0 5.0 32.6 82.6
PNECsoil (mg/kg wet wt.)g 10.4 10.4 10.4 10.4 10.4 10.4 0.63 1.6 4.1 26.5 67.1
PNECsecondary poisoning
(mg/kg food)
0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
Continental release 153,193 kg/year to air, 1,073,482 kg/year to waste water and 460,101 kg/year to surface water
Regional release 17,027 kg/year to air, 119,286 kg/year to waste water and 51,122 kg/year to surface water 
Local release (Use in 
rubber/plastics –
conversion site)
0.155 kg/day to air and 0.155 kg/day to waste water over 300 days
a) Henrys law constant estimated from water solubility and vapour pressure (also depends on the molecular weight). b) Koc estimated by EUSES from log Kow.
c) Vapour pressure and molecular weight appropriate for C14, 51-53% wt. Cl congeners. d) Vapour pressure and molecular weight appropriate for C15, 51-53% wt. Cl congeners.
e) Vapour pressure and molecular weight appropriate for C16, 51-53% wt. Cl congeners. f) Vapour pressure and molecular weight appropriate for C17, 51-53% wt. Cl congeners.
g) PNECs for sediment and soil calculated by the equilibrium partitioning method – dependent on Koc value.
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Table H. 2  Resulting concentrations for the various scenarios considered
Endpoint Value estimated in EUSES calculation
Main 
assessme
nt
A B C D E F G H I J
Local concentrations (use in rubber/plastics – conversion site)
Surface water (µg/l) 0.68 0.48 0.87 0.91 0.93 0.93 1.23 1.14 0.96 0.39 0.18
Sediment (mg/kg wet wt.) 8.7 6.1 11.2 11.6 11.9 12.0 0.96 2.27 4.84 12.5 15.1
Agricultural soil (30 days 
average) (mg/kg wet wt.)
3.72 3.58 3.88 3.79 3.67 3.66 2.41 2.96 3.45 3.64 3.43
Pore water (agricultural soil) 
(µg/l)
0.36 0.34 0.37 0.36 0.35 0.35 3.8 1.83 0.84 0.14 0.051
Air (during emission episode) 
(mg/m3)
4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5 4.3.10-5
Fish (for secondary poisoning) 
(mg/kg wet wt.)a
0.55-1.65 0.33-0.99 0.76-2.28 0.80-2.40 0.83-2.49 0.83-2.49 1.01-3.03 0.94-2.82 0.79-2.37 0.31-0.93 0.15-0.45
Earthworms (for secondary 
poisoning) (mg/kg wet wt.)
152 92.2 175 178 178 178 30.0 59.3 102 188 204
Total daily human intake (mg/kg 
bw/day)
0.137 0.127 0.138 0.132 0.126 0.125 0.053 0.076 0.109 0.157 0.172
Predicted regional concentrations
Surface water (µg/l) 0.39 0.19 0.58 0.62 0.64 0.65 0.72 0.67 0.56 0.22 0.10
Sediment (mg/kg wet wt.) 8.80 4.27 13.2 14.0 14.6 14.6 0.97 2.32 4.95 12.5 15.0
Agricultural soil (mg/kg wet wt.) 50.4 29.4 58.6 59.6 60.2 60.2 8.23 17.9 33.3 63.0 69.9
Pore water (agricultural soil) 
(µg/l)
4.9 2.8 5.6 5.7 5.8 5.8 13 11.1 8.2 2.4 1.04
Air (mg/m3) 3.4.10-6 6.2.10-6 1.2.10-6 8.9.10-7 6.6.10-7 6.5.10-7 6.4.10-6 5.8.10-6 4.7.10-6 2.1.10-6 1.4.10-6
Total daily human intake (mg/kg 
bw.day)
1.71 1.0 1.99 2.02 2.04 2.04 0.173 0.44 0.97 2.51 3.27
a) The concentration in fish is estimated using the methods outlined in the Technical Guidance Document, taking into account accumulation through the food chain. The range reflects the range for the BMF (1-3).
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Table H. 3  Resulting PEC/PNEC ratios for the various scenarios considered
Endpoint PEC/PNEC ratio
Main 
assessment
A B C D E F G H I J
Local concentrations (use in rubber/plastics – conversion site)
Surface water 0.68 0.48 0.87 0.91 0.93 0.93 1.23 1.14 0.96 0.39 0.18
Sediment 0.68 0.48 0.87 0.91 0.93 0.93 1.23 1.14 0.96 0.39 0.18
Agricultural soil (30 days 
average) 
0.35 0.34 0.37 0.36 0.35 0.35 3.83 1.85 0.84 0.14 0.05
Fish (for secondary poisoning) 3.3-9.9 2.0-6.0 4.5-13.5 4.8-14.4 5.1-15.3 5.1-15.3 6.0-18.0 5.7-17.1 4.8-14.4 1.8-5.4 0.9-2.7
Earthworms (for secondary 
poisoning) 
894 542 1,029 1,047 1,047 1,047 176 348 600 1,106 1,200
Predicted regional concentrations
Surface water 0.39 0.19 0.58 0.62 0.64 0.65 0.72 0.67 0.56 0.22 0.10
Sediment 0.69 0.33 1.03 1.09 1.14 1.14 1.24 1.16 0.99 0.38 0.18
Agricultural soil 4.8 2.8 5.6 5.7 5.8 5.8 13.0 11.2 8.1 2.4 1.0
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As can be seen from Table H3, there is some variation in the results obtained. Lowering the water 
solubility (or increasing the Henrys law constant to values of around 25 Pa.m3.mole-1) and increasing 
the log Kow value above 7-7.5 appeared to have the largest effects on the resulting PEC/PNEC ratio, 
leading to generally lower ratios for surface water, sediment and soil. 
The extremes of the PEC/PNEC ratios obtained vary by a factor of around 7 for surface water and 
sediment and by a factor of up to 60 for agricultural soil. However, for most scenarios (e.g. B, C, D, E, 
F, G, H) the variation in PEC/PNEC ratio seen is much less than this, and indicates that only the 
extremes of the values of the range of physico-chemical properties would result in a significant change 
to the PEC/PNEC ratios obtained. The values for physico-chemical properties used in the main 
assessment results in PEC/PNEC ratios that are generally in the middle to upper end of the range 
determined, and indicate that the results are reasonably representative for the majority of the 
components of the commercial mixtures.
Degradation rate
Since medium-chain chlorinated paraffins are not readily biodegradable, the appropriate default rate 
constants for degradation in surface water (6.93.10-7 day-1), soil (6.93.10-7 day-1) and sediment 
(6.93.10-8 day-1) were used in the EUSES modelling in the main report. These correspond to
degradation half-lives of the order of 2,740 years in soil and surface water, and 27,400 years in bulk 
sediment. The regional concentrations estimated using these values were generally higher than the 
available monitoring data indicated. One explanation for this would be if medium-chain chlorinated 
paraffins are less persistent in the environment than is indicated by these default degradation halflives. 
Therefore the sensitivity of the calculations to these degradation rates was investigated. In this analysis 
the physico-chemical properties and regional and continental releases were as in the main report and 
the EUSES model was run several times with different values for the degradation rate constants. The 
results are shown in Table H4.
Table H. 4  Effects of varying the biodegradation half-life on predicted regional concentrations
Biodegradation Half-life PECregional
Surface 
water, soil
Bulk 
sediment
Surface 
water, soil
Bulk 
sediment
Surface 
water
Sediment Agricultural soil
6.93.10-7 6.93.10-8 2,740 years 27,400 years 0.39 µg/l 8.8 mg/kg wet wt. 50.4 mg/kg wet wt.
6.93.10-6 6.93.10-7 274 years 2,740 years 0.27 µg/l 6.04 mg/kg wet wt. 10.6 mg/kg wet wt.
6.93.10-5 6.93.10-6 27.4 years 274 years 0.24 µg/l 5.32 mg/kg wet wt. 1.19 mg/kg wet wt.
6.93.10-4 6.93.10-5 2.74 years 27.4 years 0.21 µg/l 4.71 mg/kg wet wt. 0.12 mg/kg wet wt.
1.90.10-3 1.90.10-4 1 year 10 years 0.19 µg/l 3.92 mg/kg wet wt. 0.044 mg/kg wet wt.
6.93.10-3 6.93.10-3 100 days 2.74 years 0.13 µg/l 2.3 mg/kg wet wt. 0.012 mg/kg wet wt.
0.0139 1.93.10-3 50 days 1.37 years 0.10 µg/l 1.45 mg/kg wet wt. 0.006 mg/kg wet wt.
0.0231 2.31.10-3 30 days 300 days 0.08 µg/l 0.97 mg/kg wet wt. 0.004 mg/kg wet wt.
Measured data 0.1 µg/l 0.7 mg/kg wet wt. 0.088 mg/kg wet wt.
As can be seen from the data presented in Table H4, the regional soil concentration is particularly sensitive to the value of the degradation rate 
chosen. A degradation half-life in soil of around 2 years leads to predicted levels that are consistent with the measured data. 
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Appendix I
MEASUREMENT OF WORKPLACE EXPOSURE
Summary
No references were located which referred specifically to the measurement of occupational exposure to 
medium-chain chlorinated paraffins. Most work on these materials relates to their occurrence in the 
general environment such as water, sediments and biological material. There are few references to 
airborne measurement so there is little experience to draw upon in collecting samples from the air. 
Given the low vapour pressures of C14-17 chloroparaffins, sampling vapour may not be an issue in the 
workplace. However, aerosols generated from the use of, for example, metal working fluids may 
contain chloroparaffins which could have an associated vapour. Experience also shows that collection 
on filters of aerosols of substances with relatively low vapour pressures can lead to losses during 
sampling due to evaporation from the filter.
The most frequently used analytical methods include GC-HRMS (see abbreviations), GC-LRMS and 
GC-ECD. Analysis is difficult because medium-chain chlorinated paraffins are a complex mixture of 
compounds which will have different response factors to the various methods of detection. One paper 
(Tomy et al, 1997) tried to estimate the number of positional isomers possible for C10-13
chloroparaffins by assuming no more that one chlorine atom per carbon atom and produced a figure of 
6,304 compounds. The authors estimated that the true number of compounds is probably an order of 
magnitude greater than this because of the possibility of optical isomerism on adding subsequent 
chlorines. The situation is expected to be no less complex for C14-17 chloroparaffins. Thus selectively 
distinguishing and quantifying C14-17 chloroparaffins is an extremely challenging task. With so many 
possible compounds, calibration of the measurement method becomes a compromise which to some 
extent relies on matching the profile of the sample to the profile of the substance used to calibrate. 
Deviations from such profile matching as, for example, in degraded samples can be expected to give 
rise to measurement errors.
Few attempts have been made to establish the quality of the results from this difficult measurement. 
No references were located on interlaboratory trials on the measurement of MCCPs. However, an 
interlaboratory trial involving seven laboratories on the measurement of short-chain chlorinated 
paraffins resulted in reasonably good agreement between laboratories for one sample but large 
discrepancies for another sample for reasons which were unclear (Tomy et al 1999). The measurement 
difficulties for medium-chain chlorinated paraffins are similar to short-chain chlorinated paraffins and 
it might be expected that the problems identified with short-chain materials would also apply to 
medium-chain chlorinated paraffins. 
In measuring airborne exposures in the work place, measurement methods should conform to the 
requirements of BS EN 482 and its associated standards (BS EN 483, BS EN 1076). While it is likely 
that the methods used for environmental applications could be adapted for occupational measurement, 
it is unlikely that they would meet the requirements of BS EN 482, mainly because of the complexity 
of the mixtures and the calibration difficulties. The analytical method of choice would probably be 
GC-MS (low or high resolution) but additional work would be required to specify an appropriate 
method for capturing airborne samples.
If aerosols containing medium-chain chloroparaffins are generated in the workplace then there is the 
potential for subsequent contamination of surfaces through deposition of the aerosol. No measurement 
information was found which considered this possibility. Before surface contamination with these 
materials could be investigated, appropriate means of sampling from the surfaces would have to be 
validated. There would also be the possibility of preferential evaporation, over time, of the lighter 
fractions from the surfaces which would make matching of the sample to a suitable calibration 
standard difficult during analysis.
The summary was drawn from the following publications amongst others. These publications comprise 
a cross section of material on chloroparaffins and are intended to include examples of the principal 
methods of measurement.
Hollies et al (1979)
Thin layer chromatography methods are described which will are said to distinguish between shorter 
chain C13-17 chloroparaffins and those with longer, C20-30, chains in various environmental media. 
Samples are cleaned up with solvent extraction and column chromatography followed by analysis with 
thin layer chromatography in a procedure which is time-consuming. The method is said to be capable 
of measuring concentrations down to 500 ng/l in water but is likely to be semi-quantitative without a 
densitometer. 
Campbell and McConnell (1980)
The TLC method of Hollies et al (1979) was used to analyse various environmental samples but was 
able to discriminate only between C10-20 and C20-30 chloroparaffins. It could not differentiate between 
C10-13 and C14-17 types and will therefore not fulfil the requirements of this review.
Sistovaris and Donges (1987)
Catalytic reduction of the chloroparaffins to their corresponding alkanes and analysis by GC-FID was 
proposed. The catalyst is inserted into the GC injector so that samples are reduced on injection 
producing quite high conversion efficiencies to the alkanes. The method offers a reduction in the 
complexity of analysing chloroparaffins but clearly alkanes or other materials which can also be 
reduced to alkanes could be a significant source of interference. Consequently it would be difficult to 
positively confirm the presence of chloroparaffins in a sample and the technique is likely to produce 
only a total chloroparaffin figure.
Junk and Meisch (1993)
A measurement method was reported based on GC-EI-MS after clean up of the sample using solid 
phase extraction. It is claimed that monitoring two fragments with masses 105 and 107, produced by 
chloroparaffins, overcomes some of the calibration difficulties experienced by other methods. 
However, the development work used a C10-13 chloroparaffin only so it is not clear whether the method 
could also be used selectively for C14-17 types.
Schmid and Muller (1985)
Samples were cleaned up with solid phase extraction and analysed by GC-NCI-MS. Method testing 
included one chloroparaffin from each type, C10-13, C14-18 and C20-28 together with various 
environmental samples. While the method is sensitive and can clearly indicate the presence of 
chloroparaffins, it was not clear if it could selectively distinguish between the types of chloroparaffin. 
Accurate quantitation also depends on matching the chloroparaffin used to calibrate with the 
chloroparaffins in the sample. Any significant deviations from a match will give rise to errors.
Tomy et al (1997)
A method is described a sensitive method for quantifying C10-13 chloroalkanes using GC-ECNI-
HRMS. This approach was adopted to eliminate self-interference between the chloroalkanes and also 
to overcome the potential interference from other chlorinated materials such as PCBs and 
organochlorine pesticides. The method attempts to separate the chloroparaffins into formula groups, 
which is said to allow corrections for differences in patterns between analyte and standard. The method 
could probably be adapted for C14-17 chloroparaffins but it is not clear that they could be selectively 
measured in the presence of other chloroparaffin types.
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Peters et al (1998)
Environmental air samples were collected with Graseby-Anderson PS1 and PM10 high volume 
samplers. Particulates were retained on a glass fibre filter and the vapour phase components on two 
polyurethane foam plugs. The filters and plugs were solvent extracted together so no phase partitioning 
information was provided in this study and the samples were analysed with GC-ECNI-HRMS.  
Concentrations of SCCPs are quoted (C10-13) but there are no data for the higher homologues. The 
samples from a semi-rural site at Lancaster produced a total chloroalkane concentration of 99 pg/m3
(±101). No information was provided on collection efficiencies of the sampling devices or recoveries 
from those media.
Randegger-Volrath (1998)
An application is reported in which cutting fluids and lubricants are classified on the basis of the chain 
length and degree of chlorination of the chlorinated paraffins in the products. Samples were cleaned up 
with solid phase extraction and screened using GC-ECD. Positive identification and quantitation was 
then performed using GC-NCI-MS. The procedure was applied to 37 cutting fluids or lubricants and 
produced detection limits of 0.02 to 0.08% using the ECD method and 0.2 to 2.6% for the NCI 
method. Chlorinated paraffins were detected in 57% of the samples comprising 21% short chain and 
30% medium chain. Long chain chlorinated paraffins were detected in 2 samples. Only the short chain 
compounds were quantified producing concentrations from 1 to 70% (w/w). The authors stated that the 
differing classes of chlorinated paraffins can be characterised based on their specific masses and GC 
retention times. The prime purpose of the study was to demonstrate the presence of chlorinated 
paraffins in various products but investigation of quantitation showed NCI to be superior to ECD. 
Tomy et al (1999)
An interlaboratory study between seven laboratories using two solutions of known concentration and 
two fish extracts is reported. The laboratories used GC-LRMS, GC-HRMS or GC-EC. The mean 
concentration in the first sample was 99.3 ng/ml compared with a true value of 74 ng/ml. The mean 
concentration in the second sample was 297 ng/ml compared with a true value of 118 ng/ml. The 
reason for the large discrepancy in the second sample was unclear but was taken to imply that different 
commercial formulations used as calibration standards would provide different estimates of short-
chain chlorinated paraffins. Co-eluting substances were thought to contribute to the errors.
Appendix J
Contribution on Biological Monitoring
There are no published occupational studies involving biological monitoring for medium-chain 
chlorinated paraffins (MCCPs).  
It may be possible to develop a biological monitoring method by adapting methods used for 
environmental and tissue samples. MCCPs have been measured in human adipose tissue (Schmid & 
Muller 1985) and short-chain chlorinated paraffins in human breast milk (Stern et al 1998). Both 
techniques used extensive sample preparation followed by high resolution gas chromatography with 
detection by negative ion chemical ionisation mass spectrometry.   
However, the analysis is complicated by the fact that MCCPs are a group of substances rather than a 
single substance, the lack of suitable reference substances and the lack of suitable internal standards. 
Unlike conventional biological monitoring for single substances any methods for MCCPs are likely to 
be semiquantitative.
Further contraindications for biological monitoring for MCCPs are:
· the invasive nature of sampling (blood or adipose tissue)
· the long-half life of MCCPs in the body making interpretation difficult
· the likely high cost of sample analysis.
In view of this, it seems likely that any biological monitoring for MCCPs will be confined to specialist 
investigations rather than occupational hygiene investigations. Overall, therefore, MCCPs are not 
considered to meet HSE’s criteria for the development of a BMGV.
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